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Metabolism in myocardial ischaemia and reperfusion with specific reference to the role of glucose. 
Linda Mary King, MRC/UCT Ischaemic Heart Disease Research Unit, University of Cape Town 
Medical School, Observatory, Cape Town, South Africa. June, 1996 
Hypothesis: Glucose is known to be protective in moderate low flow ischaemia due to the production of 
glycolytic ATP. However, it is questioned whether glucose would still be protective in ultra low flow 
ischaemia. Firstly, glycoiysis is thought to be inhibited, and secondly, deleterious glycolytic metabolites 
accumulate. Our hypothesis was that in ultra low flow ischaemia, glucose utilisation is not inhibited at 
the level of glycolysis, but by delivery. Increased delivery of glucose should result in increased 
production of protective glycolytic ATP, but the rate of metabolite accumulation would also increase. 
Using ultra low flow rates, I wished to investigate how to achieve optimal rates of glycolysis, and how 
such rates would be balanced by any detrimental component of metabolite accumulation. 
Methods: The isolated Langendorff-perfused rat heart, with a left ventricular balloon to record 
ischaemic contracture and reperfusion stunning, was used, with severe flow restriction. Glucose 
concentrations were changed and pre-ischaemic glycogen contents were altered by perfusion with 
different substrates (acetate - depletion~ glucose + insulin - loading) or by preconditioning, with 5 min 
ischaemia and 5 min reperfusion prior to sustained.ischaemia. 
Results: Analysis of glucose uptake relative to delivery showed that in severe low flow ischaemia, the 
extraction of glucose was increased, and glycolysis was thus limited more by substrate supply than by 
enzyme inhibition. Analysis of metabolites confirmed this concept. The optimal glucose concentration 
during severe low flow ischaemia was 11 mM, giving maximal recovery on reperfusion. Both lower and 
higher glucose concentrations increased ischaemic contracture. Changes in pre-ischaemic glycogen 
levels correlated with the time to onset of contracture, such that a reduction in glycogen accelerated 
contracture. Prior glycogen depletion or loading did not improve functional recovery. The benefits of 
preconditioning on reperfusion function following sustained total global ischaemia could not be related 
to glycogen depletion. If preconditioning were followed by sustained low flow ischaemia, glucose uptake 
was increased, but no benefit was found, possibly because a low residual flow abolished the effects of 
preconditioning. Many of the above results are consistent with the hypothesis that too low a rate of 
glycolysis results. in insufficient ATP production for protection, while excess glycolytic rates lead to 
excess metabolite accumulation with detrimental effects. 
Conclusions: Provision of glucose at the correct concentration, when the benefit associated with 
glycolytic ATP outweighs the detriment associated with moderate metabolite accumulation, is protective 
to the low-flow ischaemic myocardium, which can upregulate its ability to extract glucose. Improved 
residual flow enhances this benefit. Prior glycogen depletion is not beneficial, despite a reduced 
metabolite accumulation. This mechanism cannot be related to the protective effect of preconditioning. 
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Glucose is generally considered to be protective to the ischaemic myocardium. Glucose reduces 
ischaemic contracture and arrhythmias, and increases functional recovery on reperfusion, possibly by 
maintaining the sarcolemmal pump function by production of glycolytic ATP and thus regulating 
ionic concentrations in the cytosol. Glucose has been administered clinically to patients with 
myocardial infarction, in the form of glucose-insulin-potassium therapy, but this has generally been 
under-utilised. Glycolysis is thought to be inhibited in ischaemia at the level of glyceraldehyde 3-
phosphate dehydrogenase {GAPDH), and some studies have indicated that there may be detrimental 
effects associated with increased glycolysis, due to increased accumulation of the metabolites of the 
pathway, specifically lactate and protons. These detrimental effects may be present especially under 
ultra low flow conditions, when the detriment of the metabolites may outweigh the benefit of 
increased glycolytic ATP. These ultra low flow rates (0.015 to 0.2 ml/g wet wt/min), are of particular 
relevance given that in vivo flow rates in severe ischaemia in larger animals are in this range. Study of 
any therapy for ischaemia should therefore be undertaken with experimental models using similar 
rates of delivery and washout. I wished to test the hypothesis that the residual coronary flow may be a 
crucial determinant of the effectiveness of the provision of glucose, and then to determine the optimal 
conditions for provision of glucose to the ischaemic myocardium. 
I used the Langendorff isolated perfused rat heart, with a left ventricular balloon to record ischaemic 
contracture (a rise in resting tension during ischaemia, associated with ATP depletion and calcium 
entry) and functional recovery on reperfusion. 
My first goal was to establish at what low residual flow rate would the detriments associated with 
glucose provision (at the standard concentration of 11 mM) outweigh the benefits, such that the 
absence of glucose would lead to better tolerance of ischaemia. However, at no residual flow rate 
(even as low as 0.015 ml/g wet wt/min) was the presence of glucose more detrimental than the 
absence of glucose during the ischaemic period. Having established that the presence of glucose was 
beneficial, I then wished to determine the optimal concentration of glucose under a variety of low 
flow conditions, looking at functional recovery. I found that the standard glucose concentration of 11 
mM, used in almost all perfusions with the isolated rat heart (in the absence of any alternate substrate) 
was optimal over a range of ultra low flows. Even when an alternate substrate (acetate) was present, 
11 mM glucose was optimal. At higher flow rates (0.5 ml/g wet wt/min) the hearts perfused with 11 
mM glucose resulted in almost 100% recovery after 30 min ischaemia and reperfusion. 
At low flow rates (0.1 and 0.2 ml/g wet wt/min) the use of 22 mM glucose exacerbated ischaemic 
contracture and reduced . functional recovery. These findings pointed to an impairment of function 
associated with excess glycolytic substrate. Even with a residual low flow of 0.5 ml/g wet wt/min, the 
effects of 22 mM glucose with and without insulin were worse than 11 mM glucose hearts. Thus, at a 
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flow rate of 0.2 ml/g wet wt/min, provision of 11 mM glucose appears to be optimal. I used this as the 
standard reference model for further work. 
No difference in the time to onset of ischaemic contracture was· found with different glucose 
concentrations at a low flow of 0.2 ml/g wet wt/min. I then reasoned that a change in glycogen may 
alter the time to onset of contracture. Glycogen levels were altered by perfusion with different 
substrates (acetate or substrate-free to reduce glycogen; addition of insulin to glucose-containing 
perfusate to increase glycogen). Increased glycogen was associated with a delay in time to onset; 
reduced tissue glycogen reduced time to onset of contracture. The provision of glucose also reduced 
the peak contracture in all hearts. I was thus able to draw inferences regarding the respective roles of 
glucose-derived versus glycogen-derived ATP, acting at different sites in the myocyte. Glucose-
derived ATP may regulate the Na+/K+ ATPase pumps in the sarcolemma (and thus the cytosolic Ca2+ 
gradient following inhibition of the Na+/Ca2+ exchange), as well as the SR Ca2+ ATPase pump, and 
thus be responsible for maintaining ion gradients. Glycogen-derived ATP may be present mainly at 
the sarcoplasmic reticulum (SR) and the myofibrils, maintaining SR Ca2+ ATPase-mediated Ca2+ 
uptake and ensuring relaxation of actin-myosin bonds. These mechanisms needs to be defined further 
on a molecular level. 
I analysed the kinetics of glucose uptake in ischaemia, over a range of glucose concentrations and 
residual flow rates. I established that if glucose uptake is expressed as a function of the glucose 
delivered to the myocardium (determined by the glucose concentration and the coronary flow) that in 
fact glucose extraction increases as the residual flow rate decreases below about 1-2 ml/g wet wt/min. 
Thus the ischaemic myocardium appears to be able to upregulate its ability to take up glucose from 
the perfusate delivered to the cells. This may be achieved by increased translocation of GLUT4 
insulin-sensitive glucose transporters to the membrane, or an upregulation of transporters already in 
the membrane. The kinetics of glucose uptake over the range of glucose concentrations and low flows 
I studied establishes that glucose uptake follows Michaelis Menten kinetics, consistent with enzyme-
driven glucose uptake i.e. by facilitated diffusion. In addition, measurement of glycolytic metabolites 
did not confirm inhibition at GAPDH, although there may be a bottle neck effect at 
phosphofructokinase, especially when glycolytic substrate in excess, resulting in increased sugar 
phosphate accumulation. Thus the concept that glycolysis is inhibited in ischaemia is challenged by 
these results. Rather, I suggest that glycolysis is limited in ischaemia by the availability of substrate. 
Increased substrate availability should thus increase the benefit. However, an excess glycolytic 
substrate is detrimental by producing excess metabolites. Thus an optimal concentration of 11 mM 
glucose is confirmed, at which delivery of glucose and subsequent rates of ATP production are 
balanced by any detrimental effect of metabolite accumulation. Increased delivery of glucose and 
washout of metabolites by increased residual flow is of additional benefit, such that at 0.5 ml/g wet 
wt/min, functional recovery after 30 min approaches pre-ischaemic values. 
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Glycogen is the endogenous glycolytic substrate, and its content at the onset of ischaemia is thus a 
primary determinant of the rate of glycolytic ATP production, metabolite accumulation, and 
ischaemic injury. Preconditioning, whereby one or more brief episodes of ischaemia and reperfusion 
protect the heart against the effects of a subsequent sustained ischaemic period, has received much 
attention in the literature. The preconditioning protocol ( one 5 min episode of ischaemia and 5 min 
reperfusion) results in a depletion of pre-ischaemic glycogen, and this has been proposed as one of the 
mechanisms whereby preconditioning may exert its protective effects. A much-quoted paper 387 
suggests that the accumulation of lactate and protons from the breakdown of glycogen is deleterious 
to the ischaemic myocardium. This finding is in contrast to our results which found that provision of 
glucose is beneficial, even at very low residual flows. I investigated the effect of changes in pre-
ischaemic glycogen content (glucose - control; acetate - depleted; glucose + insulin - loaded) on the 
subsequent response to total global ischaemia with reperfusion, and preconditioned similar hearts to 
determine any correlation between pre-ischaemic glycogen content, preconditioning, and functional 
recovery. I could find no benefit associated with increased glycogen levels, with a significant increase 
in sugar phosphate levels during ischaemia to account for this detrimental effect. In addition, no 
benefit was associated with glycogen depletion, with exacerbation of ischaemic contracture. 
Preconditioning resulted in a doubling in functional recovery in hearts perfused with glucose alone 
(standard pre-ischaemic glycogen content) but preconditioning had no effect on either glycogen-
loaded or glycogen depleted hearts, correlated with maintained high sugar phosphate levels, and 
severely reduced ATP levels respectively. thus for preconditioning to occur, a "normal" level of 
glycogen is required, and glycogen depletion is not related to the protective effects of 
preconditioning. 
I subsequently tested the effects of preconditioning (5 min total global ischaemia + 5 min reperfusion) 
on sustained low flow ischaemia (0.2 ml/g wet wt/min) with 11 mM glucose. Preconditioning 
significantly increased glucose uptake, and attenuated contracture compared to preconditioning zero 
flow hearts, but contracture was no different compared to control low flow hearts. In addition, 
functional recovery was not altered by preconditioning. If pre-ischaemic glycogen content and 
ischaemic glucose uptake were modulated as described above, I could find no relationship between 
changes in glycolysis and the effects of preconditioning. No benefits were associated with 
preconditioning on low flow ischaemia under any circumstance. Unaltered functional recovery after 
preconditioning and low flow ischaemia could be related, firstly, to an increase in glucose uptake with 
preconditioning to a value higher than optimal, which resulted in excess accumulation of glycolytic 
metabolites despite a reduction in pre-ischaemic glycogen levels, and thus outweighed any possibly 
benefit associated with preconditioning. Preconditioning did not additionally increase glucose uptake 
in insulin-treated hearts, suggesting that preconditioning may exert effects on glucose uptake in a 
similar fashion to insulin i.e. translocation of the GLUT4 transporter. However, these hearts showed 
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increased sugar phosphate accumulation because of a high pre-ischaemic glycogen. Secondly, 
reduced glucose uptake and reduced tissue glycogen in acetate preconditioned hearts resulted m 
exacerbated contracture with poor recoveries because of low ATP production. 
Alternative explanations for these findings are that in the presence of a low residual flow, 
preconditioning may not exert any protective effects, and the subsequent changes in glycolytic flux 
(from both glucose and glycogen) are independent of any possible protective effects brought about by 
preconditioning. Other: workers support the concept that a residual low flow abolishes the protective 
effect of preconditioning, in terms of functional recovery in rats, and infarct size in larger animals. 
Finally, I wished to confirm previous results showing that the addition of lactate to a glucose-
containing perfusate infused at a low residual flow of 0.5 ml/g wet wt/min is deleterious to the 
myocardium. However, I found that only at a low residual flow of 0.2 ml/g wet wt/min was any 
detrimental effect with lactate noted. Thus I could not confirm a detrimental effect of the lactate 
produced in the presence of sufficient glycolytic ATP i.e. with an optimal concentration of 11 mM 
glucose. In addition, the role of lactate as a major inhibitor of glycolysis in ischaemia is questioned, 
following results obtained from: direct application of extracellular lactate; analysis of glucose uptake 
in ischaemia which suggests that glycolysis is limited mainly by the availability of substrate and not 
by enzyme inhibition; and metabolite accumulation which does not suggest inhibition at GAPDH, and 
shows a large accumulation of lactate directly related to glucose uptake. 
Thus glucose provision, at an optimal concentration of 11 mM, is beneficial to the ischaemic 
myocardium. The benefits associated with glycogen loading are not as clear. Rather, moderate 
glycogen, together with an optimal glucose is required for ensuring recovery. The addition of insulin 
would lower the optimal concentration in vivo, as would the presence of fatty acids and other 
substrates. These factors need to be investigated further prior to application of glucose-insulin-
potassium therapy in patients. 
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DAG- diacylglycerol 
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dinucleotide (phosphate) (reduced) 
NO - nitric oxide 
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PEP - phosphoenolpyruvate 
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PFK - phosphofructokinase 
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Overview - aims and organisation of thesis 
1) AIMS AND GENERAL HYPOTHESIS OF THE THESIS 
Glucose is a simple hexose sugar utilised by all cell types, especially the brain and erythrocytes. In 
the isolated perfused rat heart, glucose at a concentration of 11 mM is generally the sole extrinsic 
substrate. 
Besides its physiological role, provision of glucose may have a protective effect on the ischaemic 
myocardium by reducing arrhythmias and ischaemic contracture, and improving functional recovery 
on reperfusion. These benefits are hypothetically mediated by increased glycolytic ATP production, 
which may be involved in control of SR and membrane pumps. However, the advantages of increased 
ATP could theoretically be outweighed by the accumulation of possibly deleterious end-products 
including lactate, NADH, protons and sugar phosphates. The extent of harm caused by these end-
products is not clear, particularly when balanced against the benefits of glycolytic ATP. 
The major aim of this thesis was to clarify the role of glycolytic flux under ischaemic conditions more 
. representative of those in the in vivo myocardium. 
I wished to determine an optimal glucose concentration, at which the production of glycolytic ATP is 
maximal, and its benefit is not outweighed by excess deleterious metabolite accumulatio~. A major 
determinant of both the amount of glucose made available to the cells, and the rate of washout of end 
products, is the coronary flow. Some residual flow is usually present in ischaemic tissue in vivo, but 
this factor is not usually considered in an experimental isolated rat heart. Another major determinant 
of the rate of glycolysis is the amount of glycogen, the endogenous glycolytic substrate, available in 
the tissue at the onset of ischaemia. Tissue glycogen can be modified by perfusion with different 
substrates, and also by preconditioning, a fairly recent phenomenon whereby an initial ischaemic 
episode(s) with subsequent reperfusion can protect against the consequences of a subsequent 
sustained ischaemic period. Glycogen is reduced by the initial ischaemic episode(s), and a reduction 
in glycogen has been shown to be beneficial by reducing the accumulation of glycolytic end products. 
Thus glycogen reduction may be a mechanism involved in preconditioning. However, preconditioning 
is also known to stimulate glucose t5ptake in a model of sustained low flow ischaemia. 
Our basic hypothesis was that provision of glycolytic substrate to the ischaemic heart should always 
be beneficial except under circumstances where the accumulation of metabolites from excess 
substrate could outweigh the benefits of increased ATP production. I thus investigated changes in 
glucose uptake over a range of low coronary flows and different glucose concentrations, and 
modifications in glycogen by a number of mechanisms, and determined the response of the tissue to 
ischaemia. 
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2) ORGANISATION OF THESIS 
The thesis is divided into several sections. The literature review describes the validity of the ischaemic 
model used in the majority of studies presented in this thesis, with reference to the clinical correlates. A 
broad overview of the changes brought about in the tissue by ischaemia is given. lschaemic contracture, 
the main functional index of ischaemic injury used in the studies, is discussed in terms of the 
mechanisms which trigger contracture and potentiate its effects. The changes on reperfusion, and 
functional recovery, are also discussed. The specific actions of glucose on the ischaemic heart are then 
discussed in depth, expanding the argwnent over the benefit vs. the detrimental effects of glucose, 
extending into the role of glycogen. Some of the postulates of the thesis are elaborated in this section. 
The concept of compartmentation, as the possible mechanism for distinguishing the benefits of ATP 
from glucose, glycogen and oxidative phosphorylation, is discussed. An extensive review of 
preconditioning is then given, a much investigated phenomenon, but with little indication that the 
mechanism has yet been fully clarified. One hypothesis, that glycolysis is involved in preconditioning, is 
discussed with reference to the various proposals for the effector of preconditioning. A summary of each 
chapter is added at the end. 
There are six sections of results, each of which describes a complete study (as published, or m 
preparation for publication). The first two reports deal largely with experimental data describing 
glucose uptake at a range of low flows with or without insulin, the consequences to the heart in terms of 
ischaemic contracture and functional recovery, and the role of glycogen which appears to be involved 
specifically in determining the time to onset of contracture. The third paper focuses specifically on 
glucose uptake, reviewing old concepts of regulation of glucose utilisation under ischaemic conditions. 
The next two reports look at preconditioning, firstly concentrating on glycogen, and secondly on glucose 
uptake. Both of these are dissociated from the mechanism of preconditioning by these studies, but the 
findings explain further the roles of glucose and glycogen in ischaemia. The final report is a brief 
investigation of the role of lactate, as a major end product of glycolysis. This study directly refutes a 
previous report, suggesting that lactate is always deleterious. 
The discussion focuses on different aspects emphasised by the results. The first chapter expands on Ch 
III of the Results section, with a more in-depth analysis of previous concepts that glycolysis is inhibited 
in ischaemia, which are challenged by the present findings . The second chapter focuses on ischaemic 
contracture, and its modification by glycolytic ATP. Several points of contradiction were brought out in 
the studies, which are hopefully clarified in this section. A brief reappraisal of preconditioning is then 
given, based on the experiences in trying to obtain a consistent model of preconditioning. 
Finally, a brief description of the possible clinical applications of the use of glucose in ischaemia are 
described, to place the findings in a clinical context. An appendix is included, describing uptake and 
metabolism of glucose and of glycogen, for reference purposes. 
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Literature review 
I. ISCHAEMIA 
1) ISCHAEMIC HEART DISEASE 
a) Definition 
"Ischaemia" is derived from the Greek, "tcrXEtv" - to hold back, and "atµa" - blood, and can be 
defined simply as a local and temporary deficiency of blood supply to a tissue (although even this 
simple definition has been challenged 187). Ischaemia is thus a reduction in blood flow with 
metabolic consequences for the tissue. Thus a more exact definition of myocardial ischaemia in terms 
of metabolic demand is "whenever the flow of arterial blood through the diseased vessels is reduced 
to a volume below that required by the myocardium for adequate function" 221 , (although the vessels 
themselves may not be diseased) and on a molecular level "whenever the arterial blood flow is 
insufficient to provide enough oxygen to prevent intracellular respiration from shifting from the 
aerobic to the anaerobic form" 221 . Myocardial ischaemia can thus arise either from a reduction in, or 
complete stoppage of flow, or an imbalance between supply and demand. Within the limits of this 
definition, there is a wide range in severity, and extent of "ischaemia" with differing consequences for 
the metabolism of the tissue. 
The biochemical consequences of ischaemia are many and varied, stemming mainly from a reduction 
in energy supply and an accumulation of harmful end products, leading to mechanical and electrical 
changes in heart function. Prolonged ischaemia may develop into a pathological state. The associated 
clinical manifestations include angina pectoris or chest pain, shortness of breath, ECG changes and 
arrhythmias, contractile dysfunction with left-sided heart failure, and myocardial infarction. 
"Ischaemia" is a heterogeneous state, both in its genesis and at a cellular level. The different degrees 
to which supply and demand are altered are reflected in the variety of laboratory models used to study 
the pathological changes associated with ischaemia. This thesis is concerned with models of global 
zero flow or very low residual flow, representative of compromised tissue at the centre of an 
underperfused region with some degree of residual flow, as is usually found in vivo. After a brief 
description of clinical ischaemia, the validity of this model in terms of its clinical relevance are 
discussed. A broad review of the consequences of ischaemia for the heart is given, discussed in terms 
of cellular and tissue dysfunction during ischaemia and on restoration of flow. The following chapters 
then focus on specific aspects of ischaemia and reperfusion affected by glucose, glycogen, and 
preconditioning. 
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b) Causes of ischaemic heart disease 
Ischaemic heart disease is the clinical entity of coronary vessel disease, the underlying pathology of 
which is mostly atherosclerosis. This is an chronic, age-related degenerative disease with fibrous, 
fatty plaques or atheromas, developing in the arterial walls of the coronary circulation. Narrowing of 
the vessel, or complete occlusion, results, especially if a thrombus develops at the constriction. Other 
causes of ischaemia from changes in the coronary circulation include reflex coronary spasm in 
response to emotion, cold, upper gastrointestinal tract disease, or smoking, and hypoxia. The standard 
experimental models mimic some degree of occlusion of the arteries, although hypoxia has also been 
used extensively. 
c) Clinical complications - causes and consequences 
i) Angina pectoris 
Angina pectoris indicates chronic compromised flow to a portion of the myocardium. The symptoms -
chiefly chest pain - may become evident only under strain, e.g. exercise - angina of effort; or may be 
persistent at rest - unstable angina. These differences are due to variations in the degree of obstruction 
across the artery, and the extent of tissue perfused by the affected artery. Unstable angina is 
characterised by ST segment elevation. In rare cases, vasospasm may result in Prizmetal' s angina, 
which is generally distinguished by changes in the ECG including T wave inversion, although this is 
variable. 
ii) Myocardial infarction 
Myocardial infarction is due to partial or complete occlusion of a coronary artery, possibly by a 
thrombus, resulting in an ischaemic insult. Chest pain and ECG changes are evident, followed by 
more severe manifestations, including enzyme loss from ruptured cells. Cell death, or necrosis, occurs 
after about 15-20 min, with the beginning of an infarct. After 6 hrs, the infarct is probably fully 
developed i.e. the total area at risk (that perfused by the affected artery below the site of occlusion) is 
affected. Infarct size must be limited by reperfusing as much of the remaining viable tissue as 
possible. A myocardial infarct consists of a region of no perfusion with dead tissue, surrounded by 
tissue with a gradient of underperfusion. Collateral flow from the surrounding arteries, and residual 
flow through the affected area determine the limits of the infarct. The area surrounding an established 
infarct, or scar tissue, develops increased collateral arteries to improve perfusion. 
iii) Ventricular .fibrillation and sudden death 
The generation of ischaemia arrhythmias is complex, largely involving cAMP accumulation and 
subsequent cytosolic Ca2+ overload, resulting in disturbances in ion currents across the membrane 
329. Arrhythmias result from ischaemia of Purkinje cells, which become the focus of 
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arrhythmogenesis, with a disruption in atrio-ventricular conduction. Ventricular arrhythmias have a~so 
been attributed to electrically disturbed cells at the "border" of the ischaemic zone, arrhythmogenic 
substances released from the ischaemic zone, and circus movement, as the path of conduction is 
altered, and the refractory periods are disturbed 90, 336. Ventricular arrhythmias may then develop 
into fibrillation, resulting in complete cardiac failure and sudden death. The presence of an old infarct 
predisposes to arrhythmias, as the route of electrical conduction around the myocardium is affected. 
d) Experimental models of ischaemia 
Ischaemia has been investigated using a number of experimental models, each with specific 
characteristics. Ischaemia can be broadly categorised as either supply or demand ischaemia. These 
categories merge as deprivation of oxygen is prolonged, leading to irreversible changes. 
Hypoxic/anoxic models are also frequently used. However, despite the validity of most models, care 
must be taken in extrapolating between models, and to the clinical condition. 
i) Hypoxia vs. ischaemia 
The consequences of a reduced blood supply during ischaemia are an inadequate supply of oxygen 
and impaired washout of metabolic products. The effect of drugs, or changes in the composition of the 
blood in ischaemia are difficult to study because of the absence of flow in most models; therefore 
many studies have used hypoxia or anoxia which enable the effects of oxygen deprivation to be 
studied. In addition, isolated cell models can only mimic ischaemia, using hypoxia and metabolic 
inhibition. The continued delivery of substrate (unless removed) and other substances, as well as 
continued washout of metabolites, modulates the response of the hypoxic tissue compared to that of 
"true" ischaemia. These differences must be taken into account. 
ii) "Demand" ischaemia 
"Demand" ischaemia results from insufficient supply of oxygen to the heart following a reduction in 
blood oxygen content (from pulmonary complications - hypoxia; anaemia), or when the oxygen 
demand of the heart is increased (extreme exercise, excitement), generally with some degree of 
coronary narrowing 15. The latter is typical of angina of effort. Washout of metabolites is still 
present, which reduces the impairment. Pathologic increases in heart rate, metabolic rate 
(thyrotoxicosis, increased catecholamine secretion), left ventricular wall stress, inotropic state and 
preload (aortic stenosis, aortic insufficiency, diastolic hypertension, hypertension); all increase 
myocardial oxygen consumption and result in ischaemic heart disease if the coronary flow reserve is 
impaired. While this definition may now be a little outdated, it still has important implications. 
Experimental models of "demand" ischaemia include rapid pacing, increased preload, and 
hypertrophy. 
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iii) Supply ischaemia 
"Supply" ischaemia arises from reduced supply of oxygen to the tissues because of a reduced 
coronary flow. This is typical of coronary occlusion and resultant myocardial infarction 36, 530 and is 
by far the most commonly used experimental model. 
Regional ischaemia - results from a narrowing or obstruction of an artery, reducing perfusion in the 
area distal to the constriction 36. Experimentally, regional ischaemia is induced by ligation, usually of 
the left descending coronary artery. While this blockage may be fully reversible, a central area of 
necrosis may develop if sustained, surrounded by cells with varying severity of ischaemia. This model 
predisposes to the development of arrhythmias, and depression of left ventricular function, with 
reduced cardiac output and aortic pressure. The heart does not cease to beat. 
Global ischaemia - results from a shut down of total coronary blood supply. This is generally only 
found in experimental conditions, but occurs clinically following aortic cross clamp and 
cardiopulmonary bypass. This model in an isolated perfused heart allows study of a reasonably 
homogenous ischaemic tissue. Global ischaemia can either be total ( complete absence of coronary 
flow), or a low residual flow may be maintained using a lowered constant pressure or a constant flow 
infusion. This low flow can be termed the sum of residual and collateral flow to an ischaemic region 
in vivo. The term, residual, henceforth applies to the low flow supplied to the globally ischaemic 
isolated perfused rat heart model. 
iv) Model of global low flow ischaemia used in this thesis 
While the majority of isolated heart studies use total global ischaemia, low flow ischaemia allows a 
more clinically relevant evaluation of changes in ischaemia. However, the degree of low flow used is 
also important. The extent of residual and collateral coronary flow is important in determining the 
eventual recovery 485, and some flow is usually present, even with very severe in vivo ischaemia. In 
in situ pig or dog hearts, the normal coronary flow is about 1-2 ml/g wet wt/min, with differences 
between the endo-and epicardium, the latter usually better perfused. With a flow restriction, the 
endocardium is more at risk with flow restricted to 0.05-0.15 ml/g wet wt/min 360, 421 , 507, about 
2.5-15% of normal flow rates. 
In vivo flow rates in a rat heart are about 5-6 ml/min/g wet wt 279. In excised, buffer-perfused hearts, 
coronary flow is about twice to three times the flow in vivo (Langendorff mode less than working 
mode). The reduced oxygen-carrying capacity of the crystalline solution results in maximal dilation of 
the vessels, which in turn lack autoregulation 39. The flow rate is determined largely by the perfusion 
pressure. If the residual flow in ischaemia is set at about 10-20% of pre-ischaemic perfusion flow 
rates, this is equivalent to 20-40% or more of normal in vivo flows - enough to produce hypoxia, but 
not necessarily "true" ischaemia with greatly impaired washout. Lower flow rates more representative 
Literature review Ch I. Ischaemia 5 
of true "in vivo" ischaemic flow rates need to be investigated. This premise is the basis of the standard 
model used in this thesis. I have chosen 0.2 ml/g wet wt/min as a reference point, a rate which delivers 
sufficient coronary flow and substrate to allow some residual cell function, such that after a relatively 
long period of ischaemia, the hearts recover about 50-60% of pre-ischaemic mechanical function. 
However, under these conditions (with 11 mM glucose), a moderate but marked contracture (about 
40-50%) is seen. Thus both contracture and functional recovery can be either improved, or 
exacerbated. This flow rate represents a flow reduction to about 3-5% of normal in vivo flow rates in 
the rat, and about 1-2% of in vitro flow rates in the isolated organ. This flow rate is thus comparable 
with those in subendocardial ischaemia in larger animals, and more truly representative of ischaemia 
than flow rates more often used (0.5-0.6 ml/g wet wt/min 14, 123, 218, 389, 390, 424, 468, 469). 
While differences certainly exist between species ( cf. in vivo flow rates of rats vs. larger animals 
above) and there is also a significant difference between hearts perfused with crystalloid solution, 
compared to blood, at these very low flows, the rate of delivery and of washout between the different 
models becomes negligible. At flow rates of 0.5-0.6 ml/g wet wt/min, more divergence between the 
different models would be present as other factors could affect the response of the tissue (oxygen 
content, friction forces , oedema, other substrates, degree of ischaemia, autoregulation). 
e) Consequences of ischaemia 
i) Systolic vs. diastolic contractile failure 
"Demand" ischaemia leads to a rise in diastolic tension with reduced compliance. Insufficient high 
energy phosphates from increased utilisation leads to intracellular calcium accumulation and a 
reduced relaxation. Diastolic dysfunction leads to pulmonary dysfunction with shortness of breath, 
reduced relaxation, an upward shift of the diastolic pressure-volume curve and an absence of 
increased late systolic filling as compensation. A reduced cardiac output results. Systolic failure may 
also be present, with a shift in the pressure-volume relationship (less pressure generated for a given 
diastolic volume). Demand ischaemia may thus cause predominantly diastolic dysfunction with 
pulmonary congestion, with a reduced return of blood from the lungs to the heart because of reduced 
filling time. 
Systolic failure following supply ischaemia is accompanied by low cardiac output, left ventricular 
pump failure and reduced pump function. With total global ischaemia, the accumulation of 
metabolites including Pi and protons leads to contractile failure (see below), and the tissue becomes 
flaccid. As ATP falls, an increase in resting tension, or contracture (see below), follows, compounded 
by an increased intracellular Ca2+. On reperfusion, diastolic failure is often present as a result of 
contracture, and of calcium-induced depression of relaxation. Thus measurement of contracture can 
be used as a rough index of ischaemic injury. 
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ii) Functional recovery, stunning and necrosis 
The degree of functional recovery after an ischaemic period (supply ischaemia) is determined by three 
entities. On reperfusion, some function is usually restored immediately (non-injured tissue). Some 
tissue may be stunned. Stunning is strictly defined a transient, reversible depression in function 
following a brief period of ischaemia ( < 15-20 min), insufficient to cause necrosis 44. Reperfusion for 
a sustained period should result in full recovery of function. The period of reperfusion required can 
vary depending on the species and severity of ischaemia. The third determinant of recovery is the 
degree of injury to the tissue, i.e. alterations in ultrastructure, which may be reversible on reperfusion, 
or irreversible leading to necrosis. Irreversible injury occurs after 20-25 min or more. Broadly 
speaking, the relative degrees of fully recovered tissue, stunning, and of necrosis (infarct size), will 
determine the eventual outcome of a more prolonged period of ischaemia. In addition, reperfusion 
injury, that which occurs on reperfusion, but which appears to be directly related to the degree of 
ischaemic injury, determines the degree of recovery. Thus functional recovery is an index of 
ischaemic and reperfusion injury. The issues of reversible vs. irreversible injury, and reperfusion 
injury, are discussed more fully below. 
iii) Preconditioning 
Preconditioning is defined as one or more brief periods of ischaemia providing protection against the 
consequences of a subsequent sustained ischaemic episode. The interest in preconditioning has been 
extensive, as an endogenous mechanism of protection. This phenomenon alters the concept of 
ischaemia as a purely deleterious event, and it can now be seen to trigger protective actions. The 
concept therefore is that if an ischaemic episode must occur, it is preferential for this to be preceded 
by a brief episode of ischaemia to precondition the heart. A more clinically applicable method of 
preconditioning has been much researched, and is one of the issues discusses in this thesis with 
respect to glucose. 
2) ISCHAEMIC INJURY 
a) Ultrastructural changes in ischaemia 
Ischaemic injury ranges from fully reversible to irreversible cellular modifications, dependent on the 
duration and severity of ischaemia. Manifestations of ischaemic injury include changes in the cellular 
ultrastructure with membrane rupture, mitochondrial swelling, oedema, and shortening of the 
sarcomeres, with an overall reduction in contractile function 222, 484, 540. Patches of necrosis may 
be present, weakening the myocardial wall, and acting as a focus for arrhythmogenesis. Changes to 
the myocardium are caused by depletion of energy stores, accumulation of waste products, membrane 
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disruption. intracellular acidosis and Ca2+ accumulation, free radical activity, and activation of 
catalytic enzymes. The functional changes broadly reflect cellular changes. 
b) Reversible vs. irreversible injury 
Reversible injury implies that restoration of flow will lead to full recovery of tissue. Changes may be 
seen in the mitochondria and other organelles, but these disappear on reperfusion, although possibly 
with a lag time. Irreversible injury occurs with changes in the cellular components which are not 
reversed by reperfusion. Irreversible injury may be termed the changes in the cellular ultrastructure 
such that the cell will not recover full function, which can lead to cell death and permanent scarring. 
There is an continuum of ischaemia/reperfusion injury, from reversible to irreversible changes, and 
ultimately cell death. An increased duration of ischaemia means that a greater proportion of the area 
at risk becomes irreversibly injured. Using a totally globally ischaemic dog heart, with severe 
ischaemia (60 min), histological and biochemical evidence of cell damage is apparent (contraction 
bands, swollen mitochondria with loss of dense granules, leakage of extracellular enzymes). On 
reperfusion, recovery is very slow 484. These changes do not necessarily precipitate cell death. After 
90 min ischaemia, the damage is irreversible, with severe cellular distortion 456, 484. Cell death, or 
necrosis, is associated with loss of membrane integrity 456, occurring at the level of the individual 
cells and spreading to adjacent cells if ischaemia is maintained. Derangement of the cellular structures 
occurs, resulting in the development of an infarction with scar tissue 148. 
3) MECHANICAL CHANGES WITH FLOW REDUCTION 
a) Early contractile failure 
After the onset of total global ischaemia, developed pressure falls rapidly. The mechanism for early 
contractile failure is as yet not fully understood. A reduction in ATP is an obvious candidate -
however, the fairly slow rate of ATP depletion is not temporally correlated with rapid contractile 
failure 7. Inorganic phosphate (Pi) and protons (Ir) can also reduce contractility 31, 284, and are 
likely candidates for pump failure . Pi binds to sites in the myofilaments inhibiting actin-myosin 
binding, resulting in less cross-bridge formation and reduced force development. Pi may also decrease 
SR Ca2+ loading and thus decrease Ca2+ dependent Ca2+ release, and thus reduce contractility 592. Ir 
compete for Ca2+ binding sites, such that for a given concentration of Ca2+, less tension is developed 
288. The mechanical influences of a reduced vessel turgidity following vascular collapse may also be 
important 560. With a reduction in filling pressure, the stiffness and stretch are reduced - the so-called 
"garden hose" effect. 
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The trigger for contraction, the action potential, is affected by ischaemia. A slowed rate of rise of the 
upstroke of the action potential and slower conduction velocity reduces Ca2+ influx into the cell and 
Ca2+-induced Ca2+ release from the SR 130. Ischaemia induces a rapid membrane depolarisation 
attributed to rapid K+ efflux, mediated in part by the KATP channel 233. Extracellular K+ may increase 
to about 15 mM, changing the membrane potential to -50 m V 258 at which the 'membrane is 
inexcitable. Cell-to-cell uncoupling also occurs reducing excitability. 
b) Ischaemic contracture 
After 5-10 minutes of total global ischaemia in an isolated perfused heart, developed pressure is 
usually absent. After 10-15 min a rise in resting tension (ischaemic contracture) develops 189. 
Ischaemic contracture is defined as a rise in resting tension over time, with shortening of the muscle 
and increased stiffness. Contracture is a useful index of cell injury, linked to ATP depletion and Ca2+ 
accumulation 42, 184, 189, 271, 511, and is a possible predictor of functional recovery 32 ( see below 
for discussion). If perfusion is restored before the onset, or in the early stages, of ischaemic 
contracture, recovery should be virtually complete 7, 484. However, if contracture is well established, 
developed pressure does not recover fully on reperfusion. 
Cell damage may be accelerated by reperfusion, with extensive enzyme release 192, 406. Reperfusion 
may lead to contraction band formation, with excess Ca2+ entry through fragile membranes 148. 
Contraction bands are a pathological feature of severely injured myocytes 14 7. Regions of the 
sarcomere become disrupted, with aggregated clumps of actomyosin. 
4) CHANGES IN METABOLISM IN ISCHAEMIA 
a) Hypoxia vs. ischaemia - the role of oxidative phosphorylation 
In hypoxic hearts, developed pressure falls by about 70%, but may remain stable for about 30 min. 
The immediate consequence of a reduced oxygen supply is a rapid inhibition of oxidative 
phosphorylation, and reduced ATP production. However, anaerobic glycolysis is stimulated 20-fold in 
the first minute (in dogs) via reversal of the Pasteur effect, and can be maintained at this level if 
substrate is available 276. With only 2 ATP mol vs. a maximum of 38 mol per mol glucose produced 
under aerobic conditions, this is a temporary measure. Hypoxic hearts gradually weaken as ATP 
production cannot keep up with demand. Alternatively, pump function may be lowered to meet 
reduced supply but eventually hearts are impaired by insufficient ATP. 
In ischaemia, the reduction in function is rapid. NADH increases rapidly, lowering the redox 
potential. Some residual oxidative phosphorylation may continue, with CO2 accumulation. Glycolysis 
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may be stimulated initially, but declines rapidly. While cellular strategies exist to reduce ATP 
utilisation, ATP content falls rapidly. 
b) Energy balance 
Protective mechanisms activated to conserve available energy include K+ efflux to inhibit electrical 
activity, a fall in pHi which reduces Ca2+ binding, a decrease in contractile force , and cessation of 
contractile function mediated by Pi. The balance of supply and demand may be maintained for a brief 
period, especially with the breakdown of CP 50. Energy production is dependent on substrate 
availability. Neither free fatty acids nor lactate can be utilised because oxygen is required, thus 
glucose and glycogen become the primary substrates. As ischaemia progresses, energy production is 
lowered as substrate levels fall . 
i) Creatine phosphate 
Although ATP is rapidly utilised with ischaemia, the levels do not fall as fast as would be expected. 
This is due to creatine phosphate utilisation (CP), which buffers the level of ATP for a few minutes 
via creatine kinase (CK) activity (see appendix). The fluxes through this reaction are very rapid. 
Reductions in ADP and Pi lead to marked shifts from CP to ATP. CP falls very rapidly as ATP is 
hydrolysed, to 20% of normal values in 1-3 min ischaemia 276. Once CP is depleted, ATP levels drop 
rapidly. Pi levels increase linearly with a breakdown in CP 276, affecting contractile function. Thus 
rates of CP breakdown may be a major determinant of the rate of contractile failure. 
ii) ATP production and utilisation 
ATP is required for virtually all cellular processes, including contraction, 10n regulation, and 
membrane integrity. In the first few minutes of total global ischaemia in an isolated rat heart, ATP 
falls to about 3 µmol/g wet wt (about 40-70% of basal). This level remains fairly stable for a few 
minutes, until a second rapid decrease occurs 189. For many years, a "critical level" of ATP was 
sought as a determinant of recovery 189,456. However, values for this critical level of ATP differed 
widely (2 µmol/g wet wt 189, 276; 0.4-0.6 µmol/g wet wt 223 etc. - see 408 for further discussion). 
Total tissue ATP appears to give little indication of the ability of the tissue to recover 278, 387. Neely 
et al. 387 reported a wide range of functional recoveries after 30 min ischaemia, but with little 
difference in adenine nucleotide levels. This lack of correlation has been attributed in part to 
compartmentation of ATP (see Ch. II), and the involvement of the many other factors altered by 
ischaemia (see below). Only if ATP values are very low can it be reasonably surely predicted that 
recovery will be largely impaired. 
In addition to the absence of correlation of ATP levels and recovery, several processes are known to 
occur in ischaemia e.g. opening of KATP channels, and formation of rigor cross-bridges, occur in vitro 
10 Literattrre review Ch I. Ischaemia 
only at very low ATP concentrations, far less than gross tissue levels e.g. the Km for rigor formation 
is 0.05 mM 131. This effect can be attributed to the heterogeneity of ischaemia, with different rates of 
ATP depletion in different cells. In addition, different rates of ATP utilisation within the cell, and 
breakdown of processes for ATP transport, can result in localised areas of ATP depletion below 
critical levels. Total tissue ATP reflects the mean value of many cells at different stages. 
Functional compartmentation within the cell also affects ATP utilisation (see Ch II). Certain 
membrane processes, including inhibition of the KA r P channel 571 , maintenance of the integrity of the 
membrane 49, and maintenance of the Na+/K+ ATPase pump 167, appear to utilise glycolytic ATP 
preferentially. The location of glycolytic enzymes, attached to the sarcolemma 434, may account for 
this preference. The mitochondria are closer to the sarcomeres - thus it is postulated that ATP from 
oxidative phosphorylation is utilised more by the contractile elements 570. The concept of 
compartmentation is crucial to understanding many of the observations of protection by glucose and is 
discussed in depth in Ch II. 
In addition to compartmentation, a given amount of ATP in ischaemia may be less efficient when 
broken down than it would be under normal conditions. The free energy change with hydrolysis of 
ATP is reduced as ADP and Pi rise, even though there may be no change in the concentration of ATP 
7,235 (see appendix). A fall in ATP will further reduce the free energy change. Each ATP-dependent 
process requires a different free energy change 7, thus some processes are more affected by others. 
The affinity of various cellular processes for ATP may also be altered in ischaemia, such that ATP 
binding is reduced, and the efficacy of ATP lessened. These effects all contribute to the lack of 
correlation of ATP levels with cellular changes. 
iii) Adenosine production 
With continued ATP hydrolysis without metabolite recycling, adenosine accumulates. Adenosine is 
an important regulator of Ca2+ entry, glycolysis, and vessel contraction 372. As ischaemia is 
prolonged, adenosine is broken down into inosine, xanthine and hypoxanthine, which may contribute 
to free radical genesis on the reintroduction of oxygen 346, although this mechanism has been 
disputed in the human heart because of the lack of xanthine oxidoreductase activity 436. On 
reperfusion, the adenine nucleotides are washed out reducing their availability for build-up of the 
depleted stores of ATP 455. This effect contributes to poor recovery on reperfusion. 
Breakdown pathway of ATP to adenosine and other products: 
ATP ~ ADP+ P04·+ tr~ AMP+ po4· +tr~ Adenosine + Po4· + tr 
Adenosine ~ lnosine ~ Xanthine ~ Hypoxanthine 
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c) Glycolytic ATP production 
i) Glycolysis 
11 
Glycolysis and glycogep.olysis are an important source of energy in compromised cells. In hypoxia, or 
with a relatively high residual flow, glycolytic metabolites are washed out, allowing glycolysis to 
proceed at a high rate· 389. In severe or total ischaemia, glycolysis falls rapidly within 2-3 min, 
although a residual flow can provide glucose to maintain flux but at a rate lower than control. The 
small amount of ATP produced from residual glucose delivery and endogenous glycogen is crucial for 
recovery of the ischaemic tissue 404. The rate of glycolysis then becomes dependent on the 
availability of glucose and glycogen. 
i i) Glucose vs. glycogen 
Glucose availability is determined by the coronary flow and its concentration in the perfusate. When a 
molecule of glucose is anaerobically broken down, 2 lactate + 2 ATP are produced. After breakdown 
of ATP, the total sum is 2 lactate + 2 ADP+ 2 Ir. When glycogen is broken down into C6 units and 
subsequently catabolised by glycolysis, the end products are 2 lactate + 3 ATP, or 2 lactate+ 3 ADP + 
2 Ir. Glycogen should therefore be more advantageous as an energy source. However, glycogen 
depletion prior to ischaemia has been shown to increase recovery of function 387 possibly by a 
reduction in lactate and Ir accumulation, although this is very controversial (see Ch. II). Many 
studies indicate a beneficial role of glucose, also a source of lactate and Ir. This paradox remains to 
be explained. The roles of glucose and glycogen are discussed in depth in Ch. II. 
5) ION REGULATION IN ISCHAEMIA 
a) pH 
i) Source and removal of protons 
pH falls rapidly from the onset of ischaemia (after an initial transitory rise due to CP breakdown) 
from about 7.2 to 7.05 by 5 min, and 6.5 by 15 min 76. After an hour, intracellular pH may drop as 
low as 5.8 76. Ir accumulation is due mainly to continued ATP hydrolysis with reduced ATP 
regeneration 107, 156. While there is some controversy over this point 584 with the view that Ir 
come from lactic acid production, the pKa of lactic acid (3 .9) suggest that only 0.08% of the total is 
lactic acid at physiological pH 156. The sum for ATP production from glycolysis shows that Ir 
production is balanced by consumption 107, 156. Ir may also come from CO2 produced by residual 
oxidation, from adenosine breakdown, and from increased NADH + Ir production without re-
oxidation to NAD+ 107. 
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Intracellular pH is partially dependent on the buffering capacity of the myocyte, which is determined 
by the COi HC03- system, phosphate concentration, lactate and pyruvate, and proteins. The 
myofilaments, SR and mitochondria also buffer pH. The total buffering capacity (62 mM) is made up 
of the intrinsic buffering capacity (mainly from histidyl residues - about 40 mM), from CO2 (14 mM), 
and from Pi (8 mM) 545. Increases in Pi and lactate should increase the buffering capacity in 
ischaemia, but this is counteracted by the increased Ir load. 
Mechanisms to remove Ir include the Na+/Ir and the Cr/HC03- exchangers of the sarcolemma. At 
normal pH, the Na+ /Ir exchange removes intracellular Ir, while the cr/HC03- exchange mediates Ir 
influx. The Na+ /Ir exchanger becomes important particularly on reperfusion, when a [Na +]i load 
results from acidosis 119. Lactate and Ir also exit the cell in a co-transport. An increased 
extracellular lactate inhibits this efflux 239, resulting in intracellular acidosis 102. 
ii) Deleterious effect of proton accumulation 
A drop in pHi may initially be protective by combating the effects of increased [Ca2+]i, as Ir compete 
with Ca2+ for intracellular binding sites 288. Acidosis may protective in hypoxia 31 by reducing 
contractility and conserving ATP, although there is little correlation between the time course and 
extent of depression of mechanical function with acidosis 345, suggesting that acidosis is not involved 
in contractile failure in these hearts 7. In ischaemia, an acidotic cardioplegic solution offers more 
protection than an alkaline solution 564, while reperfusion with an acidotic solution is also beneficial 
257, 306. Acidosis may inhibit 5' nucleotidase, and thus help to preserve adenine nucleotide levels in 
ischaemia, and enhance resynthesis of ATP on reperfusion 20. However, too great a drop in pH 
activates proteases and lipases, reduces sarc'olemmal binding, and alters many pH-dependent 
processes 89. Increased intracellular Ir accumulation may also increase Ca2+ influx via the Na+/Ir 
and Na +/Ca2+ exchange mechanisms 303, a major factor in reperfusion injury. On reperfusion, while 
restoration of intracellular pH is mediated primarily by lactate and CO2 washout, with Na+/Ir 
exchange contributing only about 35% to total Ir efflux 545, about 5 mmol/1/min of Na+ enters in 
exchange for the Ir, which would make a large contribution to Ca2+ overload 545. 
Despite many reports implicating Ir accumulation in ischaemic injury 239, 240, 387, the drop in pHi 
during ischaemia is not well correlated with recovery of function 92, 151, 306. While a drop in pHi 
may contribute to ischaemic injury, this effect may be outweighed other, more significant factors 306. 
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b) Calcium 
i) Cellular role of calcium 
Ca2+ is central in the regulation of myocyte function 157, 330, 441 and is thought to be the major 
mediator of ischaemic and reperfusion injury 405, 412, 413. Ca2+ modulates the rate of ATP 
utilisation and contractile activity, and maintains the integrity of the plasma membranes 144 and the 
intercalated discs 461 . Ca2+ regulates excitation-contraction coupling, transmembrane ionic current 
flow. and mitochondrial respiration. The main cellular compartments of Ca2+ are the myoplasm, the 
SR and the mitochondria, and that bound to membrane phospholipids and proteins. 
In ischaemia, an excess influx of Ca2+ is thought to occur 4, 251, 374, and the ability of the cells to 
handle the load is reduced 356. Although absolute values do not necessarily increase, particularly in 
the fust 5-10 min, the distribution of Ca2+ within the cell may change with release of Ca2+ into the 
cytosol 230, 356. Cytosolic Ca2+ subsequently increases in an almost linear fashion 510. However, 
due to technical difficulties associated with measuring intracellular concentrations, the precise 
changes that take place are not fully understood. Glycolytic flux may be crucial in ischaemic Ca2+ 
regulation 87,229 as re-uptake mechanisms are dependent on ATP 593. 
ii) Ca2- release into cytosol 
Ca2+ enters the cell via the L-type Ca2+ channel during the action potential 78, and stimulates Ca2+ -
induced Ca2+ release from the SR 130, the Ca2+ thought to be responsible for initiation of contraction. 
The size of the Ca2+ current determines the amount of Ca2+ released by the SR. The SR Ca2+ release 
channel is the site of ryanodine binding 467. Ca2+ release by this mechanism is altered by a number of 
factors including pH (acidosis inhibitory) and ATP (stimulatory). Inositol (1,4,5)-trisphosphate (IP3) 
from stimulation of a receptors, also induces Ca2+ release from internal stores, but acts on a different 
receptor 124. Cyclic ADP-ribose, a compound derived from NAD+ stimulated by cGMP, may also 
enhance Ca2+ release from the SR 146, although its role in the heart has not been clarified. Free fatty 
acids may exert some harm by increased Ca2+ entry. Long chain fatty acids activate sarcolemmal Ca2+ 
channels 207 as does lysophosphatidylcholine, a fatty acid metabolite 589. Release of Ca2+ from the 
SR may contribute to stunning 356 although this has been disputed 238. 
iii) ca2+ removal from the cytosol 
Intracellular Ca2+ levels are tightly controlled against a large extracellular concentration. The Ca2+ 
entering via the channels must be all extruded if equilibrium is to exist. Ca2+ can be removed from the 
cytosol in several ways; either extruded from the cell into the extracellular space, or taken up into 
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intracellular stores (mainly SR). Ca
2+ can also bind to intracellular buffers, or be taken up by the 
mitochondria. 
Extrusion of Ca2+ from the cell is accomplished by two mechanisms - the sarcolemmal Ca
2+ A TPase 
pump, and the Na+/ Ca2+ exchange. 
The sarcolemmal Ca
2+ ATPase pump has a low maximum transport rate with a low capacity, but a 
high affinity for Ca2+. The sarcolemmal Ca
2+ pump seems relatively unimportant in cardiac muscle. 
The Na+/ Ca2+ exchange has a relatively low affinity for Ca
2+, but a high capacity, with a 
stoichiometry of 3 Na+:l Ca2+ 125. The Na+/ Ca
2+ exchanger serves mainly as a means of Ca2+ 
extrusion under normal conditions, removing about 30% of the Ca
2+ from the cytoplasm during 
relaxation, approximately the amount of Ca
2+ entering via the Ca2+ channels of the sarcolemma - a 
requirement for steady state. A change in [Na +]i has a direct and immediate effect on contraction. The 
Na+/ Ca2+ exchange can also mediate Ca
2+ influx when the gradients for Na+ and Ca2+ are reversed, as 
occurs in ischaemia. 
The exchange is activated by depolarisation leading to increased Ca
2+ entry, ATP 183 (decreases the 
Km for Ca2+ possibly by phosphorylation), and phospholipase C and D activity. The exchange is 
inhibited by a reduced pH 433, and inorganic cations including Mg
2+. 
SR Ca2+ ATPase pump - the SR Ca
2+ pump has a high affinity and high capacity, and utilises 1 ATP 
per 2 Ca2+. The amount of Ca
2+ available for release from the SR pool for contraction is dependent on 
cytosolic Ca2+ availability, and the activity of the Ca
2+ re-uptake mechanisms. This pump is largely 
responsible for lowering cytosolic Ca
2+ levels (70% of total), and its activity determines the rate of 
relaxation. Phospholamban, activated by protein kinase A in response to catecholamines, stimulates 
the pump by lowering the Km (Ca2+) 520, causing release of Ca
2+ into the lumen of the SR, increasing 
pump efficiency and accelerating relaxation. 13 stimulation may bias Ca
2+ extrusion such that uptake 
by the SR pump exceeds extrusion to the extracellular space. The size of the SR Ca
2+ pool will 
increase, allowing increased Ca2+ release on stimulation, and enhanced contractility 54. 
SR Ca2+ pumps are highly dependent on ATP 56. The large concentration gradient between the 
cytosol and the SR (9-14 mM vs. 125 nM in diastole) requires a highly efficient, but highly energy-
dependent pump. If SR Ca2+ ATPase pump activity is reduced (reduced ATP concentration, reduced 
free energy of hydrolysis by ischaemia), the SR Ca
2+ pool becomes depleted and cytosolic Ca
2+ may 
rise 499, with a slowing in relaxation. The SR pump is also sensitive to pH as W compete with Ca
2+ 
for binding sites. The SR Ca2+ ATPase can be inactivated by altered phospholamban phosphorylation 
as well as a specific loss in A TPase activity 492. 
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iv) Changes in intracellular Ca2+ in ischaemia 
An increased cytosolic Ca2+ is a primary candidate for ischaemic injury 4, 374, 405, 412, 413 
Inhibition of Ca2+ re-uptake or extrusion mechanisms increase cytosolic Ca2+ 72, 356, 559 . In 
addition, Ca2+ enters down its diffusion gradient through membranes made leaky in ischaemia by 
reduced phosphorylation 70, 383 and acidosis lowers the affinity of the Ca2+ binding sites of the 
various Ca2+ buffering proteins 30, 263 . Intracellular Ca2+ overload also reduces the stability of the 
cell membranes, and Ca2+-dependent phospholipases in the membrane may be activated 461 . Lipid 
peroxidation ensues, with the appearance of holes in the lipid bilayer, through which intracellular 
enzymes are lost. Conformational changes in the membrane may also occur with inhibition of 
sarcolemrnal ATPase activity 315. Ca2+-sensitive proteases may also be activated 3 83 , 461 . 
v) Mitochondria 
A significant consequence of intracellular Ca2+ overload is changes in the mitochondria. A Na+/ Ca2+ 
exchanger is present on the inner membrane of the mitochondria, as well as a Na+ /Ir exchange 
mechanism and a Ca2+ uni port 7. Ca2+ entry via the uniport exhibits a sigmoid dependence on 
intracellular Ca2+ concentration, with a Km >30 µM for Ca2+. At normal [Ca2+]i, (0.1-1 µM) the influx 
pathway is at a relatively low level. Ca2+ accumulates in the mitochondria at the expense of ATP via 
the Ir gradient of the electron transport chain 56 (the proton motive force) , the same as that used to 
convert ADP to ATP. Thus, when intramitochondrial Ca2+ increases, ATP production is reduced. 
If ischaemia is prolonged, calcium phosphate granules may be deposited in the mitochondria, 
uncoupling oxidative phosphorylation and inhibiting mitochondrial recovery on reperfusion 222. 
Energy production on reperfusion is affected, as well as predisposing to free radical generation as the 
oxygen levels are not reduced by mitochondrial respiration 602. 
vi) pH and Ca2-
pH is a major modulator of Ca2+ action in the cell, and thus in ischaemia 52, 382, 383, 597. Ca2+ and 
H+ compete for binding sites 25, 288, 442, such that acidosis has a negative inotropic effect 126 by 
binding to the troponin C of the myofibrils and decreasing the sensitivity of the troponin-tropomyosin 
complexes to Ca2+ 23 , 69. A fall in pHi of 0.2 units reduces developed tension by about 50% 440. 
Even at saturating levels of ca2+, Ir reduce the maximum tension developed 126, 288. 
SR Ca2+ ATPase activity is reduced at low pH 6, 25 and the Na +/Ca2+ exchanger is also inhibited by 
acidosis 433 . Ca2+ binding to phospholipids is reduced with a lower pH 288 with release of Ca2+ into 
the cytosol. Cell-to-cell coupling may be affected by acidosis with a reduction in junctional 
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conductance 105, 442. Thus under ischaemic conditions, Ir may only partially antagonise the 
deleterious effects of Ca2+. 
c) Sodium 
Intracellular Na+ is normally at a concentration of 10 mM. Influx of Na+ occurs mainly via voltage-
dependent channels, and exchangers, such as the Na+/Ca2+ and Na+/Ir exchange mechanisms. These 
exchangers are reversible, depending on the gradients, and membrane potential. The Na+ /K+ ATPase 
pump is responsible for maintaining the gradient by extruding Na+ in exchange for K+ (3 Na+/2 K+ per 
ATP). The pump activity is largely dependent on ATP. Inhibition of the pump by decreased ATP 
levels will tend to increase [Na +Ji. The major consequence of an increase in [Na +Ji is the subsequent 
increase in [Ca2+Ji. Developed tension is thus strongly dependent on Na+. 
A decreased intracellular pH increases [Na+Ji via the Na+/Ir exchanger, which leads to subsequent 
Ca2+ accumulation, when Na+ is extruded in exchange for Ca2+ via the Na+/Ca2+ exchange 30, 303. 
During ischaemia, with a reduced intra- and extracellular pH, the Na+/Ir exchanger may be inhibited 
212. On reperfusion, however, this mechanism becomes extremely important 119. [Na+]i 
accumulation may have other detrimental effects including increased osmolarity and cell swelling, as 
well as disturbing the ionic gradients for the generation of action potentials. 
d) Potassium 
K+ efflux and extracellular accumulation are primary consequences of ischaemia 139, 258. Increased 
extracellular K+ lowers the resting membrane potential and reduces the amplitude and duration of the 
action potentials 232,258, 336, 366. Loss ofK+ is complex 583, but partially attributed to an efflux of 
K+ down its concentration gradient through the semi-permeable membrane and the KATP channels 
which are normally blocked by ATP 236. In addition, the Na+/K+ ATPase pump, which normally 
restores the K+ gradient, is inhibited by a reduced ATP. 
Provision of glycolytic ATP has been closely linked to inhibition of the KATP 571. With a reduction of 
glycolytic activity, the channel opens, despite a high overall ATP concentration 571 . Specific blockers 
for this channel e.g. glibenclamide may be protective by reducing arrhythmias 236. Maintaining 
inhibition of this channel may be an important function of glycolysis. However, the role of this 
channel is unclear, given that KATP openers e.g. chromakalim, pinacidil, have cardioprotective effects 
170 and preconditioning may also act by opening KATP channels 172. K+ efflux via this channel, by 
depolarising the membrane and inhibiting excitable activity, may be a defensive mechanism whereby 
energy is conserved - the heart is effectively "arrested". 
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e) Inorganic phosphate 
Pi starts to rise as soon as there is a net breakdown of CP and ATP, and exerts a major depressant 
effect on tension 246, 284. Pi accumulation decreases maximal force output for a given increase in 
Ca2+. The most prominent effect is observed at concentrations below 10 mM. If normal Pi is 1-3 mM, 
increasing to 20 mM in ischaemia or hypoxia, maximum Ca2+ activated tension falls by about 50%. Pi 
also shifts the pCa curve rightward, although not to a large extent 245. Pi reduces force development, 
possibly by reducing the percentage of force generating cross-bridges. Accumulation of Pi also 
reduces the free energy of hydrolysis from the available ATP 234, and may thus reduce SR Ca2+ 
loading and decrease Ca2+ induced Ca2+ release 592. 
6) SIGNAL TRANSDUCTION PATHWAYS IN ISCHAEMIA 
Most of the cell signalling systems regulate intracellular ca2+, which rise in ischaemia. The signalling 
systems are affected by ischaemia, and contribute largely to ischaemic injury. Preconditioning (see Ch 
III) acts on several of these signalling pathways, which in turn are also involved in regulation of 
metabolism. 
a) J3 adrenergic stimulation and cAMP 
13 adrenergic receptor stimulation activates a GTP binding protein (Gs) which activates adenyl cyclase 
and produces cAMP. cAMP in turn activates the cAMP-dependent protein kinase (PKA), which is the 
final messenger in the signal pathway initiated by 13 receptor stimulation. The enhanced myocardial 
contractility associated with 13 stimulation is mediated via 131 receptors. PKA has several effects, 
including phosphorylation of the L-type Ca2+ channel, increasing the opening probability of the 
channel and hence increasing the Ca2+ current. Gs may also exert a direct effect on Ca2+ channel 
activity 277. While single channel conductance is not altered, the number of active channels in the 
sarcolemma may be increased 277,531. The result is that the Ca2+ transient is much larger and faster, 
with a subsequent increase in cardiac contraction. An anomaly in the effect of J3 stimulation is that 
cAMP reduces the Ca2+ sensitivity of the myofilaments by phosphorylation of troponin I, and thereby 
promote the rate of relaxation. The increased lea increases the amount of Ca2+ released by the SR via 
Ca2+-induced Ca2+ release 54, 130. Because more Ca2+ enters the cytosol with each action potential, 
SR Ca2+ ATPase activity must be increased to ensure relaxation. PKA phosphorylates 
phospholamban, the regulatory protein of the SR pump, thus a larger fraction of the cytosolic Ca2+ 
pool is taken up during relaxation, which is subsequently available to enhance contraction on 
stimulation. 
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The increased energy demand with the increased inotropic state can increase oxygen consumption_ 
dramatically. 13 receptor activation increases the metabolic rate and rate of glycogenolysis via PK.A. 
PK.A activates phosphorylase b kinase, which in turn activates phosphorylase b, resulting in increased 
glycogen breakdown for high energy phosphate production. 
In ischaemia, the lack of ATP causes release of noradrenaline from neuronal storage vesicles 490. The 
density of 13 receptors on the sarcolemma is increased, and adenyl cyclase activity, possibly mediated 
by protein kinase C (PKC) 277, is enhanced. Thus cAMP levels rise in ischaemia after five to ten 
minutes of coronary occlusion 531, peaking at 10-20 min. An increased cAMP is hypothetically 
deleterious by increasing cytosolic Ca2+ and predisposing to arrhythmias 329,437,531. The increased 
energy utilisation following increased contractility with cAMP may increase the cytosolic free fatty 
acid concentration, with the production of arrhythmogenic lysophospholipids 531 which in turn 
increase cytosolic Ca2+ levels by acting on Ca2+ channels 207, 589. cAMP levels are also decreased in 
preconditioned myocardium 479 (see Ch III). 
b) a adrenergic stimulation and the IPy'protein kinase C pathway 
a adrenergic receptor stimulation initiates the inositol polyphosphate cascade acting via a Gs protein 
209. Gs binds to phospholipase C which catalyses the conversion of phosphatidylinositol 4,5-
bisphosphate (PIP2) to 1,2-diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG remains 
in the membrane, where it activates protein kinase C (PKC) 526, a Ser-Thr kinase with many cellular 
actions. IP3 mediates the release of Ca
2+ from intracellular stores acting on a specific IP3 receptor 213. 
lP3 is then broken down in a cascade ofreactions to inositol. Several other phosphoinositols (IP4, IP5, 
IP6) exist, the functions of which are not fully clarified. IP3 is an important regulator of intracellular 
Ca2+. IP3 levels fall during ischaemia, but rise rapidly on reperfusion 369, and may be involved in the 
deleterious rise in Ca2+. al blockade has been shown to decrease the rise in cytosolic Ca
2+ in 
ischaemia, and attenuate reperfusion injury 365. 
PKC has a number of isozymes (at least eleven) 514, which regulate cellular processes by 
phosphorylation. PKC requires phospholipids such as phosphatidyl serine and may also need Ca
2+. 
PKC regulates cellular Ca2+ levels, and has a feedback effect on the phosphoinositol system 396. PKC 
~ay act on a large number of substrate proteins including Ca
2+ ATPase, Na+ /K+ ATPase, Na+ !Ir 
exchange system, the glucose transporter, troponin T and I, myosin light chain, glycogen synthase, 
glycogen phosphorylase kinase, phosphofructokinase, 13-adrenergic receptor, insulin receptor and 
many others 396. PKC has been implicated in the regulation of contraction, by phosphorylation of 
substrates and modulation of calcium and other ion levels with inotropic and chronotropic effects, 
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gene expression, secretion of cardiac factors and hypertrophy. PKC often has effects similar to PKA, 
for instance PKC also phosphorylates phospholamban. PKC activation may sensitise the adenyl 
cyclase, resulting in cross talk between the two systems 515 . PKC may modulate cAMP and 
calmodulin-dependent protein kinases. Increased al receptor stimulation also increases adenosine 
production 255 . 
In ischaemia, the number of a receptors increases 443. a stimulation in ischaemia has arrhythmic 
effects 443 . a I blockade attenuates adenosine release from ischaemic myocardium, possibly via 
reduced PKC activation which would normally activate 5'-nucleotidase ( enzyme responsible for 
adenosine production from 5' -AMP) 256. PKC can also be translocated to the membrane in ischaemia 
independent of al-stimulation 515. PKC activation aggravates hypoxic injury by stimulating Ca2+ 
overload, possibly secondarily to accelerated Na+ II-t exchange activity 211 . However, 
preconditioning induces PKC translocation, and this has been linked to its protective effects 60 I (see 
Ch III). 
c) Adenosine 
Adenosine, formed from the breakdown of ATP, is an important cellular messenger, with both intra-
and extracellular effects. Adenosine is a potent local vasodilator, increasing oxygen delivery to the 
heart 26,277. It has a very short half life (ls), therefore its effects are very localised 371. Adenosine 
acts via Al or A2 receptors (an A3 receptor has also been proposed 16). Al receptors are generally 
found on the myocyte and nodes, while A2 receptors are located in vascular smooth muscle. A 1 
receptors bind to Gi proteins, which affect a variety of systems, including adenyl cyclase, 
phospholipase A2 and C (activates PKC), K+ and Ca2+ channels, guanylate cyclase and Na+/Ca2+ 
exchange. KArP channels are specifically activated by adenosine 254. Adenosine is anti-adrenergic by 
inhibiting both norepinephrine release 460, and adenyl cyclase activity 255. These energy-sparing 
effects inhibit ATP degradation 596. A2 receptor activation, however, stimulates adenyl cyclase, 
enhances phospholipase C stimulation, and KArP channel opening. Adenosine may also inhibit 
neutrophil activation and preserve endothelial cell integrity. 
Increased adenosine may be protective in ischaemia, an effect mediated by Al rather than A2 
receptors 292. Al stimulation decreases cAMP in nodal tissue and the myocytes, whereas A2 
stimulation increases cAMP in vascular smooth muscle. Adenosine reduces energy utilisation by 
reducing contraction, and depressing heart rate 372, and may also be involved in glucose uptake and 
stimulation of glycolysis, although this is controversial. Some reports find that adenosine stimulates 
glucose utilisation 333 , 591 ; others finds that adenosine limits or inhibits glycolysis 134, 135, 141 , 
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546, 573 or fail to show any difference in glucose uptake with adenosine 96. Stimulation of glycolysis 
by adenosine may only occur in the presence of insulin 295,296. 
Determination of ATP, glycogen and lactate in dog hearts show that adenosine slows the rate of ATP 
depletion, glycogen utilisation and lactate accumulation during ischaemia 546. The potent 
vasodilatory effect of adenosine increases the delivery of substrate to the myocardium, and improves 
washout. Inhibition of adenosine breakdown by an adenosine deaminase inhibitor, and reduced 
washout by using a nucleoside transport blocker, is also beneficial with reduced stunning in dogs 606. 
This finding suggests that enhanced levels of endogenous adenosine, acting intracellularly, is 
beneficial. Adenosine is one of the most studied mechanisms of preconditioning protection (see Ch 
III). 
d) Nitric oxide and cGMP 
Nitric oxide is a short-lived molecule freely permeable to cell membranes, inactivated by oxidation. 
NO is produced by endothelial cells by NO synthase acting on L-arginine, and causes vasodilation 
( endothelium-derived relaxing factor - EDRF). Many of the effects of NO are mediated by Ca2+ and 
cGMP. cGMP is derived from GTP by the action of guanylate cyclase, which is stimulated by NO 
138. cGMP regulates levels of cyclic ADP-ribose (cADPR) 29 which is derived from NAD+. cADPR 
mobilises Ca2+, by causing release of Ca2+ from internal stores, possibly acting on the ryanodine 
receptor 146. The role ofthis compound in the heart is not as yet clear. 
Depre et al 109 reported a rise in cGMP in ischaemia and hypoxia. An inhibitor of NO synthase, L-
NAME, reduced cGMP levels in ischaemic tissue, and was protective to the ischaemic heart 110 
delaying the onset of ischaemic contracture and increasing functional recovery. These effects were 
associated with increased glucose uptake. However, administration of 8-bromo-cGMP, an analogue of 
cGMP had no effect, implying that these effects were not mediated by cGMP. These results were 
corroborated 118, but the role of the NO pathway is still largely unresolved. 
7) ISCHAEMIC CONTRACTURE 
I have used contracture as an index of ischaemic injury throughout this thesis, but its initiation and 
development are not simple indices of injury. Because of the complexity of the phenomenon, 
contracture is discussed in depth with reference to available literature. A hypothetical model of 
contracture, with specific reference to the role of glycolysis based on the findings of this thesis, is 
presented in the discussion. 
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a) What is contracture? 
i) Definition 
Contracture is defined as an increase in resting myocardial stiffness with shortening of myofibrils. In 
total global experimental ischaernia, the whole heart contracts slowly over time, with a rise in 
intraventricular pressure. Contracture develops in ischaernia or with metabolic inhibition. 
ii) Clinical correlate 
Myocardial ischaernic contracture was first described as a clinical manifestation, the "stone heart" 86. 
Following open heart surgery with cardiopulmonary bypass, the development of "a small spastic 
heart" "literally frozen in systole" was described in some patients following prolonged ischaemia 86_ 
This condition was said to be analogous to rigor in skeletal muscle 242, and is linked to rigor mortis 
327_ Increased myocardial stiffness was reported in patients with angina, with increased ventricular 
end-diastolic pressure 22. These changes were reversible, but indicative of sustained contraction, or 
failure of relaxation of a portion of the left ventricle during angina. This finding was attributed to 
contracture of the affected tissue. 
iii) Time course of contracture 
Following initiation of total global ischaernia in an isolated heart, contractile activity ceases, and 
pressure development is absent. After about 5-15 min (dependent on model), the resting tension 
begins to rise (= onset of contracture), and reaches a peak within minutes, with a sigmoid curve. A 
decline in tension then follows if ischaernia is maintained. Reperfusion at this stage shows incomplete 
recovery, an indication of irreversible injury. The time to onset of contracture has been used 
extensively as an index of ischaernic injury with a delay in time to onset implying protection 110, 189, 
5 3 7. Peak contracture may also be an important determinant of the extent of ischaernic injury, but has 
not been used as frequently as time to onset. 
iv) Ultrastructural changes in the myocardium during contracture 
Papillary muscles which have undergone contracture show focal irregularities of A, I and Z bands 
with sarcomere mal-alignment, hypercontracture and fibre disruption 32. In fully developed 
contracture, severe disruption of the myocardial fibres is observed, with distortion of adjacent 
structures, especially at the intercalated discs. Morphological changes correlate to mechanical changes 
of increased tension 32. In tissue from hearts perfused with acetate (leads to high peak contracture 
424), at 5% of maximum contracture (100%), foci of contracted myocytes are found, predominantly 
in the subendocardium and papillary muscle 181 . With 30% contracture, damage spreads to the 
subepicardium, with increased number and size of foci of contracture. Swelling of the tubular 
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sarcolemmal system is found. At 50% contracture, lanthanum uptake is increased, indicating 
increased membrane permeability. At full contracture, the majority of cells are contracted. 
b) Mechanism of contracture - drop in ATP, or rise in Ca
2
+ 
i) Possible mechanisms 
Initiation of contracture has been attributed to two mechanisms: i) a decrease in ATP at the contractile 
proteins, with formation of fixed cross-bridge attachments and increased stiffness, i.e. rigor bonds; ii) 
an increase in diastolic Ca2+ that maintains the contractile system in a partially or completely activated 
state, i.e. tetanic contracture (tension development without associated cyclic changes in membrane 
potential). While there is some controversy over whether a rise in Ca
2+ or a depletion of ATP 
precipitates ischaemic contracture, both appear to be determinants of the extent of contracture, and its 
subsequent deleterious effects on the myocardium. Contracture occurs at the level of the cross-bridge 
cycle. 
ii) The cross-bridge cycle 
The cross-bridge cycle (see Fig I.I) is closely regulated by ATP, ADP, Ca
2+, Ir and Pi. For normal 
contraction, an increased cytosolic Ca
2+ is required to remove troponin (Tn) inhibition of actin-myosin 
binding. The troponin-tropomyosin (Tn-Tm) complex consists of 26 components, including troponin 
C (Ca2+-binding), troponin I (inhibitory component), and tropomyosin which binds the complex to the 
actin filament. Ca2+ binding engenders a conformational change in the complex such that actin is 
exposed to myosin, to allow binding of the myosin S 1 heads to the actin. Actin binding to myosin 
enhances myosin ATPase activity 45 and ATP hydrolysis, and the release of the Pi thus generated 
results in the power stroke. Cross-bridge attachment serves as a positive feedback mechanism that 
transiently increases the Ca2+ affinity of TnC 176, 179. TnC is an essential element in the chain of Tn-
Tm molecules that transmit co-operative signals along the strand 43. Thus one cross-bridge relays the 
signal for contraction down the myofibril via the troponin-tropomyosin complex. With increased ca2+, 
more sites on Tn will be occupied, further removing inhibition of binding. 
ATP when bound to myosin at rest inhibits actin binding in the absence of Ca
2+. ATP is also required 
for relaxation, and by hydrolysis provides the energy for contraction. In the absence of ATP, actin and 
myosin bind strongly forming rigor cross-bridges. There are several models of the cross-bridge cycle 
which vary in the detail. One of these is described in Fig I.I, showing states of normal contraction, 
and of rigor. 
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Fig 1.1 : A chemical model of the steps in the cross-bridge cycle based on Goldman and Brenner 275_ The top 
row shows the states in which actin (A) interacts with myosin (M) . The heavy arrows indicate the normal 
reaction pathway, but all the reactions can occur and are reversible. Two energetically different states of A-M-
ADP are indicated by the asterisk on the more strongly bound. 
At rest myosin (M) is mostly complexed with ATP (M-ATP) or in the rapidly equilibrated M-ADP-Pi where ATP 
is hydrolysed by myosin ATPase, but the energy has not been used. As ca2+ rises and binds to Tn C, M-ADP-Pi 
interacts with actin, and the phosphate group is rapidly released. This step may represent the "power stroke" or 
myosin head rotation, with an increase in the affinity of binding represented by the two energetic states of A-M-
ADP, as the angle of the head changes from 9rJ' to 45°. The affinity of myosin for actin increases along this 
series of steps, and is strongest after ADP dissociates (A -M). At normal ATP, A-M binds ATP rapidly, inducing 
the dissociation of actin and M-ATP. The cycle then continues until C«+ declines, thereby stopping myofilament 
interaction (in the M-ADP-Pi state) or until ATP is depleted (rigor, with cycle stopped in the A-M state). 
iii) Rigor development 
Rigor tension develops when the ATP concentration is depleted to micromolar levels(~ 100 µM 307) 
at the myofibrils. Relaxation can be restored by increased ATP. Increased tension, increased stiffness, 
and muscle shortening, are observed on withdrawal of ATP from skinned muscle, in the absence of 
Ca2+ 580. The final tension developed is independent of the initial ATP concentration 580. The 
contraction is induced by actomyosin complex formation in the absence of ATP. The rigor complex 
then stimulates actin cofactor activity of adjacent myosin ATPase molecules 45, which in turn 
depletes ATP further, increasing actin-myosin affinity. Rigor complex formation also increases the 
affinity between Ca2+ and troponin 176, such that a small rise in Ca2+ may result in considerable Ca2+-
dependent tension production. Rigor bonds also alter the conformation of TnC and elicit contraction 
in a similar manner to Ca2+ binding 179. The rigor bonds also act on the Tn-Tm complex, with the 
subsequent co-operative spread of transmission of the signal down the length of the myofibril 4 3. 
Rigor increases the stiffness of muscle i.e. the number of heads attached, compared to the normally 
contracting state, an indication of increased cross-bridge attachment. 40-60% 595 or 94-100% 85 
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attachment of cross-bridges in rigor vs. 30% in normal cells have been estimated. These rigor cross
-
bridges exist in two states of myosin head attachment - at 90° and 45° - thought to represent myosi
n 
heads "trapped" at different stages of the power stoke 529 (see Fig 1.2). The 45° heads are thos
e 
though to bind first, and complete the power stroke before "seizing" in the fixed 45° position. The 90
° 
heads represent heads which have bound but still need to complete the power stroke - i.e. they exert 
a 
positive force, and will switch to 45° if released. The 45° heads prevent slippage of the 90° heads
, 





/ positive pull 
strong AM binding - slewed and 
bent around thin filament 
exerting positive force 
Fig J.2: 9(/' and 45° heads in rigor showing opposing force 529 




more strain on bond at this angle 
- restricting force on 90° heads 
slipping 
Rigor mortis in dog hearts is temporally associated with ATP depletion 327. In an ischaemic heart
, 
interventions which increase ATP consumption increase resting tension 384, while those whic
h 
reduce ATP consumption or increase production, delay time to onset of contracture 189. The fall i
n 
tissue ATP follows a biphasic pattern. Time to onset is correlated with the second phase of depletio
n 
189. In isolated rat myocytes, this second phase of ATP depletion was correlated with an increase in
 
the number of cells which had undergone contracture, suggesting that in any cell, contracture i
s 
preceded by a loss in ATP (possibly following glycogen depletion) 184, 185. These results suggest th
e 
involvement of rigor cross-bridges in ischaemic contracture. 
Further evidence for the involvement of rigor bridges in contracture comes from studies with hypoxi
a 
and metabolic inhibition. Muscle with hypoxic contracture shows increased stiffness, indicative o
f 
rigor bonds 309. In a model using quick alterations in length of isolated papillary muscles, the rise i
n 
tension with metabolic inhibition is shown to be maintained by rigor bonds rather than cycling cross
-
bridges557. Heat generation during hypoxic contracture in papillary muscles, once peak tension i
s 
reached, is significantly less than that produced by cross-bridge cycling contraction induced by KC
l 
205, which implies that ATP is not utilised in maintaining tension. The heat developed during th
e 
development of ionic contracture (induced by low Na+, high K+) was attributed to the ATP require
d 
for Ca2+ homeostasis, while the tension was attributed to rigor formation 74. 
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v) ATP levels required/or rigor bond formation 
The arguments against rigor bonds as the mechanism of contracture come from the lack of correlation 
between absolute ATP levels and those required for rigor bond formation (slOO µM 307). 100 µM 
approximates to 0.02 µmol/g dry wt, much lower than average ATP levels in the tissue at the onset of 
contracture (12 µmol /g dry wt 189). However, the lack of correlation may be due to tissue 
inhomogeneity of ATP, and intracellular compartmentation(see Ch II). A transmural gradient of 
ischaemia. and of ATP, exists in the globally ischaemic heart 327. ATP depletion occurs fastest in the 
subendocardial layer, in which contracture initially occurs. As the depletion of ATP spreads to the 
epicardium, the layer of contracture also spreads. The heterogeneous dispersion of rigor complexes, 
and of individual cells with contracture 181 , would increase overall resting tension of the heart, 
despite an overall maintained level of tissue ATP. Haworth et al. 185 used the terms "synchronous'' 
and "asynchronous" to describe ATP depletion in single cells. Asynchronous ATP depletion means 
that the ATP levels in individual cells could be depleted to 90% of their original levels without 
undergoing contracture, if glycolysis were maintained. In a whole heart, this approximates to a slow 
increase in resting tension with reasonably high ATP levels, as is found 189. A "synchronous'' 
depletion of ATP in all cells at once would precipitate contracture coincident with total ATP 
depletion in a whole heart, which only occurs when ATP is rapidly depleted e.g. by glycolytic 
inhibition 189. 
In an individual cell, ATP levels are approximately 2.2 nmol/mg cell weight or less (approx 1.5 mM) 
when contracture is initiated 185, which is still higher than that at which rigor is thought to occur 
(approx 100 µM 307). However, this ATP measurement was made in a gross sample of many cells 
185. In individual cells, a far lower value was attained 42. Cell shortening occurred at approximately 
150 µM ATP 42. This value corresponds far more closely to the ATP required for rigor formation but 
there is also the component of compartmentation within the cell 48 (Ch II), including a large 
proportion of the cellular ATP retained in the mitochondria 153. This factor increases the total cell 
ATP, but does not reflect the local ATP content e.g. at the myofibrils which may be depleted relative 
to the rest of the cell. 
Other factors which may affect contracture at a given ATP are ADP, Pi and pH, as well as Ca2+. 
vi) Increased cytoso/ic calcium 
An increased intracellular Ca2+ is implicated in ischaemic injury 441 although the exact relationship 
between the rise in [Ca2+]i and injury is unclear. A consistent relationship between the degree of 
stunning and the rise in intracellular Ca2+ has been found 509. Evidence to suggest that cytosolic Ca2+ 
accumulation precipitates contracture was found following administration of nifedipine, a Ca2+ 
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channel blocker, during low flow ischaemia, which prevented contracture and led to almost complete 
recovery 197, as does nisoldipine 474. A low Ca2+ (0.05 mM) delays and reduces contracture in 
isolated hearts 210. However, whether Ca2+ is a precipitating factor in contracture, or only modifies 
contracture once initiated by rigor formation, is still a matter of debate. 
Increased [Ca2+]i was thought to contribute to contracture development early after metabolic 
inhibition in isolated myocytes, in that a Ca2+-dependent phase preceded ATP-depletion rigor 23. This 
finding did not, however, show that Ca2+ is necessary for the onset of contracture, and is not always 
reproducible but appears to be protocol-dependent 9. The role of Ca2+ in the onset of contracture was 
further discounted in isolated myocytes, given that the sigmoid fall in % rod-shaped cells vs. time was 
not affected by the presence or absence of Ca2+ 184. 
Several authors have reported isolated cell shortening before a rise in [Ca2+]i, which supports the 
argument that contracture is initiated by ATP depletion. Severe injury in metabolically-poisoned 
myocytes precedes a rise in [Ca2+]i 77. Spontaneous shortening also occurred prior to a sharp rise in 
[Ca2+]i in cells subjected to glucose-free anoxia 8 and to metabolic inhibition 311. A fall in ATP was 
coincident with cell shortening, and this preceded a rise in [Na+]i, and presumably in [Ca2+]i 42. The 
rise in Ca2+ would deplete ATP further 189. [Na+]i increases with metabolic inhibition, following 
increased Na\ iJI' exchange activity with a reduced pHi, and inhibition ofNa+/K+ ATPase 481. No rise 
in [Ca2+]i was found. Cells underwent contracture, following which [Ca2+]i began to rise. Restoration 
of glucose at this point resulted in a large increase in [Ca2+]i, possibly from increased Na+/Ca2+ 
exchange which is inhibited by severe energy depletion 183. Contracture was therefore linked to 
rigor, and not to Ca2+ overload 481. 
In isolated perfused hearts, arrest with K+ or Mg2+ to achieve total Ca2+ block prior to ischaemia also 
affected the rate of ATP depletion, and the rise in ischaemic contracture 511 . In all cases, contracture 
development was initiated after depletion of total ATP to less than 50% control, with a progressive . 
rise in Ca2+ during and after contracture development. These findings in whole hearts do not 
determine whether Ca2+ leads to contracture, or whether the rise in Ca2+ is a result of ATP depletion, 
and only modifies contracture. Evidence that a rise in cytosolic Ca2+ may precede contracture was 
provided by using a fluorescent probe to determine the distribution of Ca2+ between cytosolic and 
internal membrane stores 230. Membrane-bound Ca2+ and Ca2+ from the SR were released into the 
cytosol prior to the onset of contracture. Similarly, in isolated ferret hearts, [Ca2+]i was increased 
greatly by 20-25 min, prior to onset of contracture at 40 min 271. However, only after ATP was 
depleted to less than 10% of basal levels, did contracture occur. In hearts with glycolytic inhibition 
(iodoacetate), onset of contracture was much sooner, and preceded the rise in [Ca2+]i 271. At close to 
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maximal contracture. the [Ca2+]i started to rise. These results thus dissociate the rise in [Ca2+]i from 
the initiation of contracture. 
vii) Relationship between ATP and Ca2+ 
Ischaemia increases [Ca2+]i, and reduces high energy phosphate levels. Attenuated [Ca2+)i 
accumulation has been shown to reduce peak contracture 189, 197, 210, but this may be due to the 
ATP-preserving effects rather than a direct effect of Ca2+. An increased [Ca2+]i increases ATP 
consumption by contractile proteins, while a reduced ATP concentration slows the energy-dependent 
sequestration of Ca2+ from the cytosol, contributing to intracellular Ca2+ accumulation 182. Release of 
Ca2+ into the cytosol may activate Ca2+ -dependent ATPases, further accelerating the rate of ATP 
depletion, and increasing contracture 182. Interventions which lower Ca2+ entry affect the 
development of ischaemic contracture but are associated with a change in ATP; thus inhibition of 
Ca2+-induced ATP utilisation may delay contracture by conserving ATP 189. 
The time course of Ca2+ increase is dependent on the metabolic status of the heart 189, 271. When 
ATP falls below a critical level, especially when glycolysis is inhibited, Ca2+ rises quite rapidly 
( within minutes) , possibly because of failure of the various Ca2+ pumps (Km (ATP) - SR Ca2+ A TPase 
- 0.18 mM) 7. While onset of contracture is associated with a 50% depletion in ATP, a rise in [Ca2+]i 
is always associated with the development of contracture 511. A modification in Ca2+ entry modifies 
the subsequent contracture. 
Compartmentation affects the role of ATP, such that glucose-derived ATP maintains ion homeostasis 
and attenuates the positive feedback between ATP depletion and Ca2+ overload. Glycolytic ATP also 
delays the onset of contracture, possibly by affecting overall ATP concentration. This issue is 
discussed in depth in Ch II. 
c) Rise in tension and peak contracture 
Once contracture is initiated, the tension may be amplified by a rise in intracellular Ca2+. Ca2+ entry 
can occur via several mechanisms (discussed previously). As Ca2+ levels rise, the probability of it 
binding to Tn increases, thereby increasing actin-myosin binding. Rigor bonds increase the affinity of 
TnC for Ca2+ 176, so a small increase in Ca2+ will have a potentiated effect on removal of Tn 
inhibition of actin-myosin binding. A Ca2+-contraction will be imposed on the rigor "contraction". 
This effect is pH-dependent, given the inhibitory effects of W on Ca2+ binding. An additive effect 
ensues, especially as an increase in contraction of the myofilaments further depletes ATP. As 
contracture of the myofibrils increases, the cell-to-cell attachments, already weakened by an increase 
in cytosolic Ca2+ and W, are strained. As the membranes stretch, the leakiness increases, adding to 
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Ca2+ entry. A positive feedback cycle is then set up, which, if leading to excess contracture, will result 
in irreversible injury. 
Peak contracture appears to be related to a number of factors , including i) the rate of ATP depletion 
(relative rates of production and utilisation) ii) the drop in pH, and iii) rise in Pi (both modulate 
contractile force in the normally beating myocardium), and iv) Ca2+. 
d) Modifiers of contracture 
i) pHi 
A drop in pH modifies virtually every cellular system involved in Ca2+ regulation and force 
development because of competition with Ca2+ for binding sites. Tn C buffers about 40% of the Ca2+ 
at normal systolic levels. An increased [W]i may thus displace this ca2+, increasing free [Ca2+]i, 
although this should only be a transient effect. A lowered pH may also increase cytosolic Ca2+ 
accumulation via the Na+/Ca2+ exchange 303, although this may only be active on reperfusion 413. A 
drop in pH reduces the myofilament sensitivity to Ca2+ and decreases maximum force production 41 7, 
possibly by decreasing the maximum force generated by each cross-bridge as well as the turnover rate 
of the ATPase. Acidosis depresses myocardial contractility 31 and has a larger depressing action on 
rigor tension than on stiffness 558. W decrease the number of cross-bridges attached. Trimetazidine, 
an "anti-ischaemic " drug which may act as an intracellular buffer, reducing acidosis, reduces 
contracture at therapeutic doses 41. 
Myosin A TPase activity may also be modified by acidification. W are released at the Pi dissociation 
step, when ATP binds to myosin, while two W are taken up when ADP dissociates. The ATP at 
which cell shortening occurs is 120 µMat a pH of 7.2, and 185 µMat pH 6.7 42. Thus as pH falls , the 
amount of ATP required to inhibit rigor development increases. However this effect is counteracted 
by effects of increased W on Ca2+ binding and cross-bridge attachment described above. A fall in pH 
partially inhibits the development of contracture, but only if a low pH is present during the 
development of tension, and not once tension is fully developed 500. With a drop in pH from 7 to 6.5 , 
a reduction in peak tension of about 40% is found. 
The onset of contracture has been linked to a levelling off in the drop in pH, attributed to cessation of 
glycolytic activity 253. Glycogen depletion reduced the drop in intracellular pH but also reduced time 
to onset of contracture. There was no relationship between the extent of the drop in intracellular pH 
and peak contracture under these conditions. The role of pH in ischaemic contracture is thus 
dependent largely on other factors, particularly ATP. 
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ii) Pi 
Pi is the major depressant of contractile force at the onset of ischaemia 284. Pi reduces the maximal 
Ca2+ -regulated force, ascribed to changes at the level of the cross-bridge cycle, and not to reduced free 
energy of hydrolysis of ATP 247. Pi shifts the sigmoid curve of force vs. Ca2+ to higher Ca2+ 
concentrations, but increase the cross-bridge cycling rate in normally contracting myocardium. In 
skinned ventricular fibres with rigor tension, Pi does not affect maximal tension development, as 
release of Mg2+ -ADP becomes the main rate-limiting step in the actomyosin reaction, minimising the 
effects of Pi accumulation 558. Pi may decrease the sensitivity of the rigor tension development to a 
decrease in Mg2+-ATP 558. In skinned ventricular trabeculae, Pi has a similar, if lesser, effect to pH, 
by reducing maximal rigor tension, but only if changed prior to peak tension 500. This has 
consequences for the development of ischaemic contracture - once initiated, its course cannot be 
altered. 
iii) Mg2--ADP and CP 
Local ATP regeneration by the CK mechanism is important in maintaining SR Ca2+ -ATPase function, 
and therefore cytosolic Ca2+ levels 272. Myofibrillar CK activity may also be important in preventing 
ischaemic contracture by sustaining a high local ATP/ADP ratio 558. Because of the importance of 
ADP in the cross-bridge cycle (release of ADP appears to limit the rate of cross-bridge detachment 
thus limiting shortening velocity), increased [Mg2+-ADP]i potentiates isometric tension and slows 
kinetics 558 by binding strongly to cardiac myosin, slowing the detachment rate. Mg2+-ADP increases 
maximal rigor force when ATP is reduced, and increases the susceptibility of rigor tension 
development to decreased levels of Mg2+-ATP. A decreased CP and local Mg2+-ADP accumulation 
increase stiffness 558. Mg2+-ADP may inhibit dissociation and/or further binding of Mg2+-ATP and 
cross-bridge detachment, even in the presence of Pi and acidosis. In addition, the free energy of 
hydrolysis of ATP (determined by ADP and Pi concentrations) 235 may alter the effectiveness of a 
given amount of ATP. High CP levels remove the effect ofMg2+-ADP by the action of CK. A creatine 
analogue delays ATP depletion and also the onset of ischaemic contracture 462. 
e) Fall in tension 
After contracture reaches a peak, the tension falls off. The rate of decline appears to be related to the 
peak reached - the greater the peak, and the sooner it is reached, the more rapid the fall-off. The 
decline in tension can be attributed to rupture of the myofibrils, as the highly contracted myofibrils 
pull the cells apart 32. Cell membranes rupture, with severe and irreversible injury, precipitating cell 
death. Morphological changes observed in contracture involve the disruption of the myofibrils and 
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intercalated discs, followed by separation of sarcomeres and a decline in developed tension. Physical 
stress is increased with contracture, leading to increased cell fragility and injury 148. Thus peak 
contracture may also reflect the ability of the heart to recover - the less the peak, the less rupture of 
myofibrils, and the less irreversible damage. 
f) Reperfusion of contracted hearts 
Ischaemic contracture compresses subendocardial blood vessels, enhancing ischaemic injury. This 
may result in non-reperfusion of these vessels when blood flow is restored, thereby contributing to 
reperfusion injury. The subendocardial vessels are the first to be compressed by contracture, an effect 
which spreads through to the epicardium as ischaemia progresses 210. The vessels lose their ability to 
dilate and allow reperfusion, with reduced compliance, possibly accounting, at least in part, for the 
"no-reflow" phenomenon. The extent of reflow is increased if pre-ischaemic Ca2+ is lowered, while 
iodoacetate (glycolytic inhibitor) increases the loss of vascular compliance from an increased 
ischaemic contracture. 
2,3-butanedione monoxime (BDM) inhibits excitation-contraction coupling, and thereby inhibits 
contracture. This compound improves functional recovery, an effect which may be related to reduced 
contracture or its effects on attenuating ATP depletion 551. When the ischaemic period is extended, 
there is still no evidence of contracture, with preservation of ATP, if BDM is present, but membrane 
damage, and contractile failure on reperfusion are found. If the rate of glycolysis is increased during 
ischaemia, a reduced CK leakage and improved recovery of function are found with BDM. Thus 
insufficient ATP production results in ischaemic injury, while only a very small component can be 
attributed to mechanical changes following of contracture 551. However, this study looked only at the 
effects of reducing contracture from a relatively small amount (50% of peak). If contracture were 
exacerbated, then a more detrimental effect of contracture by mechanical stresses might be found. 
Reperfusion in itself may increase diastolic tension above that seen prior to reperfusion. This 
"contracture" is Ca2+ -dependent in that it results from a rise in cytosolic Ca2+ with active shortening of 
the myofibrils 210. On reoxygenation, the stiffness component is reduced although tension is 
maintained or increased, indicative of Ca2+-induced active force 309. A repletion of ATP is required 
for relaxation of the myofibrils, as well as restoration of the Ca2+ homeostasis. Reoxygenation or 
reperfusion tend to increase [Ca2+]i 405. If cytosolic Ca2+ levels do not rise above a critical point 
during ischaemia, they can be restored to normal on reperfusion. If the Ca2+ load is too high, with 
inhibited mitochondrial activity and increased cell fragility, the injury will be irreversible. The cell 
undergoes hypercontracture, leading to cell death. This concept was confirmed by Allshire et al. 8 
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who found that reoxygenation of isolated cells with Ca2+ less than 2-3 µM restored function; a higher 
Ca2.,. precipitated cell shortening and cell death. 
8) REPERFUSION INJURY 
a) Recovery of hearts after short term ischaemia 
Restoration of flow after a period of ischaemia is essential for recovery. However, both the extent of 
injury during the ischaemic period, and the consequences of reperfusion itself may impair the degree 
of recovery. After a brief period of ischaemia (< 20 min), mechanical function may be depressed, but 
can be restored with maintained reperfusion (stunning). Increased duration of ischaemia (> 20-25 
min) , increased severity (determined by extent ofresidual flow) and an increased area at risk, increase 
the degree of ischaemic injury and of irreversible functional impairment ( see above). 
The main end-points of recovery after ischaemia are reperfusion arrhythmias, infarct size and 
functional recovery. In an isolated rat heart, the latter is the primary means of determining ischaemic 
injury. Functional recovery is determined by the relative proportions of fully functional, stunned, 
irreversibly injured, and dead cells. The number of cells in each state is determined by the length of 
ischaemia, and the modifications made to protect the heart, both during ischaemia, and on reperfusion. 
b) Reperfusion injury 
Restoration of flow after ischaemia, while essential to maintain viability, may actually exacerbate 
cellular injury 186. While it is impossible to dissociate entirely the consequences of ischaemic from 
those on reperfusion there are three points to consider: 1) the extent of ischaemic injury directly 
influences the degree of functional recovery on reperfusion and 2) events can be modified only on 
reperfusion which suggests that distinct mechanisms are brought into play by the act of restoring 
coronary flow but 3) restoration of coronary flow as soon as possible is an absolute requirement for an 
ischaemic heart. There is some controversy over whether reperfusion kills cells that would otherwise 
have lived. This issue is, however, difficult to resolve because one cannot determine cell viability 
without some form of reperfusion. 
Reperfusion-associated events include 1) reperfusion arrhythmias, 2) vascular damage and no-reflow, 
3) myocardial stunning, 4) acceleration of necrosis in non-lethally injured cells, possibly by cell 
swelling and 5) acceleration of necrosis in cells irreversibly injured by ischaemia 406. Ultrastructural 
cell damage, release of cytoplasmic enzymes, massive influxes of Ca2+ and Na+, Ca2+ deposition in the 
mitochondria, and contraction band necrosis all contribute to reperfusion injury. Accumulated 
metabolites increase the osmotic load, such that on reperfusion, there are large transmembrane 
gradients and cell swelling. 
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The possible mechanisms ofreperfusion injury include facets of the calcium and oxygen "paradoxes". 
The calcium paradox 604 occurs when Ca2+ is removed from cells, and then restored, leading to cell-
cell uncoupling and disintegration of the membranes. This phenomenon is largely experimental, but 
there may be areas in the ischaemic tissue where this may occur, and the findings from calcium 
paradox studies apply to reperfusion injury, implicating Ca2+ in many of the deleterious effects found 
on reperfusion. The oxygen paradox (formation of free radicals on reintroduction of oxygen to anoxic 
tissue) 191 has also been implicated in the genesis of stunning, and may also precipitate cell death. 
While there has been some controversy over whether Ca2+ overload or free radicals are the main 
determinants of "reperfusion injury", the two phenomena are likely to be closely interrelated. 
c) Calcium overload 
The increase in cytosolic Ca2+ is a primary mechanism of ischaemic and reperfusion injury. 
Prevention of Ca2+ overload during ischaemia is beneficial to the heart, while reduction of Ca2+ entry 
immediately on reperfusion, using either reduced Ca2+ levels, Ca2+ channel antagonists 120, reduced 
SR Ca2+ release 121 or inhibition of the Na+llr exchange mechanism 119 are all beneficial by 
reducing reperfusion arrhythmias and improving recovery of function. 
Ca2+ may enter the cell during ischaemia, but the rate of entry appears to be accelerated on reperfusion 
353, 413. Ca2+ enters through sarcolemmal Ca2+ channels and permeabilised membranes, while SR 
Ca2+ re-uptake is reduced, and the release of Ca2+ from intracellular stores is increased. During 
ischaemia, intracellular Ca2+ rises slowly in a more or less linear fashion 305, 353. Thus the duration 
of ischaemia should roughly determine the amount of Ca2+ available at the start of reperfusion 353. 
An increased intracellular Ca2+ is associated with increased tissue damage 305, 509. On reperfusion, a 
further accumulation of intracellular Ca2+ can result from the Na+llr- Na+/Ca2+ exchange interaction 
303. A rise in cytosolic Ir concentration ischaemia, mainly from reduced ATP turnover 156 activates 
the Na+/Ir exchange on reperfusion, leading to Na+ influx. Reduced activity of the Na+/K+ ATPase 
with depleted ATP may also contribute to increased cytosolic Na+. In addition, the fast Na+ channel 
may be activated in ischaemia. Na+ is extruded in exchange for Ca2+ via the Na+/Ca2+ exchange, 
resulting in greatly increased intracellular Ca2+ levels 528. Inhibition of the Na+ !Ir exchange by 
amiloride or its derivatives has a significantly protective effects on reperfusion function, confirming 
this hypothesis 119. SR Ca2+ ATPase function is also impaired by ischaemia 273, 315, 353 and is 
limited by ATP availability. Thus increased [Ca2+]i cannot be removed efficiently in reperfused tissue 
353 
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d) Free radicals 
Oxygen free radicals have been implicated as the causative agent in a number of pathological 
conditions 177. Oxygen free radicals have an unpaired electron which makes these species highly 
reactive. These include the superoxide anion (02-) and the hydroxyl radical (OH). In addition, 
hydrogen peroxide (H20 2) , and singlet oxygen are also highly reactive oxidising species. Superoxide 
dismutase (SOD) is a ubiquitous enzyme which catalyses the conversion of 62- + 2 Ir to H20 2 + 0 2. 
H20 2 can then be reduced to H20 by catalase (produces 0 2) or glutathione peroxidase which converts 
GSH to GSSG. This change affects the redox state in the cell and many of the proteins which are 
activated by changes in SH binding 602. 
62- can be generated from endothelial cells by one or more pathways (xanthine oxidase, cyclo-
oxygenase, catecholamine oxidation, or mitochondria) 602. 62- formation can then initiate a series of 
reactions leading to neutrophil adherence (not in isolated rat heart) which subsequently release a 
variety of toxic products including free radical species. The release of these substances can lead to 
membrane permeability and damage to the myocyte 320. Damage by free radicals can occur as a result 
of metabolic and structural changes including peroxidation of lipids. 
Myocardial stunning can be partially relieved by the presence of free radical scavengers 38. How free 
radicals result in stunning is not fully understood, but may be linked to injury to the SR or 
sarcolemma, possibly via lipid peroxidation, resulting in uncoupling of excitation-contracture and an 
overload of cytosolic Ca2+. A predisposition to arrhythmias has also been attributed to free radicals, 
although this is not the most important mechanism 594. 
Oxidant stress may exacerbate intracellular Ca2+ overload by changes in membrane phospholipids, 
impaired Ca2+ regulation by mitochondria, increased ATP depletion, changes in the Ca2+ release 
channel of SR, reduced uptake of Ca2+ by the SR, changes in the Na+/K+ ATPase pump and Na+/Ca2+ 
exchange, and a slowed rate of inactivation of Ca2+ ATPases 413. Ca2+ overload can initiate oxidation 
by damaging the mitochondria 222 which may affect their ability to reduce 0 2 to H20 , Changes in the 
SR induced by free radicals affect Ca2+ flux across the sarcolemma. The role of free radicals is, 
however, controversial, as the magnitude of the effects does not appear to be sufficient to explain all 
the deleterious consequences associated with reperfusion 594. However, there is little doubt that free 
radicals do exert some effect, but whether this is triggered by increased ca2+, as one of the deleterious 
effects of cytosolic Ca2+ overload, or whether free radicals precipitate the increased cytosolic ca2+, is 
still questioned. 
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9) FUNCTIONAL RECOVERY 
a) Myocardial stunning 
i) Definition 
Stunning is a consequence of relatively short periods of ischaemia (<20 min) and is defined as a fully 
reversible defect of myocardial mechanical function developing on reperfusion, in the absence of 
necrosis 3 7. This statement implies that if reperfusion is sustained for a sufficient period of time the 
hearts will recover full function. The mechanism of stunning is as yet unclear, but may involve both 
cytosolic Ca2+ overload and oxygen free radical generation (see above). 
Post-ischaemic stunning may occur in two phases 413. On reperfusion, over a period of 0-5 min, 
cytosolic Ca2+ is in excess, during which a "normal" mechanical function may be found. Inotropic 
interventions at this time which increase cytosolic Ca2+ exacerbate eventual recovery (after 20-30 min 
reperfusion) 120. After 5 min the more prolonged phase of 'classical" stunning is found, with 
underfunctioning and hypocontractile myocardium 413 . At this point, interventions with positive 
inotropic effects improve function 120. Ca2+ availability does not appear to be the problem in 
stunning, as cytosolic Ca2+ levels are high. 
ii) Dissociation of fanction and oxygen consumption 
In stunned myocardium, oxygen consumption is maintained at levels equivalent to those in control 
hearts, but functional activity is depressed 397. ATP levels in stunned myocardium take time to 
recover, although there appears to be little correlation with recovery of ATP and recovery of function. 
Some ATP is required; however, full restoration of ATP does not necessarily result in full functional 
recovery 3 7. The source of ATP appears to be important i.e. glucose-derived vs. oxidative substrates 
229, 325 (discussed Ch II). Reperfusion after differing severities of ischaemia showed similar levels 
of oxygen consumption, despite large differences in severity of injury 165. The recovery in oxygen 
consumption was disproportionately high, and dissociated from recovery of contractile recovery. This 
dissociation was attributed not to metabolic inefficiency but rather to abnormalities in contraction or 
electromechanical coupling 293. In addition, an increased intracellular Ca2+ should increase the rate of 
cross-bridge cycling, but instead the work rate and pump function are reduced in stunned 
myocardium. The myofibrils may be partially disrupted, but this is insufficient to account for the 
reduced recovery of function. In addition, arrhythmias are prevalent on reperfusion which predispose 
to reduced function. These findings imply some mechanism acting at the level of excitation-
contraction coupling is responsible for reduced function. 
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iii) Myofilament sensitivity to ca2+ and excitation-contraction coupling 
Myofilament Ca2+ responsiveness is expressed as the relationship between free [Ca2+]i and force, such 
that a decrease in the Ca2+ transient results in reduced force. A decrease in myofilament 
responsiveness also results in reduced force, even if Ca2+ transients are unchanged. A shift in calcium 
sensitivity may occur, such that the range of contractile activation shifts to a higher ca2+, or a 
decrease in maximal Ca2+ -activated force scales down the overall response. 
A decrease in the maximal Ca2+ -activated force and decreased sensitivity to extracellular Ca2+ of the 
myofilaments from stunned myocardium imply reduced sensitivity to Ca2+ 283. A reduced sensitivity 
is likely given the increased cytosolic Ca2+ in stunned myocardium, but reduced force development. A 
possible explanation for decreased activity of the myofilaments may be due to activation of Ca2+ -
dependent proteases by increased cytosolic Ca2+ which may attack the myofilaments and decrease 
their responsiveness 281. 
However, stunned myocardium has an inotropic reserve which can be utilised with inotropic stimuli in 
"late" reperfusion 120. A decrease in maximum calcium-activated force (Fmax) has been observed, 
but desensitisation of myofilament was discounted because of no change in the slope of the curve of 
force versus Ca2+ 58_ No depression of Ca2+ transients was found. The decrease in Fmax was 
attributed to increased Pi levels, a change in cross-bridge kinetics, a decrease in the relative force 
generation per attached cross-bridge and interaction with the inositol polyphosphate-diacylglycerol 
system which may affect excitation-contraction coupling 58. Soei et al. 503 however, suggest that 
Ca2+ desensitisation of the myofibrils is involved in stunning, as a calcium sensitiser increases systolic 
segment length shortening in stunned myocardium, more so than in control myocardium. An increased 
myosin ATPase activity could then be responsible for the decreased mechanical efficiency, with 
excess oxygen consumption for the work output 293. Gao et al. 149 found evidence for decreased 
myofilament responsiveness and altered diastolic function in stunned myocardium. At any given ca2+, 
force generation was significantly lower in stunned tissue, with no differences in calcium transients. 
A decrease in maximal Ca2+ -activated force and an increased [Ca2+]i was required for 50% activation. 
An accelerated rate of diastolic relaxation was found. With high Ca2+ concentrations, diastolic tone 
increased more in stunned tissue. Thus the primary lesion of excitation-contraction coupling appears 
to be at the myofilaments 149. Stunning primarily involves decreased cycling rates of myofibrillar 
cross bridges, with a reduction in myofilament Ca2+ sensitivity after more severe ischaemia 347. 
iv) Preconditioning 
An important possible consequence of "stunning" is the recently described phenomenon of 
preconditioning, whereby brief periods of ischaemia, which may lead to stunning, protect the heart 
against a subsequent sustained period of ischaemia. Some protective mechanism may be switched on 
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during the preceding ischaemic episode, which may also be involved in stunning 491 . However, the 
effects of stunning and preconditioning have been dissociated 358. 
b) Diastolic dysfunction and irreversible injury 
A transient, reversible rise in L V diastolic pressure is commonly observed in angina pectoris. This 
may be due to an increased end diastolic volume because of reduced cardiac function, or because of a 
reduced diastolic distensibility of the L V chamber. Reoxygenation or reperfusion may bring about, or 
exacerbate, an existing diastolic tension or contracture, largely mediated by a rise in resting Ca2+ on 
reperfusion 229, 283. An increased end-diastolic resting tension is undesirable because of a reduced 
left ventricular filling, physical occlusion of coronary blood vessels, and possible damage to the 
sarcolemma induced by increased shortening of the cells with stretch of the membranes. Increased 
resting tension can exacerbate cell damage and precipitate death. The ability of the heart to recover is 
limited by the extent of irreversible damage, such that only the reversibly injured tissue will recover. 
A lower Ca2+ on reperfusion, or application of Ca2+ blockers at this time reduce Ca2+ entry, thereby 
inhibiting contracture development, and subsequent injury 229. Glucose is also beneficial by 
improving Ca2+ homeostasis and increasing ATP availability. ATP on reperfusion may be limited by 
Ca"+ accumulation in the mitochondria during ischaemia, and glycolysis may provide essential ATP at 
that point. Acidosis is beneficial on reperfusion by inhibiting Ca2+ binding and Ca2+ entry 257. 
c) Reperfusion arrhythmias 
An increased incidence and duration of reperfusion arrhythmias leads to a decline in function and a 
reduced ability of the tissue to recover from ischaemia. Increased cytosolic calcium has been 
implicated in the development ofreperfusion arrhythmias 270. Free radical generation leading to loss 
of membrane integrity and Ca2+ overload has also been implicated 590, 594. Arrhythmias can also be 
attributed to re-entrant circus effects due to the presence of an infarcted area 336. Increased Ca2+ 
oscillations (delayed after depolarisations - DADs) on reperfusion increase the excitability of the 
membranes and may precipitate arrhythmias 80. A reduction in DADs has been noted with increased 
glycolytic ATP availability 79. An interesting point is that arrhythmias cannot arise from dead cells; a 
certain degree of viability is necessary to generate arrhythmias. 
d) Myocardial infarction 
Infarct size is dependent on the extent and severity of ischaemia, and the degree of reduction in 
oxygen delivery, determined by residual and collateral coronary flow 194,485 The size of the area at 
risk i.e. the area perfused by the affected artery, and variation of ischaemia within this area also 
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determine eventual infarct size. The severity of ischaemia can be determined by the imbalance 
between the metabolic requirements of the myocardium and the supply of oxygen and substrates by 
any residual flow to the tissue. Collateral blood flow is thus an important determinant of infarction, 
the extent of which varies greatly between species. Increased subendocardial pressure restricts flow to 
the area at risk, thus the subendocardium is generally more ischaemic than outer regions 485, 507 
( especially if an intraventricular balloon is present), and more prone to early infarction. Infarction 
spreads as a wave from the endo- to the epicardium 327. Preconditioning has been shown to be the 
most effective mechanism of protection against infarct size, but the mechanism and its consequences 
are not yet fully understood. 
e) Chronic sublethal ischaemia 
Coronary perfusion pressure, coronary flow, myocardial oxygen consumption and contractile 
performance are tightly coupled 3 9, 464. Thus even a relatively small reduction in blood flow ( 10-
20%) will result in a significant compensatory reduction in contractile performance 552. The term, 
"hibernation", has been coined to describe a prolonged subacute or chronic reduction in coronary 
blood flow, in which the myocardial contractility, metabolism and ventricular function are reduced to 
match the reduced blood supply 448. Restoration of normal blood flow should result in rapid, 
complete restoration of myocardial function 497. 
However, there is much dispute as to whether the coronary flow is in fact reduced in hibernating 
tissue. It has been suggested that "hibernating" myocardium may in fact be tissue exposed to repeated 
brief, sub lethal episodes of ischaemia, followed by restoration of blood flow 15 5, 464. Over time 
there may be an overall reduction in contractile performance, with repetitive stunning 155, 464. Thus 
a reduction in blood flow in chronically dysfunctional segments may not be present 340. Positron 
emission tomography is used to predict viable tissue, usually indicated by a "mismatch" between 
coronary flow (unchanged or reduced) and glucose extraction (increased). This concept contradicts 
the accepted inhibition of glycolysis in ischaemia, and indicates an adaptation of the tissue to a 
chronic condition. 
10) SUMMARY 
"Ischaemia" describes an imbalance between supply of energy substrates and demand. Most 
experimental models of the isolated perfused heart use total global ischaemia i.e. complete cessation 
of flow. However, in vivo some residual flow is almost always present. Thus a low flow model of 
ischaemia is more representative. 
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On reduction or cessation of flow, the globally ischaemic heart undergoes contractile failure , and 
ceases to beat. After a few minutes, a rise in resting tension, or contracture is found. The time to onset 
and extent or peak of contracture are dependent of the availability of ATP and of Ca2+i, which in turn 
are related to changes in [Na+]i and pHi. The ion contents of the cytosol are closely regulated by 
pathways which are disturbed by ischaemia, including the metabolic and signalling pathways. 
Intermediates or metabolites of these pathways can seriously affect the compromised tissue. 
On reperfusion, the extent of injury caused by cellular perturbation results in ischaemic injury which 
may be exacerbated on reperfusion. Thus the resultant functional recovery is the sum of ischaemic 
and reperfusion injury. In addition, arrhythmias and infarct size can reflect ischaemic injury and are in 
turn important determinants of eventual outcome. Glucose modifies many of the cellular changes 
induced by ischaemia, which is reflected in a change in contracture and function on reperfusion. 
Modifications of glycogen also alter the response to ischaemia, as does preconditioning. These issues 
are discussed in detail in the following chapters. 
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II. GLUCOSE IN ISCHAEMIA 
1) THE "GLUCOSE HYPOTHESIS" 
Following on from early work establishing a role for enhancement of substrate supply in ischaemia, 
Opie 401 propounded the "glucose hypothesis". Several possible beneficial actions of glucose in the 
ischaemic myocardium were proposed, including increased energy production, reduced loss of K+ 
ions and attenuated arrhythmias, inhibition of changes in the transmembrane action potential, altered 
extracellular volume, and decreased circulating free fatty acids which are toxic to the ischaemic heart. 
These mechanisms have been reflected in reduced incidence of arrhythmias, reduced ischaemic 
contracture, and improved recovery of function following administration of glucose. 
Despite many laboratory studies showing benefits of increased glucose, there are several important 
exceptions. These include 1) the British Medical Research Council trial published in the Lancet which 
did not find a beneficial effect associated with glucose-insulin-potassium (GIK) treatment of patients 
with infarction 352, 2) addition of glucose in cardioplegic solutions which was detrimental to the 
myocardium 193, and 3) reduction in glycogen was found to be beneficial to the globally ischaemic 
rat heart, an effect attributed to reduced lactate accumulation 387_ These studies have contributed to 
the controversy over the therapeutic use of glucose, and in particular have resulted in the 
discontinuance of the use of GIK therapy for patients with myocardial infarction. However, these 
deleterious effects may be largely determined by the incorrect dosage and rate of removal of 
metabolites, Our hypothesis is that glucose is beneficial at an optimal concentration, and that 
increased glucose, possibly with insulin, may indeed be deleterious by increased metabolite 
accumulation. Removal of the metabolites by increased residual flow should result in increased 
recovery with higher glucose concentrations. 
2) GLUCOSE METABOLISM IN ISCHAEMIA 
a) Glucose in hypoxia/anoxia 
Hypoxia stimulates glucose utilisation by reversal of the Pasteur effect, with a 20-fold increase in 
glycolytic flux in dogs in vivo 276, and a 3-fold increase in isolated rat hearts perfused with 11 mM 
glucose 469_ Glycolytic inhibition at the level of PFK by citrate and ATP is removed, and glycolysis 
is stimulated 586 (see appendix). If hypoxia is severe, heart function declines slowly, from 
insufficient ATP. If glycolysis is inhibited, developed tension dissipates completely 7. Contracture 
may develop following ATP depletion 5, 9_ 
Hypoxia depletes tissue glycogen by increasing glycolytic rates to maintain ATP levels. If high 
glucose concentrations are present, heart failure is attenuated 470. However, similar rates of lactate 
40 Literature review Ch. II. Glucose in ischaemia 
production are found, and thus similar rates of glycolysis. A high glucose thus inhibits glycogenolysis, 
as well as increasing glucose utilisation by glycolysis. Utilisation of glucose appears to be better than 
glycogen utilisation, despite similar rates of ATP production 470. The mechanism for this preference 
may lie in the localisation of glycogen granules in the cell, with functional compartmentation of the 
ATP produced, and of localisation of the metabolites (see below). Glucose in hypoxic hearts prevents 
contracture 116 and reduces enzyme leakage in the rat 190. 
b) Energy production in ischaemia 
Reserves of high energy phosphates (ATP and CP) are sufficient only for 3-4 contractions of the 
normal heart. However a rapid cessation of contractile function reduces the demand for high energy 
phosphates. 
Jennings and Reimer 225 have described the metabolic changes occurring in ischaemia as cessation of 
aerobic metabolism, depletion of CP, onset of anaerobic glycolysis, and accumulation of glycolytic 
products (lactate, a-glycerophosphate, adenine nucleotide breakdown). The demands of the 
myocardium for ATP exceed supply, such that net ATP decreases. These changes lead to contractile 
failure, as Pi increases. In the absence of flow, the majority of ATP is derived from anaerobic 
glycolysis. Pyruvate is converted to the dead-end molecule of lactate, a temporary measure to reduce 
accumulation of NADH, and restore NAD+ levels. If washout is not maintained, the end products 
accumulate, which may be deleterious. After a short period (a few minutes) glycolysis in inhibited in 
ischaemia despite an initial stimulation. 
c) Rate-limiting steps in glycolysis - original ':oncepts 
Kubler and Spieckermann 276 found that when p02 becomes critical (less than 5 mmHg) in ischaemic 
myocardium in dogs in vivo, glycolysis is initially stimulated by reversal of the Pasteur effect, with a 
build-up of lactate. The subsequent decline in glycolysis was attributed to the limiting effect of 
reduced ATP for the phosphofructokinase step, i.e. the conversion of F6P to FDP (see appendix). The 
level of ATP (3.5 µmol/g wet wt) at this point was said to be critical, with ischaemic injury occurring 
at lower values. 
This concept of glycolytic inhibition was revised by Neely and Rovetto 389, 390, 468, 469 who · 
proposed that glycolytic flux in ischaemia was inhibited at GAPDH by an accumulation of end 
products, specifically lactate, F, and NADH. This concept was derived from work on the isolated 
working rat heart. A 60% reduction in coronary flow (from 15 ml/min to 6 ml/min) reduced oxygen 
consumption and accelerated glucose utilisation by 100%. At a flow rate of 0.6 ml/min, glucose 
utilisation was less than in control conditions ( about 50% ). After 16 min of low flow ischaemia, the 
hearts were clamped and levels of metabolites assessed. Lactate values were high, suggesting that 
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ADH was increased, because of the equilibrium of the LDH reaction. Increased NADH would, in 
tum, inhibit GAPDH, which is regulated by the NADH/NAD+ ratio 362 (see appendix). GAPDH 
inhibition was shown by an increase in DHAP levels 468 and application of the crossover theorem 68. 
Following on from these publications, it has been widely accepted that glycolytic enzymes are 
inhibited in ischaemia by a build-up of glycolytic metabolites, and glycolytic flux thus inhibited. For 
the purposes of the following discussion, this view is applied. However, our analysis of glucose 
uptake in low flow ischaemia indicates that this interpretation i.e. that glycolysis is inhibited in 
ischaemia, is not strictly true (See Results 1,2,3); rather, glycolysis is limited by substrate supply. The 
limitations of the above interpretations are discussed further in the Discussion of the thesis. 
3) ROLE OF GLUCOSE IN ISCHAEMIC MYOCARDIUM 
a) Specific role of glycolytic ATP 
Despite the limitation of glycolytic flux in ischaemia, cell viability may be determined by the residual 
rate of glycolytic flux 404. Glycolytic ATP appears to have a preferentially effective role as opposed 
to ATP derived from oxidative phosphorylation 49. A basal level of glycolytic activity is required to 
prevent irreversible injury 227, with control of cytosolic Ca2+ during ischaemia 441 and on 
reperfusion 229, prevention of ischaemic contracture 48, 424, inhibition of enzyme release 190, and 
inhibition of free radical activity 405. Glycolytic ATP is thought to have several effects on membrane 
functions: blocking the KA TP channel 571, maintaining the activity of the Na+ /K+ ATPase pumps in the 
sarcolemma 167, sustaining membrane integrity 49,203, and maintaining Ca2+ homeostasis by the SR 
Ca2+ A TPase pumps 593 . These cellular effects modify functional responses to ischaemia with 
reduced diastolic tension 14, 48,316, 424, and improved functional recovery on reperfusion 14, 123, 
228, 550. Much indirect evidence suggests that ATP production within the cell is spatially 
compartmented 49, 428, 593 , accounting for differences in the effectiveness of different sources of 
ATP. In ischaemia, the processes for transport of ATP within the cell may break down. Thus 
provision of ATP near to the sites of utilisation becomes a crucial determinant of its effectiveness. 
The role of glycolytically-derived ATP therefore appears clear-cut in terms of its beneficial effects. 
However, during the breakdown of glucose and glycogen, a number of metabolites accumulate which 
may contribute to some of the deleterious effects of ischaemia. The benefit of glycogen in particular 
has been questioned in this regard, especially given the interest generated in the recently described 
phenomenon of preconditioning. A reduction in glycogen is postulated as one of the mechanisms 
whereby preconditioning may exert its beneficial effects 224 and is investigated in this thesis (see Ch 
ill). 
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My proposal is that a crucial balance exists between rates of ATP production and rates of metabolite 
washout. This relationship is determined largely by the rate of residual coronary flow and the glucose 
concentration, as well as the level of the endogenous glycolytic substrate, glycogen. The role of 
coronary flow in determining the benefit of glucose is crucial, and is one of the focal points of this 
thesis. 
b) Membrane integrity 
The role of glucose in maintaining the integrity of the cell membrane was illustrated initially by de 
Leiris et al. 104. Enzyme release from severely damaged cells is a frequently-used indicator of 
myocardial cell death and infarction in patients. These markers include the isozymes of CK and LDH. 
In isolated rat hearts perfused with high concentrations of free fatty acids, enzyme release is 
attenuated in the presence of glucose 104, as shown in hypoxic hearts 190, 192. In a low flow 
ischaemic model, glucose provision also reduces the release of LDH, compared to pyruvate, despite 
similar ATP levels 49. The effectiveness of glycolytically-derived ATP appears greater than that 
derived from residual oxidative phosphorylation, accounted for by spatial compartmentation of ATP 
49. Glucose-derived ATP may maintain the phosphatidic acid cycle, thereby preventing 
lysophospholipid accumulation which leads to membrane breakdown 89. Glucose limits 
phospholipase C degradation of membranes 203, and increased phosphorylation with increased ATP 
availability may enhance the stability of the phospholipid membrane 202. Cell swelling in ischaemia 
may be reduced by the osmotic effects of glucose, which also helps to reduce cell rupture 225. In 
addition, reduced contracture with glucose will limit cell rupture from stretching. 
c) Membrane pump and channel activity 
Glucose plays a major role in ion homeostasis. When cells are made ischaemic, a large efflux of K+ 
results, which depolarises the membrane, and renders the cell inexcitable, a positive effect with 
depleted ATP. However, the excess extracellular K+ can precipitate arrhythmias if the efflux is 
maintained 328. The ATP-dependent K+ (KATP) channel, one of the major channels involved in the 
efflux of K+ in ischaemia 233 , 236, is blocked by ATP. However, the experimental levels to which 
ATP must fall to allow channel opening in excised patches 233 are well below those in ischaemic 
tissue with a noted K+ efflux 233. The observed changes in K+ efflux through this channel despite 
relatively small changes in ATP levels can be explained firstly by the high density of channels present 
such that a small change in maximal conductance can result in a large change in action potential 
shortening and K+ loss 572; and secondly, a localised fall in ATP near the membrane allowing for 
individual channel opening. Glucose-derived ATP, as opposed to that from oxidative phosphorylation, 
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preferentially maintains closure of the KATP channel supporting the concept that this ATP is localised 
near the membrane 570, 571 . Sarcolemmal-associated glycolytic enzymes may maintain the ratio of 
ATP/ADP in the vicinity of the KATP channel 572. 
Recent studies have shown that Na+ /K+ A TPase pump inhibition by ouabain abolishes protection by 
glucose 94, 167. A reduced energy supply from glucose inhibits Na+/K+ ATPase, and increases 
osmolarity and cell swelling 94. Eventually, Ca2+ overload may occur from an increased [Na+]i. In 
addition, glycolytic enzymes are functionally coupled to SR Ca2+ transport 593. Ca2+ transport could 
thus be maintained specifically by ATP produced by glycolysis. Glycogenolytic enzymes and 
glycogen granules are also associated with the SR 128, 593. A preferential role for glycolytic ATP in 
preserving Ca2+ homeostasis by maintained Ca2+ re-uptake is postulated. Jeremy et al. 229 report that 
glycolysis plays a central role in maintenance of Ca2+ homeostasis on reperfusion, possibly by 
activation of the SR Ca2+ A TPase pump, the activity of which is affected in stunned hearts 273 , 315 
(see Ch I). 
Glycolytic ATP has been associated with maintenance of Ca2+ homeostasis during 13-adrenergic 
stimulation, by continued activity of the SR Ca2+ ATPase pump 380. Maintained glycolysis also 
inhibits the release of noradrenaline from nerve terminals 57, which should attenuate the effect of 
increased catecholamines on cellular damage in ischaemia (see Ch I). 
d) Arrhythmias and free fatty acids 
Ventricular arrhythmias generated during ischaemia or on reperfusion are complex in origin. Changes 
in cell membrane integrity, ionic fluxes across the membrane, and impairment of conduction, all result 
in arrhythmias. Reperfusion arrhythmias are attenuated in hearts perfused with glucose, compared to 
those with acetate or palmitate 49. The vulnerability of the dog heart to arrhythmias is reduced when 
glucose is administered intravenously 4 71. Glucose also protects against arrhythmias in a model of 
regional ischaemia in the isolated perfused rat heart 28 . 
Glucose may reduce the arrhythmoticity of ischaemic tissue by a number of factors , mainly those 
involved in membrane integrity and pump and channel activity, as discussed above. Glucose 
maintains action potential duration in the isolated perfused rat heart 416, presumably by blocking the 
KATP channel, thereby limiting K+ loss 571. Glycolytic ATP also reduces cAMP accumulation, and 
lowers LDH release, an effect associated with reduced arrhythmias on reperfusion 49. In addition, 
glycolysis reduces cytosolic Ca2+ accumulation on reperfusion 229, a precipitating factor in 
reperfusion arrhythmias 412, 539. Preserved Na+/K+ ATPase function 94, 167 would attenuate the 
increase in [Na +]i, which in turn would reduce [Ca2+]i 303. Glucose may also have a free radical 
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scavenging effect 199, important especially on reperfusion in maintaining membrane integrity and 
reducing arrhythmias 594_ 
A recent editorial has highlighted the benefit of glucose and insulin in lowering the levels of 
circulating free fatty acids 399. Glucose and fatty acid utilisation are closely related - the so-called 
glucose fatty acid cycle, whereby glycolysis provides glycerol 3-phosphate ( aGP) required for the 
formation of triglycerides451 _ Glucose uptake inhibits free fatty acid release from adipose tissue, an 
effect enhanced by insulin 451. Free fatty acids have a toxic effect on ischaemic hearts, and lead to 
increased arrhythmias 399_ This effect may be due to the accumulation of intracellular acylcarnitine 
and acyl Co-A which are thought to promote intracellular Ca2+ overload 207, 399, 589_ A recent paper 
has described detrimental effects of acyl Co-A on contracture, an effect attenuated by glucose 75 . 
Lysophospholipids from the breakdown of lipids are arrhythmogenic, with a detergent effect on the 
membranes 88. Lipid compounds may also inhibit Ca2+ reuptake mechanisms and activate Ca
2
+ 
channels 207, 399, 589_ Glucose provision counters many of the deleterious effects associated with 
free fatty acids in ischaemia, by reducing free fatty acid availability in the circulating blood, as well as 
combating the deleterious effects of free fatty acids on Ca2+ overload in the cell 399_ 
e) Glycolytic ATP and ischaemic contracture 
Another important role for provision of glucose during low flow ischaemia is a reduction in ischaemic 
contracture. There is some controversy over whether ischaemic contracture is indicative of injury or 
not 551, given that under certain conditions increased contracture is associated with improved 
functional recovery on reperfusion e.g. preconditioning 266 (see Ch ill). However, increased 
contracture is generally considered to reflect increased cell injury 110, 189, and may in itself add to 
cell damage, thereby further impairing functional recovery. 
The level of ATP is thought to be a major determinant of the time to onset of contracture 189 (see Ch 
II). In general, a depletion in ATP levels reduces the time to onset; increased ATP availability delays 
contracture. Glucose + atractyloside (inhibits translocation of mitochondrial ATP) lessens 
contracture, compared to mitochondrial substrates ( acetate and pyruvate) with inhibited glycolysis 
(iodoacetate or 2-deoxyglucose) 48, despite similar levels of ATP production. Thus ATP from 
glycolysis appears better able to prevent contracture. Similar results were obtained in acetate-perfused 
hearts without glycolytic inhibition 316. Time to onset of contracture was greatly reduced compared 
to glucose-perfused hearts despite much higher ATP levels 316. 
In moderate low flow (50%) ischaemia (termed "hibernation" by the authors), a preference for 
glucose rather than pyruvate has been observed in terms of reducing contracture 483. Glycolytic ATP 
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was essential to ensure recovery of CP. ATP derived from oxidative phosphorylation (pyruvate) was 
not sufficient to promote metabolic recovery or to maintain diastolic function 483 . Apstein et al. 14, 
123 showed that provision of glucose in rat models of low flow ischaemia (0.5 ml/min/g wet wt or 
0.06 ml/min/g wet wt) maintains diastolic function, and improves recovery of function on reperfusion. 
A higher concentration of glucose (27 mM vs. 5 mM) with insulin, and a higher of residual flow, were 
more effective. 
The onset of contracttire has been linked to cessation of glycolysis, as measured by a levelling-off in 
the drop in intracellular pH 253. These studies were performed in hearts exposed to total global 
ischaemia, where glycolytic flux is determined by the level of endogenous glycogen. With low flow 
ischaemia (0.5 ml/g wet wt/min), a minimum rate of at least 2 µmol/min/g wet wt glycolytic ATP 
production is required to prevent contracture 424. Similar or larger amounts of ATP derived from 
glycogen or non-glycolytic substrates were not effective in delaying contracture, which showed a 
graded response to increased glucose concentrations 424. Therefore the onset of contracture is not 
associated so much with cessation of glycolysis, as with a fall in glycolytic flux below a threshold. In 
total global ischaemia, this occurs rapidly. Vanoverschelde et al. found that the rate of glycolysis 
during ischaemia was directly related to the degree of ischaemic injury i.e. contracture, and functional 
recovery 550. A high glucose (11 mM) + insulin prevented contracture in rabbit hearts with a low 
flow of 0.4-0.5 ml/g wet wt/min. Increased pre-ischaemic glycogen also reduced contracture. 
Lessened contracture was associated with improved functional recovery. 
Other mechanisms which increase glycolysis, including a slower glycogen depletion and less severe 
acidosis 12, 189, inosine (putatively acting by increasing pyruvate-to-alanine conversion, and 
removing glycolytic inhibition by lactate) 308, adenosine 291 (See Ch I) and reduced free fatty acids 
5 50 delay the onset of contracture. Glycogen depletion tends to reduce time to onset of contracture 
278; glycogen loading delays time to onset of contracture 189. Glucose attenuates the deleterious 
effects of long-chain a~yl carnitine (LCAC) on contracture 75. LCAC 's may disrupt Ca2+ homeostasis 
75, 399, an effect counteracted by glucose-derived ATP. 
Again, in considering the role of glucose on contracture, the local concentration of ATP appears to be 
crucial, rather than total ATP content. Intracellular compartmentation of ATP can explain many 
observations (see below). Contracture is triggered by the formation of rigor complexes, which in 
experimental conditions, bond only at very low ATP concentrations (<100 µM 307). Individual cells 
can have very low total ATP levels without contracting as long as glycolysis (from glycogen) is 
maintained 185. However, a drop in ATP to less than 150 µM in isolated myocytes precipitates 
contracture 42. Glycolytic ATP may also be essential for direct relaxation of the actin-myosin 
complexes, the so-called "plasticising" effect, reversing the formation of rigor complexes 13 
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However, there are some difficulties associated with this concept, namely that glycolytic i.e. glucose-
derived ATP, appears to be functionally associated with the sarcolemma and SR rather than the 
myofibrils (see above and below for further discussion). Glycolytic ATP may therefore be more 
important in maintaining ion homeostasis, rather than ensuring direct relaxation of the cross-bridges 
by binding to myosin. Only under conditions of high glycolytic flux rates, may the diffusion of 
glycolytic ATP to the myofibrils be sufficient to increase the rate of relaxation and prevent rigor 
formation. However, this would only be under conditions of relatively unimpaired function i.e. a 
fairly high residual flow rate, and a high glucose concentration, ensuring a large intracellular ATP 
production 14, 123. Glycolytic ATP may reduce contracture mainly by reducing intracellular Ca2+ 
accumulation by maintaining activity of the Na+ /K+ ATPase and SR Ca2+ ATPases and attenuating 
intracellular Ca2+ accumulation. While Eberli et al. 122 propose that Ca2+ is not involved in ischaemic 
diastolic dysfunction, in a low flow model with maintained developed pressure, these results do not 
translate directly to the truly ischaemic heart, which has severely impaired flow. The exact 
mechanism of glycolytic ATP protection against ischaemic contracture is unclear, and is investigated 
further in this thesis. 
f) Mechanical function on reperfusion 
Recovery of mechanical function is determined by the degree of ischaemic injury, and the conditions 
on reperfusion (see Ch I). At both periods, substrate provision can be altered, affecting eventual 
recovery. Increased glucose provision during low flow ischaemia increases the functional recovery of 
hearts 14, 49, 123, 550, mainly by reducing diastolic pressure on reperfusion, a consequence of 
reduced contracture during ischaemia, and impraved relaxation on reperfusion 13. 
Sufficient levels of ATP are essential for complete restoration of function. Sako et al. suggest that 
optimal recovery on reperfusion requires the presence of several compounds, one of which should be 
glucose 476. Glucose is necessary to ensure recovery as opposed to mitochondrial substrates 
including pyruvate (in glycogen-depleted hearts) 334, or palmitate 325. Pyruvate does, however, add 
to the beneficial effect of glucose, but glycogen or glucose appear essential to ensure a basal recovery 
334. Pyruvate may be beneficial by providing anaplerotic substrates 198. Glycolysis in early . 
reperfusion is therefore required to prevent energetic and contractile collapse. Jeremy et al 228, 229 
found that glycolysis is specifically required on reperfusion to facilitate Ca2+ homeostasis. 
Alternatively, free radicals, one of the possible causes of stunning and arrhythmias, inhibit glycolysis, 
and thus impair Ca2+ homeostasis 87. Inhibition of glycolysis, despite the presence of pyruvate and 
oxygen, depressed functional recovery severely, with a persistent Ca2+ overload 228, 229. The 
glycolytic ATP may required to reduce [Na +]i by maintaining the activity of the Na+ /K+ ATPase, 
thereby resulting in reduced Ca2+ overload 228. Na+ /K+ ATPase inhibition during ischaemia has been 
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shown to remove the protective effect of glucose on functional recovery, possibly by increasing 
cytosolic ca2+ via the Na+/Ca2+ exchange 94, 167. ATP derived from glycolysis is also functionally 
associated with the sarcoplasmic reticulum 593 , thereby providing a means of restoring Ca2+ overload 
on reperfusion by enhanced SR Ca2+ ATPase function. 
The role of glucose versus pyruvate on reperfusion does not seem clear cut. Hearts pre-treated for 1 h 
with 5.5 mM glucose and 5 U/1 insulin, or pyruvate, subjected to ischaemia, and then reperfused with 
pyruvate, lactate, acetate (all at 5 mM), or glucose and insulin, showed that reperfusion of the pre-
ischaemic glucose hearts was maximal with 5 mM pyruvate as opposed to glucose (these would have 
high glycogen) 60. Pre-ischaemic perfusion with pyruvate increased ischaemic contracture (following 
reduced glycogen), but subsequent recoveries with pyruvate and glucose were similarly high. This 
finding was similar to that reported by Kupriyanov et al 278, with a similar improvement in functional 
recovery in hearts subjected to 2h pre-ischaemic perfusion with pyruvate. This effect was attributed to 
a decreased glycogen. Deboer et al 106 found that pyruvate enhanced recovery on reperfusion, an 
effect attributed to reduced free radical generation. Pyruvate may also replenish the Krebs cycle 
(anaplerotic effects), reduce the NADH/NAD+ ratio, and increase the activity of pyruvate 
dehydrogenase, an important regulator of the Krebs cycle (see appendix). 
While palmitate is the preferred substrate on reperfusion, accounting for over 90% of ATP from 
exogenous substrates, inhibition of palmitate oxidation with increased glucose oxidation improves 
functional recovery 325. High levels of fatty acids on reperfusion limit glucose utilisation by 
competitive inhibition 459. This deleterious effect is primarily due to inhibition of glucose oxidation 
and not of glycolysis 326. Increased glucose oxidation is beneficial while insulin has no effect as lack 
of substrate is not the problem. A recent review has resolved two main hypotheses as to why 
increased glucose oxidation should be beneficial on reperfusion 354. Stimulation of glucose oxidation 
would speed the initial rate of return to total oxidative metabolism, resulting in a more rapid return to 
normal levels of high energy phosphates, which is then sustained by fatty acid or pyruvate oxidation. 
Secondly, a reduced intracellular acidosis from increased glucose oxidation versus glycolysis may be 
beneficial by reducing intracellular Ca2+ overload. 
g) Preconditioning 
Glycolytic flux is stimulated in preconditioned hearts subjected to low flow ischaemia, and may exert 
its positive effects by this mechanism 218. Several preconditioning studies have used different 
substrates on reperfusion and found that the use of pyruvate with or without glucose 142, 400, or 
deoxyglucose+acetate 142, eliminates any protective effect of preconditioning on functional recovery. 
This reduction in function is associated with impaired calcium homeostasis. Finegan et al. 136 found 
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that glucose oxidation is increased relative to glycolysis in preconditioned hearts, which may be 
beneficial (see above). However, preconditioning is associated with a reduced glycogen, which 
attenuates the fall in pHi and the rise in lactate, and may be beneficial by these mechanisms. This 
phenomenon adds to the controversy over glycogen and glycolysis, and is investigated in this thesis 
(see Ch ill). 
4) DELETERIOUS EFFECTS ASSOCIATED WITH INCREASED GLYCOLYSIS 
a) Benefits associated with depleted glycogen 
While there is much evidence to suggest that ATP derived from glycolysis is beneficial to the 
ischaemic myocardium, this may be outweighed by the accumulation of deleterious end products. A 
great deal of controversy arose from a much-quoted paper published in 1984 by Neely and 
Grotyohann 387. Beneficial effects were associated with glycogen depletion prior to sustained total 
global ischaemia. A greatly improved recovery of function was found when hearts were exposed to 10 
min anoxia prior to the ischaemic period, with or without an intervening period of reoxygenation. The 
improved recovery was correlated with a reduced lactate content at the end of ischaemia. Thus it was 
hypothesised that increased glycolysis is associated with a detrimental effect due to an increase in 
lactate and other end products. The concept then arose that increased glucose should be detrimental. 
Several other studies have shown a beneficial effect of reduced glycogen levels. 2h perfusion with 
pyruvate depleted tissue glycogen by 40-50 %, which reduced the fall in pHi but lowered ATP levels 
278. However, glycogen-depleted hearts showed a similar peak contracture to glucose hearts, although 
time to onset of contracture was greatly reduced. Functional recovery after 25 min total global 
ischaemia was significantly improved in the glycogen-depleted hearts, attributed to reduced [Ir]i 
accumulation. Glycogen reduction by hypoxic perfusion, followed by 25 min total global ischaemia, 
reduced lactate accumulation, and improved function 3. 10 min perfusion prior to ischaemia with the 
glycolytic inhibitor, 2-deoxyglucose, improved recovery of function only in hypertrophied hearts 3. 
The possible benefits of glycogen depletion also apply to preconditioning. The brief episode(s) of 
ischaemia deplete tissue glycogen prior to the sustained ischaemic period. An increased duration of 
intervening perfusion was correlated with repletion of glycogen stores but loss of recovery 588. 
A more complicated protocol compared hearts subjected to 10 min substrate-free perfusion followed 
by 30 min perfusion with pyruvate (50% glycogen depletion) with and without a subsequent period of 
glucose perfusion, hearts perfused with glucose throughout the pre-ischaemic period, and 
preconditioned hearts 482. Recovery of function was improved in the preconditioned and the pyruvate 
glycogen-depleted hearts, but only if glucose was not provided to the latter. The drop in pHi was 
lessened by interventions to reduce pre-ischaemic glycogen, but the fall in ATP was greater in these 
hearts. The conclusion reached was that glycogen depletion per se was not sufficient to explain the 
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beneficial effects of preconditioning, but interventions which limited glycolysis and thus Ir 
accumulation were beneficial. 
b) Mechanism of benefit of glycogen depletion 
i) Protons 
While intracellular pH always falls in ischaemic hearts, the extent of the drop can be modified by 
changes in the amount of glycogen in the tissue at the onset of ischaemia. Glycogen-depleted hearts 
show less of a fall in intracellular pH during ischaemia 151 . Increased [Ir]i accumulation increases 
[Na+]i, and in turn increases [Ca2+]i via the Na+/lr and Na+/Ca2+ exchange mechanisms 303_ 
Glycogen depletion is associated with reduced [Na +Ji accumulation, linked to reduced Ir 
accumulation 528 . Recovery of function is improved, with reduced cytosolic Ca2+ overload. However, 
while some reports have correlated intracellular pH with ischaemic injury 99, others have dissociated 
these effects 92, 151 . The relationship between increased acidosis and increased ischaemic injury is 
not clear (in cardioplegia, for example, a lower pHo is protective 564). 
ii) Lactate 
Lactate is utilised as a substrate by the heart if oxygen is present. If the blood supply is reduced, 
stimulation of glycolysis increases intracellular lactate levels. Lactate added to the perfusate of an 
isolated heart has been shown to impair recovery of an ischaemic heart 92, 239, 387. Lactate exits 
from the cell in a Ir-coupled efflux 439 such that increased extracellular lactate would reduce the 
gradient, preventing Ir extrusion which may in turn lead to intracellular Ca2+ accumulation. A Na+ !Ir 
exchange inhibitor diminishes the deleterious effects of increased extracellular lactate 239, 
presumably by attenuating the consequences of Ir overload. Cross et al. 92, however, dispute this 
hypothesis, given that no change in pHi during ischaemia with increased extracellular lactate was 
found. The effects of lactate were attributed more to glycolytic inhibition, accounting for the reduced 
Ir load, but also for its deleterious effects by reduced ATP production. Lactate may inhibit glycolysis 
at the level of GAPDH 362,468, both directly and by a build-up ofNADH (see appendix). As lactate 
accumulates, the conversion of pyruvate to lactate is inhibited. This also prevents the oxidation of 
NADH, which then accumulates 362. The altered redox balance may affect many other enzyme 
reactions. Lactate in itself may harm cells by imposing an osmotic load, and possibly contributing to 
mitochondrial damage 225. Lactate can leak into the extracellular space and affect the membrane, 
thereby shortening the action potential 342, 478 by affecting the KATP channel 249 or by increased 
Na+ channel conductance 17 4 ( see Ch II for further discussion on role of lactate). 
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Lactate may activate KATP channels 249, thereby shortening the action potential and predisposing to 
arrhythmias. However, in a myocyte model of anoxia and reoxygenation, Geisbuhler et al 154 
reported no deleterious effect of high concentrations of lactate (10 mM and 50 mM) on anoxic 
myocytes. Damage was, however, found if pH was lowered. The role of lactate is unclear (see Ch I). 
Studies altering pre-ischaemic glycogen have found no correlation between end-ischaemic tissue 
lactate and functional recovery 163, 286. In addition, the addition of 10 mM lactate together with 11 
mM glucose on reperfusion improves functional recovery by 75% 163. I have briefly attempted to 
clarify these issues by repeating previous work 92 and do not find that the addition of lactate with a 
reasonably high residual low flow (0.5 ml/g/min) confers any particular disadvantage (see Results 6). 
iii) Sugar phosphates 
Kusuoka and Marban 282 found increased diastolic dysfunction with glycolytic inhibition in normally 
perfused hearts. This effect was associated with increased sugar phosphates, which may impair Ca
2
+ 
homeostasis. Phosphomonoester resonance, which reflects the phosphorylated compounds including 
G6P, F6P, a-GP and AMP, increased during ischaemia and has been correlated with reduced recovery 
219. A similar predictive correlation was found by Schaefer et al. 483 . However, glycolytic ATP is 
linked to Ca2+ homeostasis by functional coupling with SR Ca
2
+ ATPase re-uptake 593. A decreased 
Ca2+ would be expected to reduce diastolic impairment. The relative rates of sugar phosphate 
accumulation vs. ATP production may thus be crucial in determining the efficacy of glucose. 
Increased G6P production would also lower ATP levels, as this step (from glucose) consumes an ATP 
(see appendix). If glycolysis were inhibited, this would be detrimental as no replacement ATP would 
be provided 28. 
The above factors may account for any detrimental effects of a high glucose concentration, and for 
some of the controversy surrounding glucose and glycogen (see Results). 
c) Evidence contradicting benefit of glycolytic inhibition 
i) Failure of glycogen depletion to provide benefit 
Taegtmeyer et al. tried to replicate the findings of Neely and Grotyohann 387, with little success. 
Lagerstrom et al. 286 reported that a period of anoxia or substrate-free perfusion prior to 30 min total 
global ischaemia reduced tissue glycogen, but did not improve recovery of function on reperfusion; 
rather, function was significantly impaired. Interestingly, the anoxic hearts did not show a reduction 
in tissue lactate despite a 60% decrease in glycogen. This lactate could be accounted for by the 
residual glucose remaining in the tissue following cessation of flow. In substrate-free hearts with no 
residual glucose, lactate levels decreased substantially. A later publication by the same group 163 
found similar results with a shorter period of ischaemia (15 min). There was no correlation of lactate 
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build-up with functional recovery, but a depletion of glycogen was detrimental. Postischaemic 
glycogen availability and functional recovery were well correlated. 
A possible reason for discrepancies between results may be differences in the actual tissue glycogen 
levels due to differences in perfusion conditions and protocols. Reported values of normal tissue 
glycogen after a period of perfusion range from 403,286,487 to 120 93,348,387 µmoVg dry weight 
(8 - 24 µmoVg wet weight). However, there is no consistency in findings from different reports with 
the same pre-ischaemic tissue glycogen levels. For example, Neely et al. 387 found that glycogen 
depletion from a high level was beneficial. Cross et al. 93 , with a similar pre-ischaemic high glycogen 
level and the same duration of ischaemia (albeit with a residual flow rate) found that recovery was 
impaired with reduced tissue glycogen. Alternatively, McElroy et al. 348 found that glycogen loading 
to values twice that of Neely et al. 387 was beneficial. 
ii) Increased glycogen 
Contrary to studies which suggest that glycogen depletion is beneficial, a number of reports show that 
glycogen loading can benefit hearts exposed to ischaemia. Oldfield et al. 398 noted that preoperative 
glucose-insulin-potassium administration increased tissue glycogen levels, and this was associated 
with a lower incidence of postoperative hypotension, reduced arrhythmias and fewer complications. 
Glycogen loading with insulin greatly improves the tolerance of isolated rabbit hearts to ischaemia, 
while glycogen depletion by epinephrine infusion severely impairs ischaemic tolerance 348. Fasting, 
which increases glycogen content, also increases the resistance of hearts to an ischaemic episode 487. 
Improved recovery of function, reduced membrane damage and reduced loss of adenine nucleotides 
were recorded in hearts from fasted animals. V anoverschelde et al. 549 reported that increased 
glycogen by adding palmitate to the perfusate of isolated rabbit hearts significantly improved recovery 
of function while Doenst et al. 114 reported that glycogen loading and lactate perfusion mimicked the 
protective effects of preconditioning, improving tolerance to ischaemia. 
A recent paper by Cross et al. 93 purports to explain the controversy over glycogen, suggesting that 
while glycogen is being utilised, the ATP provided supplies necessary energy. Reperfusion at this 
stage results in good recoveries. However, once the glycogen has been used up (in the absence of 
glucose), the accumulation of intracellular metabolites outweighs the advantages conveyed by ATP, 
with impaired functional recovery. Provision of a Na+llr exchange inhibitor on reperfusion after 
extended ischaemia resulted in improved recovery of function, suggesting that Ir concentration was 
high following glycogen depletion 93. This finding was reported in an ischaemic model of relatively 
"high" coronary flow (0.5 mVmin/g wet wt) in isolated rat hearts. In a model of ultra low flow 
ischaemia, the results may differ slightly due to differences in the relative rates of ATP production 
and metabolite accumulation. 
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iii) Glucose versus glycogen 
Major concerns with studies purporting to show deleterious effects of glycolysis are 1) glycogen is 
confused with glucose as the source of glycolytic ATP and 2) most studies have been done using 
models of total global ischaemia, where glycolysis is limited by substrate and may also be inhibited 
by metabolite build up. Glucose is therefore not supplied throughout the totally ischaemic period. If 
glycogen loading is detrimental, this does not necessarily imply that increased glucose is detrimental; 
alternatively, if glycogen depletion is beneficial, glucose should not necessarily be removed. In 
addition, many of the early studies using brief periods of anoxia can now be said to mimic 
preconditioning 83 , 290, 498, 603 (see Ch ill), which may act by completely different pathways other 
than glycolytic involvement. I have attempted to correlate changes induced by preconditioning with 
changes in glycolysis and find no significant relationship (see results 4 and 5). Studies implicating a 
deleterious effect of glucose must be considered carefully in terms of the experimental model, and the 
source of glycolytic substrate. The hypothetical basis for the effects of the different sources of ATP 
lies partly in the functional compartmentation of ATP within the cell. 
d) Changes in glucose concentration and coronary flow 
High concentrations of glucose have been used in several different models. Runnman et al 470 found 
that in hypoxic hearts an increased glucose concentration lowered glycogen utilisation with no change 
in ATP production, and was associated with improved cardiac function. On the contrary, Owen et al 
425 found that a high glucose concentration in a cardioplegic solution administered at intervals during 
the arrest period was detrimental to the hearts, also linked to inhibited glycogen breakdown. Reduced 
glycogen utilisation reduced overall ATP production from glycolysis. This effect was detrimental 
despite a reduced lactate production. Different mechanisms exist in hypoxia compared to the heart 
arrested and maintained with cardioplegia which would account for different responses to glycogen. 
Apstein et al. 14 compared the effects of a high concentration of glucose (28 mM) with insulin ( 100 
U/1) compared to a low glucose concentration (5.5 mM) without insulin, at two different low coronary 
flow rates (0.6 and 0.5 ml/g/min). The higher glucose concentration inhibited the development of 
contracture at both flow rates, but improved functional recovery on reperfusion was found only with a 
higher flow rate. Vanoverschelde et al. 550 also found that a high glucose concentration+ insulin (in 
the presence of palmitate) abolished contracture ( 10 mM glucose + 140 mU/L insulin) compared to a 
lower glucose concentration (5 mM glucose+ 70 mU/1 insulin) at a low flow rate of 0.4-0.5 ml/g/min. 
Recovery of function was also significantly improved. 
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5) PROPOSED COMPARTMENTATION OF GLYCOLYTIC ATP 
a) Compartmentation of ATP 
Many cell components are compartmented - e.g. intracellular Ca2+ is highly compartmented in the 
myocyte, distributed among the SR, the Ca2+ -binding proteins and the cytosol. The adenine 
nucleotides including ATP are also strictly compartmented, as highlighted in ischaemia 153. 
Functional compartmentation of the high energy phosphates, CP and ATP, was proposed by 
Gudbjarnason et al. 173, with CP used as a shuttle of ATP to the myofibrils. A reduction in CP 
inhibits the transfer of ATP. Local ATP regeneration near the SR Ca2+ ATPase pump in skeletal 
muscle 272 and maintenance of a local high ATP/ADP ratio at the myofibrils 558 show a preferential 
diversion of ATP to sites of utilisation. In liver cells, clear gradient of ATP have been shown, with 
nonuniform distribution of ATP-generating and ATP-consuming systems 19. Substrates may also be 
compartmented, such that two intracellular "pools" of lactate may exist, with little interchange 
between these 71 . One pool may be tightly bound to macromolecules, while the other is free to diffuse 
out of the cell, or to exchange with pyruvate. 
Ottaway and Mowbray 419, in an extensive review, provided evidence for the compartmentation of 
glycolysis, with "microenvironments" within the cell. A high degree of functional organisation of the 
glycolytic enzymes, particularly in muscle cells, would allow for efficient "channelling" of the 
substrate through its catabolic pathway 576. Other studies have provided evidence of 
compartmentation of glycolytic ATP versus oxidative ATP in different cell types e.g. liver 19 
vascular smooth muscle 427, myometrium 453. A further separation can be made between ATP 
derived from glucose and from glycogen on the basis of cellular location 331 , 332, and preferential 
oxidation of glycogen in the normoxic heart 161. 
In myocardial ischaemia, it has been postulated that ATP derived from the anaerobic breakdown of 
glucose (glycolysis) is of particular benefit to the myocyte, in that the ATP is synthesised near the 
membrane, and thus can be utilised by the membrane processes, with maintenance of membrane 
integrity and ionic homeostasis 410. In addition, ATP near the cell membrane may be preferentially 
involved in maintenance of the activity of the sarcolemmal pumps which help to maintain the normal 
ionic composition of the cell (see above). While compartmentation is difficult to prove, this concept 
explains many observations and has been invoked by a number of authors 49, 108, 424, 570, 571. 
Lynch and Paul 332 suggested that glucose and glycogen metabolism form two functionally exclusive 
compartments in the cytoplasm of vascular smooth muscle. The pathways are coupled to the specific 
cellular processes which utilise the ATP. Oxidative phosphorylation and glycogen (which supplies 
substrate for the oxidative pathway) may supply ATP for contraction, while glycolysis (glucose) may 
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be required to maintain sarcolemmal pump function and membrane integrity 570. Evidence to support 
this hypothesis in the isolated rat heart comes from the observation that glycogen is preferentially 
oxidised, compared to glucose, with glycogen mobilised following an increase in contraction 161. The 
explanation for the functi~mal distinction of ATP may be the physical location within the cell of the 
different substrates and enzymes. 
b) Location of enzymes within the cell - basis for compartmentation theory 
i) Oxidative phosphorylation 
Oxidative phosphorylation occurs in the mitochondria, which are localised in the myocyte near the 
myofibrils 381 . The ATP produced in the mitochondria needs to be transported to the sites of 
utilisation. In the muscle cell, the myofibrils are the primary energy consumers. Transport of ATP to 
the myofibrils is carried out by the CK shuttle, which is required to maintain a local ratio of 
ATP/ADP around the myofibrils 173, 272, 558, thereby maintaining contraction. In ischaemia, CP 
levels fall and mitochondrial activity is inhibited. ATP becomes trapped in the mitochondria 153, 
which in turn become major sites of ATP utilisation as the mitochondrial ATP synthase reverses, and 
becomes an ATPase 466 (this mechanism is not thought to be important in the rat 465). Inhibition of 
oxidative phosphorylation has a major depressant effect on tension 7,116,571, an effect slowed down 
by the presence of glucose. Inhibition of glycolysis with maintained oxidative phosphorylation has a 
much lesser effect on reduction in tension 571. These findings and others 410 suggest that ATP from 
oxidative phosphorylation is used preferentially by the contractile apparatus. In vascular smooth 
muscle, the evidence is very convincing for compartmentation of glycolytic vs. oxidative ATP in 
terms of membrane function (glycolytic) and contraction (oxidative phosphorylation) 332, 427, 
findings which presumably can extend to the myocytes. Hasin et al. 182 showed a functional 
compartmentation of glycolysis (Na+ /K+ ATPase function) and oxidative phosphorylation 
( contraction) in isolated cardiac myocytes during metabolic inhibition. 
ii) Glucose breakdown 
In vascular smooth muscle, an unexpectedly high proportion of glucose is converted to lactate under 
fully oxygenated conditions. Paul 427, 428 suggested that this was due to a preferential utilisation of 
glycolytic ATP by the Na+/K+ ATPase membrane pump. Following Na+/K+ ATPase inhibition by 
ouabain, glycolysis (in terms of lactate production) was reduced, with no change in force 
development. When Na+/K+ ATPase activity was stimulated, lactate production was increased 427. 
While this mechanism requires a feedback regulation of ATP utilisation on glycolytic flux which is 
difficult to understand, the evidence for association of glycolysis with the membrane is fairly 
convincing. Paul et al. 429 found that the enzymes of the glycolytic cascade are associated with the 
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plasma membrane in smooth muscle, allowing isolated vesicles to produce ATP and maintain Ca2+ 
pump function. Pump function was blocked by iodoacetate. 
It was initially thought that the enzymes and substrates of glycolysis were freely dispersed in the 
aqueous medium of the cytoplasm 419. However, subsequent studies have shown specific localisation 
of the glycolytic enzymes within the cell 419. The glycolytic enzymes, GAPDH and PK, have been 
shown to bind to sarcolemma and SR membranes, more so to the former 434. The binding was 
attributed to attraction to charged phospholipids, which occur in greater amounts in sarcolemmal 
membranes. Further evidence for physical compartmentation comes from excised inside-out patches 
of sarcolemmal membrane. Addition of substrates for the ATP-producing steps of glycolysis 
(phophoglycerokinase and pyruvate kinase) block the KATP channel 571, by a localised production of 
ATP. This finding suggest that key glycolytic enzymes are located in or near the sarcolemma. 
Glycolytic enzymes are also functionally coupled to the SR, maintaining Ca2+ homeostasis 593 . The 
coupling of glycolytic enzymes to the sites of ATP utilisation, to allow efficient utilisation of glucose, 
substantiates the hypothesis of functional compartmentation. 
Glycolytic ATP appears to be utilised preferentially by the membrane functions, on the basis of 
measurements of K+ efflux. If glycolysis were inhibited in myocytes with maintained oxidative 
phosphorylation, a large efflux of K+ was found, with little change in tension 571. However, if 
oxidative phosphorylation were inhibited, tension was depressed, but K+ efflux was much lower. 
While glycolytic ATP therefore appears to prevent K+ efflux, this does not imply that glycolytic ATP 
cannot be distributed to the contractile apparatus. However, the means of ATP transport may be 
limited in conditions of metabolic impairment such as hypoxia and ischaemia. Glycolytic enzymes are 
not found near myofibrils in any great quantity 419, suggesting that glycolytic ATP is not synthesised 
in these regions, and thus is of less importance than oxidatively derived ATP for the contractile 
apparatus. 
Higgins et al. 203 found that individual myocytes incubated with phospholipase C were more resistant 
to enzyme loss if glucose were present. Glucose may inhibit membrane degradation, possibly by 
increasing the degree of phosphorylation of the phospholipids, thought to be important in maintaining 
membrane stability. Energy is also required for membrane repair. Extending this finding to normoxic 
isolated rat hearts, iodoacetate increased enzyme release, while cyanide had no effect 202. 
iii) Glycogen 
Glycogen particles are located along the mitochondrial columns between myofibrils, and are also 
present in the perinuclear sarcoplasm and the SR including the sub-sarcolemmal cisterns 381 . The 
enzymes for glycogen breakdown (phosphorylases etc.) have been found near the sarcoplasmic 
reticulum in cardiac muscle 128. Two forms of glycogen are found, proglycogen, and macromolecular 
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glycogen (see appendix). The former constitutes about 50% glucose moieties, with the rest consisting 
of glycogen enzymes. This form is thought to be the precursor of macromolecular glycogen 322. 
Classic macromolecular glycogen particles also contain enzymes for glycogen synthesis and 
breakdown 506, including all the glycolytic enzymes. Thus the glycogen-enzyme complexes form 
"metabolons" 506 for the efficient synthesis and breakdown of glycogen 
The substrate supply from glycogen is co-ordinated with mitochondrial substrate utilisation whereas 
glucose utilisation correlates with Na+ /K+ ATPase activity in smooth muscle cells 427. This 
arrangement would maximise the efficiency and response time of energy transduction within the 
smooth muscle cell. In the myocyte, the distances are greater because the cell is much larger, and the 
demands on energy are also increased with the much greater contractile component of the cell. Thus 
compartmentation within the myocyte is plausible given the requirement for sustained efficiency of 
contraction. In hepatocytes, Aw et al. 19 also suggest that there are 2 pools of ATP - one cytosolic, 
and one near the membrane, on the basis of ATP utilisation by membrane (Na+ /K+ ATPase) and 
cytosolic (ATP-sulfurylase) enzymes. Differences in the mechanisms of ATP depletion show that the 
different elements are not exposed to the same average overall ATP level. Intracellular 
inhomogeneities of ATP can be attributed to different rates of ATP-producing and ATP-consuming 
sites, such that ATP produced in large amounts from the mitochondria supply the cytosolic elements. 
These elements reduce the amount of ATP at the membrane because of rapid utilisation of ATP 
diffusing from the mitochondria, such that at further distances the ATP is depleted. Thus 
mitochondrial ATP utilisation by the membrane components appears to be limited by diffusion and 
steepness of gradients within the cell. A localisation of energy-producing pathways near energy 
consuming pathways thereby ensures efficient supply and utilisation of energy. Paul et al 429 suggest 
that glycogenolysis is linked to the contractile and cytosolic elements in vascular smooth muscles, 
rather than membrane functions. In conditions when ATP supply is plentiful, the different systems 
may compensate for each other. However, if energy supply is limited, the source of energy is crucial 
depending on the relative importance of the various cell components. In ischaemia, the different 
effects of glycogen-derived, glucose-derived and oxidative ATP on contracture and on functional 
recovery observed in the present studies may be explained by these differences. 
6)SUMMARY 
Glucose has many benefits for the ischaemic heart, including maintenance of membrane activity, 
inhibition of contracture, reduced arrhythmias, and improved functional recovery. However, the 
possible deleterious effects associated with increased glycolysis cannot be ignored, and may explain 
some of the controversial findings reported in the literature. In addition, glucose must be distinguished 
from glycogen on the basis of the effects of modified pre-ischaemic glycogen levels vs. changes in 
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glucose concentration on subsequent ischaemic tolerance. These differences may be explained by 
functional compartmentation within the cell. 
Many of the studies above support the hypothesis of the importance of an optimal balance between 
glucose delivery and removal of metabolites as a crucial determinant of ischaemic and reperfusion 
damage. While at moderate low coronary flow rates, the benefit of glycolysis appear extensive, the 
controversy arises at very low flow rates, or in the absence of flow; and when glycolytic substrate may 
be provided in excess. There is good evidence that glycolytic substrate can be in excess during 
ischaemia, which would prove deleterious. Under conditions of total global ischaemia, an excess 
accumulation of lactate, Ir, NADH, sugar phosphates and Pi may indeed prove detrimental, by a 
variety of mechanisms. However, an optimal balance between the rate of ATP production and rate of 
accumulation of metabolites ( determined by the glycolytic rate, and removal of metabolites by the rate 
of washout), may ensure optimal recovery. I wished to test this hypothesis under conditions of ultra 
low flow ischaemia, where the balance between the rates of glycolytic ATP production and metabolite 
accumulation may be especially crucial in determining the tolerance of the myocardium to ischaemia. 
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III. PRECONDITIONING 
1) WHAT IS PRECONDITIONING? 
a) Introduction 
Preconditioning is defined as one or more brief periods of ischaemia and reperfusion (preconditioning 
period) which protect against the effects of a subsequent sustained ischaemic episode. Manipulations 
which mimic preconditioning i.e. improved tolerance of ischaemia, have also been defined as 
preconditioning. The strongest, and most reproducible, result of preconditioning is a reduction in 
infarct size. 
The phenomenon of preconditioning, or so-called "endogenous" protection, was first described by the 
group of Reimer, Murry and Jennings 457, where contrary to expectations, repeated brief episodes of 
ischaemia in the dog did not further deplete the tissue of ATP, and did not cause necrosis. This 
followed on from earlier work showing inhibited necrosis with repeated ischaemic events despite an 
overall occlusion time of 200 min 152. The protective effects of four 5-min episodes of ischaemia (I), 
with intervening 5-min periods of reperfusion (R) were then tested on coronary occlusion sustained 
for 40 min or 3 hrs 375. The degree of necrosis associated with the shorter, but not with the longer 
period of sustained ischaemia, was attenuated. While ATP is depleted by the initial ischaemic period 
378, the subsequent rate of fall in ATP is slower. Two general mechanisms whereby preconditioning 
could afford protection were mooted: slowed ATP depletion, and limited catabolite accumulation 
during sustained ischaemia 3 7 5. Reduced glycolysis following glycogen depletion by a preceding 
period of anoxia is beneficial, an effect attributed to reduced accumulation of end products 387. Our 
hypothesis focuses on the possible role played by a reduction in glycolysis brought about as a result of 
glycogen depletion following preconditioning. In addition, the role of glycolysis from glucose was 
investigated (see Results 4 and 5). 
These early studies were followed by a burst of publications particularly from 1991 to the present. 
Preconditioning has been shown to protect against many of the consequences of ischaemia. Many 
different hypotheses of the mechanism of preconditioning have been proposed, several of which 
revolve around the initial observation of preserved energy supply. A number of possible "triggers" 
have been investigated, including stunning, free radicals, PKC activation, cAMP, adenosine, KATP 
channel activity, and glycogen depletion (see Ch I for background). Many of these are interrelated, 
and in order to put our particular hypothesis in context, a full understanding of possible mechanisms, 
and interrelated events is required. 
Despite all this work on preconditioning, there is still some controversy over the degree and 
reproducibility of protection, and the mechanisms involved. While reduction in infarct size appears to 
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be a consistent result, some other end points do not show the same degree of reliability. Sufficient 
evidence from a number of researchers suggests that the effects of preconditioning on these alternate 
end points are not always certain. However, the interdependent relationship between the different end 
points (as discussed below) should imply that if one shows a difference, the others should also -be 
affected. A clear understanding of the mechanism of protection for each end point is required. In 
addition, the equivocal findings with regard to the mechanism of preconditioning suggests that either 
the phenomenon is not as remarkable as has been suggested, or else that the experimental approach 
has often been inappropriate. The choice of end point, an appropriate protocol, and interpretation of 
the evidence must be correct. These issues are analysed in depth, with particular reference to the 
proposed role of glycolysis, ATP and glycolytic metabolites in the mechanisms associated with 
preconditioning. A figure (Fig ill.1) is included to illustrate different terms and concepts discussed 
below . 





i) no of 1/R episodes 
ii) duration of I episodes 
iii) duration of R 
episodes 
iv) extent of reperfusion 
Sustained ischaemia Reperfusion 
Contracture Arrhythmias 
Coronary flow Functional recovery 
High energy phosphates Infarct size 
Regional ischaemia Changes in substrate 
Total global ischaemia 
Low flow ischaemia 
Hypoxia 
Trigger of protection Measurement of protection 
Fig IIl.1 . Diagram of preconditioning showing points of measurement of indices of protection, changes in 
protocols of preconditioning, and changes in sustained, or "test " ischaemia 
b) Protection conferred by preconditioning 
i) Infarct size 
The most significant and reproducible effect of preconditioning is a reduction in infarct size after a 
period of reperfusion, the main predictors of which are the size of the area at risk, the collateral blood 
flow, and myoc~dial oxygen consumption 194, 485. 
Preconditioned dog hearts ( 4x5 min I + 5 min R prior to 40 min sustained occlusion followed by 
reperfusion) have a 75% reduction in infarct size compared to control animals 375. Most other studies 
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with preconditioning have shown a reduction in infarct size, in dogs 169, 172, 421 , pigs 269, rabbits 
82, 318 and rats 220, 313 , 319, 504, 588, 598, with coronary occlusion models or with total global 
ischaemia. 
ii) Jschaemic contracture and diastolic dysfanction on reperfasion 
Despite improved infarct size and functional recovery (see below), preconditioning paradoxically 
appears to increase contracture in the majority of cases. Attenuated time to onset of ischaemic 
contracture in an isolated perfused heart following preconditioning was first described by Asimakis et 
al. , with one or two episodes of preconditioning (5 min I+ 5 min R) 18. While both preconditioning 
protocols reduced time to onset of contracture, two periods of preconditioning had the greater effect. 
Peak contracture during ischaemia was also increased with increased preconditioning. Both groups 
however, recovered function to a similar degree on reperfusion, which was better than in control 
hearts (see also 66). Preconditioning with either 5 min I or 5 min hypoxia (hypoxic preconditioning -
see below) also reduced time to onset of contracture, but reduced diastolic pressure on reperfusion 
290, possibly reflecting improved Ca2+ handling on reperfusion 528. 
In contrast, Steenbergen et al. found that with an increased number of cycles ( 4x5 min I + 5 min R), 
the time to onset of contracture was not significantly affected by preconditioning, and in fact slightly 
delayed 512. These results have not always been reproduced, in that using a similar protocol resulted 
in a significant reduction in time to onset of contracture in preconditioned rat hearts 171 , with 
improved functional recovery. 
Contracture and functional recovery are thus not well-correlated in preconditioned hearts, and 
highlight the problem of using contracture as an index of ischaemic injury in all cases. 
The effects of preconditioning on the precipitators of contracture are contradictory. Preconditioning 
tends to reduce both ATP and intracellular ca2+, which have opposing effects on contracture 512. 
While preconditioning is thought to attenuate high energy phosphate utilisation 224, an increased 
ATP depletion in early ischaemia ( <20 min) has been found in preconditioned rat hearts, and 
correlated with accelerated contracture 266. Provision of glycolytically-derived ATP is thought to be 
especially crucial in delaying the onset of contracture 424 and improving recovery, and yet glycolysis 
is usually attenuated in preconditioned hearts 136, 224, largely as a result of glycogen depletion 588 
or slowing in the rate of glycogenolysis 574. In preconditioned rabbit hearts exposed to sustained low 
flow ischaemia ( 10% of normal - 0 .4 ml/min/ g wet wt), however, contracture is reduced, followed by 
improved recovery of function 218. During the low flow ischaemia, however, preconditioning 
increased glucose uptake and ATP production, which could explain the lessened contracture 424. 
Thus precipitation of contracture by preconditioning is consistent with previous findings of the level 
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(or rate of production) of ATP as a determining factor in contracture 189, 271 (see Ch I). Reduced 
intracellular Ca2+ overload found in preconditioned myocardium 512 is inconsistent with increased 
peak contracture 189; however, the decreased Ca2+ is only evident after 15 min ischaemia, at which 
time contracture has usually occurred 512. 
The question remains as to how the heart is protected despite an increase in contracture with 
preconditioning. The answer may lie partially in the degree of contracture which the heart can 
tolerate. Increased contracture (within certain limits) may be well tolerated by improved protection 
with preconditioning. If the contracture precipitated by preconditioning were excessive, this could be 
deleterious. I also wished to confirm the role of glycolysis in preconditioning, and the effects of 
increased glucose uptake by preconditioning on ischaemic contracture and functional recovery. 
iii)Functional recovery and stunning - an index of protection 
There is little evidence to suggest that preconditioning improves functional recovery after the 
sustained ischaemic period in large animals. The early studies of preconditioning, in the dog, did not 
record recovery of myocardial function 224, 375, 377, 457. In a subsequent study, also in the dog, no 
difference in functional recovery between control and PC hearts was found, after 15 min sustained 
ischaemia and 3 hrs reperfusion, despite marked protection against infarction 421. The short 
ischaemic period was chosen to induce stunning, against which preconditioning was not effective. All 
hearts with an ischaemic subendocardial blood flow of more than 0.2 ml/min/g were excluded from 
the study (as in the Murry, Reimer and Jennings studies) (normal in vivo flow rates - 1-1.6 ml/min/g). 
Preconditioning with a longer period of ischaemia which would induce necrosis ( 4x3 min occlusion + 
5 min R, followed by 60 min occlusion and subsequent reperfusion), showed a similar lack of 
protection against stunning and/or reversible injury with improved functional recovery, despite 
marked reduction in infarct size in dogs 420. Ischaemic preconditioning also does not improve 
systolic shortening on reperfusion in dogs 498. Preconditioning in the pig heart, which has a low 
collateral flow during ischaemia, also showed no difference in segment shortening between control 
and preconditioned hearts 360, although CP levels were improved in ischaemia and reperfusion, and 
recovery of ATP was better. pHi was also higher in preconditioned hearts during ischaemia. 
The only evidence of protection against stunning in dog models is from a model using repeated brief 
episodes of ischaemia and reperfusion, showing an attenuated decline in function with succeeding 
episodes 1, 81 . These findings do not, however, necessarily extend to a "true" preconditioning 
protocol, with improved mechanical recovery following a sustained ischaemic episode. 
In smaller animals, improved functional recovery is commonly used as an index of protection with 
preconditioning. In the isolated rabbit heart, improved developed tension has been found on 
reperfusion after 5 min I+ 5 min R followed by 60 min total global ischaemia, increasing from 16% 
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in controls to 74% with preconditioning 400. Improved wall motion on reperfusion after sustained 
coronary occlusion has been observed in preconditioned hearts, with a significant improvement in 
segment shortening 82. End-diastolic pressure, or "diastolic stiffness" (change in end diastolic 
pressure with incremental changes in intraventricular balloon volume) is also attenuated following 
reperfusion in the preconditioned rabbit heart 368. However, several reports testing preconditioning 
effects on ischaemia induced by coronary occlusion 358, 532 or with total global ischaemia 447, 479 
have found no improvement in functional recovery on reperfusion in rabbits. 
Cave and Hearse purported to be the first to examine the role of preconditioning in an isolated 
globally ischaemic rat heart. Using one cycle of 5 min I+ 5 min R, an improved cardiac output during 
recovery from varying periods of sustained ischaemia (10-25 min) was observed 65. A significant 
difference between control and preconditioned hearts was observed when these were subjected to 15 
min or more sustained ischaemia. The "half-life" of the curve relating reduction in function vs. time of 
ischaemia, was delayed by preconditioning, from 15.6 min to 22 min. These findings were 
corroborated by Zhai et al. 603, also in an isolated working rat heart. Asimakis et al. also reported 
improved functional recovery following preconditioning with one or two cycles, in an isolated 
Langendorff-perfused rat heart with a left ventricular balloon 18. However, two reports 97, 577 did 
not find improved recovery with only one or two cycles of preconditioning in the rat. At least 4 cycles 
were required for protection against postischaemic mechanical dysfunction. In general, in larger 
animals preconditioning does not appear to improve functional recovery; in rabbits, the results are 
equivocal; and in rats, the tendency has generally been for improved recovery of function. 
iv) Functional recovery vs. infarct size 
An important question is whether a reduction in infarct size explains improved functional recovery in 
preconditioned rat hearts. These variables were correlated in isolated rat hearts, with changes in the 
duration of sustained ischaemia following preconditioning. Recovery was directly correlated with 
infarct size, suggesting that the improved function is due to reduced infarct size, and not to reduced 
stunning 220. Thus if either functional recovery or infarct size are affected, the other index should be 
likewise altered. This report does not, however, offer conclusive evidence that preconditioning does 
not protect against stunning, but is consistent with observations on infarct size protection by 
preconditioning. A working hypothesis is that preconditioning delays the onset of necrosis and thus 
irreversible injury, rather than the short term effects of stunning, which do not involve the 
mechanisms of necrosis, but rather have a transient effect at the level of the myofilament (see Ch I). 
However, results with shorter periods of ischaemia in rats (15 min 65) or measurement of segment 
shortening in rabbits 82 suggest that stunning may be partially attenuated by preconditioning. 
(Stunning has also been proposed as one of the mechanisms triggering preconditioning- see below). 
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v) Changes on reperfusion in preconditioned hearts 
Some investigators have looked at the changes on reperfusion in preconditioned versus control hearts. 
A lesser fall in pHi was recorded in preconditioned myocardium following sustained ischaemia, 
together with a higher coronary flow 98. A higher coronary flow on reperfusion was also reported 
following total global ischaemia with preconditioning in the rat heart 18, 237. 
Substitution of pyruvate for glucose upon reperfusion after sustained ischaemia eliminates any 
beneficial effects of preconditioning on functional recovery 400, despite the benefits usually 
associated with pyruvate on reperfusion (see Ch I and II). Pyruvate given in addition to glucose on 
reperfusion also attenuates the effect of preconditioning on functional recovery, Ca2+ accumulation 
and pH 140. This points to a beneficial effect of glycolysis on reperfusion of preconditioned hearts. If 
preconditioned hearts were reperfused after sustained ischaemia with lactate + glucose, no effect was 
found. However. if preconditioned hearts were reperfused with pyruvate or 2-deoxyglucose + acetate, 
high energy phosphate levels were lower and functional recovery was impaired 142. Glycolytic 
substrates may therefore be better on reperfusion in preconditioned hearts, although restoration of 
mitochondrial function appears essential. Glucose provision could be a stop-gap measure, prior to the 
delayed recovery of mitochondrial function following ischaemia (see above for controversy over 
pyruvate on reperfusion). However, in contrast Finegan et al. found that glycolysis (in the presence of 
palmitate) was inhibited by preconditioning on reperfusion after sustained ischaemia, although 
glucose oxidation was unchanged 136. The reduced glycolysis with preconditioning was associated 
with a reduced W accumulation, which may be beneficial by reducing Ca2+ influx. The effects of 
different substrates on reperfusion in preconditioned hearts are a point of controversy, and difficult to 
understand. 
vi) Ventricular arrhythmias 
Following 5 min ischaemia with increasing durations ofreperfusion in rat hearts in vivo, the incidence 
of postischaemic ventricular arrhythmias was recorded after a second episode of 5 min regional 
ischaemia 495. With intervening periods of 10 to 20 min, the incidence of ventricular arrhythmias 
after the second ischaemic period was very low. Although an increased duration of reperfusion 
increased the incidence of arrhythmias after the second ischaemic period, a substantial antiarrhythmic 
effect was still evident. The incidence of arrhythmias is also reduced with increased numbers of 
ischaemic episodes 418. 
Preconditioning also substantially reduces the arrhythmias during the ischaemic period in rat models 
ofregional ischaemia 299,313,319,504 and in the dog 555. One study reports an increased incidence 
of arrhythmias in the preconditioning reperfusion period (following 5 min coronary occlusion), but 
not at any later stage 598. This effect was surmised to be due to the duration of ischaemia associated 
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with vulnerability to arrhythmogenesis 27. A "dose" dependency of protection against arrhythmias has 
been found in the blood-perfused rat heart, with reduced arrhythmias with increased episodes of 
preconditioning 299. The mechanism of reduced arrhythmias may be related to reduced cAMP found 
in preconditioned hearts 479 (see below). 
vii) Hypoxic injury and low residual flow 
The effect of 5 min I + 5 min R was tested on 30 min total global ischaemia, 25 min substrate free 
hypoxia, or 60 or 90 min hypoxia with substrate 66. No protection by preconditioning against 
hypoxia-induced injury was found, with functional recovery as the index of protection. During 
hypoxia, any accumulated metabolite possibly responsible for the preconditioning effect may be 
washed out, accounting for the absence of protection. However, Janier et al. did find a small but 
significant improvement in functional recovery in rabbit hearts preconditioned with 3 min total global 
I+ 12 min R, followed by 60 min global ischaemia with a low flow of 0.4-0.45 ml/g wet wt/min 218. 
These results must be dissociated from the protection which can be induced by hypoxic 
preconditioning (discussed below), as opposed to the protection afforded by preconditioning against a 
sustained hypoxic period. 
Infarct size and collateral flow during sustained ischaemia have been correlated, with a significant 
difference between control and PC hearts with collateral flows less than 0.07 ml/min/g 310, as 
previously described 3 7 5. At higher flow rates, the results for the two groups converged 310. These 
results were taken to mean that factors other than collateral flow were responsible for protecting the 
myocardium, but also imply that at higher coronary flows the preconditioning effect is not apparent. 
In addition, the observation that preconditioning can occur in pigs, which have very little collateral 
flow, and in isolated rat hearts subjected to total global ischaemia, suggest that improved collateral 
flow in not a determinant of protection in a preconditioned heart 313, 491. However, as described 
above, whether protection is apparent when collateral flow is improved is not clear. 
The discrepancies in these results is unexplained, and is one of the points investigated indirectly in 
this thesis. 
c) Protocols of preconditioning 
i) Number and duration of ischaemic episodes 
The original "preconditioning" studies 375, 378 used a protocol of 4 cycles of 5 min ischaemia + 5 
min reperfusion, based on findings from previous studies 152,457. The importance of the number and 
duration of preconditioning cycles has since been tested. One episode of ischaemia versus 6 or 12 
cycles of 5 min duration were compared prior to 60 min sustained occlusion in dogs 310. No 
differences in haemodynamic parameters was noted on reperfusion among the three groups. Infarct 
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size was significantly reduced in all protocols of preconditioning, but with no difference among the 
three groups. 0, 1, 2 and 4 cycles of 5 min I + 5 min R were compared in rabbits prior to 30 min 
ischaemia 359. Repetitive episodes were no more advantageous than a single episode in terms of 
infarct limitation. In addition, no difference in infarct size limitation among 2x2-min I, lx5-min I or 
2x5-min I was found in rabbits 358. Isolated rat hearts subjected to either one or two cycles of 5 min I 
+ 5 min R, followed by 40 min sustained ischaemia showed significantly improved function compared 
to controls, but with no difference between the two groups 18. 2.5 min I (no stunning) compared to 5 
min I (with stunning) followed by 5 min R was equally efficacious against infarct development in the 
dog heart 423. 
On the contrary, rats exposed to 3x2 min total global ischaemia + 10 min R vs. 3x5 min I + 10 min R 
561 show a proportional increase in recovery of function after 20 min ischaemia with increased 
duration of preconditioning ischaemia. lschaemic periods of 1,2 and 4 min followed by 10 min R prior 
to 18 min sustained total global ischaemia in an isolated rat heart show a gradual increase in the 
degree of protection afforded in terms of functional recovery, related to the duration of 
preconditioning ischaemia 486. A pronounced reduction in infarct size with 3 cycles (5 min I+ 5 min 
R) but not with a single episode of preconditioning prior to 30 min coronary occlusion was found in 
the in situ rat heart 319. 1 and 4 cycles of 5 min I + 5 min R both showed protection in terms of 
reperfusion-induced arrhythmias after 30 min global ischaemia, but this was significant only with 4 
cycles of preconditioning 538. 
In general, functional recovery after short periods of ischaemia (stunning) seems to be better with 
increased preconditioning ischaemia duration, made up of an increased number of episodes. 
Protection against infarct development seems less sensitive to the preconditioning protocol. With long 
term ischaemia (and development of infarction) increased preconditioning ischaemia does not seem 
necessary because the recovery is determined more by infarct size 220. This relationship is tenuous, 
and dependent on many contributory factors, but may partially explain the lack of reproducibility 
between protocols. I have chosen a protocol of 5 min ischaemia + 5 min reperfusion, as this resulted 
in a significant improvement of functional recovery on reperfusion after 30 min sustained total global 
ischaemia in the isolated rat heart. 
ii) Duration of reperfusion between intermittent ischaemic episodes and prior to sustained ischaemia 
The duration of reperfusion between the intermittent episodes of preconditioning ischaemia, 
determines the extent of metabolite washout, substrate restoration, and return of function prior to 
sustained ischaemia. Murry et al. suggested that an extended reperfusion between successive episodes 
of ischaemia would gradually reduce the effectiveness of preconditioning 376. However, the time 
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course of decay in protection may be largely species-dependent, as well as determined by the protocol 
and model used. 
Protection against infarction is similar with 1 min and 10 min reperfusion, but is lost when only 30 
secs reperfusion is used 2. Protection conferred by 5 min I prior to 30 min ischaemia in rabbit hearts is 
lost if reperfusion is longer than 15 min 359. If reperfusion is extended to 1 hr between 
preconditioning and sustained ischaemia 313 , any benefit associated with preconditioning in rats is 
lost. Similar results were reported by Wolfe et al, who correlated the loss of protection with 
restoration of glycogen levels 588. In dogs, 2 hrs reperfusion prior to occlusion attenuated the effect 
of preconditioning on infarct size, although there was still some slight protection compared to control 
animals 377. In an open-chest pig model, 10 min occlusion followed by 15, 60, 120 180 or 240 min 
reperfusion prior to 60 min occlusion showed no gradual decline in protection, but rather an "all-or-
none" response, the incidence of which did decline with increased duration of intervening reperfusion 
269. Repeat preconditioning after 1 hr has similar effects to preconditioning followed immediately by 
occlusion 312, and can be regarded as a separate event. 
A so-called "second window of protection" has been demonstrated following preconditioning, 
whereby dog hearts are shown to tolerate ischaemia better after 24 h than after 3 h or 12 h reperfusion 
285. This protection was comparable to that found with immediate (5 min R) re-occlusion, but is 
attributed to different mechanisms. Stimulation by the initial ischaemic episode may lead to DNA 
transcription or RNA translation of heat shock and other stress proteins, which are protective to the 
heart over the long term 599. 
iii) Restoration of flow in intermittent reperfusion periods 
Most models have complete restoration of blood flow following the preconditioning ischaemic period. 
Collateral flow in the 10-min reperfusion period after a single 5 min ischaemic episode was well 
correlated with functional recovery after sustained ischaemia in dogs 81 . However, this relationship 
was reduced with increasing numbers of cycles. Partial stenosis (50% reduction in flow) followed by 
60 min total coronary occlusion did not confer protection compared to control dogs, but if an 
intervening restoration of flow was present, a significant protection against infarction was seen 422. 
No difference in stunning was observed. This finding suggests that full restoration of blood flow is 
required after an ischaemic period to precondition hearts, but that the preconditioning ischaemia itself 
need not be severe (see below for different mechanisms of mimicking preconditioning protection). 
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2) POSSIBLE MECHANISMS OF PROTECTION BY PRECONDITIONING 
a) Introduction 
The possible mechanisms involved m preconditioning suggested to date include: 1) changes in 
myocardial blood flow; 2) energy sparing effects - depressed contractility (stunning), maintained ATP 
levels, improved glycogen synthesis; 3) limitation of acidosis; 4) oxygen free radicals; 5) modified 
release of endogenous myocardial substances (adenosine, nitric oxide, catecholamines etc.) which 
affect phospholipase C, G proteins, protein kinase C and protein phosphorylation; 6) reduced release 
of possibly injurious substances; 7) KATP channel activation; 8) induction of protective proteins or 
enzymes 426. 
The search for the "mechanism" of preconditioning can be divided into several components, namely: 
1) induction of endogenous protective mechanisms by the initial ischaemic period(s). The duration of 
the preconditioning ischaemic episodes should not be too long, otherwise irreversible damage may 
occur, and the natural protective mechanisms triggered may be overwhelmed by adverse changes. The 
ischaemia needs to be relieved by reperfusion. 
2) washout of substances in reperfusion/upregulation of mechanisms stimulated by ischaemia with the 
reperfusion stimulus. The number of ischaemia/reperfusion cycles may determine the effectiveness of 
"reperfusion" stimuli, either by relieving the heart of the burden of ischaemia - giving it a rest before 
the next onslaught and thereby allowing increased duration of exposure to ischaemia; or by providing 
a stimulus in itself, of a rapid re-infusion of blood/perfusate, which can switch on mechanisms, or by 
flushing out harmful metabolites. 
(The above components may explain why the different preconditioning protocols have different 
effects, but it is difficult to differentiate between these factors) 
3) onset of sustained ischaemia, where after a reasonable length of time (greater than 10-15 min 
ischaemia) mechanisms induced by preconditioning exert their effects i.e. more long term 
consequences of changes brought about by prior ischaemia/reperfusion. These changes could be 
initiated in the previous episodes, and then over time the myocardium would adapt to ischaemia, with 
deferment of necrosis. A delay in the onset of necrosis would ensure improved recovery of function if 
the ischaemia were of sufficiently short duration (less than 3 hrs 375) i.e. the extent of irreversible 
injury is not complete (see Ch I). 
In seeking the mechanism of preconditioning, certain criteria need to be fulfilled, and a careful 
distinction between changes involved in preconditioning, and those attributed to other effects must be 
made: 
1) the mechanism should be apparent in all species in which preconditioning works (while there may 
be multiple mechanisms, several of each working together in different models and species, the 
ultimate aim is one single effector) 
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2) when mimicking the effects of preconditioning, a careful analysis of the mechanisms involved is 
required to ensure that the many interventions ( see below for those which have been said to mimic 
preconditioning, but which can include any modification made prior to ischaemia and found to be 
protective) found to be protective when given prior to ischaemia which may result in similar changes 
in the end-point measured, are not confused with the "endogenous" mechanism of preconditioning 
3) a distinction between cause and effect must be made - while many factors appear to be altered in 
the preconditioned heart, these may not be at all involved in the mechanism of preconditioning, but 
may occur simply as side effects. While these side effects may in tum contribute to the beneficial 
effects of preconditioning, this does not necessarily mean that these are the mechanisms. In addition, 
many changes can result in a single convergent point e.g. many cellular changes affect pHi. 
Alternatively, a change in pHi can affect many cellular processes. Thus, is reduced acidosis a 
protective mechanism in preconditioning, or a consequence of many of the changes induced by 
preconditioning, but not required for protection? Many of the observed changes with preconditioning 
appear to contradict some of the accepted concepts of ischaemic injury, particularly the controversy 
over glycolysis, glucose and glycogen. Whether these changes are involved in the protective effects, 
or are simply outweighed by the benefits of preconditioning, is largely unresolved in the majority of 
cases. 
4) the choice of end-point is crucial in the study of preconditioning. The changes in an ischaemic 
heart, while closely interacting, are also distinct from each other. Consistent protection against a given 
index does not extend to other indices. The question then to be asked is whether preconditioning 
protection against one index e.g. infarct size, is worthwhile in the absence of protection against 
another index e.g. functional recovery. The mechanisms involved in protection for the different 
indices may be very different, and may only related as cause and effect i.e. infarct size may partially 
determine the extent of functional recovery. 
The majority of the hypotheses presented below are those of the authors of the respective 
manuscripts, and do not necessarily reflect the consensus opinion. Some of these concepts are 
difficult to resolve with other findings. The lack of consistency contributes to the confusion regarding 
preconditioning. While an attempt has been made to review the subject as thoroughly as possible, so 
many manuscripts are published and it is impossible to mention every one. The more important 
aspects of each topic discussed have hopefully been covered. 
b) Mechanisms other than ischaemia resulting in or mimicking "preconditioning" 
The mechanism of preconditioning can be studied by mimicking the protection conferred by 
preconditioning. Several manipulations have been tested, using mainly infarct size and functional 
recovery as indices of protection. The validity of comparing these manipulations with preconditioning 
is not, however, always justified - any manipulation prior to ischaemia which improves the end points 
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can be regarded as mimicking preconditioning and therefore pointing to the mechanism of 
preconditioning. A major point in this regard is the study by Neely and Grotyohann 387 which 
purported to show the deleterious effects of glycolysis in total global ischaemia (see Ch II). The 
protocol used in this study has subsequently been used to initiate preconditioning (see below). Thus 
the conclusions of the original study i.e. that glycolysis is detrimental, are not necessarily valid given 
that pre-ischaemic hypoxia may induce preconditioning by completely different mechanisms, and the 
effects on glycolysis may be coincidental. A positive balance between the detriment brought about by 
glycolytic inhibition versus the benefit conferred by other simultaneously active preconditioning 
mechanisms may lead to improved recovery. Alternatively, "hypoxic" preconditioning may act simply 
by depleting glycogen, and may not be "true" preconditioning. While glycolytic inhibition is one of 
the major proposals for the mechanism of preconditioning, there is also a large body of evidence to 
contradict this possibility. Under conditions when "preconditioning" is not present, the inhibition of 
glycolysis would normally be considered detrimental. 
i) Anoxia, hypoxia and underperfusion 
Neely and Grotyohann 387 found that a pre-ischaemic period of anoxia conferred protection to the 
heart in terms of functional recovery. Four different protocols were used - control, IO or 15 min 
anoxia, and IO min anoxia + 10 min reoxygenation, prior to 30 min total global ischaemia in the rat. 
The recoveries (% rate-pressure product) were 28%, 68%, 92% and 75% respectively. Similar 
protocols (with preconditioning under investigation), with 5 min hypoxia + 5 min R, conferred 
protection in in vivo dog hearts 498, or isolated rat 290, 603 and rabbit hearts 83. In dogs, this 
protocol was more effective than 5 min I + 5 min R, with improved functional recovery. 
Reoxygenation after the initial hypoxic period is not required for protection 567, contrary to the need 
for reperfusion after an ischaemic period (see above). 
However, there is some controversy over these findings. In particular, Lagerstrom et al. 286 and 
Goodwin et al. 163 were not able to replicate the findings of Neely and Grotyohann 387 using similar 
protocols and measuring functional recovery. The main controversy arises from the debate about the 
role of glycogen (see previous discussion, Ch. II). Thus the involvement of glycogen in 
preconditioning needs to be addressed (see below for further discussion). 
Dog hearts can be preconditioned with cyclical variations in flow with maintained stenosis 422, and 
with a 15 min period of partial stenosis, with a 50% reduction in blood supply 422. The oxygen 
balance is disturbed by these manipulations. However, while significant protection against infarct size 
was found, none of these protocols were able to reduce stunning. In the rat heart, the effects of 
preconditioning by hypoxia, low flow ischaemia (1.6 ml/min/g) or total ischaemia, each of 5 min 
duration, and with 5 min reperfusion, were compared 603. Equivalent protection against reperfusion 
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mJury, m terms of functional recovery, was found in all three preconditioned groups. Isolated 
myocytes subjected to short periods of hypoxia, and a subsequent sustained hypoxic period followed 
by reoxygenation, showed reduced cell damage 569. These studies suggest that the accumulation of 
catabolites is not required for preconditioning, but rather that the lack of oxygen triggers the 
protective mechanism, and that accumulated metabolites cannot be the mechanism responsible. 
However, Cohen et al. suggest that hypoxia preconditions rabbit myocardium by adenosine and 
catecholamine release during the hypoxic period, as these are present in sufficient amounts to account 
for preconditioning 83. Blockade of both these effects abolished preconditioning. 
ii) Pre-ischaemic changes in metabolism 
While hypoxia can induce preconditioning, the specific component of hypoxia involved has not been 
elucidated. Several authors 364, 569, 603 suggest that oxygen deprivation and not catabolite 
accumulation triggers preconditioning, but the effect of inhibition of mitochondrial activity was not 
investigated directly. Cyanide preconditioning (2x5 min infusion, followed by 10 min washout) was 
compared to ischaemia-preconditioned and control hearts 99. Over 30 min global ischaemia, cyanide 
hearts showed the highest end-diastolic pressure, but this was lowest on reperfusion. Developed 
pressure was highest with cyanide hearts, while control hearts had very little recovery. Recovery was 
correlated with improved CP and ATP, and with less acidosis. Interventions to lower pHi during 
ischaemia significantly attenuated the effect of preconditioning, both with ischaemia and cyanide. The 
benefits of preconditioning were thus attributed largely to an attenuated fall in pHi, and not to 
mitochondrial activity per se. 
A recent publication reports that a transient inhibition of glucose uptake rmm1cs the effect of 
preconditioning on infarct size 166. 15 min glucose-free perfusion followed by 30 min with glucose 
present prior to ischaemia, significantly reduced infarct size, an effect which could be blocked by a 
PKC inhibitor (see role of PKC below). Transient addition of 20 mM pyruvate or 1 mM acetate (both 
presumably inhibiting glucose uptake) to glucose buffer prior to ischaemia also decreased ultimate 
infarct size. Glycolytic inhibition was proposed to open the KArP channel, which could subsequently 
trigger PKC activation. If acetate were present throughout, no protective effect was evident, 
suggesting that a substantial basal rate of glycolysis is required to enable protection to be evident. 
This concept is unexplained. In in situ hearts, pre-treatment with pyruvate did not precondition the 
hearts, possibly due to the presence of free fatty acids, which have an effect similar to that of acetate 
in perfused hearts. The mechanisms involved in these findings are, however, largely unclear. 
Alternatively, pyruvate abolishes the effect of preconditioning if present prior to ischaemia 140, 480 
and on reperfusion 142. However, if the preconditioning protocol was changed from 4 x 5-min cycles 
of ischaemia and reperfusion, to 4 x 7-min I+ 5 min R, with a 40% increase in total preconditioning 
ischaemia, protection in the presence of pyruvate was found to be similar to results from the initial 
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protocol with glucose only present 480. Pyruvate thus appears to increase the threshold for 
preconditioning. The inhibition of preconditioning by pyruvate on reperfusion was associated with the 
requirement for glucose 142. However, this has been disputed in the literature in non-preconditioned 
hearts (see Ch II). 
iii) Supply-demand imbalance 
Cardiac adrenergic nerve stimulation raises energy demand. If energy supply were concomitantly 
increased by increasing the blood flow prior to ischaemia, no change in postischaemic infarct size was 
found 215. If blood flow, and thus energy supply, were not increased with increased adrenergic 
activity, infarct size was attenuated. The transient energy-supply imbalance may thus trigger 
preconditioning-mediated protection. An absolute reduction in energy supply does not appear to be 
necessary i.e. a relative flow deficit of 36% can induce protection against infarction ( comparable to 
effects of partial stenosis 422). These results also partially corroborate the effects of a transient 
inhibition of glucose uptake in rats which would be expected to reduce energy supply 166, as well as 
the effects of hypoxic preconditioning. 
Rapid cardiac pacing ("demand" ischaemia) prior to a sustained ischaemic episode can also induce 
protection in dogs 556. Pacing a dog ventricle at 300 beats/min for two 2 min periods, with 
intermittent periods of 5 min (normal heart rate = 140 beats/min) followed by 25 min occlusion 
reduced ST segment elevation, and lowered the incidence and reduced the severity of arrhythmias. 
Increased pacing can also induce preconditioning in the rabbit, and is associated with increased tissue 
cGMP, and reduced tissue cAMP levels 519. 
iv) Acidosis 
A transient acidosis, one of the components of ischaemia, was used to precondition the isolated rat 
heart 603. However, no change in recovery after ischaemia compared to control hearts was seen, 
suggesting that pre-ischaemic changes in pH are not a mechanism of preconditioning protection. Pre-
ischaemic changes must be distinguished from changes in pHi during sustained ischaemia, which have 
been mooted as being of importance in preconditioning 99. 
c) Stunning - a possible protective mechanism? 
A brief period of ischaemia (5-20 min) leads to stunning (see Ch I), which could play a role in the 
protective effects of preconditioning. Stunning can reduce ATP utilisation and catabolite 
accumulation due to the depressed contractile state, similar to the effects of preconditioning on energy 
balance. If stunning is involved in preconditioning, the protective effect should last as long as 
stunning is present 377. Protection against infarct size is evident if hearts are reperfused for 5 min 
prior to sustained occlusion. However, if reperfusion is continued for 120 min prior to re-occlusion, 
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the protection against infarct size is 50% less, despite persistence of severe stunning. No correlation 
between the degree of "pre-ischaemic" stunning with different preconditioning protocols and 
subsequent infarct size limitation was observed 358. In addition, stunning was precluded as the 
mechanism of preconditioning by showing an equivalent protection with 2.5 min as opposed to 5 min 
I followed by 5 min R, despite a lack of stunning in the former protocol 423. Preconditioning 
ischaemia followed by hyperkalaemic perfusion prior to sustained ischaemia, which eliminates 
contractile activity, indicated that the reduced energy demand in PC hearts is not due to stunning-
induced mechanisms 224. The use of hypoxia to precondition hearts also negates the role of stunning, 
as a short period of hypoxia does not show reduced function on reoxygenation, but does protect the 
heart 83,290, 387, 498, 603. 
d) Changes in energy metabolism 
i) Glycolytic inhibition and high energy phosphate preservation 
Changes in glycolytic intermediates were monitored in dog hearts during total global ischaemia, 
preceded by 4 x 5 min I (or control) and hyperkalaemic perfusion 224. ATP levels were initially lower 
in preconditioned tissue. Almost 40 µmol/g more high energy phosphates were used in the control 
myocardium in the first 15 min. The differences between the two groups became less evident with an 
extended duration of ischaemia. Lactate, G6P, G lP and aGP accumulated substantially in the first 60 
min, but thereafter G lP and aGP declined. In each case, control tissue had a higher metabolite 
content than did the preconditioned hearts. Tissue glucose levels, normally very low, increased 
initially in preconditioned hearts, but then declined, whereas control hearts showed a continued 
increase. Glycogen was depleted in the preconditioned hearts prior to ischaemia, and glycogen 
utilisation was also reduced. The increased tissue glucose was attributed to cleavage by debranching 
enzymes of a, 1-6 linkages of glycogen, which releases glucose rather than G 1 P. Thus preconditioned 
hearts had decreased high energy phosphate utilisation and decreased glycolytic metabolite 
accumulation. Intermittent aortic cross-clamping in dogs also reduces the loss of high energy 
phosphates compared to an equivalent sustained ischaemic period 1. The addition of a nucleoside 
transport inhibitor and an adenosine deaminase inhibitor had similar effects. Both groups were 
associated with maintained function. Preconditioning may therefore slow ATP utilisation and reduce 
the glycolytic rate, attributed to a reduced energy demand in ischaemia. 
A CP "overshoot" occurs after a brief period of ischaemia and reperfusion 525, and is a consistent 
observation in preconditioned hearts. In pig hearts with 4x5 min cycles of coronary occlusion, 
followed by 20 or 60 min sustained ischaemia, CP was significantly higher than control hearts after 
preconditioning, and declined at a slower rate during ischaemia 250. ATP is depleted in 
Literature review Ch III . Preconditioning 73 
preconditioned hearts, ·but may decline subsequently at a slower rate, partly due to increased CP. 
However. the CP effect can only be relatively short-lived because of a rapid breakdown. 
In contrast. increased ATP depletion has been temporally related to increased contracture m 
preconditioned hearts 266. The preceding ischaemic period depletes ATP, a difference which is 
maintained over the first 20 min total global ischaemia (the absolute amounts utilised must be 
distinguished from the rate of utilisation i.e. the slope). After 20 min ischaemia, no difference was 
observed between the 2 groups, with very low residual values of tissue ATP (although preserved ATP 
has been found after 25 min total global ischaemia following preconditioning, compared to control 
hearts 237). 
Metabolism may also be slowed by hypothermia, or by cardioplegia. Preconditioning has an additive 
effect to the degree of protection conferred by hypothermia, allowing much longer maintenance of 
function 65 . However, this is a transient effect in that after an extended time, no additional protection 
is found. With cardioplegia, no additive benefit with preconditioning is seen 265. While preservation 
of high energy phosphates would normally be considered beneficial, high ATP levels do not always 
imply protection (see Ch I and II for discussion on "critical" levels of ATP). Other factors must also 
be considered. 
ii) Glycolysis and glycogenolysis 
The role of glycolysis in preconditioning is very controversial. Provision of glucose to the ischaemic 
heart may generally be considered advantageous; inhibition of glycolysis should therefore be 
detrimental. Many reports 18, 99, 250, 512 show that the fall in pHi during sustained ischaemia 
fo llowing preconditioning is reduced, presumably because of reduced glycogen breakdown. If a fall in 
pHi contributes to ischaemic injury, an attenuated fall should be beneficial. Preconditioning reduces 
total tissue glycogen prior to the sustained ischaemic period, and attenuates the rate of glycogenolysis 
during sustained ischaemia 224, 574, consistent with the reduced acidosis. A reduced glycogen 
breakdown also lowers tissue lactate accumulation, which may be protective 387. However, these 
results have not always been replicated 163, 286. A positive relationship between glycogen content at 
the end of ischaemia and improved recovery is found 163. Further controversy is added by the 
findings of the preconditioning effects of hypoxia 83, 290, 498, 603 (see above). 
The precise role of glycogen in preconditioning (as being separate from hypoxia-induced changes -
see above for argument) has not been fully elucidated. Wolfe et al. drew specific attention to the role 
of glycogen depletion in preconditioning 588. Rats were subjected to 4 cycles of 5 min regional I+ 5 
min R, followed by immediate re-occlusion for 45 min, or with an additional 30, 60 or 360 min 
reperfusion prior to re-occlusion. Myocardial glycogen content of the ischaemic tissue was 
determined prior to sustained re-occlusion. Longer reperfusion increased repletion of glycogen stores, 
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such that by 60 min, full restoration of glycogen was found. Glycogen repletion was correlated with 
loss of protection in terms of infarct size. However, this study did not necessarily take into account 
previously documented evidence that the time of intervening perfusion between preconditioning and 
sustained ischaemia is an important determinant of the efficacy of preconditioning 269,359, 377, and 
that the protection from preconditioning wanes with time 285, 375. Thus these findings did not fully 
dissociate changes in glycogen from other changes associated with maintained reperfusion. Another 
report showed that the total amount of glycogen broken down during ischaemia is reduced by 
preconditioning, with reduced lactate and ft accumulation 574. However, these changes were not 
necessarily correlated with the effect of preconditioning. More recently, Asimakis correlated the 
diurnal change in myocardial glycogen content with improved functional recovery on reperfusion 
after sustained ischaemia following a preconditioning protocol . No correlation was found, implying 
that glycogen is not involved in preconditioning 17. 
Contrary to these findings, glycogen-loading by fasting, together with pre-ischaemic perfusion with 
lactate, improved tolerance to ischaemia to a similar extent as that found by preconditioning 114. This 
study followed on from previous observations, that fasting protects the heart against ischaemia-
induced injury 487. There is thus still some controversy over the role of glycogen, both in itself, and 
in tandem with preconditioning, which I have attempted to clarify in this thesis. 
Utilisation of glucose in preconditioned hearts has not been much investigated because the majority of 
studies have used total global ischaemia. In hearts subjected to 2 x 5 min I+ 5 min R, followed by 35 
min aerobic perfusion, glycolysis from glucose was inhibited (in the presence of palmitate) 136. If 
these hearts were subjected to 30 min total gl_obal ischaemia and reperfusion, glycogen utilisation 
during ischaemia was reduced, and glycolysis was lower on reperfusion. Glucose oxidation was 
similar in the two groups, indicating improved coupling of glycolysis with oxidation. ATP and 
adenosine were higher in PC hearts at the end of ischaemia, with improved functional recovery. The 
reduced glycolysis is consistent with a reduced [ff']i in preconditioned hearts, which would attenuate 
Ca2+ overload as recorded in preconditioned hearts 142. However, glycolysis is stimulated during low 
flow ischaemia by preconditioning 218, which challenges this finding. Reduced contracture and 
improved functional recovery were recorded in rabbit hearts after preconditioning with 3 min I+ 12 
. min R and 60 min low flow ischaemia (0.4 ml/min/g wet wt) 218. The perfusate also contained 
palmitate, insulin, and 5 mM glucose ( cf 136). Preconditioning increased glucose uptake and lactate 
production during ischaemia, with higher ATP levels at the end of ischaemia. Glycogen levels prior to 
ischaemia were no different between control and preconditioned hearts, but there was a significant 
preservation of glycogen at the end of ischaemia in preconditioned hearts, presumably from increased 
glycogen synthesis, or from decreased glycogenolysis. Thus preconditioning increased glucose but not 
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glycogen utilisation. The mechanism whereby glucose uptake is stimulated by preconditioning is 
unclear. but may be related to GLUT 4 translocation by the initial ischaemic episodes 517. This 
hypothesis is partially corroborated in this thesis. 
iii) Inhibition of mitochondrial ATPase 
Mitochondria are a major site of ATP utilisation in ischaemia 465. During ischaemia, the cytosolic 
[I--r] increases, reducing the I--r gradient across the inner mitochondrial membrane (matrix pH is 
usually less than cytosolic pH and provides the proton-motive force to allow for ATP extrusion from 
the mitochondria). ATP synthase function may be reversed when the pH gradient is affected, and then 
may function as an A TPase, consuming an ATP and pumping I--r out of rather than into the 
mitochondria (although this is controversial 488). Mitochondria contain an endogenous ATPase 
inhibitor protein which binds to the ATP synthase in ischaemia 465, 466 and can prevent this loss in 
ATP. The inhibitor is triggered by a low pH and has been implicated in preconditioning, particularly 
in species with slow hearts rates (pigs, dogs, rabbits) 226. This mechanism would prevent the large 
wastage of ATP associated with mitochondrial activity in ischaemia 226. However, this hypothesis 
has been disputed, given that preconditioning can occur in the rat which has very low concentrations 
of this protein 319, 598. However, despite these low levels, the inhibitor could be activated by 
preconditioning 598, and thus exert a greater effect than would be predicted. 
e) Ionic changes 
i) pHi, Na+ i and Ca2+ i
pHi falls in ischaemia, leading to [Na +Ji accumulation, and Ca2+ entry by activation of the Na+ !Ir and 
Na +/Ca2+ exchanges 303. If pHi is reduced during sustained ischaemia, the protective effects of 
preconditioning are removed 99. In preconditioned hearts, the pHi does not fall as low. The lesser fall 
in pHi in preconditioning 18, 99, 250, 512 may be a major point of convergence for many 
"preconditioning mechanisms", possibly leading to a reduced [Ca2+]i 303. A reduced acidosis may be 
attributed to reduced ATP hydrolysis 156, or reduced glycogenolysis 151 (which indirectly reduces 
ATP hydrolysis). Lactate accumulation during ischaemia is reduced in preconditioned hearts 18, 224, 
suggesting that the change in pHi is related to reduced glycogenolysis. These issues are thus 
intimately related with the investigations carried out in this thesis. 
4 cycles of 5 min I + 5 min R prior to 30 min global ischaemia in rats and guinea pigs did not affect 
ATP levels during sustained ischaemia and reperfusion, but CP levels recovered slightly better in the 
preconditioned hearts 512. Levels of [Na+]i were generally higher towards the end of ischaemia in 
control hearts, but not significantly so, while [Ca2+]i and [I--r]i were significantly reduced. pHi 
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levelled off in both groups, but at different values, while [Ca2+]i continued to increase 512. Mg2+, 
which blocks Ca2+ entry via the Na+/Ca2+ exchange, and is beneficial by itself when given prior to 
ischaemia, has no additive effect on preconditioning, suggesting that preconditioning does retard Ca2+ 
entry 512, possibly by reducing the fall in pHi. 
Another puzzling study showed that preconditioning significantly increased [Na+]i prior to sustained 
ischaemia, but did not alter [Na +]i during ischaemia 449. On reperfusion, the decline in [Na +]i in 
preconditioned hearts was far greater than in control hearts. Na+t'lr exchange inhibition prior to 
sustained ischaemia limited [Na+]i accumulation, and reduced the beneficial effects of 
preconditioning. Transient acid load prior to sustained ischaemia greatly increased [Ir]i m 
preconditioned hearts compared to control, but these hearts showed a faster recovery of pHi. This 
recovery was also abolished by Na+ t'lr exchange inhibitors. Thus preconditioning appeared to 
stimulate Na+ !'Ir exchange, although this seems contrary to the accepted benefits of Na+ !'Ir exchange 
inhibitors during ischaemia and on reperfusion 119, 489. The difference may lie in the absolute loads 
of Na+, Ir and Ca2+ at different times, although this is difficult to reconcile. 
ii) ca2+ release channels 
Preconditioning may alter the ryanodine SR Ca2+ release channels such that the channel density is 
reduced, with reduced Ca2+ efflux 605. The time course of changes in channel density is correlated 
with the protection conferred by preconditioning. This observation remains to be explored 
iii) ATP-dependent potassium channels 
Opening of KATP channels may provide a cardioprotective effect by exerting a localised mechanical 
arrest, although this may also precipitate arrhythmias 236 (see Ch I). Preconditioning is thought to 
increase opening of these channels via adenosine (see below), an effect usually counteracted by 
glycolytic ATP 571 (see Ch II). The role of these channels in usual models of ischaemia is equivocal 
(see Ch I, II). In preconditioned hearts, glibenclamide administered to dogs prior to preconditioning, 
abolished any protective effect, compared to pre-treated control hearts 169, 172. A pre-ischaemic 
coronary infusion of adenosine resulted in a degree of protection against necrosis similar to that with 
ischaemic preconditioning 596, but this protection was abolished by glibenclamide, suggesting a role 
for the KATP channel. The possible effect of preconditioning in attenuating glycolysis (see above) may 
also result in opening of these channels. This effect does not agree with concepts of protection 
conferred by glycolytic ATP (see Ch II). However, glibenclamide has no effect on preconditioning in 
rats 14 3, 171, 319, suggesting that KATP channel activation is not a universal mechanism of 
preconditioning in all species, but rather an epiphenomenon which when it occurs may exert positive 
effects. A recent paper has implicated opening of this channel in preconditioning in human atrial 
tissue 565. 
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KATP channel opening does not appear to be involved in the pronounced antiarrhythmic effects of 
preconditioning, as administration of glibenclamide to preconditioned dog hearts failed to affect the 
reduction in ventricular fibrillation and increased survival 555. In preconditioned rabbit hearts, 
however, activation of the KATP channel, which reduces action potential duration, may be responsible 
for the delay in the onset of electrical uncoupling 527. Therefore the role of the KATP channel in 
preconditioning seems controversial and species-dependent. 
f) Receptor activation 
i) Adenosine 
Adenosine released in the preceding ischaemic period( s) can bind to receptors, and exert a beneficial 
effect on subsequent sustained ischaemia. This has been one of the more thoroughly investigated 
mechanisms of preconditioning. A significant reduction in interstitial adenosine accumulation during 
sustained ischaemia is seen in preconditioned hearts, despite a large release in the first reperfusion 
period (with 2 cycles of preconditioning) 544. A significant transient increase in adenosine is seen in 
control hearts during sustained ischaemia. No difference in the release of the other purines i.e. 
xanthine, hypoxanthine and inosine is found. 
Adenosine acts in a number of ways which are beneficial to the ischaemic heart (see Ch I). Adenosine 
may be a key regulator of energy metabolism in the heart, but its actions are still unclear. Adenosine 
may stimulate glycolysis, an effect noted in hypoxic hearts 591 . However, this effect in 
preconditioned hearts is contradicted by the observations of a reduced rate of glycolysis 224. The 
actions of adenosine on glycolysis are, however, quite controversial (see Ch. I, II). 
Adenosine exerts its actions by binding to several receptors on the myocyte and endothelial cells (see 
Ch. I). Infusions of 8-phenyltheophylline (8-PT) (non-selective adenosine antagonist) and PD 115,199 
(Al/A2 antagonist) block preconditioning, while adenosine pre-treatment mimics the protective effect 
of preconditioning on infarct size in rabbits 318. 8-PT also abolishes the protective effect of 
preconditioning on stunning in rabbits 542. More recently, Armstrong and Ganote have added to the 
debate using specific Al and A3 antagonists on isolated rabbit myocytes undergoing contracture. 
Only A3 antagonists (A3 receptor still putative) were effective in delaying cell contracture, an effect 
which could be blocked by PKC inhibitors 16. 
Most beneficial effects of adenosine appear to be modulated via A 1 activation 2 91, the receptors 
found mainly on the myocytes. Al activation causes translocation of PKC to the membranes in close 
association with the adenosine receptor. When PKC is removed from the membranes, the protective 
effect of preconditioning is lost 3 5 5, 601. A 1 receptor stimulation also activates the KA TP channel via 
Gi proteins 254. However, these channels are not involved in preconditioning in all species (see 
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above). Adenosine also has many effects on energy metabolism, although the reports are somewhat 
contradictory (see Ch I). 
While adenosine may be central in the mechanism of preconditioning in dogs, pigs and rabbits, a large 
amount of evidence refutes this mechanism in the rat. Administration of adenosine prior to ischaemia 
does not improve functional recovery in isolated rat hearts, while administration of 8-PT does not 
abolish preconditioning 64, 373. In rats, PD 115,199 was not effective, although an A2 specific 
blocker did reduce infarct size 313. Induction of preconditioning by a period of hypoxia or low flow 
ischaemia also disputes the adenosine proposal in a rat 603. A maintained coronary flow should 
prevent any accumulation of adenosine, inhibiting stimulation of the receptors. Hypoxic 
preconditioning is also effective in dogs, suggesting that adenosine is also not required for 
preconditioning in this species 498. However, a contradiction to this particular argument has been 
provided by Cohen et al., albeit in rabbits where adenosine has been shown to be important 318. 
Sufficient amounts of both catecholamines and adenosine were released during hypoxia to account for 
preconditioning protection 83 . 
ii) al-adrenergic receptor stimulation, protein kinase C translocation and preconditioning 
Reserpinised rabbits (with reduced catecholamine stores) subjected to ischaemia with or without a 
preconditioning protocol show no difference in infarct size, suggesting that catecholamine release is 
crucial for preconditioning 536. More specifically, al-adrenergic stimulation was identified as a 
prerequisite for preconditioning in the rat heart 21. A pre-ischaemic infusion of norepinephrine or 
phenylephrine reduced infarct size in normal and reserpinised hearts, while al-adrenergic blockade 
inhibited preconditioning. Increased PKC translocation to the membranes following al-adrenergic 
activation ( or adenosine) may be protective to the heart, and thus a possible mediator of 
preconditioning 601 . 
Preconditioning may, by a number of pathways, cause PKC translocation, thereby activating 
protective mechanisms. Both the trigger for PKC translocation, and the subsequent benefits to the 
heart, are unclear. In addition, there are several isoenzymes of PKC 514, which may have opposing 
effects. In the study of PKC and preconditioning, little attempt has been made to dissociate the effects 
of the different isoenzymes (see Ch I for further discussion on PKC and al activation). 
PKC translocation exacerbates hypoxia-induced injury 211, and sensitises adenyl cyclase 515, leading 
to accumulation of cAMP, stimulation of Na+/lr exchange, and an increase in Ca
2+ influx 211. PKC 
phosphorylation is also energy-utilising (see Ch I for summary of effects - note particularly effects on 
glycogen, glucose uptake and glycolysis). In addition, phorbol esters are very pro-arrhythmic by 
reducing action potential duration 33. KATP channels may be phosphorylated by PKC translocation, 
with increased opening probability, and increased ion perturbation. Alternatively, KATP channel 
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opening is thought to be involved in preconditioning in some species, but this may be a consequen~e; 
not a cause. There are many isoenzymes of PKC 514, and phorbol esters may target those not 
necessarily involved in preconditioning. The protective effect of PKC activators against infarction 
was tested in rabbits 601 and rats 355. Preconditioning is abolished by PKC antagonists, while 
reduced infarct size (in rabbits) and improved functional recovery (in rats) follows infusion of 
diacylglycerol (DAG) and phenylephrine, which induces PKC translocation to the cell membranes. 
Phorbol 12-myristate 13-acetate (PMA - phorbol ester - potent activator of PKC) confers a 
comparable protection to that afforded by a brief period of "preconditioning" hypoxia on isolated 
hypoxic myocytes 569. 
While tyramine-induced catecholamine release prior to sustained ischaemia is protective, additional 
adenosine A 1 receptor stimulation appears to be necessary for preconditioning in rabbits 533 . 
Conversely, infarct size limitation by Al stimulation is mediated by PKC activation in rabbits 475. 
These findings have not always been replicated in the rat. Reserpinisation did not affect the response 
to preconditioning in terms of infarct size, suggesting that endogenous catecholamines are not 
required 577 ( contrary to previous findings 21 ). In addition, chelerythrine, a specific PKC inhibitor, 
failed to inhibit preconditioning in the isolated rat heart in terms of functional recovery 264. Moolman 
et al. also could not find an effect of a receptor blockade or PKC inhibition on functional recovery in 
preconditioned rat hearts 363. However, PKC inhibitors did abolish preconditioning effects in terms 
of infarct size reduction in the rat heart 504. In dogs, the effect of PKC translocation on infarct size 
reduction has been disputed 445. 
The role of PKC in normal and preconditioned hearts is unclear, and appears to be species-specific, as 
well as involving different isoenzymes. However, this remains the most tenable hypothesis as yet 
presented, and remains the major focus of investigation of preconditioning. 
iii) ~adrenergic receptor stimulation 
An increased cAMP is implicated in the deleterious effects of ischaemia (see Ch. I). A reduced cAMP 
was noted by Sandhu et al. in preconditioned rabbit hearts 4 79. Adenosine A 1 receptor activation 
inhibits adenyl cyclase through Gi, which inhibits cAMP formation. However, the reduced cAMP 
may be more a consequence of preconditioning rather than a mediator of the effect 363,479. Thus the 
attenuated adenyl cyclase activity following PKC or adenosine Al activation may not be relevant. 
However, the reduction in cAMP may well explain the attenuated arrhythmias noted with 
preconditioning (see Ch I). A reduction in cAMP may also explain a reduction in the rate of 
glycogenolysis during sustained ischaemia following preconditioning 574. 
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iv) Gi protein.function in ischaemia and preconditioning 
Following adenosine A 1 receptor stimulation, Gi proteins are activated, which may thus be the 
primary factor in preconditioning, as many putative effectors activate these proteins. Pertussis toxin, 
which catalyses ADP ribosylation of Gi proteins, thereby uncoupling them from receptors, abolishes 
preconditioning 534. Carbachol can mimic preconditioning in a rabbit heart, in terms of ischaemic 
contracture and functional recovery, by binding to M2 receptors which act via Gi proteins 195. In 
ischaemia, P adrenergic receptor activation increases cAMP levels by increasing adenyl cyclase 
activity. cAMP increases energy demand, and potentiates arrhythmias. Gi proteins, activated by a 
number of receptors, antagonise the adrenergic system by inhibiting adenyl cyclase, activating KATP 
channels, and inhibiting Ca2+ channels. Increased Gi regulation would be protective by reducing 
excessive Ca2+ loading and energy demand, and by increasing electrical stability. Alternatively an 
impairment of Gi protein-mediated regulation in ischaemia by a functional alteration of the proteins 
should be detrimental. Preconditioning may enhance the responsiveness of the adenosine Al receptor 
pathway, thereby stimulating Gi function. A sufficient amount of adenosine is usually released in the 
first few minutes of ischaemia to ensure maximal stimulation of all available A 1 receptors and thus Gi 
proteins 394. An increased responsiveness of the Gi proteins to receptor activation is found after an 
initial ischaemic period, but an intervening reperfusion period is necessary for this mechanism 394. 
Increased Gi protein activation would increase adenyl cyclase inhibition. The reduction in cAMP by 
preconditioning 479 supports this concept. However, Lawson et al. found that the antiarrhythmic 
effect of preconditioning does not involve Gi proteins, although this does not exclude the role of Gi 
proteins in the other protective end points of preconditioning 298. Further clarification of the role of 
Gi proteins in preconditioning is needed. 
g) Stimulation of protein synthesis 
While synthesis of heat shock proteins is a protective mechanism associated with ischaemia 115, the 
rapidity with which preconditioning exerts its protective effects is far quicker than can be accounted 
for by any gene process. The detection of heat shock proteins following ischaemia occurs after about 
8 hrs 115, but this is still a small effect. Hearts can still be preconditioned despite protein synthesis 
inhibition 117. However, the "second window of protection" 285, 599 may well be due to influences 
on gene transcription and translation, as this phenomenon is consistent with the time frame of heat 
stress protein induction. The mechanism whereby heat stress proteins exert protection is as yet 
unclear, but there is accumulating evidence to suggest that increased expression of these proteins 
reduces infarct size and enzyme efflux and improves functional recovery after ischaemia 339. 
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h) Free radicals and redox state 
Brief coronary occlusion results in a burst of free radical production. These would therefore be 
present at the onset of the sustained ischaemic episode, and should be detrimental. An antioxidant 
(NAC), which prevents depletion of glutathione stores, does not affect the normal response to 
ischaemia 73. In preconditioned hearts, glutathione is depleted, with a more oxidised state of the 
tissue. If NAC is used to prevent glutathione depletion, the effects of preconditioning on functional 
recovery are abolished. Prevention of thiol oxidation is normally protective, but in preconditioned 
hearts this mechanism may be responsible for adaptive responses of the myocardium to subsequent 
injury 73_ 
i) Vascular changes 
While most focus is on changes in myocytes with preconditioning, important sources of possible 
mediators are the endothelium and smooth muscle cells. Because preconditioning is initiated 
following a transient r7duction in flow or oxygen supply, the endothelium is directly affected, both 
mechanically and metabolically, which can result in release of important endogenous mediators, 
including endothelin, atrial natriuretic peptide, etc. 
A fairly recent hypothesis regarding preconditioning involves the release of bradykinin by the 
endothelial cells during ischaemia 554. Bradykinin activates L-arginine nitric oxide and cyclo-
oxygenase pathways, with production of NO and prostacyclin 138, 304, 568. NO may depress 
myocardial contractility and reduce energy demand. NO stimulates guanylate cyclase and increases 
cGN!P, which in turn may reduce Ca2+ influx through L-type channels 516, stimulates cGN!P-sensitive 
phosphodiesterase which reduces cAMP levels, and lowers oxygen consumption. The ratio of cAMP 
to cGN!P may be an important protective mechanism. cGMP is increased, inversely related to a 
decreased cAMP, in ventricular overdrive pacing-induced preconditioning 519. The NO-cGMP 
pathway may be also an important modulator of glucose uptake 110, 494 (see Ch I), and a reduction in 
cGMP may be one of the mechanisms involved in regulation of glycolysis in preconditioning. 
j) Diffusion of a protective substance 
An alternative concept to those discussed above has been proposed, with diffusion of a · protective 
substance from the ischaemic zone which could exert effects in "virgin" tissue 444, 582. Data from 
studies in the rat heart (used because oflow collateral flow) using 3x3 min I+ 5 min R followed by 90 
min coronary occlusion, and measuring infarct size was analysed using a mathematical model 582. 
The average infarct size was smaller in the preconditioned group (28% vs. 60% of area at risk), with a 
direct relationship between area at risk and infarct size in preconditioned hearts but not in controls. 
The data are consistent with the hypothesis that inward diffusion of some "protective" substance 
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occurs, which suggests that tissue remote from the site of original occlusion would be protected 
against an ischaemic insult. This hypothesis was supported by findings in dogs, where infarct size in 
remote "virgin" myocardium was smaller if the myocardium had been preconditioned at a different 
site 444. This mechanism could be explained by diffusion of e.g. adenosine, catecholamines etc. from 
the original ischaemic zone, although the degree of protection would be limited by the rate of 
diffusion through the interstitium and the half-life of the various compounds, or by the area perfused 
downstream from the original site. 
3) SUMMARY 
Preconditioning can be defined as one or more brief episodes of ischaemia which result in improved 
tolerance of the myocardium to a subsequent sustained ischaemic episode. The most reproducible 
effect of preconditioning is a reduction in infarct size measured at the end of the reperfusion period. 
Preconditioning alters many pathways in the cell, and thus the determination of the mechanism of 
preconditioning is difficult. Many of these cellular effects appear to act synergistically to bring about 
preconditioning, and the particular pathways involved seem to be partially species-dependent. The 
contribution of several factors means that a given pathway can be limited, and another upregulated to 
compensate. This confuses the issue of the mechanism of preconditioning. 
Another important consideration in determining the mechanism of preconditioning is the end point 
chosen. Much confusion results from different interpretations of the "protection" conferred by 
preconditioning, as can be seen from the above discussion of the various mechanisms putatively 
involved in preconditioning. 
The most accepted "common" mechanism of preconditioning to date is the involvement of the PKC 
system, activated either by adenosine activation of A 1 receptors, the ex 1-adrenergic receptors, or by 
cytosolic-mediated events. The trigger mechanism appears to be species-dependent. In the rabbit, dog 
and other species excluding the rat, adenosine appears to stimulate the A 1 receptor and Gi proteins. 
These in turn inhibit adenyl cyclase activity, which is also modulated by PKC. PKC may be directly 
affected by Gi protein activity. The ability of PKC to phosphorylate proteins is dependent on ATP 
levels, and is in turn responsible for increased re-energisation on reperfusion. While many reports find 
that blockade of PKC does not abolish preconditioning, there are many isoenzymes of the enzyme, 
and it is unclear which is involved. Of note is that the evidence for the PKC hypothesis comes from 
indirect observations using activators and inhibitors of PKC translocation. Attempts to ascertain 
whether PKC molecules are indeed found in the sarcolemma following preconditioning iR the dog 
have found no evidence of this occurring 445. 
I have investigated· the role of glycogen and of glucose in preconditioning, both i) because of the 
apparent contradiction in an attenuation of glycolysis by preconditioning but increased protection 
despite the large amount of evidence to suggest that glucose provision is beneficial to the ischaemic 
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heart; and ii) to determine how preconditioning may modulate glycolysis. Preconditioning was thus 
investigated both as a "mechanism" of protection, and as a "modifier" of glycolysis. In addition. the 
effect of preconditioning on hearts subjected to low flow ischaemia (as opposed to total global 
ischaemia) was tested, in order firstly to allow for the determination of glucose uptake in 
preconditioned hearts, and secondly to determine the effect of preconditioning on low flow ischaemia, 
a more physiological model and one which has seldom been used. 
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Methods 
1) THE ISOLATED HEART APPARATUS 
i) Animals 
Methods 
The isolated Langendorff perfused rat heart was used for all experiments reported in this thesis 287. 
Male Long Evans rats weighing 250 to 300g were used (some experiments were conducted in 
London, when Wistar rats were used). The rats were fed ad libitum on standard rat chow. They were 
anaesthetised with ether vapour. Once the rats were asleep, an inguinal incision was made to allow 
exposure of the femoral vein into which 200 i.u. heparin was injected. An abdominal incision was 
then made, and the diaphragm and ribs were cut to allow excision of the heart. The hearts were 
immediately placed in ice cold buffer. All animals were cared for according to the Recommendations 
of the Declaration of Helsinki and the Guiding Principles in the care and use of animals. 
ii) Perfusion apparatus 
The hearts were mounted 'within one minute of excision via the aorta on a standard Langendorff 
perfusion apparatus (see Fig M.1 ), with immediate initiation of perfusion. A perfusion pressure of 100 
cm H20 (76 mm.Hg) was used, with standard modified Krebs Henseleit solution (118.5 mM NaCl, 25 
mM NaHC03, 5.75 mM KCl, 1.19 mM MgS04, 1.18 mM KH2P04, 1.36 mM CaC!i and 11 mM 
glucose except where stated) 274. The non-recirculated perfusate was gassed throughout with 95% 0 2 
5% CO2, to maintain a p02 of 500-550 mm.Hg and a pH of 7.4. Temperature was maintained at 37°C 
in all experiments by water-jacketing, and monitored by a thermistor probe inserted into the right 
ventricle. A compliant balloon made of cling film was inserted into the left ventricle, and inflated to 
allow recording of a diastolic pressure of 4 mm.Hg on the multi-channel recorder (Grass Model 79D), 
via a Statham P23XL pressure transducer. This resulted in systolic pressures of 100-140 mm.Hg, with 
heart rates of 180-400 beats/min, and coronary flows 8-16 ml/min. Some hearts were paced, after 
excision of the right atrium, using a Grass S88 stimulator, at a rate of 360 beats/min. 
iii) Protocol 
The protocol varied between studies, and is elaborated in the methods in each section of the results. 
The standard protocol had a 15-20 min stabilisation period of perfusion prior to cessation of flow. 
Ischaemia was maintained for 30 min, mostly with a residual flow rate infused via a side arm, and 
maintained by a Gilson Minipuls 2 pump (see Fig M.l). The hearts were then reperfused for 20-30 
min. The preparation was stable over the whole duration of the experiment (90 min) with a maximum 
of 5 % deterioration in function in the absence of ischaemia. Coronary effluent was collected and 
frozen immediately to allow for analysis of glucose utilisation and lactate washout. Parallel series of 
hearts were clamped with Wollenberger tongs kept in liquid nitrogen and the tissue then freeze-dried 
(Christ Alpha 1-4 freeze dryer) to allow analysis of tissue metabolites. 
Methods 
gassing with 
95% 02 5% CO2 
2 reservoirs 
to allow perfusion with 
different buffers 
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determination of coronary flow 
Fig M 1. Langendorf! apparatus for perfusion of isolated rat heart 
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Methods 
iv) Functional measurements 
A representative trace showing pre-ischaemic, ischaemic and reperfusion left ventricular pressure is 
shown in Figure M.2. Coronary flow, heart rate, diastolic and systolic pressure were monitored at 5 
min intervals throughout the experiments. Developed pressure (the difference between systolic and 
diastolic pressure) was used as the main index of functional recovery, expressed as a percentage of 
pre-ischaemic developed pressure (measured at the end of the stabilisation period). During ischaemia, 
developed pressure fell to zero within a few minutes, after which a rise in resting tension generally 
occurred. The time to the rise in diastolic tension above basal levels was defined as the time to onset 
of contracture (in min). The peak of resting tension, or contracture was re::corded (in mmHg), as was 
the time to peak (min). Peak contracrure was expressed as a percentage of pre-ischaemic developed 
pressure. 
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Fig. M2. Representative trace of pre-ischaemic, ischaemic and reperfasion left ventricular pressure, 
showing systolic and diastolic pressure, heart rate and ischaemic contracture . . ...... . 
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2) BIOCHEMICAL ANALYSES 
After freeze-drying, the atria and connective tissue were removed, and the ventricular tissue was 
teased to allow a more homogenous sample to be obtained. The tissue metabolites were then extracted 
either using perchloric acid (for the majority of essays) or by alcohol, for the determination of tissue 
glycogen levels. Tissue metabolites were expressed as µmol/g wet wt, where wet weight = 5 x dry 
weight (a ratio determined from hearts weighed before and after drying - data not shown). 
a) Perchloric acid extraction 
i) Solutions 
5 % perchloric acid - 71.4 ml of 70% solution in IL distilled water 
Tris/KOH/K.Cl: 0.2 M Tris - 24.22 g/L- adjust pH to 7.5 with concentrated HCL 
40% w/v KOH- 40g/100 ml 
saturated KCl - saturate 40 % KOH with KCl, then mix with 0.2 M Tris in ratio of 6:4. 
ii) Method 
1) Use 5 ml flat-bottomed plastic tubes (Greyward without EDTA) and Eppendorff reaction vials. 
Label one set of 5 ml tubes and two sets ofEppendorffs 
2) For freeze-dried rat heart extraction, put 1.2 ml cold 5% PCA into the 5 ml tubes. Keep on ice. Add 
20-25 mg powdered (teased) freeze-dried tissue to PCA. 
3) Homogenise immediately on adding tissue to PCA, keeping tube on ice all the time. Homogenise 
for 15-30 secs at about 300 rpm. 
4) Spin homogenised samples in centrifuge (Sigma 202MK) at 5000 rpm for 1 mins at 4°C. 
5) Take of 1 ml of supernatant into a labelled Eppendorff tube (volume for neutralisation). 
6) Neutralise the acid extract with Tris/KOH/K.Cl buffer using 5 µl universal indicator (reverse 
titration with PCA). Solution becomes cloudy. Approximately 300 µl buffer is required to obtain a 
pH 6.5-7.5 (greenish-blue). The volume of buffer added is the neutralising volume. 
7) Allow to precipitate for 10 mins. Centrifuge in Eppendorff rotor in Sigma 202MK for 5 mins at 
5000 rpm and decant the supernatant into new labelled Eppendorff tubes. Freeze until ready to 
assay. (majority of assays should be done within one week of extraction, and preferably on same 
day) 
iii) Calculations 
Dilution factor for neutralising= F1 = [(1.2 * total volume)/dry heart weight (g)] I 5 
where total volume = neutralising volume + volume for neutralisation + universal indicator 
Metabolites (µmol/g wet wt)= concentration (µmol/ml (mM) from assay)* F1 
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b) Glycogen extraction 
i) Solutions 
40% KOH - 40 g/100 ml 
2N HCl - cone HCl about 10 N - dilute 1/5 
2NNaOH-MW 40- 80 g/100 ml 
Tris buffer- MW 121 0.2 M- 24.22 g/L- adjust to pH 7.5 with cone HCl 
ii) Method 
( adapted from 160) 
1) Weigh Eppendorff tubes (3 ml) and add 10 mg freeze-dried tissue (teased) 
2) Add 0.2 ml 40% cold KOH to digest tissue 
Methods 
3) Heat to 95°C in water bath or Eppendorff heating unit for 30 mins, shaking at 10 min intervals. 
Place weight on lids to prevent bursting open. Ensure tissue is broken up. Allow to cool. 
4) Add 0.8 ml 95 % EtOH (dilute KOH 1/5). Glycogen precipitates overnight in fridge. 
5) Eppendorff centrifuge - spin 2.5 mins at 3200 rpm 
6) Aspirate supernatant, wash sediment 3 times with 1 ml 95 % EtOH each time. Aspirate. 
7) Add 0.2 ml 2N HCl to sediment, to hydrolyse glycogen to glucose moieties. Boil at 95°C for 3 hrs. 
Allow to cool. 
8) Add 5 µl universal indicator and neutralise with 0.1 ml Tris buffer (pH 7 .5) and increments of 2N 
NaOH (about 0.2 ml total) until pH 7.5-7.7 (greenish blue). Note volume added, and weigh tubes. 
9) Measure glucose (carbon-6 units) - standard assay 
iii) Calculations 
Factor for multiplication F2 = {[Final wt (tube+ neut vol) - tube weight]/dry heart wt (g)} / 5 
or F2 = {[5 µl + 0.1 ml+ vol for neutralisation]/heart weight (g)} / 5 
(compare above factors - should be within 5%) 
Glycogen (µmol carbon-6 units/g wet wt)= glucose (µmol/ml (mM) from assay)* F2 
c) Adaptation of macrocuvette spectrophotometric methods for the Cobas Fara II Clinical 
analyser 
The Cobas Fara II multichannel analyser (Roche Diagnostics) was used to measure the concentrations 
of metabolites. The micro-cuvuette methods utilise far less sample per assay, allowing many more 
assays to be done per extract. Many assays can be done within a short time, and are far more cost-
effective in terms of enzymes, reagent volumes etc. The methods were adapted from those previously 
used on the normal spectrophotometer, with standard assay volumes of 3 ml per cuvette 24. The steps 
taken to establish the techniques, and the methods used are described in Appendix II. 
Methods 
d) Adenosine triphosphate (ATP) and creatine phosphate (CP) 
Glucose 6-phosphate dehydrogenase 
G6P + NADP ~ 6-phosphoglucono-<5-lactone + NADPH + Ir 
Hexokinase 
i) Reagent mixture 
Stocks 
Solution Molec Cone 
Wt (mM) 
Glucose 180.162 100 
NADP 743 .4 13.45 
Tris (HCl) 121.4 200 




ii) Start reagents 
ATP +glucose~ ADP+ G6P 
Creatine kinase 
CP +ADP~ ATP+ creatine 
Cobas 
Content Other /cuvette 
Vol (~l) 
1.802 g/10 ml 2 
0.1 g/10 ml 1% 4.46 
24.22g/I pH7.5 40 
0.203 g/1 4 
69.54 











1. G6PDf{ (350 U/mg - 5 mg/ml) included with reagent (1 µI/sample) (dilute 5 mg/ml stock 1/5) 
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2. HK (450 U/mg - 1500 U/ml) 1 µI/sample (20 µI of 1/20 dilution - 40 µl HK+ 760 µI H20 (in large 
diluent cup - in R position - change after first pipetting) 
3. ADP.Na3 (493.2 MW) - stocks 10 mM (0.049 g/10 ml) 5 µI/sample (200 µI in cup - Pl) 
4. CK (350 U/mg) - 2 mg/200 µl (make up fresh daily) 5 µI/sample (200 µI in cup - P2) 
iii) Standards 
0.0625-0.5 mM ATP (605 .2 MW) and CP (363 .2 MW) in same cups 
Stocks 10 mM (0.06lg/10 ml and 0.036g/10 ml - dilute 1/10) 
iv) Calculations 
(M2 - Ml)/slope = ATP mM (Al - M3)/slope = CP mM 
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e) Adenosine diphosphate (ADP) and adenosine monophosphate (AMP) 
Lactate dehydrogenase 
Pyruvate + NADH + H'" B Lactate + NAD+ 
Pyruvate kinase Myokinase 
ADP + phosphoenolpyruvate B ATP + pyruvate AMP + ATP B 2 ADP 
i) Reagent mixture 
Stocks Cobas 
Solution Molec Cone Content Other /cuvette 
Wt (mM) Vol (,:1) 
TRAM- 185.65 400 14.85g/200 ml pH7.5 24 
EDTA 372.25 100 0.185 g (after) 
KCl 74.56 500 37.28 g/1 20 
MgCh 203.3 1000 203 .3 g/1 4 
NADH.Na2 709.4 14.1 O.lg/10 ml 1% 3.11 
PEP-TCHA 168 10 16.8 mg/10 ml 8 
















TRAM buffer. - 1/2 vol TRAM. pH to 7 .5 (Na OH}, add EDT A and make up to vol (200 ml) 
iii) Start reagents 
I. LDH (250 U/mg - 100 mg/10 ml) included with reagent (I µI/sample) 
2. PK (200 U/mg-10 mg/ml) 0.5 µI/sample (5 µl of 1:10 - 20 µl +180 µl H20 in Pl) 
3. Myokinase (360 U/mg - 5 mg/ml) 0.5 µI/sample (5 µl of 1:10 - 20 µl + 180 µI H20 in P2) 
iv) Standards 
l 
0.03125-0.25 mM ADP.Na2 (471.2 MW) and AMP.Na2. 6H20 (499.2 MW) in sanie cups. 
Stocks 10 mM (0.041g/10 ml and 0.049g/10 ml) 
v) Calculations 
(M2 -Ml)/slope = ADP mM (AIO -M2)/slope = AMP mM 
Methods 
Methods 
f) Inorganic phosphate 
Phosphate ions + ammonium molybdate ~ phosphomolybdate 
i) Reagent mixture 
Stocks Cobas 
Solution Cone Other /cuvette 
Vol {!:!;Q 
Ammonium molybdate 2.1 
+ Sulfuric acid 750 use as is 150 
Total 150 
ii) Standards 
0.125 - 1.0 mMNa2HP04 .• 12H20 (358.14 MW) 
Stocks 10 mM (0.0358 g/10 ml) 
iii) Calculations 
(A25 - Al)/slope = Pi (as printed) 
iv) Notes 




Measures concentration of phosphomolybdate complex photometrically 





Glucose+ ATP~ Glucose 6-phosphate + ADP 
Glucose 6-phosphate dehydrogenase 
G6P + NADP ~ 6 phosphoglucono-&-lactone + NADPH + It 
i) Reagent mixture 
Stocks 





+HK 20 µkat/L 
+G6PDH 10 µkat/L solid (Rl) 
Tris 10 +30 ml (R2) 
Total 
ii) Standards 
0.0625 - 5 mM glucose (180.6 MW) 







(A19 - Al)/slope = Glucose mM (as printed) 
iv) Notes 
Range of assay up to 33 mM 
If expected range <1 mM, use 10 or 20 µ1 sample 
Change standards for effluent sample. 







h) Glucose 6-phosphate (G6P) and fructose 6-phosphate (F6P) 
Glucose 6-phosphate dehydrogenase 
Glucose 6-phosphate + NADPB- 6-phosphoglucono-o-lactone + NADPH 
Phosphoglucoisomerase 
Fructose 6-phosphate B Glucose 6-phosphate 
i) Reagent mixture 
Stocks Cobas 
Solution Molec Cone Content Other /cuvette /35 cuv 
Wt (mM) Vol (µl) (µl) 
Tris (HCl) 121.4 200 24.22g/I pH7.5 40 1400 
ATP 605.2 10 0.0605/10 ml 8 280 
MgCh 203 .3 1000 203 .3g/I 4 140 
NADP 743.4 13 .5 0.lg/10 ml 1% 4.44 156 
H20 63 .56 2224 
Total 120 4200 
ii) Start reagents 
1. G6PDH (350 U/mg - 5 mg/ml) 0.5 µI/sample (5 µl of 1:10 -20 µl +180 µl H20 in Pl) 
2. PGI (350 U/mg - 2 mg/ml) 0.5 µI/sample (5 µl of 1: 10 - 20 µI+ 180 µl H20 in P2) 
iii) Standards 
0.03125 - 0.25 mM G6P (304 1 MW) and F6P (304.1 MW) - in same cups 
Stocks 10 mM (0.0304g/10 ml and 0.0304g/10 ml) 
iv) Calculations 
(M2 - Ml)/slope = G6P mM 
v) Notes 
Range of assay < 0.5 mM 





i) Dihydroxyacetone phosphate (DHAP) and Glyceraldehyde 3-phosphate (GAP) 
and Fructose 1,6-diphosphate (FDP) 




Tris (HCl) 121.1 
H20 
Total 




2 GAP B 2 DHAP + 2 NADH + 2 Ir 
Glycerol 3-phosphate dehydrogenase 
2 DHAP + 2 NADH + 2ft B 2 a.GP+ 2 NAD+ 
Stocks Cobas 
Cone Content Other /cuvette /35 cuv 
(m.M) Vol {~l) {~12 
14.1 0. lg/10 ml 1% 0.048 109 
200 24.22 g/1 pH7.5 12 2100 
107.9 1991 
120 4200 
1. GDH (170 U/mg - 2 mg/ml) 1 µI/sample (20 µl of 1:20 - 40 µl + 760 µl H20 in R- change after 
first pipetting) 
2. TIM (5000 U/mg- 10 mg/ml) 0.5 µI/sample (5 µl of 1:10- 20 µl +180 µl H20 in Pl) 
3. Aldolase (9 U/mg- 10 mg/ml) 0.5 µI/sample (5 µl of 1:10 - 20 µl +180 µl H20 in P2) 
iii) Standards 
0.03125 - 0.25 mM DHAP (170.1 MW), GAP (170.1 MW) and FDP (550.2 MW) in same cups 
Stocks 10 mM (0.0701 g/10 ml; 0.0170 g/10 ml; 0.0550 g/10 ml) 
iv) Calculations 




Pyruvate + NADH + Ir B Lactate + NAD+ 
i) Reagent mixture 
Stocks Cobas 
Solution Malec Cone Content Other /cuvette /35 cuv 
Wt (mM) Vol (~l) (~l) 
NADH.Na2 709.4 14.1 O.lg/10 ml 1% 3.41 109 
Tris (HCl) 200 pH7.6 60 2100 
H20 56.6 1991 
Total 120 4200 
ii) Start reagents 
1. LDH (250 U/mg- 100 mg/10 ml) 0.5 µ1/sample (5 µl of 1:10- 20 µl +180 µl H20 in Pl) 
iii} Standards 
0.03125 - 0.25 mM pyruvate (110 MW) 
Use fresh standard each day 
iv) Calculations 
(A3 - Ml)/slope = Pyruvate mM (as printed) 
v) Notes 






Pyruvate + NADH + Ir B Lactate + NAD+ 
i) Reagent mixture 
Stocks Cobas 
Solution Molec wt Cone Content Other /cuvette /35 cuv 
(mM) (stocks) Vol {~Q {~Q Hydrazine S04 130.1 799 20.8 g 
+EDTA 404.47 9.9 0.8 g 
+ glycine 75.07 1200 30 g/ 200 ml pH9.3 
+NaOH 40 2N 80 g/1 - 9.5 60 2100 
NAD+ 663.4 15.1 0.1 g/10 ml 0.01 7.99 280 
H20 52 1820 
Total 120 4200 
ii) Solutions 
Hydrazine buffer - weigh out solutes and add water to final volume of 200 ml. Titrate with 2 N NaOH, 
with approximately equal volumes to pH 9.3-9.5. 
iii) Start reagents 
1. LDH (250 U/ml - 100 mg/10 ml) 0.5 µI/sample (5 µl of 1:10 - 20 µl +180 µl H20 in Pl) 
iv) Standards 
0.0625 - 0.5 mM Na-Lactate (112.1 MW) 
Stocks 10 mM (0.0112 g/10 ml) 
v) Calculations 
(AIO - Ml)/slope = Lactate mM 
vi) Notes 
Limit of assay 5 mM 
(For higher concentrations increase diluent volume/decrease sample volume) 
Methods 
I) L-glycerol 3-phosphate (a.glycerophosphate - a.GP) 
Glycerol 3-phosphate dehydrogenase 
a.glycerophosphate + NAD+ B glycine 1-phosphate + NADH + Ir 
i) Reagent mixture 
Stocks Cobas 
Solution Molec Cone Content Other /cuvette /35 cuv 
Wt (mM) Vol (~12 {~12 
Hydrazine S04 130.1 160 20.8 g 
+EDTA 404.47 2 0.8 g 
+ glycine 75.07 400 30 g/200 ml 60 2100 
+ NaOH 40 2N 80 g/1 pH9.5 
NAD+ 663.4 15.1 0.1 g/10 ml 1% 8 280 
H20 52 1820 
Total 120 4200 
ii) Start reagents 
1. GDH (170 U/mg - 2 mg/1 ml) 0.5 µ1/sample (5 µ1 of 1:10 - 20 µ1 + 180 µ1 H20 in Pl) 
iii) Standards 
0.03125 - 0.25 mM a.GP (216.1 MW) 
Stocks 10 mM (0.0216g/10 ml) 
iv) Calculations 





L-alanine + NAD+ + H20 ~ Pyruvate + NADH + NRi + 
i) Reagent mixture 
Stocks Cobas 
Solution Molec · Cone Content Other /cuvette 
Wt (mM) Vol {~Q 
Hydrazine S04 130.1 160 20.8 g 
+EDTA 404.47 · 2 0.8 g 
+ glycine 75.07 400 30 g/200 ml 
+NaOH 40 2N 80 g/1 pH 10 100 
NAD+ 663.4 15.1 O.lg/10 ml 1% 20 
H20 
Total 120 
ii) Start reagents 
1. ADH (20 U/mg) 0.5 µI/sample (5 µl of 1:10- 20 µl +180 µl H20 in Pl) 
iii) Standards 
0.03125 -0.25 mML-Alanine (89.1 MW) 
Stocks 10 mM (0.0089 g/10 ml) 
iv) Calculations 


















ii) Start reagents 
Citrate lyase 
Citrate B oxaloacetate + acetate 
Ma/ate dehydrogenase 
Oxaloacetate + NADH + Ir B malate + NAD+ 
Oxaloacetate decarboxylase 
Oxaloacetate Bpyruvate + CO2 
Lactate dehydrogenase 
Pyruvate + NADH + Ir B Lactate + NAD+ 
Stocks Cobas 
Cone Content Other /cuvette 




10 6mg 1.4 g/12 ml H20 57.5 
62.5 
120 
1. CL (12 U/50 mg) dilute with 300 µl H20 in Pl 
iii) Standards 
0.0625 - 0.5 mM Citrate (192.1 MW) 
Stocks - 0.395 g/1 in kit (2.056 mM) 
iv) Calculations 
(A2 - Ml )/slope = Citrate mM 
v) Notes 










Malate + NAD+ B Oxaloacetate + NADH + W 
Glutamate-oxaloacetate transaminase 
Oxaloacetate+ L-glutamate B L-aspartate + 2-oxoglutarate 
i) Reagent mixture 
Stock 
Solution Molec Cone 
Wt (mM) 
Glycylglycine 132.1 




ii) Start reagents 
1. GOT (160 U/0.4 ml) as is in kit 
2. MDH (2400 U/0.4 ml) as is in kit 
iii) Standards 
0.0625 - 0.5 mM Malate (134.1 MW) 
Stocks 0.204 g/1 in kit - 1.5 mM 
iv) Calculations 




440mg /30 ml 
210mg /6 ml H20 
L-malic acid Boehringer Mannheim kit no 139 068 
Cobas 
/cuvette /35 cuv 







p) Glycolytic flux 
Glycolytic flux is measured as the rate of cleavage of a ft from the glucose molecule to form water. 
The ft is traced using tritium (modified from 386, 468). With D [2-3H] glucose, the 3ft is cleaved in 
the phosphoglucoisomerase reaction (G6P to F6P). 
i) Materials 
D [2-3H] glucose (1 mCi/ml - supplied by Amersham) was added to the perfusate. 220 µ1 of D [2-3H] 
glucose/L Krebs ( 11 mM glucose) was used with an activity of 20 µCi/mmol glucose 
Glass Pasteur pipettes (short form) were inserted into racks, and stoppered with cotton wool. Dowex-1 
borate was used to retard the glucose and enable 3H20 to be collected. 
Dowex-1 borate was made from Dowex-1 (chloride form; 4% cross-linked, 100-200 dry mesh from 
Sigma) which comes as a dry powder. The powder was saturated with 2 N Na-borate (50 g/1 NaOH + 
100 g/1 boric acid). The solution was washed several times with distilled water (3-4 volumes of water, 
allow to settle and pour off) to remove excess NaCl until the pH of the resin was that of water. (The 
resin can be stored in the fridge in a suspension of water to retard bacterial growth. For long term 
storage, the resin must be filtered and stored as a dry paste in the freezer.) 
ii) Method 
1) Place approximately 1 ml of the resin in the column, ensuring that there are no bubbles. Wash the 
column twice with distilled water and allow to drain. 
2) Add 200 µ1 of coronary effluent sample (deproteinise blood if this is used). 
3) Wash column with 2 x 0.5 ml distilled water. 
4) Collect effluent in 10 ml scintillation cocktail in 20 ml vials and vortex (must be sufficient cocktail 
to the aqueous samples, such that cocktail does not remain cloudy). 
iii) Counting 
The sample is counted on a beta counter (Packard Tri-Carb 460) using a quench curve for tritium to 
obtain the dpm. 
Blank - non-radioactive Krebs - 45-65 dpm 
Total specific activity of 200 µ1 radioactive Krebs (not through Dowex columns) 
Standards - 200 µ1 radioactive Krebs through Dowex columns (activity absent or very minimal) 
iv) Calculations 
Rate of glycolysis (g) = (A/F) 
where A= measured rate of production of 3H20 in dpm/min/g wet (dry) wt 
F = specific activity of glucose in dpm/µmol 
A = [Sample dpm (in 200 µl) - standard dpm ] * 5 
102 
=dpm/ml 
= dpm/ml * coronary flow (ml/min)* heart weight (g) 
= dpm/min/g heart weight 
F = [Total dpm (in 200 µ1)- standard dpm] * 5 
= (dpm/ml) 




The Grass Model 79D recorder and S88 stimulator was supplied by Grass Instruments Co. (Quincy, 
MA, USA). The Gilson Minipuls 2 pump was obtained from Gilson International (Villers-le Bel, 
France). The Christ Alpha 1-4 freeze dryer was obtained from Martin Christ 
Gefriertrocknungsanlagen GmbH (Osterode am Harz, Germany). The Sigma 202MK centrifuge was 
supplied by SIGMA Chemical Company (St Louis, MO, USA). The COBAS Fara II was supplied by 
Hoffmann-La Roche Diagnostics Division (Basel, Switzerland). The Packard Tri-Carb 460 beta 
counter was obtained from Packard Instrument Co. (Meriden, CT, USA). 
The majority of enzymes were supplied by Boehringer Mannheim GmbH (Mannheim, Germany), in 
the concentrations and activities quoted. Substrates were also supplied by Boehringer Mannheim, or 
else by Sigma Chemical Company (St Louis, MO, USA). Some standard chemicals were supplied by 
BDH Chemicals Ltd (Poole, England), Saarchem (Pty) Ltd (Krugersdorp, South Africa) and E. Merck 
(Darmstadt, Germany). D[2-3H] glucose was supplied by Amersham Life Sciences (Little Chalfont, 
Buckinghamshire, UK). Ready-Safe Scintillation cocktail was supplied by Beckman Instruments Inc. 
(Fullerton, CA, USA). Scintillation vials were supplied by Packard Instrument Co. (Meriden, CT, 
USA). 
4) STATISTICS 
The ANOV A two-way analysis of variance was used to determine significance among groups, 
followed by application of the modified t-test for comparison of individual groups. The modified 
student's t-test was used to determine significance between two groups. A p<0.05 was taken as the 
level of significance. At least 6 hearts were used in each group. GraphP AD Instat™ computer 
programme was used for statistics, and MicroCal Origin™ for regression analyses. 
Results 1. Coronary flow and glucose delivery as determinants of 
contracture in the ischaemic myocardium 
Published in J Mol Cell Cardiol 27:701-720, 1995. 
ABSTRACT 
Ischaemic contracture may be avoided by the provision of glucose under low flow conditions 424. 
However, accumulation of harmful metabolic end products may inhibit glycolytic flux and lessened 
the benefit of glucose. We assessed whether during increasingly severe flow restriction, provision of 
glucose might be harmful rather than beneficial, using the Langendorff perfused rat heart. Ischaemic 
contracture (resting tension expressed as percent of pre-ischaemic developed pressure) was measured 
via a left ventricular balloon. Reductions in flow to 0, 0.015, 0.03, 0.06, 0.1 , 0.2 or 0.4 ml/g wet 
wt/min over 60 min were tested. At zero flow, peak contracture was 61.4 ± 3.5% (± S.E.) but fell to 
15.6 ± 6.3% with 0.4 ml/g wet wt/min (p<0.05) in the presence of 11 mM glucose. Time-to-onset of 
contracture was significantly delayed by the higher coronary flows. At coronary flows down to zero, 
the effect of glucose was inconstant or absent, but not harmful. With the residual flow at 0.2 ml/g wet 
wt/min, a dose response to glucose in ischaemia was elicited, using concentrations of 0, 2.5 , 5.5, 11 or 
22 mM. Maximum protection against ischaemic contracture was found with 11 mM glucose. 
However, once contracture occurred, functional recovery was severely impaired in all cases. Reducing 
glycogen prior to low flow ischaemia (0.2 ml/g wet wt/min) with 11 mM glucose increased peak 
contracture, and reduced the time-to-onset of contracture. Increased pre-ischaemic glycogen had little 
effect on contracture. 
Glycolytic flux fell in proportion to the coronary flow. However, there was an increased glucose 
extraction at lower flows of 0.1 and 0.2 ml/g wet wt/min, suggesting that it is the rate of delivery (i.e. 
coronary flow) which is the rate limiting step rather than enzyme inhibition by accumulated 
metabolites. If flow were further reduced, metabolite accumulation would become more important, 
such that with no flow, this would be the determinant of glycolytic flux rate. 
In our model, the two requirements for optimal protection from ischaemia were (i) provision of 
glucose (11 mM was optimal) and (ii) an adequate coronary flow to deliver the glucose and remove 
end product inhibition (greater than 0.06 ml/g wet wt/min). 
104 Results Ch 1. Glucose concentration, residual coronary flow and ischaemic contracture 
INTRODUCTION 
Ample experimental evidence shows that the provision of glucose ( or glucose-insulin-potassium) may 
have therapeutic potential.in the treatment of myocardial ischaemia and infarction 14, 123, 401 , 502. 
Indices of protection in the isolated perfused heart include: reduction of enzyme leakage 104, 
decreased reperfusion-induced arrhythmias 28, attenuation of stunning 133 as well as reduced 
ischaemic contracture 123, 424. The mechanisms involved may include an increased production of 
glycolytic ATP 123, 424 with a resulting improvement in the control of cell calcium 229, 405 
inhibition of the ATP-sensitive K channel 571 , and a decrease of tissue cyclic AMP in the ischaemic 
zone 438. In addition, glucose plus insulin given over 180 min in isolated rabbit hearts perfused at 
only 1 m.1/g wet wt/min with an erythrocyte suspension was markedly protective 123. Recent clinical 
studies have also shown a beneficial effect of glucose (with insulin and potassium - GIK) when given 
to patients with refractory left ventricular failure after aortocoronary bypass surgery 84. 
Despite such convincing evidence for a protective role of glucose, the more general clinical use of 
GIK has in part been restrained by the finding of Neely and Grotyohann 387 that a greater rate of 
glycolysis from glycogen had detrimental effects in zero flow global ischaemia. The harm was 
attributed to the accumulation of metabolites, especially lactate and protons, which with zero flow 
could not be washed out of the tissue. The phenomenon of preconditioning also suggests a possible 
protective effect of glycogen depletion resulting from the initial period(s) of ischaemia 378, 588. This 
finding has been corroborated by studies showing the protective effect of preconditioning is linked to 
an attenuated rise in proton 512 and lactate 18 concentrations in ischaemia, which in turn are 
attributed to reduced breakdown of glycogen. In addition, when lactate is added to the perfusate prior 
to ischaemia, a reduction in functional recovery has been found 239, 387. However, these models 
investigated utilisation of glycogen as the glycolytic substrate, and not glucose. A difference in the 
protective role of glucose versus glycogen has been suggested 424, 470. 
The potential role of a severely restricted residual coronary flow, and its effect on removal of the 
potentially harmful end products of glycolysis, has not been investigated. Hearse et al. 193 added 
glucose to a cardioplegic solution used to arrest hearts, and found a deleterious effect, contrary to 
subsequent observations where glucose in a multi dose protocol (i.e. with washout of metabolites) was 
used 563. While the classic studies of Neely et al. 390 and Ravetto et al. 468 showed an increase in 
glucose utilisation at reduced coronary flow rates compared to normal flows in an isolated perfused 
rat heart, the flows used in these studies were relatively high (0.6 - 6 m.1/g wet wt/min), albeit 
restricted, and thus may not reflect true in vivo ischaemia, where normal coronary flows are lower 
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than in an isolated organ. The role of glucose in severe low flow conditions in protecting against 
ischaemic damage has not been fully clarified. 
We, therefore, tested the hypothesis that the residual coronary flow (less than 4% of control flows in 
perfused hearts, and less than 7% of normal in vivo coronary flows) to the ischaemic myocardium 
could be the crucial factor determining whether provision of glucose would be beneficial or harmful 
in the development of ischaemic contracture. The latter is potentially an irreversible event and a cause 
of "no-reflow" on reperfusion 210. We used the isolated globally ischaemic rat heart to investigate the 
possible benefit of addition of various concentrations of glucose over a range of low coronary flows, 
much lower than those previously used 424. Lactate washout and glycolytic flux were measured, and 
ischaemic injury was assessed by the rate and extent of ischaemic contracture. In addition, reperfusion 
arrhythmias and functional recovery were recorded in some studies, to assess any correlation between 
ischaemic contracture and recovery. Because of the potential contribution of glycogen to the 
glycolytic pathway during ischaemia, we also altered tissue glycogen content prior to low flow 
ischaemia. 
The major finding of this study was that the severity of coronary flow restriction plays a critical role 
in determining the rate of delivery of glucose and hence its beneficial effect. At no flow was a 
detrimental effect of glucose observed. In addition, there was a greater benefit during ischaemia of 
glycolysis from glucose than from glycogen, confirming the proposal of Owen et al. 424. 
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METHODS 
ANIMALSANDISOLATEDRATHEARTAPPARATUS 
The isolated Langendorff-perfused rat model with a left ventricular balloon was used, as described in 
Methods. 
PROTOCOLS 
Low flow ischaemia. Three different protocols were employed: 
(i) An initial comparison of two ischaemic low flows, and the absence or presence of glucose at each 
flow, was made in terms of ischaemic contracture, functional recovery and glucose utilisation. After 
15 min normoxic perfusion, hearts were made globally ischaemic for 30 min at low flows of 0.1 or 
0.2 ml/g wet wt/min. These residual flows of oxygenated buffer were delivered by a Gilson Minipuls 
pump. Glucose was either absent, or present at a concentration of 11 mM at each flow. The hearts 
were then reperfused for 25 min with perfusate containing 11 mM glucose, and post-ischaemic 
functional recovery was recorded. 
During ischaemia, the coronary effluent was collected over each 5 min period, and glycolytic flux and 
lactate washout were measured (see later). A sample of coronary effluent was also taken just before 
ischaemia as control. On reperfusion, the total coronary effluent was collected over the first 2 min of 
reperfusion, and this was analysed for lactate content. The extent of glycogen breakdown and ATP 
production during ischaemia was calculated (see later). Ten hearts were used in each group. 
(ii) The role of residual flow in determining the extent of ischaemic contracture was investigated, and 
the requirement for glucose evaluated at each flow. After 15 min normoxic perfusion, hearts were 
rendered ischaemic for 60 min, during which time, oxygenated perfusate containing 11 mM glucose 
was infused at different flows (0, 0.015, 0.03, 0.06, 0.1, 0.2, and 0.4 ml/g wet wt/min). Initial 
experiments with a flow of 0.4 ml/g wet wt/min with 11 mM glucose showed that ischaemic 
contracture was markedly delayed in this group; thus a period of 60 min ischaemia was chosen to 
ensure attainment of peak contracture. The hearts were not reperfused after this extended period of 
ischaemia. Six hearts were used in each group. 
In a second series of experiments with the above flows, glucose was omitted throughout the ischaemic 
period. In addition, to ensure that no glucose was trapped in the heart during ischaemia, the hearts 
were perfused with glucose-free medium for 1 min just prior to the onset of ischaemia. Six hearts 
were used in each group. 
(iii) A dose response curve to glucose was elicited at two flows, in terms of ischaemic contracture and 
functional recovery. After 15 min normoxic perfusion, hearts were made ischaemic for 30 min at low 
flows of 0.06 or 0.2 ml/g wet wt/min, with glucose concentrations of 0, 2.5, 5.5, 11 or 22 mM. The 
hearts were then reperfused for 25 min with perfusate containing 11 mM glucose and functional 
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recovery was recorded. An ECG electrode was placed in the apex of the hearts in order to record the 
incidence of ventricular arrhythmias. Six to eight hearts were used in each group. 
Pre-ischaemic modification of tissue glycogen content. In a separate series of experiments the role of 
glycogenolysis in determining the degree of ischaemic contracture in the absence and presence of 
glucose was investigated. Different glycogen levels prior to the start of ischaemia were achieved by 
perfusing hearts as follows: 
(i) 20 min perfusion with 11 mM glucose 
(ii) 20 min perfusion with 5 mM acetate 
(NaCl was reduced by 5 mM to accommodate Na-acetate) 
(iii) 20 min substrate-free perfusion 
(iv) 20 min perfusion with 11 mM glucose+ 1 U/L insulin. 
All hearts were then subjected to ischaemia for 60 min, at a coronary flow of 0.2 ml/g wet wt/min, in 
the absence or presence of 11 mM glucose, following which the hearts were clamped. A parallel 
series of experiments were carried out, in which the hearts were freeze-clamped just prior to the onset 
of ischaemia. The frozen tissue was analysed for glycogen, lactate, adenosine triphosphate (ATP) and 
creatine phosphate (CP) contents. Six hearts were used in each group. 
MEASUREMENT OF ISCHAEMIC CONTRACTURE, VENTRICULAR ARRHYTHMIAS AND FUNCTIONAL 
RECOVERY 
Peak ischaemic contracture and time to onset of contracture were recorded as described in Methods. 
Arrhythmias were defined as the occurrence of ventricular tachycardia and/or ventricular fibrillation. 
These were quantified according to the Lambeth conventions 566 and the incidence of arrhythmic 
hearts following reperfusion was expressed as a percentage of the total number of hearts in each 
group. No arrhythmias were observed during ischaemia in any hearts. 
Functional recovery, where measured, was indicated by developed pressure after 5 min (early) and 25 
min (late) reperfusion expressed as a percentage of pre-ischaemic developed pressure, measured at the 
end of the stabilisation period. Early and late reperfusion are used to indicate the rate of return to 
function, or the degree of stunning. Heart rates were little changed, thus developed pressure was 
sufficient to express functional recovery. 
BIOCHEMICAL MEASUREMENTS 
Glycolytic flux and glycogenolysis. Glycolytic flux (from glucose) was determined as described in 
Methods. Effluent lactate was assayed according to Bergmeyer 24. Both lactate washout and 
glycolytic flux are expressed as µmol 6-carbon (C6) units to allow for comparison of equivalent units. 
From the average wet heart weight, (1.05 ± 0.003 g), all values were expressed as per g wet weight. 
The rate of utilisation (production) lg wet wt/min corrected for coronary flow is calculated by 
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µmol C6 units/ml x coronary flow (ml/g wet wt/min)= µmol CJg wet wt/min 
Glycogenolysis (expressed in µmol C6 units) was estimated from the lactate in excess of that 
accounted for by glycolytic flux, where total lactate production in ischaemia was derived from the 
sum of the lactate efflux in ischaemia plus that during the first 2 min of reperfusion ( as an estimate of 
tissue lactate at the end of ischaemia, corrected for by subtracting the rate of lactate efflux in normal 
perfusion, which was an average of 0.5 ± 0.1 µmol CJg wet wt/min). No allowance was made for the 
input of glycolytically derived pyruvate into the Krebs cycle or to alanine, any contribution to which 
would reduce total lactate efflux and thus give an underestimation of glycogenolysis. Anaerobic ATP 
production during ischaemia was calculated using 2 mol ATP per mol glucose utilised, and 3 mol 
ATP per mol of C6 units of glycogen broken down. 
Contribution of oxidative phosphorylation. The p02 of the solution delivered to the hearts during 
ischaemia was measured at 500-550 mm.Hg. Assuming an average uptake of 95% of the delivered 
oxygen (measured in a representative number of hearts - data not shown), this resulted in an arterio-
venous difference in p02 of 475-520 mm.Hg. Using the relationship 
PV=nRT 
the µmol Oi/ml solution at a given p02 at 37°C can be calculated using 
no ofmol 0 2/L soln = __filb/760 mm.Hg x Vg 
0.08205 L.atm.mo1-l.K-l x 310K 
where Vg = a p02/760 mm.Hg x Vol soln 
where a= solubility coefficient of 0 2 in saline solution (0.155 N NaCl) at 370c 
= 0.02273 ml Oi/ml saline per atmosphere 11 
The maximum amount of 0 2 taken up per min can then be calculated from the coronary flow. At a 
flow of 0.2 ml/g wet wt/min, and a p02 difference of 500 mm.Hg, this means an uptake of 0.08 µmol 
0 2/g wet wt/min. Assuming that glucose ( or C6 units from glycogen) is the sole substrate contributing 
to acetyl Co A formation, this would mean a maximum production of 0.46 µmol ATP/g wet wt/min 
from oxidative phosphorylation (given that 6 mol 02 are required per mol glucose to give an 
additional 36 mol ATP under aerobic conditions). Over 30 min ischaemia, this would be a maximum 
contribution of 13.9 µmol ATP. At a flow of 0.1 ml/g wet wt/min, these values would be halved. If 
fatty acids from the breakdown of endogenous triglycerides were the sole substrate contributing to 
oxidative phosphorylation, a maximum of 13.6 µmol ATP over 30 min ischaemia would be produced, 
given a P:O ratio of 2.8 424. Thus any contribution of endogenous fatty acids would only serve to 
reduce oxidative phosphorylation of glucose or glycogen, while not affecting total maximum 
production of ATP from aerobic metabolism. 
Analysis of tissue metabolites. Hearts taken for analysis were freeze dried before extraction with 
perchloric acid to determine tissue levels of adenosine triphosphate (ATP), creatine phosphate (CP) 
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and lactate, assayed according to Bergmeyer 24. Tissue glycogen was measured by assaying the C6 
unit content (glucose assay) after potassium hydroxide degradation according to Good et al. 160. 
Tissue levels are expressed as µmol/g wet weight, where wet weight is calculated as dry weight x 5. 
STATISTICAL PROCEDURES 
All results are expressed as mean ± S.E. Analysis of variance (ANOVA) tests were performed to 
determine whether any significant differences existed among groups, after which the modified 
Student's t test was used to obtain levels of significance for individual comparisons within each 
group. The t test was used to examine individual differences between groups. The Fisher's Exact test 
was used to determine statistical differences in incidence of ventricular arrhythmias. p<0.05 was taken 
to indicate significance. 
110 Results Ch 1. Glucose concentration, residual coronary flow and ischaemic contracture 
RESULTS 
Low FLOW ISCHAEMIA WITH AND WITHOUT GLUCOSE - ISCHAEMIC CONTRACTURE WITH 
METABOLIC MEASUREMENTS 
In the first set of experiments, a basic two way comparison of flow (0.1 vs. 0.2 ml/g wet wt/min) and 
glucose ( either zero or 11 mM) was made. Ischaemic contracture and recovery on reperfusion were 
recorded, and glycolytic flux rates and lactate washout determined. Ischaemic contracture, illustrated 
by the change in diastolic pressure (mm.Hg) (Figure 1 ), was influenced both by coronary flow and the 
presence of glucose. 
Mechanical function . Left ventricular developed pressure prior to ischaemia was no different 
between groups, with a mean of 124.3 ± 2.5 mm.Hg (Figure 1). Heart rate was 325.6 ± 9.4 beats/min, 
and coronary flow 12.2 ± 0.2 ml/g/min. 
With a reduction in flow to 0.1 ml/g/min, the rise in diastolic pressure in ischaemia was significantly 
greater in the absence of glucose (Figure 1). Peak contracture was 51.0 ± 2.2% of pre-ischaemic 
developed pressure in the absence of glucose , compared with 36.5 ± 4.5% in the presence of glucose 
(p<0.02). However, the time-to-onset of contracture was similar in both groups (13.2 ± 1.2 and. 11.3 ± 
0.9 min respectively). At the higher coronary flow (0.2 ml/g/min), the times-to-onset of contracture 
again were similar in the absence and presence of glucose (10.0 ± 0.8 and 11.5 ± 1.1 min respectively) 
and did not differ significantly from the values observed in the 0.1 ml/g/min flow groups. Peak 
contracture in the absence of glucose was 65.9 ± 2.9%, (p<0.01 vs. 0.1 ml/g/min) but the addition of 
glucose markedly reduced the severity of contracture (to 26.1 ± 3.5%, p<0.01 vs. zero glucose at 0.2 
ml/g/min; p<0.02 vs. 11 mM glucose at 0.1 ml/g/min). At the higher flow, glucose had a greater 
inhibitory effect on contracture, and the absence of glucose was more detrimental. 
On reperfusion, coronary flow returned to pre-ischaemic values in all groups but then diminished 
slightly with time. Heart rates during the early minutes of reperfusion were also slightly depressed but 
these returned to pre-ischaemic control values by 10 min reperfusion. Diastolic pressures increased 
slightly in all groups on reperfusion from values attained at 30 min ischaemia, and then fell gradually 
(see Figure 1). There were no differences between the groups. However, the initial recovery of 
developed pressure was significantly higher in the glucose-infused groups due to better recovery of 
systolic pressure, as shown in Figure 1. The hearts perfused with no glucose during ischaemia showed 
a significantly reduced systolic pressure, and a very poor recovery of developed pressure, in early 
reperfusion ( 14.7 ± 9.9 % at 0.1 ml/g/min; 4.9 ± 4.0 % at 0.2 ml/g/min), compared to hearts with 
glucose present in ischaemia (40.2 ± 10.9 % and 53.8 ± 11.2 % for the two flows, p<0.05 vs. lower 
flow). By late reperfusion, all hearts had recovered to a similar extent (41.6 ± 9.4 % and 55.5 ± 3.6 % 
(no glucose), and 40.3 ± 8.7 % and 58.9 ± 3.9% (11 mM glucose). 
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Metabolic data. Mean pre-ischaemic glycolytic flux rate in all groups was 1.5 ± 0.1 µmol/g/min. Such 
flux was rapidly and substantially decreased at values of 0.1 and 0.2 ml/g/min (Figure 2). Thereafter 
in the presence of glucose, flux rate increased with each 5 min period, reaching a plateau at 10-15 min 
of ischaemia. This plateau value was proportional to the residual coronary flow, being 
0.51 µmol/g/min at 0.2 ml/g/min and 0.26 µmol/g/min at 0.1 ml/g/min. Total glucose utilisation over 
the 30 min ischaemic period was 5.7 ± 0.6 µmol/g (0.1 ml/g/min) and 12.6 ± 1.3 µmol/g (0.2 
ml/g/min; p<O.O 1 vs. lower flow). 
The percentage of glucose taken up of that delivered can be calculated as follows. Glucose uptake 
(µmol/g/min) was assumed to equal the measured glycolytic flux rate from glucose and can be related 
to the glucose delivery rate (coronary flow (ml/g/min) x 11 µmol/ml). The percentage uptake of 
glucose (Figure 3) was greatly increased in ischaemia, eventually to a plateau of about 24% of 
delivered glucose ( compared with a pre-ischaemic uptake of 0.9 ± 0.1 % ). Thus although the absolute 
amount of glucose taken up was reduced during ischaemia, the relative quantity of glucose taken up 
from that available to the ischaemic myocardium was greatly increased. The percentage uptake 
reached a plateau after 10-15 min ischaemia and was not influenced by the different low coronary 
flows (0.1 or 0.2 ml/g/min). 
Lactate washout /g/min was initially reduced in all groups when compared to pre-ischaemic values. 
However, this was followed by a subsequent increase to a plateau level in glucose-perfused hearts. In 
contrast, in glucose-free hearts the lactate production from the breakdown of glycogen did not achieve 
a steady state and declined after 10-15 min of ischaemia. At a coronary flow of 0.1 ml/g/min, total 
lactate washout during ischaemia was not affected by the addition of glucose (7 .1 ± 0. 7 µmol C6 
units/30 min with zero glucose, versus 7.9 ± 1.0 µmol C6 units/30 min with 11 mM glucose). At a 
coronary flow of 0.2 ml/g/min, lactate washout values peaked early and were higher than those seen in 
the lower flow group (p<0.01). In addition, lactate output was increased by the presence of glucose 
(10.5 ±0.6 µmol C6 units/30 min with zero glucose vs. 15.2 ± 0.7 µmol C6 units/30 min with glucose, 
p<0.01). 
In the glucose-perfused groups, the measured glycolytic flux rates could account for most of the 
lactate produced (see Figure 2). There was, however, an excess lactate washout of 20-30% during 
ischaemia that could not be accounted for by the measured glycolytic flux from glucose, and was 
presumably derived from the breakdown of glycogen 424. A more detailed analysis of total lactate 
production during ischaemia was achieved by measuring the amount of lactate flushed out of the heart 
at the time of reperfusion ( an indication of total lactate remaining in the tissue at the onset of 
reperfusion) and adding this value to the total lactate washed out of the heart during ischaemia. The 
washout values for lactate during reperfusion in the 0.1 ml/g/min group were 8.3 ± 1.2 µmol C6 units 
for zero glucose and 9.1 ± 1.6 µmol C6 units for 11 mM glucose. In the 0.2 ml/g/min group the values 
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were 4.3 ± 0.6 µmol C6 units with zero glucose and 6.4 ± 0.8 µmol C6 units with 11 mM glucose, 
indicating better washout of the tissue at the higher flow during ischaemia. Once the lactate that could 
be accounted for by glycolytic flux in ischaemia was subtracted, the remaining lactate was presumed 
to be derived from the breakdown of glycogen (Figure 4). The estimated breakdown of glycogen was 
greater in the absence of glucose (15.4 ± 1.1 and 14.8 ± 0.7 µmol C6 units/30 min at 0.1 and 0.2 
ml/g/min respectively), while a greater coronary flow in the presence of glucose inhibited glycogen 
breakdown (11.3 ± 1. 7 (0.1 ml/g/min) vs. 8.9 ± 2.2 µmol C6 units/30 min (0.2 ml/g/min), p<O.O 1 vs. 
zero glucose groups). 
The total estimated production of ATP from the anaerobic breakdown of glucose and glycogen over 
the whole ischaemic period was similar in all groups (Figure 5), with values of 46.3 ± 3.3 and 44.3 ± 
2.0 µmol/g with no glucose, and 45.2 ± 5.33 and 52.0 ± 4.8 µmol/g with 11 mM glucose for the two 
flows. However, when the contribution of glucose to anaerobic ATP production is taken into account, 
the importance of the source of glycolytic ATP becomes evident in terms of protection against 
ischaemic contracture. At a low flow of 0.1 ml/g/min, glycolytic flux from glucose contributed 28.0 ± 
4.1 % of total anaerobic ATP, while at a flow of 0.2 ml/g/min, this was increased to 54.1 ± 7.6 % 
(p<0.01), with a corresponding reduction in contracture. 
The total ATP production in low flow ischaemia also includes the contribution of residual oxidation 
from the continued delivery of oxygen, even at very low coronary flows. This could utilise some of 
the pyruvate derived from glycolysis, introducing an error into the above calculations. ATP 
production from oxidative phosphorylation could account for as much as 13.9 µmol/30 min at the 
higher flow (0.2 ml/g/min) and half of this value at the lower flow (see Methods). Under optimal 
conditions, aerobic production of ATP may have contributed a maximum of 12-25 % of total ATP 
production during ischaemia. Assuming that all of the oxygen taken up was utilised in the oxidative 
phosphorylation of glucose, the calculated oxygen uptake suggests that a maximum of 4.0 ± 0.6 % at 
0.1 ml/g/min, and 3.4 ± 0.4 % at 0.2 ml/g/min of the measured glycolytic flux could enter the Krebs 
cycle, with the balance being converted to lactate. When glycogen breakdown is taken into account, 
the contribution from glucose is even less, with less than 3 % of total glycolytic substrate going on to 
oxidative phosphorylation. The aerobic utilisation of triglycerides would reduce this amount even 
further, by utilising some of the available oxygen. Thus, the residual oxidative phosphorylation would 
only account for only negligible amounts of the substrate going through the glycolytic pathway, 
reducing the significance of error in the above calculations. 
CONTRACTURE WITH CHANGES IN FLOW WITH AND WITHOUT GLUCOSE 
The initial experiments indicated that ischaemic contracture was influenced both by coronary flow 
and glucose. We next determined the relationship of contracture to coronary flows in the range of zero 
to 0.4 ml/g/min in the absence or presence of glucose (11 mM). In comparing the times-to-onset of 
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contracture, no significant difference between any of the groups was observed, except with the highest 
flow of 0.4 ml/g/min with 11 mM glucose, where a prolonged delay (28.8 ± 8.8 min; p< 0.01 vs. all 
other groups) was observed (Table IA). Peak contracture, in the absence of glucose, increased as the 
flow was increased from zero to 0.4 ml/g/min (65.5 ± 3.1 % vs. 82.8 ± 4.2%, p<0.05), although the 
incremental changes between the different flows were slight (Table IA). In the presence of 11 mM 
glucose, the opposite trend was observed, such that peak contracture decreased as flow increased 
(61.4 ± 3.5% at zero · flow, vs. 15.6 ± 6.3% at 0.4 ml/g/min, p<0.05). This glucose-dependent 
reduction was significant when flows of 0.1 ml/g/min and higher were compared with zero flow 
(Table lA). When the zero and 11 mM glucose groups were compared at each flow, marked 
differences in peak contracture were observed with flows of 0.03 ml/g/min and higher (p<0.05). 
From these data it can be concluded that (i) glucose, at a concentration of 11 mM, reduced peak 
contracture compared to the absence of glucose, (ii) the benefit was most apparent at a flow of 
0.4 ml/g/min, although still detectable even at 0.03 ml/g/min; and (iii) at the lowest coronary flow 
tested (0.015 ml/g/min), no effect of glucose on ischaemic contracture was found. 
DOSE RESPONSE TO GLUCOSE 
A dose response to glucose at two different low flows was elicited, in terms of ischaemic contracture 
(Table lB) and reperfusion recovery (Table 2B), with 30 min of ischaemia, by which time peak 
contracture had been reached in all groups. Functional data for all groups prior to ischaemia are 
shown in Table 2A. No significant differences in heart rate, systolic pressure or diastolic pressure 
between groups were seen in the control period. 
Coronary flow of 0.06 mllglmin. At this coronary flow (approximately 0.5% of the control pre-
ischaemic values - 12.9 ± 0.5 ml/g/min), changes in glucose concentration ranging from zero to 
22 mM in ischaemia had little effect on peak contracture (Table lB). A large increase in diastolic 
pressure was observed in all hearts on reperfusion, approximately double that at the end of ischaemia 
(from about 50 to 100 mmHg). Recovery of developed pressure after 5 min reperfusion was very poor 
in all groups (Table 2B). With time, this failure of diastolic relaxation on reperfusion improved. 
While systolic pressures were reduced by about 20-30% from control pre-ischaemic values, they 
remained stable throughout the reperfusion period. After 25 min reperfusion, recovery of developed 
pressure was only about 18-25% in all glucose groups (Table 2B). There was, however, a significant 
reduction in the incidence of reperfusion ventricular arrhythmias with increasing glucose 
concentrations (Table 2B). When data from both sets of 0.06 ml/g/min groups with and without 11 
mM glucose were combined (n=12) (Table lA and lB), a small but significant difference (p<0.05) in 
peak contracture was found (57.8 ± 2.3% - zero glucose vs. 50.6 ± 2.5% - 11 mM glucose). 
Coronary flow of 0.2 mllglmin. At this flow (approximately 1.5% of pre-ischaemic coronary flow -
13.8 ± 0.7), a dose response effect of glucose with respect to peak contracture was observed (Table 
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lB). Time-to-onset of contracture was shortest with 2.5 mM glucose, but no significant differences 
were found within the series (Table 1). Peak contracture was reduced at the glucose concentration 
range 5.5-22 mM, with an optimal response at 11 mM glucose (27.6 ± 3.7 % vs. 58.3 ± 3.2 % - zero 
glucose, p<0.05). 
On reperfusion, diastolic pressures increased slightly compared to the level reached by 30 min 
ischaemia, although not to the extent seen with the lower flow of 0.06 ml/g/min. Systolic pressures 
were generally slightly depressed throughout reperfusion in all groups, being about 16% lower than 
control pre-ischaemic values in all hearts. Changes in heart rates did not contribute to changes in 
function. However, the incidence of reperfusion arrhythmias was significantly reduced by increasing 
glucose concentrations (Table 2B). 
Developed pressure after 5 min reperfusion correlated well with peak contracture. Following glucose-
free ischaemia, early recovery was 20.8 ± 5.8 %, while 11 mM glucose in ischaemia resulted in a 
rapid recovery to 54.8 ± 10.9 % by 5 min. There was some recovery over time, especially in the 
glucose-free group (to 57.5 ± 6.0%) (Table 2B), while the 11 mM group reached a final developed 
pressure of 68.3 ± 5.3% by 25 min. The groups with glucose at higher or lower concentrations did not 
recover as well, but the differences were not significant. Early recovery on reperfusion correlated well 
with ischaemic contracture and incidence of reperfusion arrhythmias, while recovery late in 
reperfusion did not. 
When all peak contracture data obtained with 0.1 or 0.2 ml/g/min, with or without 11 mM glucose, 
were combined, significant differences were still found with the addition of glucose at both flows 
(p<0.01). 
PRE-ISCHAEMIC ALTERATION OF GLYCOGEN LEVELS 
A 20 min period of substrate free aerobic perfusion to reduce glycogen levels in the myocardium 
resulted in an increased diastolic pressure from 3.9 ± 0.4 mmHg (control) to 10.7 ± 1.3 mmHg 
(substrate free), and a reduced systolic pressure (95.0 ± 3.8 vs. 132.5 ± 4.3 mmHg) (Table 3B) prior to 
ischaemia. Developed pressures were therefore significantly reduced, from 128.6 ± 4.3 to 84.4 ± 4.4 
mmHg (p<0.05). Acetate pre-perfusion was also used as a means of reducing glycogen levels (Table 
3), as this had no effect on function (developed pressures 125.5 ± 2.8 mmHg), but did not reduce 
glycogen as much. Glucose + insulin pre-ischaemic perfusion, used to increase glycogen levels, also 
showed no differences in function compared to control (developed pressures 128.7 ± 11.9 mmHg). No 
differences in coronary flow or heart rate were seen between groups (Table 3). 
Glycogen levels prior to ischaemia were reduced by acetate (10.0 ± 1.2 µmol CJg) or substrate-free 
aerobic perfusion (4.0 ± 0.7 µmol CJg) compared to control values with 11 mM glucose 
(16.1 ± 1.4 µmol CJg, p<0.05). Glycogen levels were significantly increased by 20 min glucose + 
insulin perfusion to 20.5 ± 1.1 µmol CJg (p<0.05). While no differences in ATP levels were seen 
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(Table 3A), acetate pre-perfusion resulted in increased tissue CP (6.4 ± 0.8 µmol/g ), while substrate 
free perfusion reduced tissue CP levels (2. 8 ± 0.3 µmol/g ) compared to control hearts ( 4. 7 ± 0.4 
µrno l/g, p<0.05 ). Following alteration in glycogen levels, the coronary flow was reduced to 0.2 ml/g 
wet wt/min, with or without glucose 11 mM present in the ischaemic period. The changes in diastolic 
pressure are illustrated in Figure 6. 
Times-to-onset of contracture were profoundly affected by reduced glycogen levels (Table 3B), from 
9.7 ± 1.7 min (control) to 3.1 ± 1.0 min (acetate) and 2.1 ± 0.1 min (substrate-free) when no glucose 
was present in ischaemia (p<0.05 vs. control). Similar values were found when glucose 11 mM was 
present during ischaemia (Table 3). An increased pre-ischaemic glycogen content, however, had little 
effect on time-to-onset (Table 3). 
Peak contracture values were also altered by prior changes in glycogen levels. When no glucose was 
present during the ischaemic period, peak contractures increased to 88.5 ± 1.8% (acetate) and 
160.2 ± 19.3% (substrate free) compared to 63.8 ± 1.9% of pre-ischaemic developed pressures 
(control glycogen levels with 11 mM glucose) (Table 3). If, however, glucose was present during 
ischaernia, peak contra'ctures were 60.9 ± 6.7% and 137.0 ± 8.5% compared to 30.0 ± 4.0% 
respectively. Thus the presence of glucose helped to reduce the peak contracture with a low glycogen. 
In addition, the higher glycogen levels inhibited the fall off in diastolic pressure following peak 
contracture, which may be due to rupture of the cells. 
Post-ischaemic levels of glycogen were significantly reduced by 60 min ischaemia in all groups. 
However. as would be expected, a higher pre-ischaemic glycogen resulted in a higher post-ischaemic 
glycogen, and a higher tissue lactate content. The presence of glucose also resulted in higher tissue 
glycogen content, indicating inhibition of glycogen breakdown in the presence of glucose. There is 
good agreement between the calculated rates of glycogen breakdown from the first series of 
experiments, and tissue levels of glycogen measured before the start of ischaemia, such that in 
substrate free hearts, most of the available glycogen was broken down. When glucose was present, the 
breakdown of glycogen was inhibited, in agreement with the present results. The possible contribution 
of pyruvate to alanine production has been excluded from the above calculations, and must be taken 
into account 521 . However, given the good agreement between ischaemic glycogen breakdown 
measured by tissue analysis, and estimated rates of glycogenolysis from the first series of 
experiments, the significance of the formation of alanine would be relatively small. Utifisation of 
glucose throughout 60 min ischaemia was shown by (i) the higher tissue lactate when glucose was 
available, despite reduced glycogenolysis and (ii) the fact that most of the lactate produced during -
ischaemia would be washed out under low flow conditions. 
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DISCUSSION 
lSCHAEMIC CONTRACTURE AND FUNCTIONAL RECOVERY 
Ischaemic contracture, or the clinical equivalent, the "stone heart" 86, is an important complication of 
severe ischaernia, hypothetically developing as a consequence of decreased ATP availability and/or 
high cytosolic Ca2+ levels (see 259 for review). Ischaemic contracture is associated with severe 
microscopic damage 14, and may, by mechanical compression, further compromise coronary flows 
already critically low, thereby precipitating irreversibility 123 , 194, 210. This observation may 
explain why the degree of residual or collateral flow is a major determinant of the rate and extent of 
ultimate cell death 194, 485 and the degree of recovery upon reperfusion. 
Criteria for the benefit or harm of an intervention. Two main parameters - ischaemic contracture 
and recovery on reperfusion - were used to determine benefit or harm o an intervention. Ischaemic 
contracture, delimited by time-to-onset and peak, was used to indicate ischaemic injury. However, 
time-to-onset of contractute did not differ greatly between groups with two exceptions. Only when 
flow was increased to a "moderate" level i.e. 0.4 m.1/g wet wt/min (Table 1 ), or when pre-ischaemic 
glycogen was significantly reduced (Table 3), was time-to-onset of contracture affected. Peak 
contracture was found to be a better indicator of ischaemic injury. In our studies, functional recoveries 
were very poor in all hearts after 25 min reperfusion, with a maximum recovery of about 60%, 
indicating a large degree of irreversibility in the reperfused tissue. The early rate of return of function 
( at 5 min), however, varied significantly between groups. The variability of early recovery indicates 
different degrees of stunning 413, and thus different degrees of reperfusion injury. In addition, the 
incidence of reperfusion arrhythmias differed significantly between groups. Thus interventions which 
increased peak contracture and the incidence of reperfusion arrhythmias, and reduced the rate of 
mechanical recovery of hearts were deemed to be deleterious. 
Interaction of glucose and coronary flow. The data presented here indicate that the degree of 
protection conferred by glucose in an isolated perfused rat heart is dependent on the severity of flow 
reduction. At lesser degrees of ischaemia (flow: 0.4 m.1/g wet wt/min) glucose was able to delay the 
onset of contracture and substantially reduce the severity of peak contracture. At flows of 0.2, 0.1 or 
0.06 ml/g wet wt/min, the severity of contracture was still glucose-sensitive but the onset of 
contracture could not be delayed. The best results were found when glucose was present at a high 
physiological concentration ( 11 mM). At progressively lower flows (below 0.06 m.1/g w~t wt/min), 
glucose effects were marginal or absent without any evidence of harmful effects. The optimal 
condition ensuring maximal protection was at the high end of the range studied, together with a 
glucose concentration of 11 mM. We will make the novel proposition that the benefit of glucose is 
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lost at very low coronary flows, not because glycolytic flux becomes inhibited as has been proposed 
387. 468, but because the rate of delivery of glucose is too low and therefore rate-limiting. 
GLUCOSE UPTAKE AT LOW CORONARY FLOWS 
Glycolytic flux from glucose was measured at two very low coronary flows of 0.1 ml/g wet wt/min 
and 0.2 ml/g wet wt/min, with or without 11 mM glucose (Figure 2). A flow of 0.2 ml/g wet wt/min is 
a reduction to about 2-4 % of normal in vivo values, which is severe enough to be potentially lethal if 
sufficiently prolonged 194. A reduction in measured rates of glycolysis was found with low flow 
ischaemia compared to control values measured prior to ischaemia, in good agreement with previous 
reports 390, 468. 
When the rate of glycolysis was expressed as a function of the glucose concentration and ischaemic 
coronary flow, i.e. glucose delivery, no evidence of glycolytic inhibition was found when examining 
the effect of a progressively decreased flow (Figure 3). Although absolute rates of uptake were 
depressed in a flow-dependent manner, the extraction of the available glucose was greatly increased, 
as also found in the pig model by Stanley et al. 507. This finding would substantiate the computer-
based calculations that, although the absolute rate of glycolysis is reduced in ischaemia, the actual 
limiting factor is the rate of delivery of glucose to the heart 262. However, despite greatly increased 
extraction of glucose observed in low flow ischaemia, we cannot exclude some concurrent enzymatic 
inhibition of glycolysis by accumulated metabolites 468. In the absence of any such inhibition, 
glycolytic rates would possibly have been greater at low flows, with increased extraction. 
The two factors thus governing glycolytic flux rate in ischaemia, closely linked in an inverse ratio, are 
the rate of delivery of glucose, and enzymatic inhibition by metabolite accumulation. With complete 
absence of flow, there would be no delivery, and metabolite accumulation would be the major 
determinant of glycolytic flux rate. If coronary flow were increased from zero, at some point the 
measured glycolytic flux rate (glucose uptake) would be equivalent to that measured at normoxic 
flows. Further increases in coronary flow would result in glycolytic flux rates greater than normoxic 
rates, as foW1d by Neely et al. 390 and Rovetto et al. 468. In their data, at a coronary flow of 0.6 
ml/g/min, glycolytic flux was 0.4 µmol/g/min, while with a flow of 2.3 ml/g/min, glycolytic flux rate 
was 1.1 µmol/g/min. Control glycolytic flux rate was intermediate at 0.8 µmol/g/min with ,a coronary 
flow of 15 ml/g/min 390, 468. These data suggest thafthe point at which measured glycolytic flux 
rates would be equivalent to those in control hearts is between 1 and 2 ml/g wet wt/min. In addition, -
when expressed as percentage of delivered glucose, with increasing flows, the percentage extraction is 
6.1%, 4.3% and 0.5% respectively for the above glycolytic flux rates. This relationship between 
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glucose uptake and coronary flow explains why glycolytic flux may be increased in "moderate" 
ischaemia, and reduced in "severe" ischaemia 14, 123, 390, 468, 507. 
Uptake of glucose into the cell occurs via facilitative transporters, in a diffusion-dependent process 
driven by the concentration gradient across the cell membrane. The GLUT! transporter has a Km of 
2 1-26 mM, while that of the GLUT4 is 4.3 mM 395. In ischaemia, there is an increased translocation 
of the GLUT4 glucose transporters to the membrane in ischaemia 517, allowing increased extraction 
of glucose, as observed in our experiments (Figure 3). However, there would still be a limit to glucose 
transport across the membrane at low concentrations. The consequence would be a reduced rate of 
formation of glycolytic ATP, with less protective effect (see Table 1B and ::m with 2.5 mM glucose). 
A much higher glucose concentration (e.g. 22 mM as tested in the present study), however, may result 
in a faster rate of accumulation of lactate and protons from a higher glycolytic flux rate than could be 
washed out by severe low flows, imposing a metabolic burden on the cells and compromising 
recovery on reperfusion (Table 1B and 2B). In our experiments, an optimal glucose concentration of 
about 11 mM was found (}'ables 1 and 2), approximately double the Km of the GLUT4 transporter. 
This optimal concentration could possibly be altered by insulin, by the provision of alternate 
substrates, or by the nutritional state of the rat ( fed or fasted). 
GLYCOLYTIC FLUX RATES AND ATP PRODUCTION 
While glucose uptake and enzymatic regulation serve to regulate the rate of glycolysis, it has been 
proposed that it is the rate of ATP production that is the eventual determining factor in the protective 
effect of glucose 424. Anaerobic ATP (glycolytic ATP) contributed more than 75% of total ATP 
production in low flow ischaemia at 0.1 or 0.2 ml/g wet wt/min (Figure 5). However, our measured 
rates of glucose utilisation show that ATP from glucose at a coronary flow of 0.2 ml/g wet wt/min 
was well below 2 µmol/g/min , the minimal rate required to prevent ischaemic contracture in this 
model 424. The average rate of glycolytic flux from glucose was 0.43 ± 0.04 µmol/g wet wt/min (in 
the group with 11 mM glucose at a flow of 0.2 ml/g wet wt/min). Estimated rates of ATP production 
from glucose thus never rose much above 0.9 µmol/g wet wt/min which would explain why 
contracture, although partially inhibited by glucose, still occurred 424. 
At the highest coronary flow tested (0.4 ml/g wet wt/min), contracture was still observed, althqugh to 
a lesser extent, and the onset was greatly delayed when compared with lower flows. Although we did 
not measure glycolytic flux at this flow, by extrapolation of the calculated ATP production a! 0.2 ml/g 
wet wt/min, and assuming that coronary flow remains limiting, the probable rate of ATP production at 
a flow of 0.4 ml/g/µi.in was about 1.8 µmol/g wet wt/min, at which rate contracture still developed, 
albeit greatly reduced. Our previous data showing that 11 mM glucose totally inhibits contracture was 
at a slightly higher flow (0.5 ml/g wet wt/min), with a minimal required rate of ATP production from 
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glucose of 2.0 µmo l/g wet wt/~ 424 _ The crucial coronary flow and corresponding rate of deli
very 
of glucose required to prevent contracture totally would thus appear to lie between 0.4 and 0.5 
ml/g 
wet wt/min in the isolated buffer-perfused rat heart. 
BALANCE OF GLUCOSE DELIVERY VERSUS LACTATE WASHOUT- THE CRUCIAL
 ROLE OF RESIDUAL 
CORONARY FLOW 
While rate of delivery of glucose was crucial in determining the rate of glycolysis in our experiments
, 
the concurrent washout of lactate and protons by residual coronary flow is also required to reduce
 the 
extent of metabolic inhibition. While the total amount of lactate produced with glucose present 
was 
greater at the higher flow (21.5 ± 1.4 vs. 16.9 ± 1.8 µmol CJ30 min), the greater portion of the lactat
e 
was washed out during ischaemia (70% vs. 46%) at the higher flow (0.2 vs. 0.1 ml/g wet wt/m
in). 
Similar rates of lactate washout were seen with no added glucose in ischaemia when there could be no
 
contribution of glucose-derived ATP to total ATP production (Figure 5). Even at very low coro
nary 
flows, there were no detrimental effects of 11 mM glucose when compared to zero glucose in our
 
experiments. The lack of any harmful effect of a glucose-containing perfusate could be explained
 by 
the supposition that any flow bringing adequate glucose would be sufficient to wash out metabol
ites. 
However, if an additional metabolic load were placed on the myocardium, e.g. excess glucose
 (22 
mM) or the addition of lactate to the perfusate 91 , 3 87, the critical balance between deliver
y of 
glucose and washout of metabolites would be disturbed, resulting in a deleterious effect on reco
very 
following end product accumulation. In the complete absence of flow, this would explain why 
enhanced glycolysis in no flow conditions may be deleterious 193, 278, 378, 387, although cau
tion 
must be taken when extrapolating the effects of the utilisation of glycogen to that of glucose as
 the 
glycolytic substrate. 
Some estimates may be made of how these flows relate to those found in vivo. While the flow of
 the 
buffer-perfused isolated rat heart ranges from 8-12 ml/g wet wt/min, the in vivo blood flow is only
 4-6 
ml/g wet wt/min 279. Thus a reduction to 0.5 ml/g wet wt/min would be about 5% of the contro
l for 
the isolated heart and about 10% of the in vivo value. Other workers have used the blood-perfu
sed 
rabbit heart to show that a flow reduction of 10 -20% is associated with a protective rate of A
TP 
production from glycolysis of about 1.7 µmol/g wet wt/min 123 in good agreement with 
our 
protective values of 1.8-2.0 µmol/g wet wt/min 424. Therefore our coronary flow values, altho
ugh 
obtained on buffer-perfused non-working hearts, may provide data applicable in principle to bl
ood-
perfused hearts. 
120 Results Ch 1. Glucose concentration, residual coronary flow and ischaemic contracture 
GLYCOGEN AND CONTRACTURE 
The role of glycogen in ischaemia remains controversial. Depletion of glycogen prior to ischaemia 
improved ftmctional recovery by reducing the lactate and proton load in some studies 278, 387 but not 
in others 286. In addition, glycogen loading prior to ischaemia by various methods is reported to be 
either harmful 387 or protective 487. Confounding evidence regarding the role of glycogen in 
ischaemia is also provided by the phenomenon of preconditioning. The brief periods of ischaemia 
prior to preconditioning reduce glycogen levels by up to 50 % prior to the longer period of ischaemia 
378_ and this change has been associated with a reduced proton load and improved recovery 512. 
A reduction in pre-ischaemic glycogen levels in our model of low flow ischaemia hastened the time-
to-onset of contracture and increased peak contracture both in the presence and in the absence of 
glucose, as also found by Kupriyanov et al. 278 and Kingsley et al. 253 in total global ischaemia. If 
the amount of ATP produced during the first ten minutes of ischaemia, prior to the onset of 
contracture, were calculated (from the first series of experiments - Figure 2), glycogen, with glucose 
present, contributed 45% of the total anaerobic ATP produced (at a flow of 0.2 ml/g wet wt/min, with 
a rate of production of total glycolytic ATP of 10.3 ± 0.6 µmoll 10 min and contribution from 
glycogen of 4.9 ± 1.0 µmoll 10 min). In the absence of glucose, ATP production over the first ten 
minutes was 13.0 ± 0.9 µmoll 10 min. Thus glycogen breakdown contributed significantly to ATP 
production in the first ten minutes of ischaemia. However, the contribution of glycogen to ATP 
production is rapidly reduced with extended ischaemia as its levels fall, and the utilisation of glucose 
as substrate is accelerated following glycogen depletion 390. Glycogen may therefore exert its 
protective effect primarily in the first ten minutes or so of ischaemia, playing a role in determining the 
time-to-onset of contracture. This finding may explain the observations of Asimakis et al. 18, of a 
reduced time to onset of contracture and an increased peak contracture in preconditioned hearts with 
reduced pre-ischaemic glycogen. In preconditioning, glycogen depletion during the first episode of 
ischaemia is followed by reduced proton overload in the second period of ischaemia 512, which may 
participate in the protective effects of preconditioning. Nevertheless, in our experiments, glycogen 
breakdown helped to protect from the very early effects of ischaemia, in the first 5 - 10 minutes before 
glucose extraction could increase. It must be noted that these experiments were conducted un~er low 
flow conditions, with continuous removal of potentially harmful metabolites. In the absence of flow, 
glycogen breakdown could well be harmful by allowing accumulation of metabolites 278, 38?. 
In the series of experiments measuring glycolytic flux, large increases in peak contracture ~ere seen 
when comparing glycogenolysis (glucose-free hearts) with both glucose and glycogen utilisation (11 
mM glucose), despite similar rates of total ATP production (Figure 5). A greater percentage 
contribution from glucose-derived ATP to total ATP production was associated with reduced peak 
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contracture, and better rate of recovery of function. Glucose-derived ATP ( from 11 mM glucose) was 
thus more effective in inhibiting contracture. In addition, the presence of glucose inhibited glycogen 
breakdown (Figure 4, Table 3). The reason for the inability of glycogen breakdown in the absence of 
glucose to protect against contracture is a matter of speculation, especially because the rate of ATP 
production from glycogen was in the protective range (see Figure 5). Intracellular compartmentation 
of energy (glucose vs. glycogen) may be invoked 424, 470. 
RECOVERY FROM ION LOAD DURING ISCHAEMIA 
Recovery from ischaemia is a complex event which depends in part on the operation of various 
energy-dependent pwnps and exchange systems. The major ions that build up in ischaemia are 
calciwn, sodium and protons. We did not measure any of these, but existing data allow a reasonable 
inference of that could be expected in our experimental conditions. It is already known that glycolytic 
flux from glucose is required for restitution of the calcium load 229. Therefore it is extremely unlikely 
that severely ischaernic hearts perfused with glucose in the ischaernic period would have had any 
recovery at all in the absence of glucose in the reperfusion period (all hearts were reperfused with 11 
rnM glucose). 
A major ionic load is that of protons. Promotion of glycolysis during subtotal ischaernia leads to a low 
intracellular pH 278, 512, and therefore a greater activity of the Na+ M and other exchanges during 
reperfusion 545 . Inhibition of the Na+ M exchanger also helps to relieve cytosolic calcium overload 
119. Extrusion of protons leads to sodium gain, which requires energy for its restitution. The 
increased proton load as a result of enhanced glycolysis during ischaem.ia is associated with a 
lessened development of ischaernic contracture, which may be due to increased ATP production and 
reduced Ca2+ binding to myofilaments at a lower pH 259. Despite the increased proton load, recovery 
with glucose 11 mM was enhanced compared with the absence of glucose 91. These studies were 
done at an ischaemic flow of 0.5 ml/g/min. Our data show that at lower ischaemic flows (0.06 and 0.2 
ml/g wet wt/min) early recovery at 5 min reperfusion was glucose-dependent with optimal developed 
pressures at glucose 11 mM and 22 mM. Late recoveries, however, showed no difference between the 
provision of 11 mM glucose or no glucose during the ischaemic period (both groups of hearts being 
reperfused with glucose). We propose that at these very low coronary flows the ultimate, extent of 
recovery is set by the ischaemic flow i.e. by irreversible damage during ischaemia with, as expected, a 
greater recovery at the higher (0.2 ml/g/min) than at the lower (0.06 ml/g/min) flow Cf able 2B). It _ 
needs re-emphasising that in our study the coronary flow was artificially fixed during ischaem.ia, 
thereby preventing a contracture-induced decrease in flow 123, 210. If coronary flow were allowed to 
fall, for example from 0.2 to 0.06 ml/g/rnin as a result of ischaemic contracture, then it would be 
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likely that the absence of glucose during ischaemia would result in a more severely impaired recovery 
also at 25 min reperfusion. 
RESERVATIONS TO STUDY 
Several assumptions regarding the calculations of glycogenolysis and ATP production were made. We 
did not directly measure glycogen and tissue lactate levels or 02 utilisation and CO2 production 
during ischaemia. In addition, the technique of measuring glycolytic flux using D-[2-3H)-glucose may 
be questioned. The measurement depends on the washout of 3H20 from the tissue, which may be 
inhibited at low flows . In addition, Neely et al. 386 used D-[S-3H]-glucose, which may have 
theoretical advantages. However, a comparison of both isotopes failed to find any differences in the 
rates of glycolytic flux 468. We feel that within the limitations of the model, the data with D-[2-3H]-
glucose may be accepted. The present study also did not investigate recovery on reperfusion in detail. 
because of the large degree of irreversible injury observed after such long periods of ischaemia (30 
min), which was required to ensure maximum contracture. 
This study was performed using an isolated rat heart perfused with a crystalloid solution. Blood flows 
in vivo are very different to those found with an isolated preparation, and may affect the results . 
However, Eberli et al. 123, using isolated rabbit hearts perfused with an erythrocyte suspension, also 
showed a protective effect of increased glycolytic flux. Their baseline coronary flows were similar to 
those found in vivo in the rabbit (approximately 1.1 ml/g wet wt/min), and were reduced in one arm of 
their study to approximately 0.2 ml/g wet wt/min, which is in a range similar to those used in the 
present study. Blood-perfused models would be required to elucidate more exactly the relationship of 
glucose concentration to its efficacy at very low coronary flows. 
Direct extrapolations to clinical therapy of patients with acute myocardial infarction by glucose-
containing solutions such as GIK, cannot be made. We perfused isolated rat hearts with varying 
concentrations of glucose in the absence of other added substrates such a as free fatty acids. In the 
reperfusion period all hearts received a fixed glucose concentration of 11 mM. In vivo, provision of 
glucose plus insulin, for example as part of GIK therapy, decreases the levels of circulating blood free 
fatty acids, which may lessen the several deleterious effects of fatty acids on the ischaemic 
myocardium 399. Nonetheless, Eberli et al. 123 have established that glucose and insulin are still 
I 
beneficial even in the presence of high fixed levels of free fatty acids. Further work in conditions 
more closely approximating those in human myocardial infarction including a consider~tion of 
insulin resistance would be required to asses the optimal glucose concentration to protect tlie severely 
ischaemic myocardium. 
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CONCLUSIONS 
i) Avoidance of ischaemic contracture in this model requires a coronary flow of about 0.4 - 0.5 ml/g 
wet wt/min plus external glucose. At flows of 0.1 - 0.2 ml/g wet wt/min, ischaemic contracture 
consistently develops, but provision of glucose lessens development of peak contracture. At even 
lower flows where the glucose effect on contracture is minimal or variable, glucose is not harmful. 
Depletion of glycogen in the pre-ischaemic period is, however, disadvantageous under low flow 
conditions. 
ii) Glycolytic flux under ischaemic conditions is regulated both by the severity of metabolic inhibition 
and the restricted delivery of glucose. Even in severe low flows of 0.1 and 0.2 ml/g/min, the delivery 
is the rate limiting seep. As the coronary flow is further reduced, the influence of metabolic inhibition 
should become more important, such that in the absence of any delivery at all (zero coronary flow) 
such inhibition would be the rate limiting step for glycolytic flux. 
iii) While some quantity of tissue glycogen is required for optimal protection against ischaemia, the 
preferred substrate is still glucose. ATP production from glycogen is less able than that from glucose 
and glycogen to inhibit ischaemic contracture. However, some glycogen breakdown is required, 
particularly in the early stages of low flow ischaemia, to delay the onset of ischaemic contracture. 
The above study investigated changes in contracture and functional recovery in hearts subjected to 
modifications during sustained global ischaemia. However, glucose concentrations in vivo remain 
constant during pre-ischaemia, ischaemia and reperfusion. We wished to investigate the effect of 
different glucose concentrations maintained throughout the experiment, and establish a tight dose 
response of the hearts to changes in glucose concentration in terms of ischaemic contracture and 
functional recovery, with changes in residual coronary flow. 
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Fig I : Systolic and diastolic pressure (mmHg) in ischaemia and reperfusion with glucose concentrations of zero 
(open symbols) or 11 mM (closed symbols) at flows of 0.1 ml/g wet wt/min (circles) or 0.2 mllg wet wt/min 
(squares) during ischaemia. Diastolic pressure was set initially at 4-5 mmHg (pre-ischaemia) . Ischaemia was for 
30 min followed by 25 min reperfusion with 11 mM glucose. 
Systolic pressures (larger symbols) are shown before ischaemia, and with 5 min and 25 min reperfusion. The 
dotted lines follow the changes in systolic pressure over time. The actual data is not shown for clarity. Recovery 
of developed pressure at 5 min was 14.2 ± 9.9 % (zero glucose) and 40.2 ± 10.9 % (11 mM glucose) with 
0.1 mllg wet wt/min, and 4.9 ± 4.0 % (zero glucose) and 53.8 ± 11.2 % (11 mM glucose) with '0.2ml/g wet 
wt/min. By 25 min reperfusion, recoveries of developed pressure were 41.6 ± 9.4 %, 40.3 ± 8. 7 %, 55.5 ± 3.6 % 
and 58.9 ± 3.9 % respectively (n=JO in each group). 
* p<O. 05 vs. zero glucose/0.1 mllg wet wt/min 
# p<O. 05 vs. 11 mM glucose/0.2 mllg wet wt/min 
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Fig 2: Glycolytic flux (. )and lactate washout ( .) in µmo/ C6 units per minute before anq during 
ischaemia with glucose concentrations of zero ( a and c) or 11 mM glucose (b and d) at flows of 0.1 mllg wet 
wt/min (a and b) or 0.2 mllg wet wt/min (c and d) during ischaemia. Effluent was collected over each five minute 
period during ischaemia, and corrected for coronary flow (n= 10 in each group). 
* p<0.01 0.1 mllg wet wt/min vs. 0.2 ml!g wet wt/min 
# p<0.03 zero glucose vs. 11 mM glucose 
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Figure 3: The percentage of glucose uptake before and during ischaemia calculated from the glycolytic flux rate 
(utilisation of D-{2-3H}-glucose), in µmo/lg wet wt/min, expressed as a percentage of delivered glu,cose, where 
delivered glucose = concentration of glucose x coronary flow rate. With a concentration of 11 mM glucose, 
delivery at flow rates of 
12-15 mllglmin (pre-ischaemia) = 132-165 µmo/ glucose lg/min 
0. 1 mllglmin (ischaemia) = 1. 1 µmo/ glucose lg/min (Ii]) 
O.; mllglmin {ischaemia) = 2.2 µmo/ glucose lg/min (.) 
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Figure 4: Lactate in excess of that accounted for by glyco/ytic flux as an estimation of glycogen breakdown (in 
µmo/ C6 units) over 30 min by ischaemic hearts perfused under different conditions . 
0Zero glucose, 0.1 ml/min 
. 11 mM glucose, 0.1 ml/min 
• Zero glucose, 0.2 ml/min 
• 11 mM glucose, 0.2 ml/min 
The excess lactate, presumed to come from glycogen breakdown, was calculated as the difference between 
a) the total lactate produced in ischaemia, calculated from the total washout over 30 min ischaemia + washout 
during the first 2 min re perfusion, and 
b) the total glycolytic flux from glucose over the 30 min period of ischaemia (µmo/130 min) contributing to 1 mo/ 
C6 units lactate/mo/ glucose utilised. 
• p<O. 05 0.1 ml/min vs. 0.2 m//g wet wt/min 
# p<0.05 zero glucose vs. 11 mM glucose 
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Fig 5: Estimated total ATP production over 30 min ischaemia. Total ATP production in each group is made up 
of ATP from the anaerobic breakdown of glucose ( . - 2 mol ATP/mo/ glucose) and glycogen ( till -3 mo/ -
ATP/mo/ C
6 
units), together with the maximum possible subsequent generation of ATP by oxidative 
phosphorylation ( D ). 
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Fig 6: Diastolic pressure before and during ischaemia with 20 min pre-ischaemic perfusion with 11 mM glucose 
(II), 5 mM acetate (t.), substrate free (0) or 11 mM glucose + insulin ( •). Jschaemia was for 60 min, at a low 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Results 2: Relationship between glycolytic flux rates and protection against 
ischaemic/reperfusion damage in isolated perfused rat hearts 
ABSTRACT 
Background: Hypothetically, glycolytic flux reduces ischaemic contracture by increased ATP 
production, but also results in metabolite accumulation which may impair recovery. We wished to 
determine whether enhanced glycolytic flux was consistently of benefit over a range of reduced 
coronary flows, with changes in glucose concentration, in the presence of an alternate substrate. 
Methods: Isolated Langendorff rat hearts were perfused with increasing glucose concentrations (0, 
2.75, 5.5, 11, and 22 mM) with 5 mM acetate in all experiments. Hearts were subjected to 30 min low 
flow ischaemia (0.1, 0.2 or 0.5 ml/g/min), and reperfused for 30 min. In a separate set of experiments, 
insulin was added at each glucose concentration, with a flow rate of 0.2 ml/g wet wt/min. Function 
was monitored by a left ventricular balloon. Glycolytic flux was assessed by [2-3H]-glucose 
detritiation. 
Results: At each low flow rate, glycolytic flux was sustained at higher glucose concentrations, but fell 
with lower values. Hearts with residual flows of 0.1 and 0.2 ml/g wet wt/min did not recover well, 
although 11 mM glucose reduced peak contracture compared to other groups. 22 mM glucose was 
deleterious during severe ischaemia when compared to 11 mM glucose, presumably due to excess 
metabolite accumulation. With less severe ischaemia (0.5 ml/g wet wt/min - 3% of control), low 
glucose concentrations (0 and 2.75 mM) were associated with high peak contracture values and poor 
mechanical recoveries. Hearts perfused with the higher glucose concentrations had little contracture 
and good recoveries, with 11 mM glucose again having optimal recovery. 
Conclusions: Provision of glucose at a high physiological concentration (11 mM) was beneficial at all 
flow rates by attenuating ischaemic contracture. Improved functional recovery was more apparent 
with less severe coronary flow restrictions. There was an optimal rate of glycolysis, below which 
contracture was enhanced (reduced ATP), and above which (supraphysiologic glucose) recovery was 
reduced (possibly increased metabolite accumulation). 
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INTRODUCTION 
Provision of glucose during ischaemia, with increased rates of glycolysis, is beneficial to the heart in 
several ways 401. Glucose inhibits the genesis of arrhythmias 28, preserves cellular ultrastructure 192 
with reduced contracture 424, reduced infarct size 95, 341 , and improved cardiac output on 
reperfusion 14. 
However, a possible problem attributed to increased glucose provision is an excess accumulation of 
glycolytic end-products, which may be deleterious to the ischaemic myocardium 193, 387. We have 
found that no deleterious effect was associated with 11 mM glucose, compared to hearts with no 
glucose, at flow rates of O .4 ml/ g wet wt/min and less (Results Ch 1 ). In addition, 11 mM glucose was 
optimal compared to lesser or higher glucose concentrations during low flow ischaemia. However, in 
that study (Results Ch 1 ), all hearts were perfused prior to ischaemia and throughout reperfusion with 
11 mM glucose, a concentration used in most isolated rat heart perfusions. No alternative substrate 
was present. 
We wished to mimic the in vivo situation more closely, when glucose concentrations prior to, during 
and after ischaemia with a residual flow, remain constant, in the presence of an alternate substrate. In 
addition, a major clinical use of glucose which has recently come into consideration after a lapse of 
several years 399 is glucose-insulin-potassium therapy (GIK), which was originally devised by Sodi 
Pallares in the 1960s 501. The regimes for utilisation of this therapy vary widely. It is given to 
patients with infarction, and post-thrombolysis, with varying glucose and insulin concentrations. 
While the systemic effects of GIK of decreasing free fatty acid levels is possibly crucial 399, the 
consequences to the heart, and in particular to the ischaemic zone, are not as clear. Another 
application of glucose is in the more modem approach of warm blood cardioplegia, with a constant 
infusion of a low residual flow (about 0.55 ml/g wet wt/min 55) at normothermia 178, 314. 
Hypothermia in itself is known to impair membrane function 55, and cause an increase in the 
cytosolic Ca2+ level, and result in impaired recovery on rewarming 513. However, warm cardioplegia 
results in up to 10% residual ATP utilisation 55. Enhanced glucose in the warm cardioplegia may 
increase ATP production, and prove favourable. It is important to understand the consequences of 
different glucose concentrations under low flow conditions, where the balance between ATP 
production and metabolite accumulation may affect the recovery of the hearts. 
We tested the effects of different glucose concentrations used throughout the experiment, with a 
variety of low flow rates during the ischaemic period. In vivo myocardial blood flow in the rat is 
about 4-6 ml/g/min 279. Flow rates of 0.1, 0.2 and 0.5 ml/g/min were used in the present study, which 
represent reductions to 1.7-8.3% of in vivo flows, and are comparable to those in in vivo ischaemia 
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(0.07-0.15 ml/g wet wt/min). Different glucose concentrations were used, from Oto 22 mM. Acetate 
was included in all experiments to provide an alternative non-carbohydrate substrate 424. 
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METHODS 
EXPERIMENTAL APPARATUS 
The isolated Langendorff-perfused rat model with a left ventricular balloon was used, as described in 
Methods. The hearts were paced at 350 beats/min by a monopolar electrode attached to the left 
ventricle. The sinus node was removed by excising the left atrium, and the atrioventricular node was 
isolated by cutting the atrioventricular septum. The basal substrate was 5 mM Na-acetate (to make a 
total Na+ concentration of 143.5 mM), and glucose was added in varying concentrations according to 
the experiment. 
EXPERIMENT AL PROTOCOL 
Hearts were subjected to 15 min aerobic perfusion, followed by 30 min global subtotal ischaemia by 
reducing coronary flow to i) 0.1 ml/g wet wt/min, ii) 0.2 ml/g wet wt/min or iii) 0.5 ml/g wet wt/min. 
Hearts were perfused with glucose concentrations of zero, 2.75, 5.5, 11 , and 22 mM throughout the 
experiment for each of the above flow rates. 
Time to onset of contracture (TOC - min), and peak contracture (mmHg) were recorded as described 
in Methods. At the end of 30 min the hearts were reperfused for 20 min with the same buffer. The 
recovery of contractile function was monitored. Developed pressures after 20 min reperfusion were 
expressed as a percentage of pre-ischaemic developed pressure after 15 min perfusion . . 
Coronary effluents were collected immediately prior to and over each 5 minute period during 
ischaemia, and at each five minutes on reperfusion. Glycolytic flux rates were assessed immediately 
after collection of the effluents. Lactate washout was determined in hearts with a low residual flow 
rate of0.2 ml/g wet wt/min. 
BIOCHEMISTRY 
Glycolytic flux rates were measured as described in Methods. Lactate and high energy phosphates 
were determined by standard photometric assays 24. 
STATISTICS 
6 hearts were used in each group. Because of the mean wet heart weight of 1.05 ± 0.01 g, results 
could be expressed as per g wet weight. All results are expressed as mean ± SEM. Results were 
compared using ANOV A two way analysis of variance following which individual t tests between 
groups were performed, with the Bonferroni correction. A p<0.05 was taken as the level of 
significance. 
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RESULTS 
PRE-ISCHAEMIC GLYCOLYTIC FLUX RATES AND FUNCTION 
Pre-ischaemic function data from each glucose concentration group were lumped together, with a total 
of 18 hearts per group, as there were no differences within each glucose group. Pre-ischaemic 
function was not altered significantly by different concentrations of glucose (Table 1 ). Pre-ischaemic 
glycolytic flux rates were dependent on glucose concentration, with no significant differences in 
coronary flow (Table 3). 
CHANGES IN GLYCOLYTIC FLUX AND DIASTOLIC PRESSURE IN ISCHAEMIA 
Changes in flow rate with different glucose concentrations 
Changes in glycolytic flux and diastolic pressure during ischaemia for each flow rate and glucose 
concentration are illustrated in Fig 1. In the absence of glucose, TOC was not affected by increasing 
flow rate (Table 2), while peak contracture was significantly increased, from 93.8 ± 1.3 mmHg at 0.1 
ml/g wet wt/min, to 126.2 ± 2.3 at 0.5 ml/g wet wt/min (Table 2; Fig la). With glucose present, 
glycolytic flux (from glucose) was depressed initially, and then increased, to peak at 15-20 min, the 
value of which was dependent on flow rate and glucose concentration (Fig 1). With 2.75 mM glucose, 
glycolytic flux fell after 15 min ischaemia at each flow rate, such that by 30 min ischaemia, the rates 
of glycolysis were similar in each group (Fig 1 b ). Mean glycolytic flux during ischaemia increased 
with increased flow rate (Table 3). A higher flow delayed TOC, with a significant difference between 
0.1 and 0.5 ml/g wet wt/min (10.0 ± 1.1 vs. 15.4 ± 0.5 min; p<0.01), but peak contracture was 
significantly increased, from 68.3 ± 7.7 to 101.7 ± 4.2 mmHg (p<0.05) (Table 2; Fig lb). 
With a glucose concentration of 5.5 mM (Fig le), a decline in glycolytic flux was seen only with a 
flow rate of 0.2 ml/g wet wt/min This decline may have been due to the high rate reached in the first 
15 min ischaemia, which exceeded the rates with 11 mM. The rate of glycolysis at the end of 
ischaemia, however, was proportionate to the concentration, as were mean values (Table 3). An 
increase in flow rate significantly delayed TOC, (12.4 ± 0.9 min vs. 25.7 ± 2.2 min, 0.1 vs. 0.5 ml/g 
wet wt/min respectively) and peak contracture was also significantly reduced at the higher flow rate 
(10.3 ± 1.3 mmHg) compared to the lower flow rates (51.3 ± 2.4 mmHg- 0.1 ml/g wet wt/min) (Table 
2). 
With 11 mM, glycolytic flux was maintained at each flow rate (Fig ld). With a flow rate of 0.5 ml/g 
wet wt/min, and 11 mM glucose, glycolytic flux rates reached levels similar to those in pre-ischaemic 
hearts (Table 3 and Fig ld). A significant difference in TOC was observed between 0.1 and 0.2 ml/g 
wet wt/min (13.6 ± 1.2 min vs. 16.9 ± 0.9 min, p<0.05). Peak contracture was also reduced (48.2 ± 6.0 
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mmHg to 30.5 ± 3.4 mmHg, 0.1 and 0.2 ml/g wet wt/min respectively - Table 2). With 0.5 ml/g wet 
wt/min, contracture occurred in only one heart, with a mean of 6.8 ± 0.3 mmHg (Table 2; Fig ld). 
A higher glucose concentration of 22 mM was less protective than 11 mM during severe low flow 
ischaemia, with higher peak contracture (50.3 ± 2.7 and 54.5 ± 6.2 mmHg for 0.1 and 0.2 ml/g wet 
wt/min respectively) and slightly reduced TOC (11.5 ± 1.6 and 13 .7 ± 1.1 min) (Table 2). With a low 
flow of 0.5 ml/g wet wt/min, no hearts perfused with 22 mM glucose showed contracture (Table 2, 
Fig le). Mean glycolytic flux rates increased proportionately with the increase in residual flow rate 
(Table 3). 
Changes in glucose concentration with different residual coronary flow rates 
With a low flow of 0.1 ml/g wet wt/min, time to onset of contracture (TOC) was significantly delayed 
in the 2.75 mM glucose group versus zero glucose (10.0 ± 1.1 min vs. 4.5 ± 0.7 min, p<0.01 - Fig 1). 
Peak contracture was highest with zero glucose (93.8 ± 1.3 mmHg) (Table 2). Contracture was 
significantly reduced with 2.75 mM (68.3 ± 7.7 mmHg; p<0.01) and 5.5 mM glucose (51.3 ± 2.4 
mmHg; p<0.01 vs. zero and 2.75 mM glucose). There were no differences in peak contracture 
between the 5.5 and 11 mM glucose groups (Table 2; Fig 1). Higher glucose concentrations did not 
further alter TOC (Table 2; Fig 1). Glycolytic flux rates doubled with increased glucose 
concentrations from 2.5 to 5.5 to 11 mM. However, rates with 22 mM were not different from those 
with 11 mM (Table 3). 
With a residual flow rate of 0.2 ml/g wet wt/min, a clearer dependence of TOC and peak contracture 
on glycolytic flux was seen (Table 2; Fig 1). With zero glucose, TOC was 5.5 ± 0.5 min, with a peak 
of 104.0 ± 3.0 mmHg. With 2.75 mM glucose, TOC was delayed until 12 .. 3 ± 1.1 min, with a peak 
contracture of 70.3 ± 7.8 mmHg. 11 mM was the most effective concentration of glucose, delaying 
TOC to 16.9 ± 0.9 min, with a low peak contracture of 30.5 ± 3.4 mmHg (Table 2; Fig 1). With 22 
mM glucose, TOC was reduced compared to 11 mM glucose hearts, while peak contracture was 
increased (Table 2, Fig 1). Mean glycolytic flux rates during ischaemia showed a similar relationship 
to glucose concentration as at 0.1 ml/g wet wt/min (Table 3). 
At the highest residual flow tested (0.5 ml/g wet wt/min), peak contracture was very high (126.2 ± 3.3 
mmHg) with a rapid TOC (3.1 ± 0.8 min) when no glucose was present. A low glucose concentration 
of 2.75 mM delayed the onset of contracture (15.4 ± 0.5 min; p<0.02), but was ineffective in reducing 
peak contracture (Table 2; Fig 1). Very little contracture was observed with 5.5, 11 or 22 mM 
glucose, with high rates of glycolysis (Table 3), although no significant differences were found 
between then latter concentrations. 
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Lactate washout 
Lactate washout was measured in hearts with a residual flow rate of 0.2 ml/g wet wt/min at each 
glucose concentration: With 2.75 and 5.5 mM glucose, lactate washout was low initially, but 
increased to a steady state of about 0.5 and 0.8 µmol/g/min respectively. Values declined slightly by 
the end of ischaemia, as glucose uptake also decreased. Some of this lactate could be accounted for by 
glycogen breakdown which would be greater in the presence of low glucose concentrations. Lactate 
washout was significantly higher in the 11 mM and 22 mM glucose groups, reaching a steady state 
after 5-10 min. A slightly higher rate of washout was found in the 22 mM glucose group, although this 
was not significant (Fig 2), which agreed with the non-significant increase in glycolytic flux between 
these two glucose concentrations. The majority of lactate in these hearts would come from glucose 
uptake, as the glucose would inhibit glycogen breakdown (see Results Ch 1). 
High energy phosphate levels 
Myocardial ATP, ADP and AMP levels were measured at the end of 30 min low flow (0.2 ml/g wet 
wt/min) ischaemia with glucose 0, and 11 mM, and 22 mM. With no glucose present, ATP and ADP 
levels were very low, with high AMP (Fig 3). 11 mM showed the highest ATP levels. 22 mM glucose 
hearts had slightly lower ATP levels than 11 mM. 
RECOVERY OF MECHANICAL FUNCTION AND GLYCOLYSIS 
Recovery after 30 min ischaemia with varying residual flow rates 
Recovery of developed pressure after 30 min ischaemia with a residual flow rate of 0.1 ml/g wet 
wt/min was not affected by the glucose concentration, with recoveries of only 20 to 30% (Table 1). 
The poorest recovery (24.6 ± 6.6 %% ) was with 22 mM glucose. Diastolic pressure was elevated in 
all hearts throughout reperfusion (Table 1). Glycolytic flux rates at the end of 20 min reperfusion 
tended to be lower than pre-ischaemic rates, except with 2.75 mM (Table 3). Coronary flow rates 
were also reduced compared to pre-ischaemic values, possibly indicating no-reflow following high 
ischaemic contracture and high diastolic pressure on reperfusion (Table 3). 
With a flow rate of 0.2 ml/g wet wt/min, there were no significant differences in recovery of function 
in the majority of groups, except that hearts with 11 mM glucose were significantly improved 
compared to all other groups (Table 1 - 69.4 ± 8%; p<0.05), in agreement with previous results 
(Results Ch 1 ). There were no differences in glycolytic flux rates on reperfusion between the different 
glucose groups (Table 3). 
With a flow rate of 0.5 ml/g wet wt/min, recovery of function with zero glucose was very poor (20.4 ± 
2.1%) but with 2.75 mM glucose, recovery was increased to 62.6 ± 0.9% (p<0.01). However, the 
glycolytic flux rate after 20 min reperfusion was very low (Table 3), while coronary flow was also 
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reduced (Table 3). With glucose concentrations of 5.5 mM and 11 mM, recoveries were 93.2 ± 2.5 
and 97.0 ± 0.6 % respectively (p<0.01 vs. 0 mM and 2.75 mM - Table 1). Coronary flows were 
improved compared to other postischaemic groups, but glycolytic flux rates were lower than pre-
ischaemic rates (Table 3). Recoveries with 22 mM glucose were slightly lower than with 5.5 mM and 
11 mM glucose (Table 1 ). Glycolytic flux was also slightly lower than with 11 mM glucose. 
Recovery after 30 min ischaemia - effect of different glucose concentrations 
With zero glucose, increases in flow rate had no effect on recovery of function (all 20-30%). With a 
glucose concentration of 2.75 mM, an increasing flow rate improved recovery (from 33.8 ± 7.5 to 62.6 
± 0.9% - 0.1 to 0.5 ml/g wet wt/min; p<0.01), although the difference between 0.1 and 0.2 was not 
significant (Table 1). Glycolytic flux rates on reperfusion decreased with increased residual ischaemic 
coronary flow rate. With 5.5 mM glucose, the recovery attained with 0.5 ml/g wet wt/min was 
significantly higher than those with both lower flow rates (Table 1), although glycolytic flux was also 
decreased compared to 0.1 and 0.2 ml/g wet wt/min groups. With 11 mM glucose, results with each 
flow rate were significantly better than that lower (from 28.1 9.3 % to 69.4 ± 8.0 % to 97.0 ± 0.6 % 
respectively; p<0.05) - again, glycolytic flux on reperfusion was lowest with 0.5 ml/g wet wt/min 
during ischaemia (Table 3). The higher flow rate (0.5 ml/g wet wt/min) was also beneficial for hearts 
with 22 mM glucose, with a significant improvement compared to the lower flow rates. 
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DISCUSSION 
Previous studies of glucose and low flow ischaemia have used different substrates in combination, 
glucose by itself, or changes in substrate only during pre-ischaemia, ischaemia, or reperfusion. We 
tested the effect of different glucose concentrations with an alternate substrate present throughout the 
experiment. The use of an alternate substrate reflects a more physiological system, where fatty acids 
are the main substrate utilised by the normoxic heart. Acetate is a homologue of fatty acids without 
the detergent effect, and supplies acetyl CoA directly to the citric acid cycle. 
The findings of this study are: 1) the optimal glucose concentration for protection throughout the 
experiment is shown to be 11 mM; 2) even at this concentration, a very low coronary flow rate 
removes the benefit of glucose during reperfusion, although protection during ischaemia is still 
apparent in terms of reduced ischaemic contracture; and 3) enhanced glycolytic flux (by a high 
glucose concentration) at very low coronary flows may not be an advantage, even if the residual flow 
is relatively high (0.5 ml/g wet wt/min). This may be attributed to increased metabolite accumulation, 
and/or to inhibition of glycogen breakdown 425. 
ACETATE AS A SUBSTRATE - INTERACTION WITH GLUCOSE 
Acetate as sole substrate did not affect pre-ischaemic function, but 20 min perfusion with 5 mM 
acetate alone reduces glycogen content by 40% compared to glucose hearts (Results Ch 1 ). Acetate as 
the sole exogenous substrate accounts for approximately 75% of oxidation at concentrations of 1-10 
mM, with the residual oxidation accounted for by endogenous substrate including glycogen 585. An 
increased glucose concentration would reduce the amount of glycogen broken down. A concentration 
of 5 mM acetate decreased glucose utilisation in the presence of 11 mM glucose by about 20% in 
normoxic hearts (compare with Results Ch 1). However, acetate did not appear to affect glucose 
utilisation during ischaemia. Acetate perfusion sustains adenosine triphosphate (ATP) levels, and 
increases levels of creatine phosphate (CP) compared to 11 mM glucose hearts (Results Ch 1). Use of 
acetate only may eventually result in some impairment of function because of the reduced 
contribution to anaplerotic pathways with no contribution to oxaloacetate as there would be from 
glucose-derived pyruvate. Acetate by itself increases LDH washout during low flow ischaemia, 
indicative of increased tissue damage 49, consistent with the effects of free fatty acids on membrane 
function in ischaemia 399. However, even with only acetate present pre-ischaemically, during low 
flow ischaemia and on reperfusion, functional recoveries were 20-30%, indicating the role of TCA 
cycle activity in maintaining ischaemic and reperfusion function. In addition, endogenous fatty acids 
may contribute to energy production in these conditions. The addition of glucose enhanced the ability 
of the hearts to tolerate ischaemia, with reduced contracture at all flow rates, and resulted in improved 
functional recovery, especially at the higher flow rates. A proposed benefit of glucose in ischaemia is 
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inhibition of the deleterious effects of fatty acids 3 99, and this effect may be apparent in the presence 
of acetate. 
GLYCOLYSIS AND TOLERANCE OF HEARTS TO ISCHAEMIA 
Glycolysis throughout the experiment with different glucose concentrations 
Pre-ischaemic glycolytic flux rates were dependent on the glucose concentration, with evidence of 
saturation at the higher glucose concentrations. This indicates that an enzyme-regulated process may 
be involved in glucose uptake, i.e. the membrane glucose transporters which act by facilitative 
diffusion (this issue is discussed in Results Ch 3). In most hearts, glycolytic flux during ischaemia 
reached a plateau after 10-15 min. In the hearts perfused with 2.75 mM at flow rates of 0.1 and 0.2 
ml/g wet wt/min, glucose uptake then fell significantly. A similar fall in glycolytic flux rates has been 
noted previously in rabbits 14, 110, 218 with 5-6 mM glucose. Higher glucose concentrations and 
insulin maintain glycolytic flux 14, despite a significant increase in lactate production which is said to 
inhibit glycolysis 468. 
On reperfusion, there was little relationship between glycolytic flux and glucose concentration, and 
between glycolytic flux and functional recovery. It has been suggested that on reperfusion after a 
period of ischaemia, glycolytic flux and glucose oxidation may be uncoupled, resulting in excess 
glycolysis, and thus increased proton accumulation, which may be detrimental by resulting in 
increased Ca2+ entry 136, 326. Fatty acids in particular appear to uncouple glycolysis and glucose 
oxidation 326, which may partially account for the deleterious effects of fatty acids, or acetate. Thus 
the rates of glycolytic flux measured on reperfusion may not reflect the rate of glucose subsequently 
utilised by oxidation, as is presumably the case in the pre-ischaemic hearts. The mitochondria are 
known to be affected by ischaemia 137, and rates of oxygen utilisation are altered in the stunned 
myocardium relative to contractility 293, 397, with reduced efficiency. In hearts with better functional 
recovery, the coupling between glycolytic flux and glucose oxidation may have been better, 
contributing to improved recovery. Thus the enzyme-determined relationship between glucose 
concentration and glucose utilisation is altered on reperfusion, as is the relationship between 
glycolytic flux and mechanical function. The provision of glucose on reperfusion, and improved 
glucose oxidation, results in optimal recovery, but it must also be remembered that reperfusion 
function is determined largely by the extent of ischaemic injury. Ischaemic injury appears particularly 
susceptible to a lack of glucose, or an excess of glycolytic metabolites. 
Change in glucose concentration and residual coronary flow rate 
Time to onset of contracture has previously been correlated with cessation of glycolytic activity 253. 
However, only with a glucose concentration of 2.75 mM was any reduction in the rate of glycolysis 
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noted during ischaemia, although contracture was present in most hearts. An increase in peak 
contracture with increased flow was found in the 2.75 mM glucose hearts, showing that there was 
insufficient ATP production to prevent contracture, with an increased ATP demand in the face of 
increased coronary flow. A reduction in peak contracture was found with increasing glucose up to a 
concentration of 11 mM, and an increase in residual flow also increased the tolerance of the 
myocardium to 30 min global ischaemia at higher glucose concentrations. At a flow rate of 0.5 ml/g 
wet wt/min, 11 mM glucose abolished contracture in all but one heart, in agreement with a previous 
report 424. The rate of glycolysis in these hearts reached 1.02 ± 0.06 µmol/g wet wt/min by 15 min, 
which would result in a glycolytic ATP production of 2.03 ± 0.11 µmol/g wet wt/min. A minimum 
rate of glycolytic ATP of 2 µmol/g wet wt/min was also found to be necessary by Owen et al. 424 to 
prevent contracture. Reperfusion recoveries with 0.5 ml/g wet wt/min and 11 mM glucose were close 
to 100%, following reduced contracture and sustained glycolysis. 
With a concentration of 22 mM glucose at very low flows, however, peak contracture was increased, 
similar to previous findings (Results Ch 1 ). TOC was also delayed with increasing glucose up to 11 
mM, but was reduced by 22 mM. Increased contracture with a high glucose suggests that this was 
disadvantageous to the hearts during the ischaemic period with low residual flows of 0.1 and 0.2 ml/g 
wet wt/min. At a flow rate of 0.5 ml/g wet wt/min, no contracture was recorded in 22 mM glucose 
hearts, but recovery of function was slightly depressed compared to 11 mM glucose hearts, indicating 
that even with the high flow rate, some detriment was associated with excess glycolysis. 
Apstein et al. 14 compared the protective effects of 5.5 mM glucose and 28 mM glucose+ 100 i.u./1 
insulin, at flow rates of 0.5 or 0.06 ml/g wet wt/min in rabbits. A reduction in contracture with the 
higher glucose and insulin was found at both flow rates, but protective effects of glucose + insulin 
versus glucose only on reperfusion function were found only at the higher flow rate (0.5 ml/g/min vs. 
0.06 ml/g/min). Glucose+ insulin was associated with a higher effluent lactate concentration after 35-
40 min ischaemia, indicative of sustained glycolysis. In the 5.5 mM groups, independent of flow rate, 
lactate production decreased substantially during ischaemia, to levels similar to those found in non-
ischaemic hearts. This result suggests that either glucose uptake or glycolysis was inhibited at the 
lower concentration of glucose. 
Increased glucose uptake and pre-ischaemic glycogen loading by insulin treatment result in substantial 
glycolytic metabolite accumulation during ischaemia, including G6P, F6P, and lactate (Results Ch 3). 
Sugar phosphate accumulation has been associated with a reduction in diastolic relaxation 282, 
supposedly because of impaired Ca2+ homeostasis, while lactate is thought to inhibit glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and glycolysis by increasing NADH 362. We could find no 
deleterious effect of 11 mM glucose even at very low flows. If flow and washout were maintained, the 
benefits of glucose are apparent by increasing glycolytic ATP production 49, 570. However, excess 
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glycolytic substrate from higher glucose concentrations, insulin and increased glycogen may be . 
deleterious if these metabolites are not washed out. 
CLINICAL IMPLICATIONS OF FINDINGS 
Glucose-insulin-potassium therapy 
Glucose-insulin-potassium therapy was widely studied in the 1960s and 1970s with interest initially 
stimulated by the proposals of Sodi Pallares 501 , 502. However, early clinical trials suggested that 
GIK did not confer any additional benefit to the patient recovering from myocardial infarction. These 
trials were poorly designed, with incorrect dosages 132. The present study details the effect of altered 
glucose concentration present throughout the duration of normoxia, ischaemia and reperfusion, with 
an alternative substrate. A positive effect of glucose was found, especially if flow rates were 
maintained during ischaemia. An increased provision of glucose was beneficial as long as it is not in 
excess. The use of insulin with high concentrations of glucose may only be beneficial to ischaemic 
tissue if sufficient washout was maintained. Despite the adverse effects of high glucose, major clinical 
benefits in 1) zones of lesser ischaemia and 2) reduced systemic blood free fatty acids may be found. 
The adverse effects do not apply to the use of GIK post infarction, with higher coronary flows. 
Cardioplegia 
Recent advances in cardioplegia utilise a warm blood solution continually infused throughout a 
procedure 55. The glucose content of the perfusate can be manipulated during ischaemia in the case of 
blood cardioplegia, or pre-ischaemically by glucose-insulin-potassium pre-treatment 302. In such 
cases, the glucose content remains relatively constant, while the degree of residual flow is also fixed. 
Previous studies in isolated rat hearts have shown an optimal concentration of glucose of 11 mM in a 
cold cardioplegic solution (10°C) without any additional substrate, delivered in a multidose protocol 
425, 563. These findings contradcited a previous report that provision of glucose in the St Thomas' 
Hospital cardioplegic solution was detrimental. However, the latter study used a single dose at the 
onset of 70 min arrest at 28°C. The continuous flushing with multidose infusions confers protection in 
the presence of glucose. The findings of the present study substantiate the concept that delivery of 
glucose prior to, during ischaemia, and on reperfusion is beneficial, especially if some degree of 
residual flow is maintained. 
GLYCOLYTIC FLUX - RESERVATIONS OF METHODOLOGY 
There is some controversy as to whether the use of [2-3H] glucose reflects the true glycolytic flux rate. 
The 3H20 is cleaved off at the phosphoglucose isomerase step, and therefore does not measure the rate 
of glycolysis further down the pathway. We compared [2-3H] glucose with [5-3H] glucose (3H20 
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cleaved off at enolase step) and found no difference in the measurement of glycolytic flux at a low 
flow rate of 0.2 ml/g wet wt/min (data not shown) (see Results Ch 3 and Discussion A and D for 
further discussion on technique). 
SUMMARY 
Glucose at a concentrai:ion of 5-11 mM is beneficial to the ischaemic myocardium (in the absence of 
insulin). Improving residual coronary flow increases the benefits associated with glucose. High doses 
of glucose may not be beneficial if the residual flow is insufficient to wash out accumulated 
metabolites. This study has implications for the administration of glucose-insulin-potassium therapy 
to patients with infarction, where flow/dose relationships must be considered. The role of insulin, and 
its effects on glycolytic flux in conditions of severe low flow rates, and the consequences to the heart 
in terms of ischaemic contracture and functional recovery, need to be determined. 
Having established the dependency of ischaemic contracture and functional recovery on glucose 
concentration and residual coronary flow, we examined the kinetics of the glycolytic flux/glucose 
uptake data derived in this study which is discussed in depth in the following chapter. 
148 Results Ch 2. Glycolytic flux and ischaemic/reperfusion injury 
1.2 100 
- • -0.1 
- • -0.2 
- • -0.5 
1.0 
Cl '2 80 .E :r:: 
E :::: g 0 0.8 
E 
60 ~ 2- ::, 
X II) 
.2 0.6 II) - Q) ... u a. 
~ 40 .!:? 8 0.4 0 








-•- ~ 0.1 1.4 
-- 0.2 -•- 0.5 
Ar 
90 
'.? 1.2 80 Cl :r:: .E E 
Cl 70 g ~ 1.0 
Q) E 1~-._____. 60 ... ::, ::, ~0.8 II) II) ::, 
1~ 
50 ~ .;:: a. 
~ 0.6 40 .!:? 
0 






-5 0 5 10 15 20 25 30 
Time (min) 
Fig lb 




c 1.2 80 .E 
Cl Cl 
70 I ~ 1.0 E .s E 
60 ; ::J °';:;' 0.8 .. 
50 
.. ., ::J 
a. ;;:: 
.!c! { 0.6 40 ~ 0 .. 











80 Cl c1.2 J: .E 
E -- 70 g ~1.0 
0 (I) 
60 ... E ::J 
2.o.8 "' 
50 "' X (I) ... ::J 
C. ;;:: 
40 -~ o 0.6 ~ :§ 
0 30 "' Ill~0.4 
i5 a 20 
0.2 
10 
0.0 0 -5 0 5 10 15 20 25 30 
Time (min) 
Fig Id 





'2 BO J: 




E 1.0 60 ::J <I) 
2: <I) 
Q,) 
X 0.8 50 
... 
::J C. 
.;::: .~ u 
40 B ~ 0.6 <I) 






-5 0 5 10 15 20 25 30 
Time (min) 
Fig le 
Fig 1: Glycolytic flux versus time prior to and during low flow ischaemia, and changes in diastolic pressure 
reflecting ischaemic contracture with different flow rates and glucose concentrations (Fig 1 a - 0 mM, Fig J b -
2. 75 mM,· Fig 1 c - 5.5 mM,· Fig 1 d - 11 mM,· Fig 1 e - 22 mM). 
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Fig 2: Lactate washout before and during ischaemia at a flow rate of 0.2 mllg wet wt/min, with glucose 
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Results 3. Reappraisal of glucose uptake by the myocardium - relationship 
between glucose concentration, coronary flow and glucose uptake. 
Relevance to PET "mismatch" concept 
Submitted to Circulation 1996 
ABSTRACT 
Background: Glycolysis is generally thought to be stimulated by hypoxia, and inhibited in severe 
myocardial ischaemia by glycolytic metabolite inhibition of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). However, observations with positron emission tomography (PET) in 
patients with myocardial ischaemia have shown increased rather than decreased fluoro-deoxyglucose 
(1 8FDG) uptake relative to coronary flow in ischaemic tissue, or "mismatch". To clarify this apparent 
contradiction, we reassessed glucose uptake by the isolated rat heart using 1) data from our own 
laboratory dealing with ultra low flow rates and 2) data previously published that claimed to 
demonstrate glycolytic inhibition. 
Methods and Results: Absolute glucose uptake plotted against coronary flow showed that, as coronary 
flow fell, glucose uptake increased initially due to reversal of the Pasteur effect, but then fell to levels 
below those obtained at control flow rates, as expected. The percent glucose extraction was calculated 
from glucose uptake at each flow rate expressed as a percentage of that delivered to the myocardium, 
where delivery = concentration x coronary flow. At coronary flows less than about 1-2 ml/g wet 
wt/min in the rat heart, the % extraction of glucose was greatly increased. Analysis of glycolytic 
metabolite accumulation did not indicate inhibition of GAPDH. 
Conclusions: These results challenge the concept that glycolysis is limited by enzyme inhibition under 
severe low flow conditions, but rather show that glucose uptake is markedly dependent on glucose 
delivery. Even though absolute uptake decreased, the extraction of glucose rose as coronary flow fell. 
These findings are consistent with PET "mismatch" observations. 
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INTRODUCTION 
Glucose protects the ischaemic myocardium, with reduced reperfusion arrhythmias and ischaemic 
contracture, and improved reperfusion recoveryl4, 49, 123, 424 (Results Ch 1), by provision of 
glycolytic ATP. The rate of glycolysis is dependent on substrate supply and enzyme reactions. 
Glycolysis is generally thought to be inhibited in ischaemia at the glyceraldehyde 3-phosphate 
dehydrogenase step (GAPDH)362, 468 by a build up of metabolites389, 390, 468, 469, a concept 
derived from observations of significantly lower rates of glycolysis in isolated rat hearts perfused with 
a low coronary flow (0.6 ml/g wet wt/min) compared to control (12-15 ml/g wet wt/min)389, 390, 
468, 469. Thus an increase in substrate at a given low flow should not be able to overcome the 
restraint on ischaemic glycolytic flux468, and the relationship between glucose utilisation and 
coronary flow would be expected to be proportionate. This hypothesis, however, is contrary to 
observations using PET, which suggest that glucose extraction is increased at low flow rates in viable 
tissue ("mismatch")l 12, 343, 535, 562. In addition, in the in vivo pig model, absolute glucose uptake 
in the subendocardium of an ischaemic zone is not less than that in the non-ischaemic epicardium, but 
extraction is increased507. 
We re-examined data from the literature describing glucose uptake over a range of coronary flows in 
the isolated perfused rat heart, combined with new data concentrating on low flows more comparable 
to ' true' in vivo ischaemic flows (0.07-0.15 ml/g wet wt in pigs and dogs507). Under ischaemic 
conditions, the substrate supply is severely impaired, which is directly reflected in a reduced rate of 
glycolysis. At each flow rate, glucose uptake was related to glucose concentration by a relationship 
equivalent to Michaelis Menten kinetics. However, the rate of glycolysis ( or glucose uptake) is not 
reduced proportionately to the reduction in flow, and in fact is upregulated relative to flow as shown 
by an increased % glucose extraction. Ip. addition, analysis of glycolytic metabolites did not show 
evidence of inhibition of GAPDH. On the basis of these findings, we conclude that, during severe 
ischaemia, inhibition of glycolytic enzymes is not the rate limiting factor in determining glycolytic 
flux rate, but that the rate of glucose utilisation is determined primarily by the delivery of glucose to 
the cells, and its subsequent rate of transport across the cell membrane. While enzyme inhibition is 
not excluded as a modulator of glycolysis, its importance must be understood relative to delivery of 
substrate, a factor which has not previously been taken into consideration. These data support the 
"mismatch" concept, of increased glucose extraction under low flow conditions. 
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METHODS 
ISOLATED RAT HEART PERFUSIONS 
The isolated Langendorff-perfused rat model with a left ventricular balloon was used, as described in 
Methods. 5 mM acetate was used to provide an alternative substrate when glucose was absent or at 
very low concentrations, to prevent adverse effects associated with substrate free perfusion424 
(Results Ch 1). In low flow conditions, acetate does not affect glucose uptake (data not shown). The 
solution was gassed with 95% 0 2 5% CO2 to maintain pH at 7.4. 
Experimental protocol 
Hearts were subjected to 15 min aerobic perfusion, followed by 30 min global subtotal ischaemia with 
coronary flows of i) 0.1 , ii) 0.2 or iii) 0.5 ml/g wet wt /min, with different glucose concentrations (0. 
2.75, 5.5, 11 and 22 mM) for each flow rate. 6 hearts were used in each group. Coronary effluents 
were collected over 15 secs after 15 min control perfusion and over each 5 min period during 
ischaemia. 
In a second series of experiments to determine changes in metabolites with ischaemia, hearts were 
perfused with 11 mM glucose with or without insulin (1 U/1), and subjected to 30 min global 
ischaemia with no flow or a low flow of 0.2 ml/g wet wt/min. Glucose uptake was measured during 
low flow ischaemia. Hearts were clamped with Wollenberger tongs kept in liquid nitrogen at the 
onset, after 15 min and after 30 min ischaemia. 6 hearts were used for each time point. 
Biochemistry 
Glucose uptake was measured by the rate of 3H20 production from D-[2-3H] glucose389, 468, as 
described in Methods. 
Heart tissue was freeze-dried, and metabolites extracted with perchloric acid24, or with ethanol and 
NaOH for analysis of glycogen content35. The extracts were then assayed using spectrophotometric 
assays adapted for use on a Cobas Fara centrifugal analyser (Roche Diagnostics, Switzerland)24. 
Values were expressed as µmol/g wet wt. Glycogen was expressed as µmol 6-carbon units/g wet wt. 
LITERATURE ANALYSIS 
Data from articles measuring glucose uptake in the isolated perfused rat heart was analysed, 
specifically focusing on a series of articles published by the group of Neely388-390, 468, 469. The 
model used in these studies was the working heart (perfusion via the pulmonary veins - 7.5 mmHg 
preload, 60 mmHg afterload) with a one way valve. The hearts ejected against the valve which 
subsequently trapped the effluent, preventing reflux perfusion of the coronaries and resulting in 
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gradual ischaemia. Glucose utilisation, measured by D-[2-3H] or D-[5-3H]-glucose, was taken to be 
equivalent to glucose uptake. 
EXPRESSION OF RESULTS AND CURVE FITTING 
Results were expressed as mean± SEM. All data were expressed as per gram wet weight (wet weight 
= 5 * dry weight - previous determinations). The data were fitted using Origin™ (MicroCal) computer 
programme. Continuous reiterations were performed until the best fit was obtained. The goodness of 
fit of non-linear regression was assessed by the x2 value. 
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RESULTS 
GLUCOSE UPTAKE AT DIFFERENT FLOW RATES AND GLUCOSE CONCENTRATIONS 
Changes in glucose uptake in control and ischaemic hearts 
Pre-ischaemic glucose uptake rates were dependent on glucose concentration, as shown in Figs 1 and 
2. At each low coronary flow rate, glucose uptake fell initially from control levels, and then increased 
to peak at 15-20 min (see Fig la - 0.1 , Fig lb - 0.2; Fig le - 0.5 ml/g wet wt/min). With 2.75 mM 
glucose, glucose uptake fell after 15 min ischaemia at each low coronary flow, such that by 30 min 
ischaemia, the rates of glucose uptake were similar in each group ( cf. Fig 1 a, b, c ). With a glucose 
concentration of 5.5 mM, a decline in glucose uptake was seen only with a flow rate of 0.2 ml/g wet 
wt /min (Fig 1 b ). This decline may have been due to the high uptake reached in the first 15 min 
ischaemia, which exceeded that with 11 mM The rate of glucose uptake at the end of ischaemia, 
however, was proportionate to the concentration. With both 11 mM and 22 mM, glucose uptake was 
maintained at a plateau level throughout ischaemia at each flow rate (Fig la, b, c). With a flow rate of 
0.5 ml/g wet wt/min, glucose uptake rates with 11 and 22 mM glucose reached levels similar to those 
in pre-ischaemic hearts (Fig 1 c ). 
Mean glucose uptake - effect of concentration and flow rate 
The mean glucose uptake rate over the total ischaemic period of 30 min was calculated, and plotted 
against glucose concentration for each flow rate (mean value used because of lack of steady state for 
all concentrations). Double rectangular hyperbolic relationships were obtained (Fig 2), equivalent to 
Michaelis Menten kinetics, such that glucose uptake increased linearly from 0-5 mM, and was 
saturated at concentrations greater than 11 mM. Similar trends were observed at flow rates of 0.2 and 
0.5 ml/g wet wt /min, as well as with control coronary flows (Fig 2), although the curves were shifted 
upwards, and to the left. 
Mean glucose uptake plotted against flow rate showed an apparent positive linear relationship for 
each glucose concentration within the range of low flows investigated (Fig 3). The slope of the line 
increased with increasing glucose concentration. However, control values (at control coronary flows) 
were in a similar range, suggesting that the curves would decline after reaching a peak in order to fall 
to these values, giving an inverted-U shape. 
DATA AT A GLUCOSE CONCENTRATION OF 11 MM 
Absolute glucose uptake 
The standard concentration of glucose used in isolated rat heart perfusions in the absence of insulin is 
11 mM. The results from the above perfusions for glucose uptake with 11 mM glucose, together with 
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data taken from reports by Neely et ai.388-390, 468, 469, and previous data from our laboratory 
(Results Ch 1), were plotted as a function of coronary flow (Fig 4). Despite differences in models (a 
one-way valve resulted in a gradual fall in coronary flow, and a gradual reduction in glucose uptake at 
low flows389, compared to abrupt changes in Langendorff model), steady state rates of glucose 
uptake were reached. The plateau, or steady state values for glucose uptake were used for further 
calculations (mean glucose uptake not always given; steady state rates more easily comparable 
between models). With 11 mM glucose, uptake was sustained over at least 30 min at each flow rate 
(Fig 1 ). A total of 29 points, each representative of at least 6 hearts, was obtained. The points 
followed an inverted-U pattern, as predicted from Fig 3 (see above). 
Percentage glucose extraction 
While absolute glucose uptake was reduced at low flow rates, the uptake relative to that available to 
the tissue has not previously been reported for isolated rat hearts. In order to establish the relationship 
between glucose uptake and delivery of glucose, where 
delivery (µmol/min/g wet wt)= glucose concentration (µmol/ml) * coronary flow (ml/g wet 
wt/min) eqn 1 
(glucose concentration - of the perfusate) the term percentage glucose extraction was derived, defined 
as 
% Glucose extraction= [glucose uptake (µmol/min/g wet wt)/ delivery (µmol/min/g wet wt)] * 
100 eqn 2 
Because 
glucose uptake= I!,. glucose content (µmol/ml) / coronary flow (ml/g wet wt/min) eqn 3 
coronary flow appears to be cancelled out of eqn 2. However, because glucose uptake is dependent on 
coronary flow (according to Fig 4), extraction is a function of coronary flow. When percentage 
extraction of each data point in Fig 4 was plotted against coronary flow, a negative double 
exponential relationship was found (shown in Fig 5a). 
% extraction= 5.76 e<-xl7,54> + 28.69 e<-xJ0,35> eqn 4 
with x.2 = 6.64 where x = coronary flow (ml/g wet wt/min). At the "normal" range of flows for an 
isolated perfused heart (8-16 ml/g wet wt/min), % extraction was very low, below 3% of that 
delivered to the myocardium, even though glucose was the sole external substrate in the majority of 
hearts. When the double exponential curve was plotted as 2 separate components, a slow rise in 
glucose uptake was seen as flow rate was reduced over the whole range of flow rates for the first 
component. However, the second component showed a sharp increase in glucose uptake as flows fell 
below 1-2 ml/g wet wt/min, with a much shorter half life, of 0.35 versus 7.54 min. The extraction of 
glucose rose from below 3% up to 25-28% at low flow rates of 0.1 - 0.2 ml/g wet wt/min. 
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% extraction versus delivery 
When the percentage glucose extraction for different glucose concentrations (from Fig 2) was plotted 
against delivery of glucose (flow rate * concentration) rather than coronary flow, to allow comparison 
of the data, a similar negative exponential relationship was found (Fig 5b ), with a sharp increase in 
glucose extraction at reduced delivery. The graph is plotted showing different ranges of glucose 
concentrations. 
MATHEMATICAL MODEL OF GLUCOSE UPTAKE 
Predicted glucose uptake from extraction 
If the curve of% extraction versus coronary flow generated above (eqn 4; Fig 5a) were expressed as a 
function of glucose uptake, where 
[glucose uptake/(glucose cone* coronary flow)]/ 100 = f(coronary flow) eqn 5 
the predicted uptake became 
glucose uptake (µmol/min/g wet wt) = 0.63 x e<-x11.54> + 3.16 x e<-xt0.35> 
where x = coronary flow (Fig 4 - derived fit from Fig 5a). 
If this function were used to fit the data in Fig 4, the variables changed slightly to 
glucose uptake = 0.80 x e<-xt6·15> + 4. 79 x e<-x1o.t9) eqn 7 
eqn6_ 
where x = coronary flow, and X,2 = 0.165 (shown in Fig 4 - adjusted fit). There was a very good 
agreement between the predicted and the fitted curves indicating the consistency of the model. 
Non-linear regression 
If the data were fitted by non-linear regression using standard equations, the best fit was obtained with 
a polynomial function, with a X,2 = 0.09. The relationship was described by 
Glucose uptake (µmol/min/g wet wt)= 0.306 + 0.507 x - 0.049 r + 0.001 x3 eqn 8 
where x = coronary flow (ml/g wet wt/min) (see Fig 4 - polynomial regression curve). There was also 
good agreement between the curves generated from the % extraction, and that described by the 
polynomial. 
With a reduction in coronary flow, a peak glucose uptake was reached at a flow rate of about 6 ml/g 
wet wt/min, where a reduced oxygen availability would stimulate glucose uptake. At lower flow rates, 
the curve showed a reduced uptake as flow fell, rather than continuing to increase. Given a control 
normoxic uptake of 1-1.5 µmol/min/g wet wt, glucose uptake was lower than control values at flow 
rates less than about 2 ml/g wet wt/min. Flow rates of 5-6 ml/g wet wt/min are equivalent to those in 
vivo in the normoxic rat heart. 
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TISSUE METABOLITE VALUES 
The values for the glycolytic metabolites measured, as well as glycogen, are shown in Table 1. 
Metabolites can be broadly grouped into substrates (G6P, F6P, FDP, GAP, DHAP, pyruvate) and end 
products (L-alanine, a.-glycerophosphate, lactate). If the "substrates" are expressed as a percentage of 
the total (substrate+products), this value declines during ischaemia, as the product accumulation 
greatly outweighs the accumulation of the metabolites (Table 1). If the cross-over theorem is 
applied68, 468, G6P and F6P are shown to accumulate significantly in ischaemia, as do the end 
products, lactate and a.-glycerophosphate (Fig 6). However, no significant accumulation of other 
glycolytic metabolites was found, contrary to previous reports468. Only GAP increased by 30 min 
with glucose low flow ischaemia (Fig 6), but these values were widely spread and thus not of 
significance (see Table 1). Values of "substrates" tended to be higher at 15 min than at 30 min in zero 
flow ischaemia, indicating that glycolysis was limited after 30 min ischaemia by reduced substrate, 
with all available metabolites used up to provide additional ATP (Table 1; Fig 6). Only 2.5 µmol/g 
wet wt glycogen was utilised during the last 15 min, compared to 12.4 µmol/g wet wt in the first 15 
min. With maintained flow rates, this trend was not observed, with maintained glycolysis throughout 
30 min ischaemia. Glycogen breakdown was also significantly greater in the absence of flow (91 % vs. 
61.5% over 30 min). 
If insulin was present, glycogen was increased prior to ischaemia (Table 1), as was glucose uptake (to 
0.9 ± 0.1 vs. 0.5 ± 0.0 µmol/g wet wt/min; p<0.05). G6P and F6P increased significantly during 
ischaemia, from increased glucose uptake. A "bottle-neck" effect was seen. Values of FDP, GAP and 
DHAP were lower after 30 min compared to the 15 min values despite high G6P and F6P values, 
possibly indicating some enzyme inhibition with total global ischaemia and excess glycolytic 
substrate. With a maintained low flow, G6P and F6P values were lower, while the differences 
between 15 and 30 min for the other metabolites were also not as apparent. 
Lactate production was significantly greater in insulin hearts. The % substrate to total metabolites was 
subsequently higher in these hearts, although there was little evidence of GAPDH inhibition. 
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DISCUSSION 
The main finding presented in this paper is that the rate of glycolysis is not inhibited in ischaemia; 
rather, glycolysis is limited by the availability of substrate and rates of transport into the cell. We do 
not fully exclude the contribution of enzyme inhibition, but its importance appears secondary to 
limitation of substrate supply. These results are in agreement with standard concepts of substrate -
product relationships determining flux through a pathway391, and support the observations of 
mismatch as measured by 18FDG uptake. A scheme illustrating glycolytic regulation at different levels 
is shown in Fig 7. 
TECHNIQUES, DEFINITIONS AND RESERVATIONS 
Data from Langendorff and working hearts have been included together in Figs 4 and 5. While 
differences in the perfusion model certainly affect glucose uptake at normal flow rates, given that the 
working heart has a much higher demand, the values were found to be quite comparable, particularly 
at the low flow range in which we were interested. The model used by Neely et al. used lower 
perfusion pressures than others (preload - 10 cm H20; afterload - 80 cm H20 vs. 20 cm H20 and 100 
cm H20 respective1y414, 425) which reduces the demand for glucose, and resulted in values 
comparable to those in Langendorff hearts. Factors such as oxygen uptake, perfusion pressure, and 
work rate, will also modify glucose uptake under normal conditions. The values at higher flow rates 
are thus open to interpretation (see below). However, under ischaemic conditions, both working and 
Langendorff hearts show virtual cessation of pump function, and the metabolic rates are thus 
comparable. 
We measured the amount ofD-[2-3H] glucose detritiated in the phosphoglucoisomerase reaction (G6P 
to F6P), and equated this to glucose uptake. These data do not differ significantly from measurements 
of arteriovenous glucose differences ( data not shown), although the radioactive methods are more 
precise. D-[2-3H] glucose detritiation has been referred to as the "gold standard" for measuring 
glucose uptake 180. This method has also been used to measure glycolytic flux rates468 (Results Ch 
1), although D-[5-3H] glucose may give a more accurate result as this compound is detritiated "further 
down" the glycolytic pathway, at the enolase step337. However, Rovetto et ai.468 used both forms of 
glucose indiscriminately, and we found no difference in results using the two isotopes in low flow 
ischaemia (data not shown). Thus the majority of glucose phosphorylated in ischaemia appears to be 
converted to pyruvate. 
D-[2-3H] glucose detritiation does not distinguish between rates of glucose transport across the 
sarcolemma, and subsequent phosphorylation. These processes are taken as a single step, although the 
implications are discussed. Alternative fates of glucose including glycogen and intermediate 
metabolite accumulation are also not considered in the gross analysis of glucose uptake/glycolysis, for 
reasons as follows. Only about 5% of glucose goes to glycogen turnover in the normally beating heart 
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in the absence of insulin 162, and 11.6% with insulin and free fatty acids present 196. These values are 
presumably even lower in the ischaemic heart. Tissue glycogen levels during ischaemia are rapidly 
depleted, more so when it is the only substrate present, and the sole contributor to glycolysis (see 
Table 1). More glycogen is utilised in 30 min ischaemia in the absence of any exogenous glucose, and 
in the absence of a residual coronary flow (Table 1). Any residual glycogen is likely to be 
proglycogen, a form of glycogen more resistant to catabolism40, 103. These findings contribute to the 
argument that glycolysis is not limited by enzyme inhibition in ischaemia. 
The sum of glycolytic metabolites, other than the final end products of lactate and aGP, does not 
account for more than 7.5% of the total metabolite accumulation (see Table 1, and from468). In 
addition, with any residual flow, much of the lactate will be washed out and there may be some 
residual mitochondrial oxidation, which further reduces this percentage. While aGP accumulation 
also accounts for some of the glycolytic substrate, the values are relatively small compared to both 
total glycolytic substrate, and overall lactate production. 
Thus, for the purposes of this discussion, glucose uptake equates to glycolytic flux and to glucose 
utilisation (terms used interchangeably in the literature, but each of which has specific implications 
which must be considered when applied in context), i.e. glucose entering the cell, and subsequently 
phosphorylated is assumed to be converted to pyruvate, and subsequently to lactate under anaerobic 
conditions. This assumption also invokes the concept of glycolysis as a "metabolon", or single unit 
made up of multiple enzymes505, 506, which allows efficient "channelling" of the product of one 
reaction to the next, where it becomes the substrate576. Thus glycolysis is like a "funnel" - entry of 
substrate into the pathway virtually ensures eventual exit (see Fig 7). 
KINETICS OF GLUCOSE UPTAKE WITH DIFFERENT FLOW RATES AND GLUCOSE CONCENTRATIONS 
In most hearts, glucose uptake reached a peak at about 10-15 min. In hearts perfused with 2.75 mM, 
glucose uptake then decreased significantly. Hearts with 5.5 mM glucose showed similar trends, 
although not as marked. A similar decline has been noted previously in rabbits perfused with 5-6 mM 
glucose in low flow ischaemial4, 110, 550. Glucose uptake occurs by a process of facilitated 
diffusion, which implies that a certain minimal glucose gradient is required to ensure transport across 
the membrane59. In addition, if glucose supply is limited, the rate of ATP production will decrease, 
which will inhibit cell function. As the cells deteriorate, the failing heart will require less ATP, and 
thus less glucose. Higher glucose concentrations were able to maintain glucose uptake at a steady 
state throughout ischaemia. These concentrations in turn generally result in improved recovery of 
heart function 14, 550 (Results Ch 1). 
The data for mean glucose uptake versus glucose concentration for each flow rate were fitted by 
double rectangular hyperbolas, equivalent to the Michaelis - Menten relationship used to describe 
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enzyme activity. At control flow rates, the apparent Km of glucose uptake for the whole heart was 5 
mM, with a Vmax of 1.8 µmol/min . Therefore at least 5 mM glucose was required to sustain glucose 
uptake in normally perfused hearts, and preferably double this concentration in the absence of insulin. 
This result agrees with the other studies on the isolated heart, showing similar kinetics, where the 
optimal perfusion concentration was around 8-10 mM367, 415. 
The Km was shifted to the right at low flow rates (Fig 2) suggesting that, in ischaemia, a higher 
minimum glucose concentration ( at least 11 mM glucose) is required to sustain glucose uptake than is 
necessary in normoxia. This shift may be explained by the increased transit time of perfusate through 
the coronary vasculature, with a reduced coronary flow. The available glucose may be taken up 
rapidly, such that the tissue perfused further downstream would be exposed to a lower glucose 
concentration, insufficient to maintain uptake. A higher concentration may thus be required when 
coronary flow is very low, to sustain uptake throughout the passage of the perfusate through the heart. 
The maximum rate of glucose uptake (Vmax) was dependent on coronary flow (Fig 2), and thus on 
delivery of substrate. In the absence of insulin, an increase in glucose concentration much above 11 
mM had little effect on absolute glucose uptake, showing saturation of glucose uptake at these high 
concentrations. Only an increased coronary flow could increase absolute glucose uptake at each 
glucose concentration. The mechanisms for this finding may include; improved metabolism within the 
cell, such that the intracellular glucose content is continually reduced by utilisation; better perfusion 
by the coronary system allowing more tissue to take up glucose;, and reduced transit time such that at 
any given time more tissue is exposed to a high glucose concentration. The Vmax for 0.5 ml/g wet 
wt/min was greater than that for control flow rates, indicating that at higher "ischaemic" flow rates, 
the rate of glucose uptake could exceed that at control flows. 
GLUCOSE UPTAKE AND EXTRACTION VERSUS CORONARY FLOW AT AN OPTIMAL GLUCOSE 
CONCENTRATION 
Glucose uptake, at a fixed standard concentration of 11 mM, was increased at a coronary flow rate of 
6 ml/g wet wt/min compared to that in control hearts, and declined with a further fall in the coronary 
flow rate388 as delivery became limiting (see Fig 4). However, extraction increased sharply as 
coronary flows fell below about 1-2 ml/g wet wt/min, showing a disproportionate increase in glucose 
uptake relative to flow and challenging the concept of limitation of glycolysis in ischaemia. Coronary 
flow can be broadly separated into three ranges. 
Normal coronary flow rates 
At 'normal" coronary flows in the isolated rat heart (8-16 ml/g wet wt/min - Fig 4), glucose uptake is 
modified by factors including the model used (see above), work rate, heart rate, perfusion pressure, 
oxygen availability, alternate substrates, and status of the heart (diabetic, hypertrophied, starved) (e.g. 
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see refs367, 414,415,424). Rates of glucose uptake are therefore not closely dependent on coronary 
flow at "normal" flow rates. The line shown in Fig 4 over this range of flows is thus only applicable 
to the data presented. However, despite variations in absolute glucose uptake with different models, 
the % extraction of available glucose is still very low in control conditions (Fig 5). 
Intermediate reduction in coronary flow rates 
At "moderate" coronary flow rates in the isolated rat heart (2-8 ml/g wet wt/min), glucose uptakes 
may also differ from the curve illustrated (Fig 4). In the isolated rat heart model shown, glucose 
uptake was high at flow rates in the range of 4-10 ml/ g wet wt/min, peaking at a flow rate of 6-7 ml/ g 
wet wt/min with a glucose uptake of 1.75 to 2 µmol/min/g wet wt. The increased glucose uptake (and 
glycolysis) at these flow rates was presumably due to reversal of the Pasteur effect, with a relative 
hypoxia at lower flow rates, and a fall in citrate and ATP levels. At coronary flow rates of 6-7 ml/g 
wet wt/min, the heart thus presumably has optimal stimulation of glycolysis, and adequate delivery of 
substrate and removal of metabolites. As flow falls, delivery of substrate becomes limiting, resulting 
in the decline of glucose uptake. If delivery were not limiting, glucose uptake should continue to rise 
as flow falls. 
"lschaemic" coronary flow rates 
If enzymatic inhibition were the major determinant of glycolytic flux in ischaemia, as flow falls, the 
rate of glucose uptake should be proportionate to the fall in coronary flow468 , such that % extraction 
should remain reasonably constant (as shown by the first component of the exponential curve - Fig 
5a), or possibly even decrease with reduced flow rate (tending to the origin). Glycolysis was initially 
said to be inhibited because glucose utilisation in an isolated rat heart at a flow rate of 0.6 ml/g wet wt 
/min was less than that in the normally perfused myocardium390. However, as flow decreases below 
1-2 ml/g wet wt/min ("ischaemic), % extraction rose sharply (Fig 5). We also did not find evidence of 
accumulation of GAP and DHAP during ischaemia, to support the concept of GAPDH inhibition388-
390, 468, 469 (see Fig 7). We therefore propose that glucose uptake is limited mainly by delivery of 
glucose to the myocardium, which, at an optimal concentration of 11 mM, is determined by coronary 
flow; and that the heart in fact compensates for reduced delivery by increasing glucose extraction (see 
Fig 7 for illustration of concepts). We do not, however, exclude the contribution of enzyme inhibition 
at low coronary flows. If no inhibition were present, the curves of uptake (Fig 4) and extraction (Fig 
5) would be shifted upwards. Delivery and enzyme inhibition thus compete to determine the final rate 
of glucose uptake and utilisation. In zero flow conditions, some distributive control of glycolysis may 
occur, when the amount of available substrate is fixed, and the regulation of glycolysis then lies 
entirely with enzyme regulation. 
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Does this relationship occur in vivo? 
Normal in vivo flow rates in the rat are about 5-6 ml/g wet wtJmin279, thus in the middle portion of 
the glucose uptake curve (Fig 4), while in the dog, normal flow rates are about 2 ml/g wet wtJmin507 
i.e. nearing the "ischaemic" portion of the curve. In ischaemia, flow rates in the subendocardium in 
large animals in vivo are in the range of 0.07-0.15 ml/g wet wtJmin507 - about 3-8% of normal flow 
rates. Thus flow rates used in the present study (0.1-0.5 ml/g wet wt/min - about 2-8% of normal in 
vivo flow rates in the rat279) more closely reflect "true" ischaemia than do flow rates of 0.6 ml/g wet 
wt/min and higher388-390, 468, 469. 
The relationship between glucose uptake and coronary flow (Fig 4) would be altered in larger animals 
and in man, because the range of flows is much lower than in the isolated perfused rat heart. 
Measurements of glucose uptake in the in vivo pig heart showed no change in absolute glucose uptake 
with a fall in flow rate, compared to that found in the rat (Fig 4), but a negative logarithmic 
relationship between glucose extraction and coronary flow was found507, similar to the present 
findings (Fig 5). 
GLUCOSE TRANSPORT ACROSS THE MEMBRANE AND TIIE ROLE OF INSULIN 
Glucose uptake is determined by the concentration difference across the membrane, the number of 
pores, or glucose transporters, in the membrane, and the affinity of the glucose transporters. Whether 
the rate limiting step in glycolysis in ischaemia (when glucose concentration is maximal) is the rate of 
delivery of glucose to the cells ( determined by coronary flow rate), or the subsequent rate of transport 
across the cell membrane is difficult to establish. The rate of glucose phosphorylation by hexokinase 
may also be important, as this has been shown to be the most important factor in regulating glycolysis 
in normoxic conditions24 l , 3 3 5. 
The double exponential curve of extraction suggests that some mechanism is present, that results in an 
increased glucose uptake as flow falls below about 1-2 ml/g wet wt/min (Fig 5a). Kohn and Garfinkel 
proposed an increased affinity of glucose transport in ischaemia enabling increased glucose extraction 
in a computer generated mode1262. A more recent hypothesis suggests that translocation of GLUT 4 
molecules (insulin sensitive glucose transporters) to the sarcolemma is triggered by ischaemia 517. 
Alternatively, the cell surface accessibility of the glucose transporters already in the membrane may 
be increased548 or they may be upregulated454. The apparent Km of the GLUT 4 transporter in 
Xenopus oocytes is 4.3 mM as opposed to 26.2 mM of GLUT 1395, which would result in an overall 
increased affinity for glucose if the GLUT 4 membrane density were increased. 
The addition of insulin to hearts perfused with 11 or 22 mM glucose at a low flow of 0.2 ml/g wet 
wt/min increased ischaemic glucose uptake by 65% and 85% respectively (see Results 2). Thus 
insulin shifts the glucose uptake versus glucose concentration curve significantly upwards (increased 
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Vmax), indicating that membrane transport is rate-limiting when sufficient substrate is available. 
Insulin increases the number of membrane "pores", as well as increasing the overall affinity for 
glucose transport by increasing membrane GLUT 4 density. Insulin-treated hearts also showed an 
increased accumulation of tissue G6P and F6P levels in ischaemia, possibly indicating inhibition of 
glycolysis at the level of phosphofructokinase (PFK) when substrate and product (lactate) are both in 
excess (see Fig 7). The response of the tissue to excess substrate adds to the concept of glycolysis as a 
"funnel" - at some point the amount of substrate entering the pathway may transiently exceed the 
amount which can exit. However, eventual output will be increased because of increased input. 
These results highlight membrane glucose transport as a major rate-limiting factor in determining 
rates of glucose utilisation in ischaemic tissue (if external glucose present in sufficient or saturating 
concentration), as it is in non-ischaemic tissue241. 
POSITRON EMISSION TOMOGRAPHY 
PET scanning enables non-invasive measurement of regional myocardial blood flow, substrate flux, 
and biochemical reaction rates. A reduction in blood flow is frequently associated with relative or 
absolute increases in 18FDG uptake, or "mismatch", which is thought to indicate viabilityl 12, 343 , 
535, 562. The evidence presented in the present paper may explains the mechanisms involved in 
"mismatch", or increased extraction. While absolute glucose uptake may not be increased with 
reduced flow in ischaemic myocardium in vivo507, a maintained glucose uptake despite a reduced 
coronary flow would show increased extraction507, and indicate viability 111, 562 (Results Ch 1 ). 
Hypothetically, only if glucose uptake were proportionately more reduced than the reduction in flow 
rate, with reduced extraction, would the myocardium be non-viable 111. The capacity of the non-
viable tissue to take up glucose is presumably impaired, and the subsequent rate of ATP production 
would be reduced. 
Two recent papers have introduced some concerns over the validity of PET and "mismatch". 
Hariharan et at 180 found that uptake of 18FDG was not as accurate a measure of glucose uptake as 
was the use of [2-3H] glucose, as used in the present study. While this may question some of the 
measurements made by PET, this does not contradict the findings in the present paper. The concept of 
reduced blood flow and maintained glucose uptake in hibernating myocardium has also been 
challenged by Marinho et al. 340 who observed that glucose uptake and coronary flow in hibernating 
segments (not with scar tissue) was unchanged despite a reduction in left ventricular function. Thus 
extraction was not affected. This finding is not contrary to the concepts presented in the present paper, 
but emphasises the involvement in chronic left ventricular dysfunction of changes other than in 
glucose uptake and coronary flow. 
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SUMMARY 
At low glucose concentrations, glucose uptake is limited by an insufficient gradient for facilitated 
diffusion, and the glucose concentration is rate limiting. At higher concentrations (> 11 m.M), glucose 
uptake is saturated and is more dependent on coronary flow. The addition of insulin to perfusate with 
high glucose concentrations increases glucose uptake by increasing the ability of the membrane to 
transport glucose. Thus if sufficient or excess glucose is present, the transport of glucose through the 
membrane becomes rates limiting i.e. the number of transporters in the membrane determines the rate 
of uptake, which can be increased by insulin and/or ischaemia. A low coronary flow (<1-2 ml/g wet 
wt/min) appears to trigger an adaptive response in the myocardium allowing increased extraction of 
glucose at low flow rates. While absolute glucose uptake remains the same (in vivo) or falls (in 
isolated rat heart) with low coronary flows, the percentage extraction increases greatly when flow is 
reduced, indicating an ability of the myocardium to upregulate its capacity to transport glucose and 
thereby provide ATP.essential for maintained cell function. Similar conclusions have been reached by 
others using different methods of analysisl 10, 262.An increased extraction substantiates the concept 
of PET "mismatch". . 
Our findings suggest that the concept that glycolysis is inhibited in ischaemia is not complete. Rather, 
glycolysis is limited primarily by delivery of glucose, and/or membrane transport, and may be 
modified secondarily by enzyme activity and ATP demand. 
The consequences to the heart of the different rates of glucose uptake/glycolysis are presented in 
Results Ch 2. 
Glucose utilisation is closely dependent on the delivery of glucose, but the rate of glycolysis is also 
closely related to the tissue glycogen level, the endogenous storage form of glucose. The phenomenon 
of preconditioning has aroused much interest, as the intervention of a preceding ischaemic period 
confers protection against a subsequent ischaemie period. One of the many proposals for the 
protective mechanism of preconditioning is a pre-ischaemic depletion of glycogen. However, this 
concept is contrary to the findings presented in the above studies, where all results suggest that 
provision of glycolytic substrate is of benefit to the heart. We wished to test whether glycogen 
depletion is of benefit to the ischaemic heart, and whether the protective effects of preconditioning -
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Fig I . Glucose uptake versus time before and during low flow ischaemia, with different glucose concentrations at different flow rates (Fig la - 0.1; Fig I b - 0.2; Fig I c - 0.5 mllg wet wt /min). Coronary flows in control hearts were 15.5 ± 0.5, 15.3 ± 0.4, 16.4 ± 0.6, and 16.8 ± 0.6 mllg wet wt/min for glucose concentrations of 2. 75, 5.5, 11 and 22 mM respectively. 
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Fig 2: Mean glucose uptake versus glucose concentration for a range of flow rates. At each flow rate, glucose 
uptake was described by a double rectangular hyperbola, equivalent to Michaelis-Menten kinetics, where 
v=Vmax Sl(Km+S) where v=rate of reaction (uptake); S=substrate (glucose) concentration, Vmax=maximum 
rate of reaction (uptake), Km=S where v=l/2 Vmax (measure of affinity where lower Km = increased affinity). 
15 ml/g wet wt /min v= 1. 76 SI( 5.04 + S), ;( = 0.18 
0.5 mllg wet wt/min v=l.86 SI(] 3.23 + S), ;( = 12.48 
0.2 ml/g wet wt /min v=0.95 SI(] 4. 60 + S), ;( = 10.33 
0.1 mllg wet wt /min v=O. 46 S/(13. 05 + S) , ;( = 3.13 
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Fig 3: Mean glucose uptake versus coronary flow for each glucose concentration. Note that while relationship is 
apparently linear, this only applies in the range of low flows. At control flow rates, values are in the same range 
(see Fig 1), implying a parabolic relationship, with a peak glucose uptake at a flow rate of about 7-9 m/lg wet 
wt/min (given a control flow of 15-16 mllg wet wt/min). R=0.99 for all curves. 
2.75 mMy = 0.47x+0.02; 5.5 mM y = 1.28x+0.04; 
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Fig 4: Glucose uptake versus ·coronary flow in isolated rat hearts perfused with buffer containing 11 mM 
glucose. Data was taken from a number of publications in the literature388-390, 468, 469 and from Results Ch 1 
and 2. A total of 29 points (means only) were obtained. Using the relationship from Fig 5a, the predicted change 
in glucose uptake was plotted. The derived equation was y ·= 0.63 x eC-xn.s4J + 3.16 x ef-x10.JsJ_ 
When this form of equation was used to fit the data, the curve was adjusted to 
y = 0.80 X e<·"'6·15> + 4.79 X e<·"'0·19> 
with :I =0.17. The data was then fitted using a polynomial expression. The resulting equation was 
y = 0.305 + 0.507 X - 0.049 X2 + 0.001 x3, 
with R:2 = 0.85. At coronary flows greater than 12 mllg wet wt/min, factors other than coronary flow determine 
glucose uptake, and these values may vary widely (see text) . At lower flow rates, there is a sharp fall in glucose 
uptake as coronary flow rate falls . 
This graph shows that the point of division between inhibition of glucose uptake at "ischaemic" flow rates, 
versus stimulation relative to control389 is arbitrary. The point at which "ischaemic" glucose upta~e is less 
than control is dependent on the initial control values. 
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Fig 5a: Individual data points from Fig 4 expressed as a percentage of glucose delivery i.e. extraction ( delivery 
= flow x concentration), with a glucose concentration of 11 mM, versus coronary flow. The data were fitted with 
a double negative exponential equation, with ;( = 6.64 where y = 28.69 ef.:rAJ·35J + 5. 75 /-x/7.S4J_ The individual 
components of this curve are plotted. The second component, showing % extraction with low coronary flows , 
indicates the point below which glucose uptake is upregulated. A value of 1-2 mllg wet wt/min is indicated 
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Fig 5b: Mean glucose uptake derived from data shown in Fig I were calculated as a function of delivery of 
glucose to allow for different glucose concentrations and coronary flow. Different ranges of glucose 
concentrations used are distinguished. The % extraction for each point was then calculated, and plotted against 
delivery. The data points from Fig 5a (I I mM glucose) were also replotted as a function of delivery. All the 
points were then fitted with a negative exponential relationship, described by y = 20.15 /·xl4·76J + 4.23 / -x17S.4lJ , 
i = 14.ss 
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Fig 6: Percentage change from control values of tissue metabolites from hearts perfused with 11 mM glucose 
with and without 1 U/1 insulin. Hearts were clamped at the onset, after 15 min and after 30 m1n ischaemia. The 
dotted line represents control values (100%) . See Table 1 for abbreviations. 
178 Results Ch 3. Glucose uptake and coronary flow 
QJ GLUCOSE DELIVERY -t 
GLUCOSE EXTRACTION t · 
ischemia > · 1 · glycogen @J 
(±) t ~ depletion 
1 ATP T 
G6Pt (±)_ .. · CP 't 
. . . p· + 










Lactate+ --.... · ... : V 
(washout -t> 
~· .. G 
. 
pHi fall 
~ · · · · · · · · · NADH+H+ 
?8 
Fig 7: Possible sites of regulation of glycolysis. 
(]) - glucose delivery is decreased in ischaemia as the flow rate falls, resulting in reduced glucose uptake. A 
reduction in coronary flow below 1-2 mllg wet wt/min appears to stimulate glucose uptake, resulting in 
increased extraction of glucose delivered to the cells. 
(2) - glycogen is rapidly depleted during ischaemia (within the first 15 minutes, most has been utilised - Table 
1). Once glycogen is depleted, it can no longer contribute to glycolysis. The residual glycogen remaining may 
consist largely of proglycogen, a more stable intermediate of glycogen synthesis which is more resistant to 
breakdown in ischaemia40, 103_ Under total global ischaemic conditions, or when glucose is present only in 
very low concentrations, glycogen is the sole glycolytic substrate, and the tissue content at the onset of 
ischaemia determines subsequent glycolytic rates. 
(3) - phosphofructokinase (PFK) was thought to be the major site of glycolytic inhibition under, normal 
-·· 
conditions when ATP and CP levels are sufficient541. When ATP and CP levels are depleted, inhibition of PFK 
is removed allowing glycolysis to continue. However, a more recent analysis, in conditions of nor._moxia with 
sufficient substrate (glucose and insulin), has found that control of glycolysis at all sites below 
phophoglucoisomerase, including PFK, is limited to less than 25% of the tota1241_ Glucose uptake and 
phosphorylation are the main rate limiting factors. 
In ischaemia, the site of glycolytic regulation was though to be GAPDH rather than PFK468 (see below). 
However, if high glucose and insulin are present, regulation of glycolysis at the level of PFK by a drop in pH541 
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may become more important. A large accumulation of G6P and F6P was found especially in insulin hearts, 
increasing with increased duration of ischaemia (see Table I, Fig 6), suggesting that with sufficient substrate, 
some feedback is present to prevent too excessive an accumulation of end product. 
(4) GAPDH catalyses the conversion of GAP to 2,3-bisphosphoglycerate, with the reduction of NAD+ to 
NADH+F. Thus a build up in NADH and F inhibits this reaction. In ischaemia, as lactate accumulates 
because of increased production and reduced washout, balancing the lactate dehydrogenase equilibrium should 
theoretically lead to an accumulation ofNADH and F. This mechanism is then thought to inhibit glycolysis362, 
468. However, the importance of this mechanism in the overall regulation of glycolysis in ischaemia is 
challenged by the findings that: glycolysis is limited by supply of substrate, in accordance with normal 
substrate-product relationships391 (Fig 3); at low coronary flows, glucose extraction is increased (Fig 5); and 
analysis of glycolytic metabolites does not point to inhibition at the level of GAPDH (Fable 1, Fig 6) . In 
addition, with high glucose and insulin at low coronary flows, lactate washout has been shown to remain at a 
steady state for an extended period, without any evidence of attenuation of glycolysis by feedback inhibition] 4_ 
Tissue lactate levels were increased if insulin were present (Fable 1). While the role of lactate-mediated 
inhibition of glycolysis cannot be excluded, its importance appears relatively small. Only if excess external 
lactate is added92, may GAP DH inhibition regulate glycolysis, although this has not been shown directly. 
The process illustrated in the figure can be regarded as a "funnel". Hypothetically, in ischaemia, if glucose is 
taken into the cell and phosphorylated, its eventual fate must be lactate if the cell is still viable. Some 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Results 4. Does preconditioning act by glycogen depletion in the isolated rat 
heart? 
In press J Mol Cell Cardiol 1996 
ABSTRACT 
Preconditioning hastens the time to onset of ischaemic contracture and increases peak contracture in 
an isolated perfused rat heart, but improves recovery of function. The preconditioning ischaemic 
episode is also known to deplete glycogen stores. We tested whether a depletion in glycogen is related 
to the protection conferred by preconditioning. 
Methods: The isolated Langendorff perfused rat heart, with a left ventricular balloon to record 
function, was perfused with either glucose 11 mM, acetate 5 mM, or glucose 11 mM + insulin to alter 
pre-ischaemic glycogen levels prior to 30 min total global ischaemia. In addition, hearts were 
preconditioned by on episode of 5 min ischaemia and 5 min reperfusion. Time to onset of contracture 
(TOC - min), peak contracture and recovery of developed pressure after 20 min reperfusion with 
glucose-containing perfusate (both expressed as % pre-ischaemic developed pressure) were measured 
(n = 9-10). Parallel groups of hearts were clamped at various times for assessment of tissue 
metabolites. 
Results: Acetate pre-perfusion reduced glycogen levels compared to glucose hearts, from 16.27 ± 0.44 
to 10.77 ± 0.96 µmol/g wet wt. TOC was reduced and peak contracture increased, with poor 
functional recovery. Glucose+insulin pre-perfusion increased glycogen (21.39 ± 1.08 µmol/g wet wt) 
with opposite effects on contracture, but functional recovery was still poor. 
Preconditioning hastened the time to onset of contracture, which could be partially attributed to 
glycogen depletion. Preconditioning significantly improved functional recovery in glucose hearts, but 
had little or no effect in the other groups. Thus the protective effect of preconditioning on functional 
recovery could not be linked to glycogen depletion. 
Conclusions: Pre-ischaemic glycogen appeared to play a dual role. When low, preconditioning was 
ineffective, presumably because of lack of production of glycolytic ATP, and severe contracture. 
When pre-ischaemic glycogen was increased, preconditioning was also relatively ineffective, 
presumably because of excess accumulation of the metabolites of glycogenolysis. 
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INTRODUCTION 
Preconditioning can be defined as one or more brief periods of ischaemia with intermittent 
reperfusion that protects against a sustained period of subsequent ischaemia. Protection has been 
observed in terms of reduction in infarct size 313 , 319, 375, 598, reduction in ischaemia- and 
reperfusion-induced arrhythmias 298 , 495 and an improvement in functional recovery on reperfusion 
18, 61 , 528. This is generally associated with a reduced utilisation of high energy phosphates, a 
reduced intracellular lactate accumulation, and reduced fall in intracellular pH. Primarily, 
preconditioning can be said to delay the onset of irreversible injury or necrosis, such that with timely 
reperfusion, there is an increased degree of residual functional tissue, resulting in improved recovery . 
of mechanical function. However, there is a time limit on the protection conferred by preconditioning, 
such that if the hearts are reperfused after an extended period of ischaemia, no difference between 
control and preconditioned hearts will be observed 3 7 5. 
Because a brief period of ischaemia reduces the level of glycogen in the tissue 525, and following on 
from the much-quoted report by Neely and Grotyohann 387, an obvious hypothesis is that a reduction 
in glycogen levels brought about by preconditioning is protective. This was attributed to reduced 
lactate and proton accumulation, factors that have been noted in preconditioned hearts. 
There have been a number of studies which have attempted to answer the question whether glycogen 
depletion is in itself beneficial to the heart. The results are have yielded conflicting results. 
Kupriyanov et al 278 reported improved recoveries following ischaemia preceded by 2h perfusion 
with pyruvate to reduce tissue glycogen, despite a reduced time to onset of contracture (TOC). 
Lagerstrom et al found that 15 min anoxia (as used in the Neely paper) or substrate free perfusion 
prior to 30 min total ischaemia to reduce tissue glycogen impaired functional recovery compared to 
control hearts, with no change in lactate accumulation in the former case, but a significant reduction 
in the latter 286. There was thus no correlation of recovery with lactate accumulation. These 
discrepancies may be due in part to the different levels of pre-ischaemic glycogen in the different 
studies. However, studies on glycogen depletion from different reports, with the same control pre-
ischaemic glycogen levels, do not give consistent comparable results in terms of functional recovery 
(see Ch. II). 
The involvement of glycogen depletion in preconditioning has been investigated, the most notable 
publication that of Wolfe et al 588. Loss of protection against infarct development during a prolonged 
ischaemic period was correlated with a return to control tissue glycogen levels, during extended 
reperfusion after preconditioning. No differences in infarct development between control and 
preconditioned hearts were observed after 1 hour reperfusion, when glycogen levels were similar. 
However, as has been noted in a number of publications, the protection conferred by preconditioning 
wanes with time 313, 375, 377, 596. The time dependence also appears to be species dependent with 
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shorter time periods of protection available in rats 313 than in dogs 375 or pigs 269. The study by 
Wolfe et al. therefore does not offer conclusive evidence that a reduction in glycogen prior to the 
sustained ischaemic episode is a prerequisite for preconditioning, o_r that this can be defined as the 
protective mechanism. In addition, functional recovery, an important component of determining the 
effectiveness of protection, was not recorded. Studies of the role of glycogen have generally used this 
as the end point. 
We wished to test two hypotheses 1) whether a reduction in glycogen levels prior to ischaemia, by 
perfusion with acetate, is protective to the heart, and 2) whether glycogen depletion can be linked to 
the protection conferred by preconditioning. In addition, glycogen-loaded hearts (perfused with 
glucose + insulin) were investigated. If the hypothesis were true that glycogen depletion is beneficial, 
glycogen loading should be detrimental, and preconditioning should improve function in these hearts 
compared to controls by reducing glycogen. 
5 min ischaemia + 5 min reperfusion was used to precondition the hearts. A similar protocol has been 
used in a number of other studies 18, 66, 290, 364, 603. A 30 min period of sustained ischaemia was 
chosen to ensure sufficient degrees of both reversible and irreversible injury, and to enable 
discernment of a protective effect of preconditioning. While preconditioning did result in improved 
functional recovery, this was dissociated from glycogen depletion. 
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METHODS 
PERFUSION APPARATUS 
The isolated Langendorff-perfused rat model with a left ventricular balloon was used, as described in 
Methods. Glucose 11 mM was the substrate used unless otherwise stated. 
PROTOCOL 
At least 9 hearts were used in each group. The standard protocol was a 30 min period of perfusion, 
followed by 30 min ischaemia, and subsequently 20 min reperfusion (see Figure 1). In the 30 min 
period prior to ischaemia, two major modifications were made. The hearts were perfused with the 
standard glucose containing substrate ( at a concentration of 11 mM), with 5 mM acetate instead of 
glucose (the NaCl concentration was reduced by 5 mM to allow for the addition of 5 mM Na-acetate), 
or with 11 mM glucose + 1 U/1 insulin (Humulin). Acetate reduces tissue glycogen because of its 
reduced PIO ratio (2.3 - 402) which despite an increase in citrate results in glycogen breakdown 585. 
The presence of insulin stimulates glucose uptake and steers glucose towards glycogen synthesis by 
stimulation of glycogen synthase and inhibition of phosphorylase. A high insulin concentration was 
used to ensure maximal glycogen synthesis during the pre-ischaemic period. 
In each of the above three groups, hearts were perfused either for the entire 30 min, or after 20 min 
were subjected to 5 min total global ischaemia followed by 5 min reperfusion to precondition the 
hearts. 
After the pre-ischaemic perfusion period, all hearts were made totally ischaemic by complete 
cessation of flow, for 30 min. After 30 min ischaemia, all hearts were reperfused with the standard 
oxygenated glucose-containing solution for a further 20 min. 
Parallel groups of hearts were perfused as above but for each group, hearts were clamped with 
Wollenberg tongs kept in liquid nitrogen, immediately prior to sustained ischaemia, after 15 min and 
30 min ischaemia, and at the end of the reperfusion period. These hearts were freeze dried for later 
biochemical analysis. 6 hearts in each group for each time point were used. 
FUNCTIONAL MEASUREMENTS 
Indices of contracture and functional recovery were recorded as described in Methods. 
BIOCHEMICAL MEASUREMENTS 
The freeze dried samples were extracted using perchloric acid. Levels of tissue metabolites including 
high energy phosphates, glycolytic metabolites and citric acid cycle intermediates, were determined 
used spectrophotometric assays 24 adapted for use on a centrifugal analyzer (Cobas Fara, Roche 
Diagnostics, Switzerland), as described in Methods. This enabled many determinations to be made 
with small sample volumes. Glycogen levels were determined by measuring the glucose content of 
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samples following alcohol and alkali extraction. All tissue metabolites were expressed as µmol/g wet 
wt, where wet weight= 5 x dry weight (using previously determined ratios). Glycogen was expressed 
as µmol glucose units (C6 units)/g wet wt. 
STATISTICS 
The Anova two-way analysis of variance was used to determine significance among groups, after 
which the modified t-test with the Bonferroni correction was used for comparison between individual 
groups. A value of p<0.05 was used as the level of significance. 
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RESULTS 
MODEL OF PRECONDITIONING 
The standard model used in this study was 30 min zero flow ischaemia with or without a preceding 5 
min ischaemia + 5 min reperfusion for preconditioned hearts. Table 1 shows the measurements 
recorded after 30 min perfusion with and without preconditioning in glucose-perfused hearts. 
Preconditioning significantly increased coronary flow, but reduced systolic pressure and developed 
pressure before sustained ischaemia (Table 1). The changes in systolic and diastolic pressure 
throughout the experiments are shown in Figure 2. Preconditioned hearts showed faster TOC and a 
slightly increased peak contracture (Table 2), but there was still an increased recovery of developed 
pressure (47.6 ± 7.3% vs 22.5 ± 7.0%; p<0.05) due to improved diastolic pressure on reperfusion 
(Table 2). Coronary flow on reperfusion was significantly improved in preconditioned hearts 
compared to control values (Table 2). 
Pre-ischaemic tissue values of adenosine triphosphate (ATP) showed no difference between control 
and preconditioned hearts, and there was a small increase in creatine phosphate (CP) in 
preconditioned hearts (Figure 5). Following preconditioning, there was a significant reduction in 
glycogen (11.19 ± 1.05 vs 16.27 ± 0.44 µmol C6/g wet wt; p<0.05) (Figure 3a) and a significant 
increase in G6P (Figure 6). An increased citrate (0.26 ± 0.01 vs 0.16 ± 0.01 µmol/g wet wt; p<0.001) 
and malate (0.42 ± 0.08 vs 0.18 ± 0.04 µmol/g wet wt; p<0.01) were also found in preconditioned 
hearts. 
During ischaemia, glycogen levels at 15 min and 30 min were similar in the two groups (Figure 3b ), 
indicating a reduced glycogen utilisation in preconditioned hearts (9.4 vs 14.9 µmol C6/g wet wt/30 
min). ATP and CP levels were no different during ischaemia (Figure 5), nor was there a significant 
reduction in tissue lactate accumulation (Figure 7). Tissue glucose measured at the onset of ischaemia 
(indicative of the amount of glucose available for subsequent utilisation) was 5.2 ± 0.3 and 5.7 ± 0.4 
µmol/g wet wt for control and preconditioned hearts respectively, and when taken together with 
glycogen was sufficient to account for the lactate produced. 
Glycolytic metabolite accumulation ( data not shown) during ischaemia was reduced at 30 min 
compared to 15 min ischaemia in normal hearts. In preconditioned hearts an increased accumulation 
by 30 min was found (see G6P levels - Figure 6). Inorganic phosphate (Pi) levels were similar in both 
groups. 
A significant recovery of CP levels was found in preconditioned hearts after 20 min reperfusion 
(Figure 5), together with a significant reduction in Pi (Figure 6), presumably because of maintained 
CP. There was also a trend towards improved ATP levels, and reduced AMP, suggestive of better 
adenine nucleotide regeneration in preconditioned hearts. Glycogen levels were no different after 
reperfusion (Figure 3b ). 
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PRE-ISCHAEMIC REDUCTION OF GLYCOGEN CONTENT- ACETATE PREPERFUSION 
Control hearts 
Acetate perfusion for 30 min did not affect cardiac function except for a small non-significant 
increase in coronary flow, a consequence of increased oxygen requirements (Table 1). There was an 
increase in CP compared to glucose perfused hearts (Figure 5), and a reduction in tissue glycogen 
(10.77 ± 0.96 vs 16.27 ± 0.44 µmol/g wet wt; p<0.05) (Figure 3a). There was also a significant increase 
in citrate levels (0.26 ± 0.02 vs 0.16 ± 0.01 µmol/g wet wt), a consequence of increased acetyl Co A 
formation directly from acetate inhibiting pyruvate dehydrogenase and activating pyruvate 
carboxylase. 
On cessation of flow, acetate perfused hearts underwent a rapid contracture and the extent of 
contracture was greatly increased (Figure 4a, Table 2) versus glucose hearts. This resulted in a poor 
recovery of developed pressure (8.2 ± 3.0%) due to reduced systolic pressure compared to glucose 
hearts. Diastolic pressure was no different between acetate- and glucose-perfused hearts (Table 2). 
Tissue high energy phosphate levels in acetate hearts showed a greater fall in ATP (Figure 5) and an 
increase in AMP, although glycogen was similar to glucose hearts after 30 min ischaemia (1.13 ± 0.19 
vs 1.36 ± 0.13 µmol/g wet wt; p<0.05) (Figure 3b ). Citrate levels declined during ischaemia in acetate 
hearts (0.18 ± 0.06 µmol/g wet wt by 30 min). Glycolytic metabolite levels were reduced in acetate 
hearts throughout ischaemia (G6P - 0.02 ± 0.00 vs 0.13 ± 0.04 µmol/g wet wt in glucose hearts by 30 
min ischaemia; p<O.O 1) (Figure 6). There was a significant reduction in lactate accumulation in the 
acetate hearts (Figure 7), while Pi accumulation was high (Figure 8) due to increased breakdown of 
high energy phosphates, and reduced sugar p)losphate formation from glycogen. 
Preconditioning 
When acetate hearts were preconditioned, glycogen levels prior to ischaemia were even further 
reduced (5.98 ± 1.04 µmol C6/g wet wt) (Figure 3a) with very little glycogen available in the tissue by 
30 min ischaemia (0.81 ± 023 µmol C6/g wet wt) (Figure 3b). However, prior to ischaemia, acetate 
preconditioned hearts show an even greater CP overshoot (Figure 5), and an increased citrate level 
(0.78 ± 0.06 µmol/g wet wt) compared to acetate control hearts, and both glucose control and 
preconditioned hearts. However, during ischaemia, the high energy phosphates were rapidly depleted 
to values lower than in any other hearts (see Figure 5). Glycolytic metabolite levels were also very 
low (see Figure 6). A rise in diastolic pressure frequently occurred during the preconditioning episode 
of ischaemia, such that diastolic pressure immediately prior to sustained ischaemia was increased 
(Table 1 ). Thus ischaemic contracture was almost immediate in acetate preconditioned hearts, with a 
large peak contracture, both significantly different from acetate control, and glucose hearts (Table 2). 
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Recovery of acetate preconditioned hearts was also poor (Table 2), and no different to acetate control 
hearts. 
No difference in coronary flow after 20 min reperfusion was evident in the acetate preconditioned 
hearts (Table 2). 
PRE-ISCHAEMIC INCREAS~ IN GLYCOGEN CONTENT 
Control hearts 
Pre-ischaemic perfusion with glucose-containing buffer ( 11 mM) with the addition of 1 U/L of insulin 
resulted in increased glycogen synthesis and storage. After 30 min perfusion, glycogen levels were 
21.39 ± 1.08 µmol/g wet wt compared to 16.27 ± 0.44 µmol/g wet wt in glucose perfused hearts (Figure 
3a). ATP levels were no different, but there was a slight increase in CP (Figure 5). Citrate levels were 
also increased (0.24 ± 0.01 µmol/g wet wt; p<0.05). There was a general trend to an increase in 
glycolytic metabolites ( data not shown), but with continued perfusion, glycolysis would be efficient, 
without undue accumulation. Developed pressures were higher in insulin hearts compared to glucose 
perfused hearts (Table 1 ). 
TOC was significantly delayed in insulin hearts and peak contracture was slightly lower than glucose 
hearts (Figure 4b, Table 2). Glycogen levels after 30 min ischaemia were significantly higher in 
insulin treated hearts than in glucose hearts (5.03 ± 129 vs 1.36 ± 0.13 µmol/g wet wt; p<0.05) (Figure 
3b). G6P increased substantially during ischaemia in insulin hearts (from 0.17 ± 0.05 to 1.12±0.23 
µmol/g wet wt after 30 min ischaemia) compared to glucose hearts (Figure 6). Lactate was also 
significantly increased in insulin-treated hearts by 30 min ischaemia (Figure 7). Citrate levels declined 
significantly (to 0.10 ± 0.01 µmol/g wet wt) during ischaemia. Pi was high initially but decreased 
slightly as glycogen was broken down, and the sugar phosphate content increased. 
Despite a reduced contracture and a higher rate of glycolysis, recovery of insulin-perfused hearts after 
30 min total global ischaemia was not, however, improved compared to glucose hearts, and were in 
fact slightly worse (11.6 ± 4.3%). 
Preconditioning 
When hearts pre-treated with glucose + insulin were subjected to 5 min ischaemia + 5 min 
reperfusion, an overshoot in CP was found, and a reduction in glycogen (15.53 ± 1.55 µmol/g wet wt, 
p<0.05 vs control) (Figure 3a). When these hearts were subjected to a further 30 min total global 
ischaemia, TOC was much reduced compared to control insulin hearts), although peak contracture 
was not affected (Figure 4b, Table 2). Recovery of developed pressure was not improved (18.6 ± 
8.1 % ), although diastolic pressure was reduced and coronary flow was improved (Table 2). 
ATP levels in insulin preconditioned hearts after 15 min ischaemia were higher than those in other 
hearts - the only group which showed a reduced ATP utilisation (Figure 5). In addition, AMP levels 
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after 15 min ischaemia were lowest in insulin preconditioned hearts, although after 30 min ischaemia, 
these values were the highest. However, this would maintain AMP availability for restoration of ATP. 
While G6P was also greatly increased in preconditioned insulin treated hearts, preconditioning tended 
to reduced accumulation compared to control insulin hearts (0.8 ± 0.3 µmol/g wet wt at 30 min) 
(Figure 6). Lactate at the end of ischaemia was not however, different between control and 
preconditioned insulin.treated hearts (Figure 7), again accounted for by tissue glucose available at the 
onset of ischaemia (6.93 ± 0.88 µmol/g wet wt in control and 7.26 ± 0.44 µmol/g wet wt in 
preconditioned hearts). Pi in the insulin preconditioned hearts was higher than control, presumably 
because of reduced sugar phosphate accumulation. 
GLYCOGEN UTILISATION AND ISCHAEMIC CONTRACTURE 
While it was difficult to make accurate calculations of glycogen utilisation, because each time point 
consisted of a different group of hearts, some conclusions could be drawn. Glycogen utilisation 
occurred mainly in the first 15 min of total global ischaemia in the glucose and acetate hearts, but still 
continued to be broken down after 15 min in the insulin hearts. 
By the end of ischaemia, tissue glycogen levels were higher in the insulin treated hearts, but overall 
breakdown of glycogen was not greatly increased compared to glucose control hearts (16.4 µmol vs 
14.9 µmol). However, the percentage breakdown was less in the insulin treated hearts (76.5 vs 91.6%) 
despite a significant increase in pre-ischaemic glycogen, which may be attributed to the inhibitory 
effect of insulin on glycogenolysis. Tissue lactate accumulation after 30 min ischaemia was 
significantly increased in the insulin treated hearts, which could be accounted for by the increased 
glycogen breakdown as well as increased utilisation of residual glucose in the tissue. There was also a 
significant increase in tissue G6P and fructose 6-phosphate (F6P), as well as in most of the other 
glycolytic metabolites. 
There was a significant reduction in glycogen utilisation in all preconditioned hearts compared to 
controls, presumably because of reduced initial glycogen levels. Tissue levels of glycogen in the 
glucose and acetate preconditioned hearts after 15 and 30 min ischaemia were similar to controls. 
Only in the insulin treated hearts was there a significant difference in tissue glycogen between control 
and preconditioned hearts after 15 min ischaemia. There was therefore a low rate of glycogen 
utilisation in the insulin preconditioned hearts, slightly less than in the glucose preconditioned hearts 
(6.5 vs 6.7 µmol/15 min - 41.8 vs 59.5%) despite an increased tissue glycogen. By the end of 
ischaemia, glycogen levels in control and preconditioned insulin hearts were similar. However, 
percentage utilisation of glycogen was still less in the insulin preconditioned as opposed to glucose 
preconditioned hearts (67.5 vs 84.3%). 
When glycogen utilisation over 30 min ischaemia was plotted against TOC (Figure 9), a linear 
relationship was observed for control hearts, indicating that tissue glycogen availability may be one 
on the major determinants of the TOC. Peak contracture was also related to tissue glycogen, with 
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increasing peak correlated to reduced glycogen. When TOC was plotted against glycogen utilisation 
for preconditioned hearts, a less convincing linear relationship was found, given that glycogen 
utilisation in glucose and insulin and hearts was similar. A similar TOC was also found in these two 
groups. However, this slope was almost exactly parallel to the slope in non-preconditioned hearts, but 
shifted to the left. Thus in preconditioned hearts, a reduced time to onset would occur compared to 
control hearts, despite similar degrees of glycogen utilisation. 
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DISCUSSION 
Previous studies have attributed improved functional recovery with a number of different protocols to 
a pre-ischaemic glycogen depletion limiting proton accumulation. While we did not measure changes 
in pHi, the model of glycogen depletion in this study was not beneficial to the heart subjected to 30 
min total global ischaemia. Reduced tissue glycogen was associated with significantly reduced TOC, 
greatly increased peak contracture, and a poor recovery of function. Glycogen therefore appeared to 
be necessary to inhibit contracture during ischaemia. On reperfusion, however, the status of the hearts 
in terms of ATP and metabolite accumulation, determined functional recovery. 
Preconditioning with one cycle of 5 min ischaemia + 5 min reperfusion, which also depleted pre-
ischaemic glycogen, was protective in glucose-perfused rat hearts with increased functional recovery, 
despite increased contracture. This is similar to other reports 18, 66. Preconditioning was ineffective 
when the hearts were metabolically stressed, but its protective effects were not related to a depletion 
of glycogen. The effects on ischaemia and on reperfusion, of glycogen manipulation, and of 
preconditioning, were dissociated. 
GLYCOGEN AND GLYCOLYSIS IN ISCHAEMIA 
The role of glycogen in ischaemia is very controversial, with glycogen either reported to be 
deleterious to the heart 3, 278, 387, or beneficial 163, 348, 487, 551. We have attempted to resolve 
the debate, with an intermediate view - that glycogen depletion is detrimental by reducing substrate 
availability for ATP production, but that glycogen loading does not necessarily convey additional 
protection because of undue metabolite accumulation. There was a marked accumulation of end 
products in the insulin-treated hearts, possibly responsible for the deleterious effects. Manipulation of 
glycogen levels appears to be unnecessary. We can compare acetate control with glucose 
preconditioned hearts, as well as insulin preconditioned and glucose control hearts, on the basis of 
equivalent glycogen contents prior to sustained ischaemia. 
GLYCOGEN DEPLETION - REDUCED TOLERANCE TO ISCHAEMIA 
Glycogen can be depleted by a brief period of anoxia 163, 286, 387, epinephrine infusion 348, long 
term perfusion with pyruvate 278, and substrate free perfusion 189, 253, 286, each of which may 
modify heart function. After 30 min perfusion with acetate as the sole substrate, glycogen levels were 
reduced by 35%. A similar level of ATP was found compared to glucose hearts, but CP was 
significantly increased, as were citrate levels. Heart function was slightly better than control glucose 
perfused hearts (see Table 1). However, when subjected to ischaemia, there was a rapid onset of 
contracture, and a large peak contracture (Table 2) in these hearts. This may be attributed to inhibition 
of glycolysis, which has been shown to be essential in delaying contracture 424. Glycogen depletion 
was in no way beneficial to the heart, contrary to the studies of Neely and Grotyohann 387, and others 
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3, 278, despite a significant reduction in tissue lactate. A more recent study comparing the effects of 
glycogen depletion with preconditioning have shown a similar reduction in pH by both interventions, 
but glycogen depletion by itself was not effective in protecting against ischaemic injury 482. 
Acetate control and glucose preconditioned hearts could be compared on the basis of similar glycogen 
levels prior to the sustained ischaemic episode, a similar CP overshoot, as well as an increase in 
citrate levels, although glycolytic metabolites were significantly lower in the acetate hearts. Both 
groups showed a significant reduction in TOC, and an increase in peak contracture, although these 
parameters were much more severe in the acetate hearts. On reperfusion however, there was a 
significant diversion between the two groups, with a good recovery in the preconditioned glucose 
hearts and very poor recovery in the control acetate hearts. 
Preconditioning acetate hearts, however, did not lead to an improvement in functional recovery 
despite the presumed induction of the preconditioning mechanism. These hearts underwent an even 
more rapid contracture, and the peak reached was even greater than in acetate control hearts. The 
glycogen levels in these hearts prior to sustained ischaemia were very low. While glycogen depletion 
does not appear to be the mechanism whereby preconditioning exerts its protective effect, glycogen 
was required to ensure continued ATP production, to inhibit the development of severe contracture, 
which impaired functional recovery. 
GLYCOGEN LOADED HEARTS - DELETERIOUS ACCUMULATION OF METABOLITES 
Hearts perfused with glucose and insulin to increase glycogen were more tolerant to ischaemia than 
glucose hearts, as shown by a significant delay in TOC and a reduced peak contracture. Recovery of 
function was not, however, improved in these hearts. Preconditioning insulin hearts hastened TOC but 
peak contracture was further reduced. The slight improvement in recovery of function due to reduced 
diastolic pressure was indicative of some protection against irreversible injury. The large increase in 
G6P and F6P levels in the control insulin hearts was slightly reduced by preconditioning. 
An accumulation of sugar phosphates in hypoxia has been implicated in intracellular Ca2+ overload 
282, which may account for some of the deleterious effects of insulin pre-treatment, especially on 
reperfusion. An accumulation of phosphomonoesters, which includes G6P, glucose I-phosphate, a-
glycerophosphate, and other phosphate compounds, has been linked to increased ischaemic injury, 
reflected by CK release 219, 482. In addition, there was an increase in lactate which was not greatly 
reduced by preconditioning in the glycogen loaded hearts. This may be linked to a greater fall in pHi, 
a well known consequence of increased glycogen 151. Preconditioning with one episode was not 
sufficient to overcome the effects of increased metabolites following glycogen load. 
Glycogen-loaded hearts with preconditioning had similar glycogen levels to glucose control hearts 
prior to sustained ischaemia, although no similarities in the response to sustained ischaemia were 
observed. TOC was significantly lower in the preconditioned insulin hearts, although peak contracture 
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was reduced. Recoveries of developed pressure were equally poor, although the preconditioned 
insulin hearts did show a reduced diastolic dysfunction. Further episodes of preconditioning prior to 
sustained ischaemia may have shown a beneficial effect, with a more reduced glycogen and less 
metabolite accumulation, although our other results dissociate a reduced glycogen from the beneficial 
effects of preconditioning 
PRECONDITIONING, ISCHAEMIC CONTRACTURE AND FUNCTIONAL RECOVERY 
Time to onset of iscbaemic contracture 
The reduced TOC in preconditioned hearts could be attributed partially to reduced glycogen. The 
relationship between glycogen utilisation and TOC held true in both control and preconditioned hearts 
(Figure 9), although the curve was shifted to the left in preconditioned hearts. TOC is also determined 
by ATP and intracellular Ca2+ accumulation 189, 511, 558. Preconditioned hearts have been shown to 
have a reduced Ca2+ and proton accumulation 512, which would be expected to result in reduced 
contracture. However, preconditioned hearts generally have a lower ATP level because of the 
depletion by the preconditioning ischaemic episodes. A recent paper by Kolocassides et al. 266 shows 
a temporal relationship between ATP depletion and contracture, with reduced ATP and increased 
contracture in preconditioned hearts. However, by 15 and 30 min ischaemia (equivalent to the times in 
the present study) there was no difference in ATP levels. The initial 10-15 min appear to be crucial in 
determining the onset and peak of contracture. 
We did not find a reduced tissue ATP in preconditioned hearts prior to sustained ischaemia, contrary 
to other studies 266, 378, 512. A previous study, however, also found that one episode of 5 min 
preconditioning does not reduce ATP levels 18. This finding may be attributed to the use of a single 
ischaemic episode, and to the model involved. The fact that preconditioning was obtained in both this 
and the present study suggests that a pre-ischaemic reduction in ATP is not involved in 
preconditioning. A recent paper by Kolocassides et al. 266 also dissociates the reduction in ATP from 
the effect of preconditioning. The issue of reduced TOC in our study despite no reduction in ATP may 
be partially resolved by examining the role of glycolytic ATP in determining time to onset and peak 
contracture. Owen et al. 424 correlated onset of contracture (in a low-flow model) with reduced ATP 
production from glucose. In the present study, where flow was absent, the sole substrate was glycogen 
(with some residual glucose in the glucose perfused groups). With reduced glycogen levels, rates of 
glycolytic ATP production were decreased, with reduced TOC. Other factors that may be involved 
include inorganic phosphate and intracellular pH, which would in turn differ depending on initial 
glycogen levels. 
194 Results Ch 4. Preconditioning and glycogen 
Peak contracture 
In our hands, preconditioning did not significantly increase peak contracture compared to control 
glucose hearts, although the values were higher. This differs from other reports where a large increase 
in contracture in preconditioned hearts was observed 18, 66. This may be due to the preconditioning 
protocol, where the more periods of preconditioning used the greater the degree of contracture in the 
sustained ischaemic episode 18. 
The role of contracture as either an index or a mediator of ischaemic injury is still controversial. 
V anoverschelde et al. 5 51 suggest that myocardial energy metabolism ( specifically maintenance of 
glycolysis) is more important than ischaemic contracture as a determinant of survival. However, in 
their study, peak contracture was only about 48 mmHg (about 50% of pre-ischaemic developed 
pressure) and did not decrease after reaching peak i.e. the actin-myosin bonds did not break, with 
subsequent rupture of cells. If contracture were more severe, as in the case of the acetate hearts in the 
present study (from 90-120% peak contracture ), a significant fall-off in tension after peak contracture 
was seen (see Figure 4a). This relaxation in tension may indicate cell rupture, due to disruption of the 
myofibrils following extended stretch, leading to cell death and irreversible injury 181. The heart 
appears to tolerate a degree of contracture, especially if protected by some mechanism e.g. the 
effector of preconditioning. Preconditioning did not exacerbate contracture greatly in the glucose 
hearts or the insulin hearts, and contracture therefore did not modify functional recovery. However, 
contracture was greatly exacerbated by preconditioning in the acetate hearts, which had poor 
recoveries. 
Functional recovery 
Despite a presumed increase in ischaemic injury shown by the reduced time to onset and increased 
peak contracture, recovery of developed pressure in the preconditioned glucose hearts was 
substantially improved compared to control hearts. This discrepancy between the effects on 
contracture and recovery is unclear. Generally it has been argued that an increase in contracture, with 
a reduced time to onset, is detrimental to the heart 189, and has been used as a predictor of functional 
recovery. However, this correlation is disrupted by preconditioning 18, 66. The effects of 
preconditioning on ischaemia and on reperfusion should therefore be dissociated. 
Preconditioning is thought to protect against the development of irreversible injury 338. Improved 
functional recovery conferred by preconditioning was recorded mainly as a result of reduced diastolic 
dysfunction, an index of the extent of rigor development or irreversible injury. A recent report by 
Jenkins et al. fmds that preconditioning improves functional recovery in an isolated rabbit heart by 
reducing infarct size, and not by a reduction in stunning 220. Our fmdings support this concept, in that 
preconditioning reduced diastolic pressure in glucose and glucose-insulin hearts. 30 minutes of global 
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ischaemia ensures a component of reversibly (stunned) as well as irreversibly injured (infarcted) 
tissue. There was still a large component of irreversible injury (about 45-50%) which could not be 
limited by preconditioning. 
When glycolysis was inhibited (acetate hearts) preconditioning did not improve functional recovery, · 
indicating the requirement for glycolytic ATP. However, when glycolysis was increased by glycogen 
loading, slight detrimental effects were also noted in that, despite an improvement in diastolic 
function, systolic function was impaired, presumably because of increased metabolite accumulation. 
Different factors appear to determine contracture as opposed to functional recovery i.e. ischaemic vs. 
reperfusion injury. Preconditioning is generally thought to delay the onset of necrosis, with improved 
recovery on reperfusion 61. Contracture predisposes to necrosis, by cell rupture, and preconditioning 
may protect against this effect. However, contracture is generally not advantageous. There must be a 
critical balance between the deleterious effects of preconditioning i.e. energy depletion at the onset of 
ischaemia and increased contracture, versus the protective effects on reperfusion function. These 
mechanisms may well be distinct from one another. 
INHIBITION OF GLYCOLYSIS, LACTATE ACCUMULATION AND PRECONDITIONING 
Neely and Grotyohann 387 proposed that a reduction in glycogen was beneficial because of reduced 
lactate accumulation. No reduction in lactate accumulation with one episode of preconditioning was 
found in the present study, despite a significant reduction in glycogen. Lagerstrom et al. 286 also 
reported no reduction in ischaemic lactate accumulation following a 60% glycogen depletion by 
anoxia. We could find no correlation between lactate accumulation and functional recovery, except 
that glycogen loaded hearts did not respond well to preconditioning. A reduction in lactate by 
glycogen depletion was not beneficial. 
Goodwin and Taegtmeyer 163, could not replicate the results of Neely, with a short period (15 min) of 
sustained ischaemia. Similarly, no benefit of glycogen depletion by acetate was apparent with 30 min 
ischaemia. The Neely .paper used a period of anoxia before a sustained period of ischaemia. More 
recent use of similar protocols has been termed hypoxic preconditioning 290, 498. The benefits 
associated with glycogen depletion in previous studies may therefore be attributed to the 
"preconditioning" effect of a brief hypoxic period, which may stimulate a number of possible 
protective mechanisms e.g. protein kinase C translocation 601 and is dissociated from glycogen 
depletion. A more recent paper from Downey's group 166 found that a transient inhibition of glucose 
uptake by introduction of 1 mM acetate to glucose-containing perfusate for 15 min 30 min prior to 
sustained ischaemia reduced infarct size, similar to the effect of preconditioning. This was 
hypothesised to be due to translocation of PKC. The protocol was different from the present study, 
where a longer duration of acetate perfusion with acetate as sole substrate was used, with a higher 
concentration of acetate. The results of this paper 166, while interesting, offer no metabolic data to 
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substantiate their claims of reduced glucose uptake, while glycogen levels were not mentioned. In our 
studies, where glycogen was severely depleted by long term acetate perfusion, preconditioning was 
not effective in terms of improved functional recovery. 
Finegan et al. 136 report that preconditioned hearts have reduced glycolysis on reperfusion, and 
therefore reduced proton accumulation, which will in turn reduce Ca2+ overload on reperfusion. In 
addition, they report similar findings to the present report, that a reduced glycogen breakdown is 
found during ischaemia with preconditioning. However, the results of the present study suggest that 
the role of glycogen utilisation during ischaemia is not involved in the protective effect of 
preconditioning. 
RESERVATIONS 
Validity of preconditioning protocol with one cycle of ischaemia and reperfusion 
The results of the present study, together with a number of others 447, 577 indicate that 
preconditioning is not always effective. One possible reason is the metabolic status of the subject. A 
similar observation was made by Sargent et al. 480 who noted a requirement for increased ischaemia 
to precondition hearts perfused with pyruvate. We did not investigate the effect of increased episodes 
of ischaemia. While more episodes of ischaemia may have resulted in greater protection, the study by 
Asimakis et al. 18 showed that 2 episodes of preconditioning exacerbated contracture more than did 
one episode, and had no additional effect on functional recovery. Cave and Apstein 62 also recorded 
no significant benefit of increased episodes (3 vs 1 ). Because of the rapid onset of contracture in the 
acetate hearts with one episode of preconditioning, we did not wish to increase the number of cycles. 
In addition, if the protective effect could not be observed with one cycle when the metabolic status 
was altered, we questioned the validity of increasing the number of cycles, in terms of our hypothesis, 
that glycogen reduction is not involved in preconditioning. The findings of this study raise concerns 
as to the widespread applicability of preconditioning, and the fact that it may be deleterious by 
increasing contracture. 
Functional recovery vs infarct size 
In the present study, we only measured functional recovery as the index of protection. The majority of 
preconditioning studies using the rat heart have used this as the index, as have most isolated heart 
studies. While preconditioning has been shown to be most effective against infarct development 3 7 5, 
functional recovery can be regarded as the critical end point in short term experiments 61. A reduction 
in infarct size without good functional recovery is of limited value in a short term experiment. The 
inability of preconditioning to improve functional recovery under conditions of metabolic stress 
shows a limitation of preconditioning. While infarct size may have been reduced in these hearts, this 
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is not important given the inability of the heart to pump efficiently. A longer reperfusion would 
possibly indicate the benefits of reduced infarct size on functional recovery in preconditioned hearts; 
however, with the in vivo dog and pig heart, there have been, to our knowledge, no reports of 
improved functional recovery with ischaemic preconditioning, despite reduced infarct size. Our 
primary interest was whether a depletion of glycogen by preconditioning was beneficial. With an 
equivalent reduction in glycogen by acetate perfusion, we found no improvement in recovery of 
function, the index used in other glycogen studies. 
IN CONCLUSION 
A pre-ischaemic reduction in glycogen was detrimental to the myocardium. The protective effect of 
preconditioning could not be linked to glycogen depletion. A moderate level of glycogen is required 
by the hearts either with or without preconditioning, to allow maintained ATP production in the 
absence of any other exogenous substrate. The reduced TOC in preconditioned hearts could be 
attributed at least in part to the reduction in tissue glycogen. Glycogen-loaded hearts did not recover 
better than glucose hearts subjected to long term ischaemia, nor do they respond well to 
preconditioning, possibly due to sugar phosphate accumulation. These findings are supported by 
Finegan et al. 136 who also suggest that an "optimal" glycogen level is required. The effects of 
preconditioning on ischaemic injury and on reperfusion injury must be dissociated. 
Preconditioning depletes pre-ischaemic glycogen, but this is not related to the beneficial effect of 
preconditioning. Maintaining a low residual flow is protective to the heart compared to total global 
ischaemia, acting partially by providing glucose. Thus preconditioning and low flow ischaemia with 
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Fig 2: Systolic and diastolic pressure throughout the experiments for control and preconditioned hearts with 
glucose 11 mM Ischaemic contracture was hastened with a slight increase in peak. Systolic-diastolic pressure 
gave developed pressure which was significantly increased in preconditioned hearts on reperfasion, mainly due 
to reduced diastolic pressure. 
Control - filled symbols. Preconditioned - open symbols. 
* p<O. 05 control vs preconditioned 
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Fig 3a: Glycogen levels prior to sustained ischaemia with different pre-ischaemic substrates, with and without 
preconditioning. Lines show significant differences (p<0.01) between groups. * p<0.05 between control and 
preconditioned hearts. Filled bars -control. Open bars - preconditioned 
Fig 3b: Changes in tissue glycogen during ischaemia and reperfusion with different pre-ischaemic substrates, 
and control vs preconditioned hearts. Control - filled symbols, Preconditioned - open symbols. Glucose -
squares, Acetate - circles, Glucose+insulin - triangles 
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Fug4b 
Fig 4: Changes in diastolic pressure during ischaemia and reperfusion with acetate perfusion (Fig 4a) and 
insulin pre-treatment (Fig 4b), in control and preconditioned hearts. Changes in diastolic pressure for glucose 
control and preconditioned hearts are shown for comparison. Control - filled symbols, Preconditioned - open 
symbols. Glucose - squares, Acetate - circles, Glucose+insulin - triangles 
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Fig 5: Tissue adenosine triphosphate (ATP) (Fig 5a) and creatine phosphate (CP) (Fig 5b) levels prior to and 
during sustained ischaemia and reperfusion with changes in pre-ischaemic substrate, with an without 
preconditioning. Control - ft/led symbols, Preconditioned - open symbols. Glucose - squares, Acetate - circles, 
Glucose+insu/in - triangles 
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Fig 6: Changes in tissue glucose 6-phosphate (G6P) prior to and during ischaemia and reperfusion with 
changes in pre-ischaemic substrate, and in control and preconditioned hearts. Control - filled symbols, 
Preconditioned - open symbols. Glucose - squares, Acetate - circles, Glucose+insulin - triangles 
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Fig 7: Changes in tissue lactate prior to and during ischaemia and reperfusion with changes in pre-ischaemic 
substrate, and in control and preconditioned hearts. Control - filled symbols, Preconditioned - open symbols. 
Glucose - squares, Acetate - circles, Glucose+insulin - triangles 
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Fig 8: Changes in tissue levels of inorganic phosphate (Pi) prior to and during ischaemia and reperfusion with 
changes in pre-ischaemic substrate, and in control and preconditioned hearts. Control - filled symbols, 
Preconditioned - open symbols. Glucose - squares, Acetate - circles, Glucose+insulin - triangles 
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Fig 9: Correlation between time to onset of contracture and glycogen utilisation over 30 min ischaemia in 
control and preconditioned hearts. There was a linear relationship in both groups, showing a dependency of 
time to onset of contracture on glycogen availability. This curve was shifted to the left in preconditioned hearts, 
indicating a reduced time to onset at equivalent rates of glycogen utilisation. -
Control - filled symbols. y = 1.55x - 11.41 R= 0.99; P=0.01 












































































































































































































































































































































































































































































































































































































































































































































































































































































































Results 5. Dissociation between effects of preconditioning on glycolysis and 
functional recovery in low flow ischaemia 
Submitted Am J Physiol 1996 
ABSTRACT 
A current hypothesis is that preconditioning (PC) is protective by decreasing glycolysis during 
sustained ischaemia, thereby lessening metabolite accumulation. To test this hypothesis, pre-
ischaemic glycogen levels and glucose uptake (GU) during low flow (0.2 ml/g wet wt/min with 11 
mM glucose) ischaemia were altered in isolated rat hearts by perfusion with glucose 11 mM (G), 
acetate 5 mM (A) or G + insulin (G+I). PC hearts in each group were subjected to 5 min ischaemia + 
5 min reperfusion before ischaemia. Ischaemic contracture and postischaemic recovery were 
measured on reperfusion with 11 mM G. Glycogen utilisation was reduced in G PC hearts, but overall 
metabolite accumulation was greater because ischaemic GU increased from 0.52 ± 0.08 to 0.83 ± 0.05 
µmol/g/min by PC (p<0.01). However, functional recovery was not improved. If glycogen were 
reduced by A perfusion, contracture was exacerbated, with no improvement in recovery. If A hearts 
were preconditioned, glycogen levels were further depleted, and GU was inhibited. However, 
contracture was worse, as was functional recovery. Increased glycogen and GU with G+I perfusion 
also did not alter functional recovery in control or PC hearts, although contracture was reduced. Thus 
in low flow ischaemia, decreased glycolytic rates could not be related to any beneficial effects; and 
glycolytic flux was dissociated from PC. 
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INTRODUCTION 
Preconditioning, with one or more brief episodes of ischaemia and reperfusion, reduces infarct size 
and arrhythmias 319, 504, and improves functional recovery 18, 66, 290 of rat hearts exposed to 
subsequent sustained ischaemia. Preconditioning depletes tissue glycogen levels, and reduces tissue 
lactate, proton, glucose 6-phosphate (G6P) and a-glycerophosphate (aGP) accumulation during 
ischaemia 18, 224, while high energy phosphate levels are better maintained 224. Preconditioning has 
also been shown to inhibit glycolysis in rat hearts during subsequent aerobic perfusion, and on 
reperfusion after sustained total global ischaemia 136. From these observations, it has been suggested 
that preconditioning is beneficial because of reduced energy demand, and reduced glycolytic 
catabolite accumulation 224. Thus by implication, reduced glycolysis is beneficial to the ischaemic 
myocardium 387. 
In contrast, a residual coronary flow with enhanced glycolytic flux is beneficial to the globally 
ischaemic myocardium, with reduced contracture and improved functional recovery 14, 123 (Results 
Ch 1 ). Preconditioning together with maintained residual coronary flow during sustained ischaemia 
should therefore be additionally beneficial. However the effect of preconditioning on low flow 
ischaemia has not been fully elucidated. In one report of preconditioning followed by sustained low 
flow ischaemia in rabbit hearts, Janier et al. reported increased glycolytic flux during the sustained 
ischaemic period associated with improved functional recovery 218. This finding is contrary to 
accepted concepts of glycolytic inhibition by preconditioning 136,224. 
We have dissociated the effects of glycogen depletion from the effects of preconditioning prior to 
sustained total global ischaemia (Results Ch 4). The aim of the present study was to confirm the 
changes in glycolysis in hearts preconditioned prior to sustained low flow ischaemia, as reported 
previously 218, and to determine the effect of modifications in glycolysis on preconditioning, thereby 
attempting to establish clearly whether there is any relationship between glycolysis and 
preconditioning. 
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METHODS 
PERFUSION APPARATUS 
The isolated Langendorff-perfused rat model with a left ventricular balloon was used, as described in 
Methods. 
PROTOCOL 
9-10 hearts were used in each group. The standard protocol was a 30 min period of perfusion, 
followed by 30 min ischaemia, and 20 min reperfusion (see Fig. 1). In the 30 min period before 
sustained ischaemia, hearts were perfused with the standard glucose-containing solution ( at a 
concentration of 11 mM) either for the entire 30 min, or were subjected to preconditioning of 5 min 
total global ischaemia followed by 5 min reperfusion after 20 min. All hearts were then subjected to 
30 min global ischaemia, with a residual flow of 0.2 ml/g wet wt/min, following which reperfusion 
was maintained for 20 min. 
In the second set of experiments, hearts were perfused prior to the sustained episode of ischaemia 
with either 5 mM acetate instead of glucose, or with 11 mM glucose + 1 U/1 insulin (Humulin) prior to 
the sustained ischaemic episode. The NaCl concentration was reduced by 5 mM to allow for the 
addition of 5 mM Na-acetate. Control and preconditioned hearts were then subjected to 30 min low 
flow ischaemia (0.2 ml/g wet wt/min), with glucose 11 mM during ischaemia and for 20 min 
reperfusion. 
Parallel groups of hearts were perfused as above for each group, with hearts clamped before 
ischaemia, after 30 min ischaemia, and at the end of the reperfusion period, using Wollenberger tongs 
kept in liquid nitrogen. 6 hearts were used in'each group at each time point. These hearts were freeze 
dried for later biochemical analysis. 
In addition samples of coronary effluent were collected over each 5 min period of low flow ischaemia. 
These samples were analysed for glucose uptake and lactate washout. 
F'UNCTIONAL MEASUREMENTS 
Indices of contracture and functional recovery were recorded as described in Methods. 
BIOCHEMICAL MEASUREMENTS 
The freeze dried samples were extracted using perchloric acid. Levels of tissue metabolites, including 
high energy phosphates and glycolytic intermediates, were determined using spectrophotometric 
assays adapted for use on a centrifugal analyser (Cobas Fara, Roche Diagnostics, Switzerland) as 
descrbed in Methods. Effluent glucose and lactate were also measured using these methods. Glycogen 
levels were determined by measuring the glucose content of samples following alcohol extraction. All 
tissue metabolites were expressed as µmol/g wet wt, where wet weight= 5x dry weight. Washout 
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values were expressed as J..!.IllOl carbon-6 units (C6) /g wet wt/min, corrected for coronary flow, and an 
assumed wet heart weight of 1 g (previously determined), to allow comparison between glucose 
uptake and lactate washout values. % glucose extraction was determined by the relationship: 
%.glucose extraction= (glucose uptake/delivery)* 100 
where delivery = glucose concentration * coronary flow (Results Ch 1 ). 
Glycogen was expressed as µmol glucose (C6) units/g wet wt. 
STATISTICS 
The Anova two-way analysis of variance was used to determine significance among groups, after 
which the modified t-test with the Bonferroni correction was used for comparison between individual 
groups. A value of p<0.05 was used as the level of significance. 
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RESULTS 
GLUCOSE PERFUSED HEARTS WITH LOW FLOWISCHAEMIA 
Control - when control glucose hearts were subjected to a low residual flow of 0.2 ml/g wet wt/min 
(less than 2% of normal in vitro flow rates, about 3-7% of in vivo flow rats), onset of ischaemic 
contracture occurred after 12.0 ± 1.0 min, with a peak contracture of 37.0 ± 6.6 % (Table 1). 
Recovery of developed pressure was .55.1 ± 8.6 % (Table 1). There was a small reduction in systolic 
pressure compared to control levels, but the main determinant of functional recovery was diastolic 
pressure (Fig. 2). 
Glycogen breakdown during ischaemia was approximately 10 µmol C6/g wet wt/30 min. Glucose 
uptake increased during ischaemia to a plateau of 0.59 ± 0.11 µmol/g wet wt/min by 10-15 min (27.0 
± 5.2 % extraction of delivered glucose) (Fig. 3). Mean glucose uptake over 30 min ischaemia was 
0.52 ± 0.08 µmol/g wet wt/min, with a mean extraction of 25.45 ± 6.27 %. Mean lactate washout was 
0.85± 0.09 µmol/g wet wt/min, which equates to 0.42 ± 0.04 µmol C6 units/g wet wt/min (Fig. 3). The 
lactate washout was less than could be accounted for by glucose uptake. There was, however, a 
substantial tissue lactate accumulation (Table 2),and an accumulation of glycolytic metabolites by the 
end of ischaemia (Table 2) which accounted for the uptake of glucose and the breakdown of glycogen. 
The contribution of oxidative phosphorylation in low flow would also reduce lactate production (this 
can account for about 2-3 µmol glucose/g wet wt/30 min low flow ischaemia (Results Ch 1)). 
Preconditioned - when glucose preconditioned hearts were subjected to 30 min low flow ischaemia, 
no difference in time to onset of contracture or in peak contracture versus control hearts was seen 
(Fig. 2; Table 1). Recovery of coronary flow, diastolic or developed pressure was not affected by 
preconditioning (Table 1; Fig. 2). 
Glucose uptake was significantly increased in preconditioned hearts throughout sustained ischaemia 
compared to control hearts (mean 0.83 ± 0.05 vs. 0.52 ± 0.08 µmol/g wet wt/min; p<0.01 vs. control; 
Fig. 3), with an extraction of 37.9 ± 1.97 % vs. 25.45 ± 6.27 % (p<0.01). Lactate washout was not, 
however, different between the two groups, although preconditioned hearts had the higher value 
(mean 0.47 ± 0.03 vs. 0.42 ± 0.04 µmol C6/g wet wt/min; Fig. 3). Tissue lactate at the end of 
ischaemia was higher in preconditioned hearts than in control hearts (Table 2). A significant reduction 
in pre-ischaemic glycogen levels was found with preconditioning, from 16.27 ± 0.44 to 11.19 ± 1.05 
(p<0.05; Table 2). After 30 min ischaemia, however, total tissue levels of glycogen were similar 
between control and preconditioned hearts (Table 2). There was a difference in the amount of 
glycogen utilised, with approximately 6.3 µmol C6/30 min vs. 10.0 µmoll C6/30 min in the 
preconditioned versus control hearts. The lowered glycogen utilisation therefore reduced the total 
lactate production despite the increased glucose uptake, although lactate was still higher in 
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preconditioned hearts. Increases in both G6P and aGP were found in preconditioned hearts compared 
to controls (Table 2), although these were not significant. 
End ischaemic ATP and CP in preconditioned hearts were significantly lower than in control hearts 
(Table 3). After 20 min reperfusion, high energy phosphate levels tended to be higher in the 
preconditioned hearts but this was not significant (Table 3). 
INSULIN-TREATED HEARTS AND LOW FLOW ISCHAEMIA 
Control - insulin pre-treated hearts showed no difference in pre-ischaemic function compared to 
glucose hearts (Table 1). When insulin hearts were made ischaemic with a residual low flow, no 
significant difference in time to onset of contracture was observed compared to glucose hearts, 
although peak contracture was reduced (Table l; Fig. 4). Functional recovery was no different (Table 
1). Pre-ischaemic glycogen was significantly increased by insulin pre-treatment (Table 2), and levels 
were higher at the end of ischaemia compared to control hearts. Total glycogen breakdown was the 
same in glucose and insulin hearts (9.53 vs. 10 µmol C6/g wet wt/30 min). Glucose uptake (Fig. 5) 
was significantly increased compared to glucose perfused hearts (mean 0.86 ± 0.11 vs. 0.52 ± 0.08 
µmol/g wet wt/min; p<0.05 - 38.97 ± 2.38 % and 23.56 ± 1.85 % extraction). No differences in high 
energy phosphates at the end of ischaemia were observed (Table 3). 
Lactate washout was higher throughout ischaemia in the insulin treated hearts due to increased 
glucose uptake (Fig. 5), as was total tissue lactate at the end of ischaemia (Table 2). G6P and aGP 
accumulation was significantly greater in the insulin-perfused hearts by the end of ischaemia (Table 
2). Insulin and sustained glucose utilisation with low flow suppressed glycogen breakdown, although 
total glycolytic flux was increased due to increased glucose uptake. 
Preconditioned - when glycogen-loaded hearts were preconditioned, and subjected to low flow 
ischaemia, time to onset of contracture was slightly reduced compared to control insulin low flow 
hearts, but peak contracture was further reduced (Fig. 4; Table 1). Recovery was slightly less in 
preconditioned hearts but this was not significant (Table 1). While a small reduction in diastolic 
pressure was seen with preconditioning (Fig. 4; Table 1), recovery of systolic pressure was poor, 
resulting in the reduced developed pressure (Table 1 ). 
At the end of ischaemia, glycogen levels were similar in control and preconditioned low flow hearts 
despite an initial difference (Table 2). These levels were substantially higher than those seen in 
glucose perfused hearts (Table 2). By the end of ischaemia, approximately 6 µmol glycogen had been 
utilised in preconditioned hearts, compared to 9.5 µmol in control insulin hearts and 6 µmol in 
glucose preconditioned hearts. 
Glucose uptake was not increased in insulin-treated hearts by preconditioning compared to controls 
(mean 0.77 ± 0.12 µmol/g wet wt/min; Fig. 5), and the rates were similar to the values measured in 
glucose preconditioned low flow hearts (Fig. 3). Lactate washout during ischaemia was also no 
different between control and preconditioned insulin hearts (Fig. 5) while end-ischaemic tissue lactate 
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was the same in both groups (Table 2). Preconditioning and low flow also reduced G6P and aGP 
accumulation in the tissue (Table 2), with a lower overall glycolytic metabolite accumulation (data 
not shown) compared to control glucose + insulin hearts, due to reduced glycogen breakdown. 
There was no reduction in ATP levels prior to ischaemia following preconditioning, although CP was 
increased (Table 3). End ischaemic ATP in preconditioned hearts was slightly less than in control 
insulin hearts (Table 3). Reperfusion elicited no differences in recovery of high energy phosphate 
between control and preconditioned insulin hearts (Table 3). 
ACETATE PREPERFUSED HEARTS WITH LOW FLOW ISCHAEMIA 
Control- acetate perfusion did not affect pre-ischaemic function (Table 1). During low flow 
ischaemia, the acetate pre-perfused hearts showed a reduced time to onset of contracture and an 
increased peak contracture compared to glucose hearts (Table l; Fig. 4). Recovery of function was 
reduced, although this was not significant due to the large variability (Table 1 ). 
When acetate hearts were switched to low flow ischaemia with glucose there was a large initial uptake 
of glucose, reaching 84% extraction in the first 5 min (Fig. 5). Mean glucose uptake was therefore 
1.11 ± 0.10 µmol/g wet wt/min. However, this value was probably largely artefactual, given that the 
tissue was glucose-free which would dilute the effluent, and the low glucose content of the tissue 
would lead to a large uptake down the concentration gradient. After 30 min ischaemia, however, 
glucose uptake was still quite high (0.77 ± 0.14 µmol/g wet wt/min- 35.22 ± 6.31% extraction; Fig. 
5), comparable to that in glucose hearts. The reduced glycogen and G6P (Table 2) content may have 
stimulated glucose uptake. Lactate washout showed a rise initially (reaching 0.51 ± 0.08 µmol C6/g 
wet wt/min at 5-10 min) but this then decreased to 0.24 ± 0.04 µmol C6/g wet wt/min after 25-30 min 
(Fig. 5), a value half that of glucose low flow hearts (Fig. 3). Tissue lactate accumulation was reduced 
in the acetate hearts (Table 2), with glycogen utilisation over 30 min low flow ischaemia about 7.9 
µmol/g wet wt (Table 2)compared to 10 µmol /g wet wt in glucose hearts. Tissue G6P and aGP levels 
were maintained at levels equivalent to those in glucose hearts, indicating efficient utilisation of 
glucose and glycogen. 
A large CP content prior to sustained ischaemia was found (Table 3), but end-ischaemic high energy 
phosphate levels in the acetate hearts were lower than in glucose hearts (Table 3). Recovery of high 
energy phosphate levels after 20 min reperfusion was no different. 
Preconditioned - when acetate pre-perfused hearts were preconditioned, and then subjected to low 
flow ischaemia, the time to onset of contracture was immediate, and significantly reduced compared 
to control low flow hearts (Table 1; Fig. 4). Peak contracture was high, with a significant increase 
compared to control hearts (Table 1; Fig. 4). Recovery in preconditioned low flow acetate-pre-
perfused hearts was 38.0 ± 9.7%, which no different to that obtained with control acetate hearts 
(Table 1). 
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Glucose uptake in preconditioned acetate hearts was significantly reduced compared to control acetate 
hearts, with a mean washout of 0.82 ± 0.08 µmol/g wet wt/min. At the end of ischaemia, glucose 
uptake was significantly reduced compared to all other groups (0.39 ± 0.09 µmol/g wet wt/min) (Fig. 
5), as was lactate washout (Fig. 5). Tissue lactate was also higher in control hearts at the end of the 
ischaemic period (Table 2). Tissue values of G6P and aGP were reduced by preconditioning in 
acetate hearts (Table 2). Glycogen breakdown in preconditioned acetate hearts was only 4.5 µmol /g 
wet wt/30 min. 
Preconditioned acetate hearts showed an even higher CP level prior to sustained ischaemia than 
control hearts, and a reasonable recovery of CP after 20 min reperfusion, although there was no 
difference in high energy phosphate levels between control and preconditioned hearts during 
ischaemia (Table 3). Pre-ischaemic ATP was not reduced by one episode of preconditioning. 
Results Ch 5. Preconditioning, glycolysis and low flow ischaemia 215 
DISCUSSION 
We aimed to test the hypothesis that decreased rates of glycolysis could explain preconditioning. We 
applied our previously established model of preconditioning with one episode of 5 min total global 
ischaemia + 5 min reperfusion, followed by 30 min sustained total global ischaemia (Results Ch 4), 
which has been shown to be efficacious in a number of studies 18, 66, 603 . In that model, 
preconditioning reduced the time to onset of contracture and increased peak contracture, but 
significantly improved functional recovery following total global ischaemia (Results Ch 4). In the 
present study, when a low residual flow was maintained during the sustained ischaemic period, no 
protective effect of preconditioning on postischaemic function was discerned, despite large changes in 
the rate of glycolysis, one of the mechanisms proposed to explain preconditioning. Thus no 
relationship between preconditioning and changes in glycolytic flux rate could be established. 
CHANGES IN GLYCOLYTIC FLUX INDUCED BY PRECONDITIONING 
We confirm that glucose uptake during low flow ischaemia was increased by preconditioning, as 
reported previously 218. This finding, together with unchanged or increased end ischaemic tissue 
levels of lactate, G6P and aGP (Table 2), challenges previous concepts that glycolysis is inhibited by 
preconditioning 224. Only in total or near total ischaemia may glycolysis be limited in preconditioned 
hearts by the availability of substrate, specifically because of glycogen depletion. In addition, the 
present study somewhat contradicts previous findings that preconditioning inhibits glycolysis during 
aerobic perfusion after an initial preconditioning period, and on reperfusion after sustained total 
global ischaemia .136. Preconditioning thus appears to affect aerobic (normal) and anaerobic 
(ischaemic) glucose utilisation differently, although the mechanism involved is unclear. 
Glucose uptake - possible mechanisms of increased glucose uptake in low flow ischaemia following 
preconditioning include the lowered glycogen levels during ischaemia, and increased activity of 
glucose transporters in the membrane. A reduced glycogen level should result in increased glucose 
uptake, because of the reduced glycolytic substrate 206. In acetate hearts with a low pre-ischaemic 
glycogen, when the hearts were switched to a low flow with glucose present, glucose uptake rates 
were high especially in the first 15-20 min of ischaemia. By the end of ischaemia, glucose uptake was 
equivalent to that in glucose preconditioned hearts (cf. Fig 3 and Fig Sa). Lactate production was low 
in acetate hearts because of reduced glycogen levels (Fig Sb). However, glucose uptake in 
preconditioned acetate hearts was severely reduced after 15 min ischaemia, despite an even lower 
glycogen content at the onset of ischaemia. The reduced glucose uptake may be explained by marked 
ischaemic hypercontracture with compression of the vessels, and increased mechanical failure in these 
hearts. Thus, glycogen depletion can be dissociated from an increased glucose uptake. This finding is 
strengthened by the observations of Depre et al. 111 , who found that increased glucose uptake in 
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dysfunctional but salvageable myocardium ("mismatch") was correlated with increased glycogen in 
the tissue. 
Preconditioning of insulin-treated hearts resulted in no additional stimulation of glucose uptake. 
Possibly, preconditioning . and insulin may act on glucose uptake in a similar fashion. Insulin 
stimulates glucose uptake mainly via increased translocation of the insulin-sensitive glucose 
transporter, GLUT 4, to the membrane, and upregulation of transporters in the membrane 548. 
Increased sarcolemmal GLUT 4 density has also been found in ischaemic tissue 517, together with 
increased glucose extraction 507 (Results Ch 1 ). A speculative hypothesis is that preconditioning 
ischaemia induces GLUT 4 translocation to the sarcolemma, or upregulates function of GLUT 4 
already in the external membranes, such that by the onset of the sustained ischaemic period, the 
transporters would be available to increase glucose uptake. A number of factors modified by the 
preconditioning ischaemic. episode (adenosine, cAMP, cGMP, PKC) may affect glucose transporter 
number and/or activity and thus increase glucose uptake. This proposed mechanism remains to be 
investigated. 
Glycogen - the rate of glycogenolysis appears to be slowed in preconditioned hearts 574. Our results 
confirmed this concept, in that there was no significant difference in tissue levels of glycogen after 30 
min ischaemia between control and preconditioned hearts, despite large pre-ischaemic differences. 
Preconditioned hearts did tend to have lower end ischaemic glycogen levels in each group. Given that 
glucose utilisation is stimulated by preconditioning, the apparent concomitant inhibition of glycogen 
utilisation is difficult to explain. Reduced glycogenolysis may be attributed to a direct attenuation of 
phosphorylase activity following reduction of cAMP levels in preconditioned hearts 4 79 
Alternatively, the structure of glycogen may be relevant. 
After NaOH extraction, we measured total tissue glycogen, which is made up of classic 
"macromolecular glycogen" or macroglycogen (about 107 Da), and proglycogen, a 400 kDa protein-
rich form of glycogen insoluble in acid 322, The residual glycogen at the end of ischaemia may 
consist mainly of core glycogen ( a-1,6 linkages in macroglycogen requiring an additional enzyme 
step for breakdown), or proglycogen, which makes up about 15-50% of total glycogen levels and is 
more resistant to breakdown 10. De Jong et al. 103 reported that proglycogen levels were unchanged 
by intermittent periods of ischaemia, although total glycogen levels were depleted. Thus, differences 
in pro- and macroglycogen levels at the onset of ischaemia may determine the subsequent rates of 
ischaemic glycogenolysis, and the amount of residual glycogen remaining after a period of ischaemia. 
The faster rate of glycogen breakdown found in control hearts compared to preconditioned hearts may 
reflect the rapid breakdown of the macroglycogen 10, 322 which has already occurred in 
preconditioned hearts prior to ischaemia. Insulin-treated hearts showed a slower rate of glycogen 
utilisation (Table 2), which may be attributed to increased proglycogen synthesis with insulin prior to 
ischaemia. In addition, both insulin and glucose appear to retard glycogen breakdown in low flow 
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ischaemia (Table 2) (Results Ch 1). Increased glycogenolysis with acetate or preconditioning could 
reduce pre-ischaemic proglycogen levels, resulting in lower end ischaemic tissue glycogen levels. 
PRECONDITIONING AND CONTRACTURE WITH A LOW RESIDUAL FLOW 
With sustained zero flow ischaemia, contracture is increased in preconditioned hearts compared to 
control hearts, but paradoxically functional recovery is improved 18, 66 (Results Ch 4). A temporal 
correlation between depleted ATP levels and increased contracture has been found in preconditioned 
hearts 266. 
When there is maintained glucose delivery in the presence of a low residual coronary flow, 
contracture is reduced · (Results Ch 1) and there is a better recovery of function in control hearts, 
compared to hearts with zero flow ischaemia (Results Ch 4 ). A low coronary flow also attenuated the 
exacerbation of contracture by preconditioning (Fig 2, Table 1), presumably due to increased glucose 
uptake and glycolysis, and maintained ATP production 424 (Results Ch 1). In acetate hearts, the ATP 
production from glucose was insufficient, resulting in increased contracture, made worse by 
preconditioning which inhibited glucose uptake. Functional recovery tended to be worse in these 
hearts. 
The overall increase in ATP production with insulin present ( calculated from glucose uptake - 2 µmol 
ATP/µmol glucose/min; and see Table 3) reduced contracture in control and preconditioned hearts 
compared to other low flow groups. However, sugar phosphate accumulation has been implicated in a 
loss of Ca2+ homeostasis 282, and may thus exacerbate contracture. In insulin hearts, preconditioning 
lessened contracture, possibly by reducing metabolite accumulation 18, 224, 282 compared to control 
insulin hearts (Table 2), although ATP production was also slightly less (Table 2). The reduced 
contracture was not, however, reflected in a better functional recovery (Table 1 ). Contracture thus 
does not always reflect the degree of ischaemic injury. 
PRECONDITIONING AND FUNCTIONAL RECOVERY AFfER SUSTAINED LOW FLOW ISCHAEMIA 
There was no improvement in functional recovery with preconditioning in any of the groups of low 
flow hearts, contrary to previous findings 218. A significant, albeit small improvement in recovery of 
function (of 14%) was found with preconditioning in rabbits exposed to 60 min low flow ischaemia 
(0.4-0.45 ml/g wet wt/min), together with increased glucose uptake 218. Differences from the present 
study lie in the species and in the perfusion solutions used. 
The increased glucose uptake previously noted with preconditioning, and the benefits associated with 
this effect 218 may have been masked by the use of a perfusate with double the glucose concentration 
(5 mM glucose, with palmitate and 70 mU/1 insulin 218 compared to 11 mM glucose in the present 
study). Of note is that our standard glucose concentration (11 mM) is optimal in ischaemic rat hearts 
with a residual flow of 0.2 ml/g wet wt/min without insulin (Results Ch 1 ), while a higher glucose 
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concentration (22 mM) increases contracture and impairs functional recovery (Results Ch 1 ). In the 
previous study 218, with the lower glucose concentration ( 5 mM), glucose uptake decreased markedly 
during ischaemia despite the presence of insulin, compared to a steady state maintained with a higher 
glucose concentration (11 mM) (see Fig 3). A lower glucose concentration leads to insufficient ATP 
production, increased contracture and poorer functional recovery 424 (Results Ch 1 ). Thus, in the 
present study, glucose hearts may have had optimal glycolytic flux with 11 mM glucose, while with a 
lower glucose concentration, glycolytic flux was less than optimal in control hearts, and the 
stimulation by preconditioning resulted in a higher rate of glycolysis, which was protective. In the 
present study, increased glycolytic flux with preconditioning above the optimal rate may have led to 
an imbalance between excess metabolite accumulation and ATP production, such that recoveries were 
not improved. 
This hypothesis is substantiated by the effects of increased glucose uptake (and tissue glycogen) in the 
presence of insulin, which were detrimental possibly due to excess metabolite accumulation 219,282, 
387 (Table 2), despite the calculated increase in ATP production. Thus insulin treatment did not lead 
to improved recovery of function in the present study. When insulin-treated hearts were 
preconditioned, glucose uptake was not additionally increased nor was functional recovery improved, 
compared to the previous report 218. Insulin-treated hearts in the present study (15-fold increase in 
insulin and double glucose concentration compared to previous 218) may have had maximal 
stimulation of glucose transporters, such that preconditioning would have no additive effect. Janier et 
al. reported an increase in glucose uptake of about 20-25% with preconditioning, compared to a 60% 
increase in the present study, while basal rates were relatively higher. A possible greater lactate and 
sugar phosphate accumulation with a high glucose+ insulin and a lower flow rate (0.2 vs. 0.4-0.45 
ml/g wet wt/min) could also be more deleterious in the present model, partially accounting for the 
discrepancies. 
Confirmation of the findings of the present study come from two previous reports using rat hearts. 
Preconditioning (5 min total global ischaemia + 5 min reperfusion) was ineffective against hypoxia-
induced damage (sustained hypoxia 60-90 min) in terms of functional recovery 66. While it may be 
argued that low flow may increase the threshold of preconditioning, so that "more preconditioning" is 
required to discern an effect, 3 cycles of preconditioning ( 5 min isch + 5 min reperf) did not improve 
recoveries after 90 min low flow ischaemia (0.3 ml/g wet wt/min) in a blood-perfused isolated rat 
heart 67. Speculatively, low residual flow may wash out the "effector" of preconditioning, such as 
adenosine 63. A residual coronary flow as low as 0.1 ml/g wet wt/min has also been shown to 
attenuate the protective effects of preconditioning on functional recovery (F. R. Boucher - personal 
communication). 
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DISSOCIATION OF PRECONDITIONING AND GLYCOLYSIS 
Increased glycolytic substrate with glucose and insulin was not beneficial, and was associated with 
increased metabolite accumulation. When glycolytic substrate, and thus metabolite accumulation, 
were limited by acetate preperfusion, hearts subjected to sustained low flow ischaemia showed similar 
recoveries to glucose hearts, and similar end-ischaemic glucose uptakes. However, contracture was 
significantly increased. These hearts also responded badly to preconditioning, with a rapid time to 
onset of contracture and high peak contracture, and reductions in both glucose uptake and glycogen 
availability. Recoveries were generally poorer than controls, although the large variability precluded 
significance. Thus reduced glycolytic metabolite accumulation with or without preconditioning was 
not advantageous in the presence of a reduced ATP production, despite the possible presence of the 
preconditioning "effector". 
The proposal that the net beneficial effect of glycolysis in ischaemia is determined by the balance 
between the requirement for sufficient glucose for ATP production, versus an overload of glycolytic 
substrate (glucose and glycogen) with the result of excess metabolite accumulation, is substantiated 
by the present results. We could also dissociate the effects of preconditioning on glycolysis from 
those on recovery of function. With modifications in glycolysis similar to those seen in 
preconditioned hearts subjected to low flow ischaemia (increased glucose uptake, reduced glycogen), 
preconditioning was still not effective. The lack of correlation between preconditioning and 
glycolysis, and effects on contracture and functional recovery, suggest that decreased glycolysis is not 
involved in the effects of preconditioning, contrary to previous opinion 136, 218, 224. Increased 
glycolysis in preconditioned low flow hearts was beneficial by counteracting the effect of 
preconditioning on contracture. The beneficial effect on functional recovery with preconditioning in 
the previous report using a model of low flow ischaemia 218 may be attributed solely to the 
stimulation of glycolysis by preconditioning in the face of a less than optimal basal level of glucose 
uptake, rather than preconditioning per se (see above). 
The argument could be made that if preconditioning acts by inhibition of glycolysis and reduction of 
metabolite accumulation, then when glycolysis is stimulated (by preconditioning), the benefits are no 
longer apparent, suggesting that increased glycolysis is detrimental 387. While we agree that excess 
glycolysis is indeed detrimental to ischaemic hearts, this does not mean that the presence of glucose 
or glycogen is bad. An optimal concentration of glucose is required, usually 11 mM (Results Ch 1 ). 
Additional counterpoints to the above argument are: i) in low flow conditions, glycolysis is essential 
for reduced contracture and improved functional recovery 14, 48, 424 (Results Ch 1); ii) glucose was 
present throughout low flow ischaemia and reperfusion in all hearts - removal of glucose would have 
been severely detrimental (Results Ch 1 ); iii) if preconditioning exerts benefit by inhibiting 
glycolysis, but glycolysis is stimulated in low flow ischaemia, this outcome strengthens the concept 
that preconditioning is ineffective in low flow ischaemia; iv) hearts with inhibited glycolysis (acetate 
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perfused) had exacerbated contracture, particularly when preconditioned ( contrary to other glycogen 
groups), with poorer recoveries. 
FUNCTIONAL RECOVERY VERSUS INFARCT SIZE AS THE END-POINT OF PROTECTION BY 
PRECONDITIONING 
Studies in larger animals (pigs, dogs) have generally only measured infarct size as the index of 
protection by preconditioning. When functional recovery has been measured, ischaemic 
preconditioning is ineffective against an ischaemia-induced reduction in systolic shortening 498, or 
stunning 360, 421 , despite significant reductions in infarct size. Subendocardial ischaemic blood flow 
in these models ranges from 0.05 to 0.15 ml/g wet wt/min 375,421 , about 5-15% of control flows. 
Improved recovery of function with preconditioning has only been shown in rabbit 218, 368, 542 and 
rat hearts 66, 136, 143, 290, 588. The majority of these studies have used total global ischaemia, and 
have shown a consistent improvement in functional recovery in rat hearts, as have we (Results Ch 4 ). 
Less consistent results have been reported for the rabbit, in that a number of reports find no protection 
against reperfusion dysfunction 358,447, 532. 
In the present study using the isolated rat heart model, a total global flow rate of 0.2 ml/g wet wt/min 
was used, a % reduction (about 5% of normal in vivo flow rates 279) equivalent to that found in 
subendocardial ischaemia in vivo in larger animals 360, 375, 421 , 507. No improvement in functional 
recovery was found with preconditioning under these conditions. While we did not measure infarct 
size, the effect of residual flow in our model may indicate why in larger animals with collateral flow, 
preconditioning is not effective against impaired recovery of function. 
A recent paper by Jenkins et al. 220 correlates reduced infarct size with improved recovery of 
function in preconditioned rabbit hearts. The authors suggest that preconditioning does not protect 
against stunning, but that improved functional recovery is a direct consequence of reduced infarct 
size. Thus if recovery is not improved, infarct size is presumably not modified. In our results, no 
effect on functional recovery was found, implying either that preconditioning is not always effective, 
or that functional recovery is dissociated from infarct size, assuming infarct size was limited. This 
relationship, however, requires further clarification. 
Interestingly, Li et al. 310 found that infarct size was similar in control and preconditioned dog hearts 
with subendocardial flow rates of 0.07 ml/g wet wt/min and greater, suggesting that a higher residual 
flow also limits the effect of preconditioning on infarct size (see Cave and Apstein 63 for further 
discussion of this concept). The mechanism for this observation is unclear, and remains to be 
investigated. 
It may also be argued that, given that there was no improvement in functional recovery with 
preconditioning followed by a sustained ischaemic period, we did not have a model of true 
preconditioning. However, while this argument may be valid when drawing inferences regarding the 
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role of glycolysis in preconditioning, I believe that the observations presented in this paper are of 
particular concern when the application of preconditioning as a possible clinical therapy is 
considered. 
CONCLUSIONS 
The hypothesis that preconditioning acts via inhibition of glycolysis and attenuation of metabolite 
accumulation is opposed by the present results. We found that preconditioning leads to increased 
glucose uptake during low flow ischaemia, which reduces the effects of preconditioning on 
contracture found in zero flow conditions. Our data show that any benefit of preconditioning can be 
dissociated from its effects on glycolysis, either from glucose or from glycogen, and that a residual 
low flow abolishes the protection associated with preconditioning. 
A low residual flow abolishes the protection conferred by preconditioning. This effect may be 
attributed to an overload of glycolytic metabolites, following preconditioning-induced enhanced 
glucose uptake. The data from the previous studies in the thesis also suggest that increased glycolytic 
flux (whether from a high extracellular glucose concentration, or high tissue glycogen) may be 
deleterious by an accumulation of glycolytic metabolites. One of the primary metabolites of anaerobic 
glycolysis is lactate, which has been previously implicated as a mediator of ischaemic injury. 
However, the results from provision oflactate in various protocols are contradictory. We investigated 
whether the addition of increasing lactate concentrations was detrimental to the heart exposed to 
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Fig. 2: Systolic and diastolic pressure throughout the experiments for control and preconditioned hearts with 
glucose 11 mM, with low flow sustained ischaemia. Systolic - diastolic pressure gave developed pressure. There 
was no difference in recovery between control and preconditioned low flow hearts, although the latter tended to 
have a reduced systolic function. 
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Fig. 3: Glucose uptake and lactate washout during low flow ischaemia in glucose hearts subjected to 30 min low 
flow (0.2 mllg wet wt/min) ischaemia with and without preconditioning expressed as µmo/ C6/g wet wt/min. 
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Fig. 4: Changes in diastolic pressure during ischaemia and reperfasion with acetate pre-perfusion and insulin 
pre-treatment, in control and preconditioned hearts subjected to low flow ischaemia. 
* p <O. 05 precond vs. control 
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Fig. 5: Glucose uptake (a) and lactate washout (b) during low flow ischaemia in acetate and glucose+insulin 
pre-perfused hearts subjected to 30 min low flow (0.2 ml/g wet wt/min) ischaemia with 11 mM glucose with and 
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Results 6: Lactate: is it detrimental to the ischaemic myocardium? 
ABSTRACT 
Increased lactate accumulation is thought to be the major culprit in determining a deleterious effect of 
increased glycolysis 387. Increased extracellular lactate, provided in the perfusate, should therefore 
result in an attenuation of recovery. We used the isolated Langendorff rat heart with a left ventricular 
balloon, perfused with 11 mM glucose at a pressure of 76 mmHg. The perfusate was then changed to 
10 mM lactate+ 11 mM glucose, or 40 mM lactate+ 11 mM glucose 3 min prior to low flow (0.5 or 
0.2 m.1/g wet wt/min) ischaemia for 30 min with the same substrates. The hearts were then reperfused 
for 30 min with 11 mM glucose perfusate. With a low flow of 0.5 m.1/g wet wt/min, the addition of 
lactate did not result in any impairment of function, either in terms of ischaemic contracture or 
functional recovery. Only with a low flow of 0.2 m.1/g wet wt/min, was an increase in peak contracture 
noted, with a reduction in functional recovery. Thus only when lactate was in excess, at a very low 
residual flow rate, was any deleterious effect noted in the presence of glucose. The effect of lactate 
accumulation as a major factor in ischaemic injury, when lactate is not in excess, is not substantiated 
by these results . 
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INTRODUCTION 
The role of lactate accumulation in ischaemic injury is of great interest, arising from the controversies 
of whether endogenous glycogen should be augmented prior to ischaemia, and whether glucose 
should be provided to the ischaemic myocardium. The opponents to both of these strategies suggest 
that an accumulation of lactate in the tissue, and more specifically in the cytosol, is detrimental, 
largely by inhibiting glycolysis. The most frequently quoted report supporting this concept is that by 
Neely and Grotyohann 387, who found that a depletion of glycogen by a period of anoxia prior to 
ischaemia was beneficial, an effect attributed in part to reduced lactate accumulation. 
Alternatively, many studies, in particular those involved with glucose-insulin-potassium therapy, and 
others which have focused more on the role of glucose alone, suggest that glucose is beneficial when 
supplied to the ischaemic myocardium 407, and is essential on reperfusion 228, 334, 476. An 
increased residual flow adds to the beneficial effect of glucose, but at no flow is glucose more 
detrimental than the absence of glucose (Results Ch 1). Thus at an optimal glucose concentration (11 
mM), lactate accumulation does not appear to outweigh the benefits of increased ATP production. 
However, an increased glucose concentration(> 11 mM), especially if insulin is present, is associated 
with detrimental effects, in terms of increased contracture and reduced recovery of function at severe 
low flows (<0.5 ml/g wet wt/min) (Results Ch 1, 2). A higher flow rate (0.5 ml/g wet wt/min) 
removes many of these deleterious effects (Results Ch 2), although functional recovery is still 
relatively impaired (Results Ch 2). These deleterious effects can be attributed to a large increase in 
lactate production, as well as to the accumulation of other metabolites including glucose 6-phosphate 
(G6P) and fructose 6-phosphate (F6P) (Results Ch 5). Sugar phosphates have been implicated in the 
deleterious effects of ischaemia by increasing Ca2+ overload 219,380, 482. 
Looking specifically at the effects of lactate, Cross et al. found that lactate at a concentration of 10 
mM was deleterious when infused at a flow rate of 0.5 ml/g wet wt/min in the presence of 11 mM 
glucose, resulting in increased contracture and reduced recovery of function 92. This finding was 
attributed to a build-up of intracellular lactate which would inhibit the conversion of pyruvate to 
lactate and the co-conversion of NADH to NAD+. An increased build up of NADH was predicted, 
which would affect many of the redox reactions in the cell, including glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), one of the main regulatory enzymes in the glycolytic pathway 362,468. A 
reduced lactate efflux, and thus presumably reduced glycolysis, was found in the lactate + glucose 
hearts 92. These findings are contrary to our concepts that, with a residual flow rate of 0.5 ml/g wet 
wt/min, there should be sufficient washout of metabolites, while provision of glucose by increasing 
ATP production should override the deleterious effects of lactate. 
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We attempted to repeat the observations of Cross et al, both at a residual coronary flow rate of 0.5 
m.1/g wet wt/min, at a lower flow rate of 0.2 ml/g wet wt/min with reduced washout, and with a higher 
lactate concentration. When glucose was present no deleterious effect of lactate was observed at a 
flow rate of 0.5 m.1/g wet wt/min even with 40 mM lactate present, while at a flow rate of 0.2 m.1/g wet 
wt/min, recoveries in the glucose and lactate hearts were depressed compared to those with glucose 
alone. Thus only when intracellular lactate accumulation was very high, with reduced washout and 
more severe ischaemia, was any deleterious effect noted. 
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METHODS 
Experimental apparatus 
The isolated Langendorff-perfused rat model with a left ventricular balloon was used, as described in 
Methods. 11 mM glucose was included in the perfusate except where stated. 
Protocol 
The hearts were perfused for 20 minutes prior to ischaemia. Standard glucose-containing buffer 
solution was used until 3 minutes prior to ischaemia, when it was changed to one of the test solutions 
as shown in Table 1. The hearts were then made ischaemic with residual flow rates of 0.5 or 0.2 ml/g 
wet wt/min using a roller pump (Gilson Minipuls 2) with infusion of test solution via a side arm. 
Global ischaemia was maintained for 30 min following which the hearts were reperfused for 30 
minutes with the standard glucose-containing solution. Measurements were made at five minute 
intervals for assessment of function. Recovery of function was expressed as a percentage of pre-
ischaemic function measured at 15 minutes perfusion. 
Coronary effluent was collected prior to, during ischaemia and for the first two minutes of 
reperfusion, for assessment of glucose uptake and lactate washout, by arteriovenous difference. 
During ischaemia, the effluent was collected over each five minute period. Glucose and lactate were 
measured by standard spectrophotometric assays 24. Because of a mean wet heart weight of 1 g,, all 
values where relevant can be taken to be per g wet wt. 
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RESULTS 
lschaemic contracture 
0.5 ml/g wet wt/min 
With a low flow of 0.5 ml/g wet wt/min, time to onset of contracture was delayed in all glucose-
containing hearts, despite the presence of lactate (Fig 1 ). In substrate free and lactate 10 mM hearts, 
time to onset was significantly reduced, but to a similar degree in both groups. Peak contracture was 
also very low in all glucose groups (Fig 2), although the glucose 11 m.M/lactate 40 mM group showed 
an increased peak compared to the other glucose groups. Substrate-free and lactate 10 mM hearts had 
severe contracture, reaching pre-ischaemic developed pressures (Fig 2). 
0.2 ml/g wet wt/min 
With a low flow of 0.2 ml/g wet wt/min, time to onset of contracture was similar in all groups (Fig 1 ). 
Values in the glucose hearts were significantly reduced compared to the 0.5 ml/g wet wt/min groups. 
In the glucose groups, peak contracture was greater than in the respective 0.5 ml/g wet wt/min hearts, 
but peak contracture in the substrate-free hearts was less than with 0.5 ml/g wet wt/min (Fig 2). There 
was a relationship between lactate and peak contracture with increased peak contracture associated 
with increased lactate concentration in the presence of glucose. 
Functional recovery 
0.5 ml/g wet wt/min 
Functional recovery in the 0.5 ml/g wet wt/min hearts was similar in all glucose groups irrespective of 
the addition of lactate. Substrate free and lactate 10 mM hearts showed poor recoveries (Fig 3). 
Coronary flow was highest in glucose 11 mM hearts after 30 min reperfusion, while lactate 10 mM 
and substrate free hearts had the lowest values (Fig 4) 
0.2 ml/g wet wt/min 
Hearts subjected to low flow ischaemia of 0.2 ml/g wet wt/min had good recoveries of function only 
with 11 mM glucose, which were not significantly different from those attained with 0.5 ml/g wet 
wt/min although more variable. The presence of lactate significantly reduced functional recovery 
compared to the glucose-only hearts at a flow rate of 0.2 ml/g wet wt/min, and also compared to the 
respective lactate groups with 0.5 ml/g wet wt/min, although there was no difference between the two 
lactate groups (Fig 3). All hearts with 0.2 ml/g wet wt/min ischaemia showed a tendency to have 
lower coronary flow values after 30 min reperfusion compared to 0.5 ml/g wet wt/min hearts, with 
similar values between groups (Fig 4). 
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Incidence of ventricular fibrillation 
0.5 ml/g wet wt/min 
With a low flow of 0.5 ml/g wet wt/min, the only group with a significant incidence of ventricular 
fibrillation (VF) were the substrate free hearts, with 50% incidence. 1 out of 6 hearts in the lactate 1 O 
mM group had VF (Table 2). 
0.2 ml/g wet wt/min 
With 0.2 ml/g wet wt/min, all groups had hearts with VF (Table 2). The group with the lowest 
incidence of VF was glucose 11 mM/lactate 40 mM, but there were no significant differences between 
groups. The difference in VF between the two flow rates was only significant in the glucose 11 
mM/lactate 10 mM hearts, increasing from 0% to 66% (p<0.03). 
Glucose uptake and lactate washout 
0.5 ml/g wet wt/min 
Glucose uptake at a low flow of 0.5 ml/g wet wt/min was maintained at levels of 1.25 - 1.75 µmol/g 
wet wt/min throughout ischaemia in the control group, with a mean of 1.50 ± 0.13 µmol/g wet wt/min 
over 30 min (Fig 5a; Table 3). Lactate 10 mM suppressed glucose uptake slightly throughout 
ischaemia, to 1.17 ± 0.24 µmol/g wet wt/min (Table 3). Hearts with glucose 11 mM/lactate 40 mM 
showed suppressed glucose uptake in the first 15 min ischaemia, following which levels were similar 
to those attained with glucose 11 mM/lactate 10 mM (Fig Sa). Mean glucose uptake over 30 min was 
significantly reduced in these hearts compared to glucose only hearts (0.84 ± 0.11 µmol/g wet wt/min; 
p<0.05; Table 3). Lactate washout was sustained at a mean of 1.67 ± 0.18 µmol/g wet wt/min with 11 
mM glucose, and increased to 2.01 ± 0.14 and 2.42 ± 0.31 µmol/g wet wt/min for 10 and 40 mM 
lactate (both with glucose) respectively (Fig 5b, Table 3). In the absence of glucose, hearts perfused 
with lactate 10 mM showed highly variable lactate washout of 0.89 ± 0.68 µmol/g wet wt/min. 
Substrate free hearts showed a significant reduction in lactate washout from 0.75 µmol/g wet wt/min 
at the start of ischaemia, to less than 0.1 µmol/g wet wt/min by the end of ischaemia, with a mean rate 
of 0.40 ± 0.09 µmol/g wet wt/min, indicative of glycogen utilisation (Fig 5b; Table 3). 
On reperfusion, the presence of lactate greatly increased lactate washout compared to glucose only 
and substrate free hearts (Table 3). 
0.2 ml/g wet wt/min 
With a low flow of 0.2 ml/g wet wt/min, the presence of lactate reduced mean glucose uptake slightly 
(Table 3) although significant differences were only found at the end of ischaemia (Fig 6a). Rates of 
lactate washout were decreased by the presence of lactate compared to glucose only hearts at a flow 
of 0.2 ml/g wet wt/min (Table 3), while substrate free hearts again showed a drop in lactate washout 
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to very low levels by the end of ischaemia (Fig 6b ). Glucose uptake and lactate washout were 
significantly reduced in almost all hearts at the lower flow rate compared to those with the higher 
(Table 3). On reperfusion, glucose only hearts showed a greater lactate washout than glucose hearts 
with lactate 10 mM, as a result of higher glucose uptake rates. Hearts with lactate 40 mM and glucose 
showed a high rate of lactate washout on reperfusion, and thus presumably greater interstitial and 
intracellular accumulation during ischaemia. Lactate washout tended to be higher on reperfusion with 
the higher flow rate (Table 3), although glucose only hearts showed a similar washout between the 
two flow rates, possibly indicative of increased anaerobic glycolysis from glucose and glycogen at the 
lower flow, and increased oxidation of glucose at the higher flow rate. 
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DISCUSSION 
Functional recovery with glucose and lactate 
A previous study found that recovery of function was abolished in hearts perfused with 11 mM 
glucose and 10 mM lactate at a flow rate of 0.5 ml/g wet wt/min. Glucose 11 mM hearts under the 
same conditions had a recovery of 88 ± 3 % (rate pressure product) 92. With a low flow of 0.5 ml/g 
wet wt/min, and glucose 11 mM as sole substrate, we obtained a similar good recovery. However, if 
lactate 10 mM were added, no significant reduction in functional recovery was found, nor was 
contracture exacerbated. Even if 40 mM lactate was added to glucose hearts, no deleterious effect was 
noted. Only when flow was reduced to 0.2 ml/g wet wt/min, was there a deleterious effect associated 
with lactate provision. At this flow rate, there was no difference in recovery between the 10 mM and 
40 mM lactate groups, although the 40 mM hearts showed a greater contracture but a lesser incidence 
of reperfusion arrhythmias. 
We therefore cannot agree with previous findings that the presence of lactate per se is deleterious to 
ischaemic heart i.e. any detrimental effects from the lactate derived from an optimal rate of glycolysis 
are outweighed by the concomitant ATP production. Only when flow is severely reduced may an 
excess extracellular lactate accumulate intracellularly, with deleterious effects. We did not find a 
marked inhibition of glucose uptake in the presence of lactate 10 mM at either flow rate, although 40 
mM lactate did reduce glucose uptake significantly in 0.5 ml/g wet wt/min low flow hearts. We did 
not measure tissue high energy phosphates, but there was no evidence of markedly inhibited 
glycolysis (to the extent of 60% as found previously 92) from glucose and glycogen, given the 
increased lactate washout. The effects of lactate were thus largely dissociated from glycolytic 
inhibition. 
Additional studies in this laboratory using the working rat heart model have also not found any 
deleterious effect with the addition of lactate to a glucose-containing perfusate with a residual 
coronary flow of 0.5 ml/g wet wt/min (J. van Rooyen, personal communication). Even if the residual 
low flow was reduced to 0.2 ml/g wet wt/min, recovery of function after 30 min ischaemia and 30 min 
reperfusion was 71 % with glucose and lactate 10 mM. Glucose uptake was also not severely affected, 
with a value of 0.5 µmol/g wet wt/min, which is equivalent to that in non-lactate hearts 543 . ATP 
levels at the end of ischaemia was well preserved when glucose was present. 
Possible discrepancies with the previously published study 92 may arise from the use of larger rats 
(393 ± 10 g), with. a perfusion pressure of 100 mmHg, and a calcium concentration of 1.75 mM, 
compared to the model used in the present study (see Methods). However, even if these conditions 
were replicated we could not repeat the observations of an abolished recovery of function with 
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glucose and lactate with a residual coronary flow of 0.5 ml/g wet wt/min. The lack of recovery 
previously reported could have been due to the presence of severe arrhythmias which could not be 
monitored by the system in use (using NMR). However, we could not find any indication of 
irreversible ventricular fibrillation with glucose present at a flow rate of 0.5 ml/g wet wt/min, despite 
the addition of lactate. 
In the absence of glucose, lactate 10 mM was deleterious compared to glucose 11 mM in hearts with a 
flow rate of 0.5 ml/g wet wt/min. While we did not look at hearts with lactate only at the lower flow 
rate, because of the deleterious effects at the higher flow, a recovery of only 7 .5% has been recorded 
with lactate only at a flow rate of 0.2 ml/g wet wt/min in working hearts 543. The complete absence 
of substrate was equally disadvantageous, in terms of ischaemic contracture and functional recovery, 
and even more so in terms of reperfusion arrhythmias (Table 2). Thus lactate only did not confer any 
additional harm to that found with a complete lack of substrate. Both groups of hearts had continued 
utilisation of glycogen, as shown by lactate production in these hearts during ischaemia, which 
resulted in some protection. 
Function of lactate in the normoxic heart 
Lactate can be utilised efficiently by the normoxic heart as a substrate. Under conditions of increased 
blood concentration, e.g. exercise, lactate may be a primary substrate of the heart, thereby serving to 
lower excess blood lactate levels 579. When lactate is added to a glucose-containing perfusate, it 
accounts for 90% of oxygen utilised by the heart 101. Lactate also inhibits fatty acid oxidation, 
possibly by increasing the NADH/NAD+ ratio as it is converted to pyruvate under oxygenated 
conditions (see Fig 7). However, lactate stimulates triacylglycerol turnover, with increased glycerol 
release, but maintained triacylglycerol levels 101, resulting in an active pool of triacylglycerol readily 
accessibly to hydrolysis. 
Lactate-pyruvate conversion is one of the three systems involved in maintaining the NADH/NAD+ 
ratio. This ratio is kept relatively constant under normal conditions, at about 0.002, by the action of 
the lactate, a-glycerophosphate ( aGP) and malate dehydrogenases. In the presence of oxygen, 
cytosolic NADH (produced by glycolysis) is transported across the mitochondrial wall by the malate-
aspartate shuttle 473, and subsequently undergoes oxidative phosphorylation. The rate of disposal· of 
cytosolic NADH may regulate the maximal rate of glycolysis at the level of GAPDH 261 (see Fig 7). 
If oxygen tension falls and NADH accumulates in the cytosol, lactate dehydrogenase (LDH - step c in 
Fig 7) ensures that sufficient NAD+ is regenerated by converting pyruvate to lactate to maintain the 
rate of conversion of glyceraldehyde 3-phosphate (GAP) to 3-phosphoglycerate (3-PG -step a in Fig 
7), with the continued formation of glycolytic ATP. The LDH equilibrium is far to the right i.e. to 
lactate formation. Glucose to lactate has a ~G (pH 7) = -196 kJ.mor1• (Glucose to oxidative 
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phosphorylation has ~G (pH7) = -2872 kJ.mor1, and this reaction would therefore be favoured when 
conditions optimal). An alkaline pH, a high NAD+ content and very low pyruvate levels are required 
to reverse the relationship i.e. highly oxygenated conditions. The conversion of dihydroxyacetone 
phosphate (DHAP) to aGP by aGP dehydrogenase also ensures regeneration of NAD+ (step din Fig 
7). Thus both lactate and .aGP accumulate in conditions of ischaemia and hypoxia 468 (see Results 
Ch 1). 
Apart from its metabolic effects, lactate also reduces the duration of the action potential 4 78, possibly 
by increasing the opening probability of the KATP channel 249. 
Lactate and intracellular pH regulation 
Lactate passes through the cell membrane via a lactate-/Ir co-transporter, which is driven by the 
gradients of the ions 439. The co-transporter has a Km of 2.2 mM for lactate, and 200 µM for 
pyruvate. Thus transport of pyruvate will be preferred to that of lactate, although cytosolic pyruvate 
concentrations are generally very low. Increased extracellular lactate thus increases intracellular 
lactate content 361, and also reduces the pHi 102. If isolated rat myocytes are exposed to an external 
lactate concentration of 20 mM and pHo of 7.4, the pHi falls rapidly by 0.24 pH units 53. This drop in 
pHi recovers by 0.16 pH units. If the pHo is 6.4, the drop in pHi induced by lactate is about 0.70 pH 
units, with no recovery in pHi. Na+ /Ir exchange inhibitors abolish the recovery of pHi, or increase 
acidosis further. The addition of lactate results in a rise in [Ca2+]i, attributed largely to a rise in [W]i 
acting on the Na+ /Ir exchanger 303. In turn, increased intracellular acidosis should result in lactate 
efflux if the extracellular pH is higher. Vandenberg et al. found that lactate-/Ir efflux was the main 
factor involved in restoration of pH on reper:fusion after a brief period ( 10 min) of ischaemia 545. 
In ischaemic hearts, in the absence of coronary flow, intracellular lactate accumulates rapidly from 
increased anaerobic glycolysis, although the final level is dependent on the initial availability of 
glycolytic substrate 387. With increased flow, the rate of removal of lactate should increase, unless 
extracellular lactate is supplied, in which case the efflux across the membrane should be inhibited 
with a rise in cytosolic levels. Increased cytosolic levels of lactate are thought to be deleterious to the 
ischaemic myocardium. 
Evidence that lactate is deleterious to hearts subjected to total global ischaemia was provided by 
Neely and Grotyohann 387, who found that increasing lactate concentration in the perfusate 10 min 
prior to total global ischaemia was directly correlated with reduced recovery of function on 
reper:fusion. Thus lactate in the tissue was increased prior to the onset of total global ischaemia. This 
would serve to reduce pHi 102. Increased intracellular W accumulation brought about by increased 
extracellular lactate would increase Ca2+ entry 303 prior to the onset of ischaemia 53. Karmazyn 239 
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found that Na+ /I-r exchange inhibitors given with the lactate reversed the effects of 20 min pre-
ischaemic lactate perfusion prior to total global ischaemia on the subsequent depression of 
postischaemic ventricular recovery. This effect would substantiate the concept of increased [Ca2+]i 
following lactate perfusion, which would be deleterious to the ischaemic heart 406, and separate from 
a direct effect of lactate in ischaemia. 
Contrary to the findings with total global ischaemia and lactate preperfusion, Cross et al. 92 did not 
find a drop in pHi in glucose+lactate hearts with low flow ischaemia (with protocol as repeated in the 
present study), and could thus not account for the protective effect ofNa+/I-r inhibitors by a reduction 
in [lr]i accumulation as suggested by Karmazyn 239. In these hearts, lactate accumulation prior to 
the onset of ischaemia was limited by the shorter (3 min) pre-ischaemic infusion of lactate, compared 
to other reports ( 10 and 20 min - see above). Cross et al. suggested that ATP from glucose prevents 
[Na Ji build-up by maintaining the activity of the sarcolemmal Na+/K+ ATPase, an effect inhibited by 
lactate which reduced the rate of glycolysis. By inhibition of glycolysis ( and reduced turnover of 
ATP), the effects of lactate on intracellular pH via the lactate·/I-r co-transporter were nullified 92. 
Lactate and glycolytic inhibition 
The major deleterious effect of lactate in ischaemia is thought to be its effects as a feedback inhibitor 
of glycolysis. However, in terms of glucose uptake, and lactate washout we found no evidence of 
severe glycolytic inhibition, even with 40 mM lactate in the presence of glucose ( only 40% 
reduction). We therefore cannot substantiate the findings of Cross et al. 92 in terms of inhibited 
glycolytic flux rates (by 60% ), and thus abolished functional recovery in the presence of glucose and 
lactate at a fairly high residual flow rate of 0.5 ml/g wet wt/min. 
Cross et al. explained their observations of reduced glycolysis by the effects of lactate on NADH 
levels. Mochizuki et al. 361 found that at a flow rate of 6 ml/g wet wt/min (about 40% of control 
coronary flows i.e. hypoxia), 20 mM lactate with 10 mM glucose inhibited glycolysis by about 60%. 
20 mM pyruvate had a similar effect on glycolysis. The maximum inhibitory effect was reached at an 
intracellular lactate concentration of 25-30 mM. Lactate may inhibit GAPDH directly (20 mM lactate 
has a 50% inhibitory effect on enzyme activity) and indirectly (NADH found to be a potent inhibitor) 
362 
In ischaemia, lactate and aGP accumulate significantly 468 (Results Ch 3), allowing continued 
production of glycolytic ATP with maintained NAD+ regeneration, as shown in Fig 7. However, this 
process is not able to prevent the eventual maximal reduction ofNAD+ to NADH+W. NADH and W 
accumulate rapidly in ischaemic tissue, presumably largely because of inhibited mitochondrial 
oxidation. While normal NADH/NAD+ is fairly low, ischaemic conditions (isolated cells with 
metabolic inhibition, pH 6.5 and 20 mM lactate) induce maximal conversion of NAD+ to NADH 
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within 1 min (maximal amount shown by application of amytal - NADH dehydrogenase inhibitor, and 
FCCP - uncoupler of oxidative phosphorylation 129). At a residual flow rate of 0.6 ml/g wet wt/min, 
the increase in NADH/NAD+ was slower because of a relatively high residual oxygenation at this 
flow rate, increasing from 3.2 x 10-3 in control conditions to 36.9 x 10-3 after 16 min low flow (0.6 
ml/g wet wt/min)ischaemia (calculated from lactate:pyruvate ratio which increased from 27:1 to 309:1 
468). The increased NADH will favour the formation of lactate, but the relative distribution, if the 
enzyme is in equilibrium, means that NADH will increase. Lactate to pyruvate oxidation may only 
occur if the W produced from the process are removed, or pyruvate or NADH or both. While the 
lactate concentration at end of ischaemia in hearts perfused with glucose only at a low flow rate of 0.5 
ml/g wet wt/min was 20 mM 92, the conditions mimicked in the single cell preparation could be 
reached much sooner e.g. pHi falls to about 6.6 by 6 mins 92. Any further increase in extracellular 
lactate is thus unlikely to increase NADH further. In addition, the conversion of DHAP to aGP also 
increases the NADH/NAD+ ratio. We found that with the addition of insulin, which substantially 
increased glucose uptake and lactate production, the ratio of lactate to pyruvate, and of DHAP/aGP, 
were unchanged compared to glucose only hearts with less lactate production (see Results Ch 3). Thus 
the calculated NADH/NAD+ was not increased. Thus the addition of lactate in the extracellular 
medium is unlikely to alter the NADH/NAD+ ratio significantly in favour of greater NADH formation 
more than is already present. In addition, hypoxia is associated with an increase in NADH and in 
lactate from stimulated anaerobic glycolysis 585, which would in turn be expected to inhibit 
glycolysis at the level of GAPDH (step a 362, 468). However, hypoxia is associated with a greatly 
increased rate of glycolysis. Thus while overall NADH levels may rise, these are not necessarily 
associated with inhibited glycolysis as long as there is continued regeneration of NAD+ by aGP 
dehydrogenase and LDH. Each NAD(H) molecule can be used over and over again. 
The production of ATP outweighs the detrimental effects of lactate, and lactate does not appear to 
inhibit glycolytic flux at sufficiently high coronary flows, where glycolytic flux is determined by 
delivery of substrate. The ischaemic heart appears able to tolerate a relatively large extracellular 
lactate concentration as long as ATP production is high. Geisbuhler and Rovetto 154 found that the 
addition of 1 O and 50 mM lactate does not add to anoxia/reoxygenation damage in isolated myocytes, 
measured in terms of cell contraction. Lactate had no effect on high energy phosphate levels, nor did a 
lower pH affect the role of lactate. With a high glucose concentration delivered at a low flow, 
particularly in the presence of insulin (Results Ch 2), the increased lactate production, as well as 
accumulation of other deleterious metabolites of glycolysis, such as sugar phosphates 282 may 
outweigh the benefits of increased glycolytic ATP. In these circumstances, an increased lactate would 
be deleterious, as shown by the present results obtained with a low flow of 0.2 ml/g wet wt/min. 
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Lactate accumulation and preconditioning 
The possible benefits of reduced lactate accumulation have been highlighted by the phenomenon of 
preconditioning, whereby one or more brief periods of ischaemia with intermittent reperfusion are 
beneficial to the heart in terms of reduction in infarct size and increased functional recovery. A 
depleted glycogen following preconditioning tends to lower end ischaemic tissue lactate values, which 
was proposed to be a mechanism of preconditioning 224 However, we could not find a correlation 
between glycogen depletion and improved functional recovery, with or without preconditioning 
(Results Ch 4, 5) in agreement with previous findings 17, 18, 588. No correlation between end 
ischaemic tissue lactate and functional recovery was found, as has also been previously observed 163. 
The pre-ischaemic anoxic period used to deplete tissue glycogen 387 has been shown to 
"precondition" hearts, and the effects of subsequent reduced lactate accumulation 387 may thus be 
thus secondary, and not involved in any protective effect per se. In low flow ischaemia, 
preconditioning increases glucose uptake and lactate accumulation, but does not result in an increased 
recovery of function, possibly because the rate of glycolysis, and subsequently of lactate and sugar 
phosphate accumulation, then outweighs the benefits of the increased ATP production (Results Ch 5). 
Thus lactate accumulation must not be in excess of a certain threshold rate of glycolytic ATP 
production, as yet undetermined but likely to be dependent on several other factors, including insulin 
status, other substrates, health of the heart etc. 
Conclusions 
Contrary to previous results, we could find no detrimental effect of lactate added to glucose at a low 
flow of 0.5 ml/g wet wt/min, and at a flow of 0.2 ml/g wet wt/min, recoveries were reduced in the 
Langendorff hearts, but not in working hearts. This could be attributed to peak contracture in 
Langendorffhearts which was exacerbated by lactate at a low flow of 0.2 ml/g wet wt/min, but would 
not have as severe an effect in the working heart, in the absence of a balloon. Thus flow rate has an 
important effect on the role oflactate, as well as of glucose (Results Ch 1, 2). 
Discrepancies with the previous study on low flow ischaemia with glucose and lactate 92 are difficult 
to resolve. Each study is internally consistent, with reasonably plausible explanations for the 
observations, resting mainly on differences in glycolytic flux rates. Further work is required to clarify 
these issues. The best correlate of increased glycolysis and ischaemic injury appears to be 
accumulation of the sugar phosphates 219,482 (Results Ch 4, 5) which may impair Ca2+ homeostasis 
282, rather than lactate. The involvement of sugar phosphates, pHi, Ca2+ and glycolytic ATP in 
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Fig 1. Time to onset of contracture in min after onset of ischaemia in hearts with a low residual flow (0.5 
(shaded bars) or 0.2 (open bars) ml/g wet wt/min) perfused for 3 min prior to and throughout ischaemia with 
different substrates (see Table 1). * p<0.05 vs substrate free ; # p<0.05 vs 0.5 mllg wet wt/min 















O Substrate free Gluc 11 Gluc 11 + Lact 10 Gluc 11 + Lact 40 Lact 10 
243 
Fig 2. Peak contracture {°Ai pre-ischaemic developed pressure) in hearts with a low residual flow (0.5 or 0.2 
ml/g wet wt/min) perfused for 3 min prior to and throughout ischaemia with different substrates (see Table I) . 
Legend - see Fig I . * p<0.05 vs substrate free/lactate JO; # p<0.05 vs 0.5 ml/g wet wt/min; @ p<0.05 vs 
glucose 11. 
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Fig 3. Recovery of developed pressure (% pre-ischaemic developed pressure) after 30 min reperfusion following 
30 min ischaemia with a low residual flow (0.5 or 0.2 ml/g wet wt/min). Hearts were perfused for 3 min prior to 
and throughout ischaemia with different substrates (see Table 1). All hearts were reperfused with 11 mM 
glucose. Legend - see Fig 1. * p <O. 05 vs substrate free ; @ p <O. 05 vs glucose 11 
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Fig 4. Coronary flow (mllg wet wt/min) after 30 min reperfasionfollowing 30 min ischaemia with a low residual 
flow (0.5 or 0.2 ml/g wet wt/min). Hearts were perfused for 3 min prior to and throughout ischaemia with 
different substrates (see Table 1). All hearts were reperfased with 11 mM glucose. Legend -see Fig 1 
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Fig 5. Glucose uptake (a) and lactate washout (b) over 30 min ischaemia in hearts perfused with different 
substrates (see Table 1) for 3 min prior to and throughout ischaemia at a residual flow rate of 0.5 ml/g wet 
wt/min. Open circles - substrate free; closed circles - glucose 11; closed squares - glue 11, /act JO; closed 
triangles - glue 11, /act 40; open squares - lactate JO. * p<0.05 vs glucose 11 
Results Ch 6. Lactate in low flow ischaemia 








0 u B o.5o 
0.25 
0.00 +--,---.---r---..---..---.,-----,----,------.-----r---r---, 




3.5 -C: ·e 3.0 -0 
E 2.5 :J --:J 













Fig 6. Glucose uptake (a) and lactate washout (b) over 30 min ischaemia in hearts perfused with different 
substrates (see Table I) for 3 min prior to and throughout ischaemia at a residual flow rate of 0.2 ml/g wet 
wt/min. Open circles - substrate free; closed circles - glucose 11; closed squares - glue 11, /act JO; closed 
triangles - glue 11, /act 40; open squares - lactate JO. * p<0.05 vs glucose 11 
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Fig 7. Regulation of NADHINAD+ by lactate dehydrogenase and regulation of glycolysis. 
a - reaction catalysed by GAPDH, requiring oxidation by NAD+, and by phosphoglycerate kinase which requires 
ADP and Pi for ATP formation. 
Ka' (pH7, 3ff'C) = fATPl {3-PGl {NAD+l = 62 
[ADPJ[Pi] [GAP] [NADH] 
b - slow reactions to form pyruvate from 3-PG (3 enzymes). Pyruvate can then go to lactate or to further 
oxidative metabolism ( acetyl Co A) 
c - reaction catalysed by lactate dehydrogenase, requiring reduction by NADH and F. Lactate formation is 
highly favoured by LDH. 
Kc' (pH7, 3ft' c) = ljactate 7 fNAD+ 7 = 8.8 X J(/ 
[pyruvate} [NADHJ 
d - reaction catalysed by aglycerophosphate dehydrogenase which converts dihydroxyacetone phosphate 
(DHAP) to aglycerophosphate (aGP). Glyceraldehyde 3-phosphate is converted to DHAP by triose phosphate 
isomerase 
Reactions c and d may be coupled by channeling of NADH between enzymes complexes 600 enabling rapid 
equilibrium of the reactions. 
Results Ch 6. Lactate in low flow ischaemia 249 
Table 1: Glucose and lactate concentrations of perfusate used 3 min prior to ischaemia and during low 
flow ischaemia (0.5 or 0.2 ml/g wet wt/min). Prior to change in substrate, and on reperfusion, all 
hearts were perfused with perfusate containing glucose 11 mM only. 
0.5 ml/g wet wt/min 0.2 ml/g wet wt/min 
Glucose Lactate Glucose Lactate 
Subs free OmM OmM OmM OmM 
Gluc 11 llmM OmM llmM OmM 
Gluc 11 Lact 10 11 mM lOmM llmM lOmM 
Gluc 11 Lact 40 llmM 40mM llmM 40mM 
Lact 10 OmM lOmM 
Table 2: Incidence of ventricular fibrillation on reperfusion after 30 min low flow ischaemia (0.5 or 
0.2 ml/g wet wt/min) with different substrates (see Table 1). 
0.5 ml/g wet wt/min 0.2 ml/g wet wt/min 
Incidence % Incidence % 
Subs free 0/6 0 3/8 37.5 
Gluc 11 0/6 0 4/6 66.6 * 
Gluc 11 Lact 10 0/9 0 1/7 14.3 
Gluc 11 Lact 40 3/6 50 6/6 100 
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Discussion 
A. REGULATION OF GLYCOLYSIS IN CONTROL AND ISCHAEMIC MYOCARDIUM 
1) SUMMARY OF FINDINGS OF THESIS, WITH SPECIFIC REFERENCE TO GLUCOSE METABOLISM 
This thesis provides evidence for novel views on the control of glycolysis in ischaemia. A general 
summary of the findings of this thesis suggests that: 
i) the rate of glycolysis is a crucial determinant of ischaemic contracture and functional recovery 
ii) the rate of glycolysis is determined primarily by the extracellular glucose concentration, the 
coronary flow, and the endogenous glycogen level 
iii) glycolysis is limited by availability of substrate, and not by enzyme inhibition, although enzyme 
regulation is not excluded as a modifying factor 
iv) glucose utilisation in ischaemia is increased relative to that in normal conditions, when the relative 
glucose extraction is compared. This may be attributed to an ischaemia-induced translocation of 
glucose transporters to the membrane, or an upregulation of transporters already in the sarcolemma 
v) pre-ischaemic glycogen levels determine the time to onset of contracture, and may thus partially 
modify the recovery of function. However, glucose is more important than glycogen. An excess 
glycogen may be deleterious because of excess metabolite accumulation 
v) preconditioning reduces pre-ischaemic glycogen levels, and thus reduces glycolytic flux in total 
global ischaemia. Preconditioning also reduces time to onset of contracture, most probably because of 
the reduction in pre-ischaemic glycogen. However, this glycogen depletion is not related to any 
beneficial effect, despite a reduction in end products. Glycogen depletion in the absence of 
preconditioning may be detrimental because of reduced ATP production. 
vi) preconditioning with a brief period of ischaemia increases the rate of glucose uptake in sustained 
low flow ischaemia, possibly following ischaemia-induced translocation of glucose transporters to the 
membrane. However, with 11 mM glucose as the substrate, this may lead to excess glycolysis, with 
detrimental effects which may outweigh any benefit associated with preconditioning. Alternatively a 
low residual flow may abolish the protection found with preconditioning. 
The data presented in this thesis therefore show that glucose uptake is reduced in low flow ischaemia 
but that glucose extraction increases as the coronary flow rate falls. These findings are contrary to the 
earlier reports from Neely 389, 390 and Ravetto 468, 469 who proposed that glycolysis was inhibited 
during ischaemia because the rates of uptake, at a residual flow rate of 0.6 ml/min/g wet wt, were 
lower than in control hearts. This conclusion was substantiated by measurement of glycolytic 
metabolites, which, on application of the cross-over theorem 68 suggested inhibition at the level of 
GAPDH. To clarify, the reasons for the differences between the views here proposed and those that 
are usually accepted, requires a brief review of the principles of metabolic regulation in general, 
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followed by specific application to glycolysis. The relevance of changes in glucose uptake influencing 
the extent ofrecovery of the ischaemic myocardium must also be noted (see Results Ch 1 and 2). 
2) PRINCIPLES OF METABOLIC REGULATION 
A classical definition of a metabolic pathway is as a series of reactions initiated by a flux-generating 
step, where the latter is defmed as a step which "initiates a flux to which all other participant 
reactions in a pathway must respond to reach a steady state" 391. This pathway is subject to 
regulation by changes in substrate supply, product removal, allosteric regulation, and covalent 
modification of enzymes 248, 392 . 
These original principles of metabolic regulation conform to the existence of a single "rate-limiting 
step" as the major control point in a given pathway. However, metabolic control analysis 231 suggests 
that control is distributed throughout the component enzymes of a system, with more than one enzyme 
exerting significant control over flux 231, 391, 446. The distribution of control can shift with changes 
in metabolic state 241, 446. Thus neither control nor regulation of a pathway must be viewed as 
occurring at a single "rate-limiting step" 393. These different concepts are illustrated in Fig. A.2 . 
More recent analysis of metabolic control suggest that "control" and "regulation" of a pathway must 
be clearly distinguished 51 , 523. A pathway can be controlled by factors including the workload, 
oxygen availability, substrate availability, coronary flow etc., namely factors which affect the overall 
availability of substrate, and the requirement for energy provided by the substrate utilisation, with the 
concept of product removal modifying the pathway. The pathway can be controlled from either end, 
or from the middle 51. Alternatively, the pathway can be regulated by factors affecting individual 
enzyme activity, including levels of ions and cofactors, and signal transduction pathway second 
messengers 51 , 523. 
While metabolic control analysis gives useful information, modification of the activity of a specific 
enzyme is necessary. The recent method of "top-down analysis" ( also "bottom-up" 51, 446) is simpler 
to apply to a variety of systems including metabolism. This method of analysis selects a section of a 
pathway, to determine the contribution and importance of this section to control of the whole 
pathway. Summation of flux control coefficients can be used to derive the overall flux coefficient for 
a chosen section of the pathway. Using these techniques in an isolated working rat heart (top-down 
and bottom-up analysis), the control of flux in glucose utilisation is found not to be exerted by a 
single enzyme, but distributed among several enzymes 241. 
This analysis allows determination of the distributive control of a pathway, which invokes the 
concepts of channelling, and metabolons. Together, the concepts of "channelling" and "metabolons" 
(see below) confirm distributive control of glycolysis. Additional information regarding metabolic 
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regulation can be obtained by utilising recombinant DNA technology to alter specific sites of enzymes 
to determine their individual contribution to metabolism 393. 
3) GLUCOSE METABOLISM 
a) Integration of metabolism 
Glucose utilisation involves a number of major pathways, each of which is modified by, and in turn 
has a modifying influence on the others. The major pathways include glycolysis, glycogen 
synthesis/breakdown (Cori cycle), the tricarboxylic acid (TCA) cycle (also called the citric acid or 
Krebs cycle), and oxidative phosphorylation. Intersecting pathways include mechanisms to reduce the 
redox potential (the malate-aspartate and the u-glycerophosphate shuttles), anaplerotic pathways to 
replenish the TCA cycle, and the contribution of a number of amino acids, as well as fatty acid 
synthesis/breakdown (see Appendix I for discussion of these pathways). These cycles in turn are 
governed by substrate balance, hormones (insulin, adrenaline, glucagon), ions (Mg2+, Ca2+, I-f"), and 
the energy status of the cell (levels of high energy phosphate metabolites and the cytosolic 
phosphorylation potential). Michaelis Menten relationships and mass action ratios are used to 
understand and explain points of regulation, but it must be remembered that each pathway is 
controlled as a whole , not merely at one or two points along the way, and each pathway in turn is 
dependent on the others 150, 505. The more modem approaches of "top-down" and "bottom-up" 
analyses 51, 241, 446 allow better determination of sites of control, and suggest distributive control of 
glycolysis throughout the pathway, with different sites becoming more important as conditions 
change. 
b) Glucose uptake 
i) Facilitated diffusion 
Certain sugars penetrate cells at rates several orders of magnitude faster than would be predicted for 
free diffusion through the lipid bilayer from regions of high concentration to low concentration. Thus 
sugar transport is mediated by carriers, presumably proteins 59. Once glucose is taken up into a cell, it 
is rapidly phosphorylated. This prevents glucose leaving the cell, and ensures a constant gradient for 
glucose uptake. 
The rate of facilitated diffusion is determined by the concentration gradient, the number of pores 
available in the membrane, and the affinity of the carriers. Formation of a carrier-substrate complex 
similar in concept to an enzyme-substrate complex is assumed. This concept is consistent with the 
observation that the carrier exhibits Michaelis Menten kinetics, in which the number of interactions 
with a carrier or enzyme reaches a maximum when the carrier or enzyme molecules are all occupied 
by substrate molecules. The relationship between sugar flux and sugar concentration is linear only at 
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low sugar concentrations, and can be seen to saturate at higher concentrations. Such Michaelis-
Menten kinetics are characterised by two constants: Km and Vmax. 
V = Vmax.[S]/(Km+[S]) 
V = rate of reaction, (S]= substrate concentration. Vmax (the maximum rate of transport) is related to 
both the number of transporters and the translocational ability of the individual transfer proteins. Km 
([S] where V is 1/2 Vmax) is an indirect measurement of the affinity of the transporter for the 
substrate - the lower the Km the higher the affinity. 
ii) Glucose transporters 
Two types of facilitated glucose uptake mechanisms are found. The Na+ -dependent co-transport of 
glucose, which is driven by the Na+ gradient, does not occur in heart cells 430. In the absence of 
insulin, most tissues take up glucose by the facilitative transporters, designated GLUT. Up to 6 
isoforms of these transporters are found, and are expressed according to the requirements of the 
individual tissue for glucose 370, 430. GLUTl is found in the cell membrane in tissues which do not 
respond to insulin, and are particularly abundant in red blood cells as well as in myocytes. The 
insulin-sensitive glucose transporter is designated GLUT4 217 and these are distributed between 
vesicles in the cytosolic pool, and the plasma membrane. These transporters are specific for glucose, 
and glucose analogues 260, and can be inhibited by cytochalasin B 260 which is used in assays for 
determination of GLUT4. 
Insulin acutely stimulates glucose transport in muscle and fat by recruiting GLUT4 to the plasma 
membrane 260, 294. About 40% of GLUT4 transporters are translocated to the membrane, compared 
to a normal level of 1 %, with a 10-40 fold increase in glucose transport following insulin stimulation. 
GLUTl translocation may also occur with insulin stimulation 127. A recent finding using a transgenic 
mouse model is that ablation of the GLUT 4 gene results in cardiac hypertrophy 24 3, suggesting that 
this mechanism of metabolic regulation is an important determinant of cell growth. 
GLUTl has a low affinity (apparent Km= 26 mM 395, although this may be lower (5-10 mM) in 
different cell lines 216), but a high capacity for glucose (apparent Vmax = 3.5 nmol/min/cell) while 
GLUT4 has a low capacity (0.7 nmol/min/cell) and high affinity (4.3 mM) 395. However, the relative 
numbers of transporters in the cell indicate that GLUT4 is largely responsible for insulin-stimulated 
glucose uptake, with a far greater efficiency 395. 
iii) Regulation of glucose uptake 
The rate of glucose uptake is dependent on the metabolic requirement of the cell, the availability of 
the different substrates, and the number and activity of transporters in the membrane. Glucose 
utilisation is regulated by the dietary state, oxygen availability, and hormones (insulin, glucagon, 
catecholamines, thyroid) 367, 523. Glucose uptake is increased with increased work rate 385 or 
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exercise 164 in direct response to increased energy requirements. The majority of glucose is oxidised. 
An increased glucose concentration in a perfused rat heart increases glucose uptake sharply in the 
range of 1.25-5 mM glucose, and levels off above 11 mM 415. 
A fall in metabolic rate has the opposite effect. Fatty acids compete with glucose as the substrate of 
choice 385, and limit entry of glucose when present in high concentrations - the so-called "glucose-
sparing" effect 450. In vivo, glucose is directed to the liver for storage as glycogen when blood free 
fatty acids are elevated. Insulin enhances glucose uptake and lowers free fatty acid level in the blood 
451 
Insulin is the major regulator of glucose uptake, and directs glucose towards glycogen synthesis 523. 
Glucose uptake is increased if glycogen is depleted in the normally perfused heart 206. Adenosine is 
also an important regulator of glucose utilisation, although its effects are controversial (see Ch I). 
Adenosine may specifically enhance insulin-stimulated glucose uptake, an effect inhibited by 
isoprenaline 548. cAMP stimulates glucose uptake following 13 adrenergic stimulation 244, 454 by 
increased translocation of glucose transporters 454. cGMP may also stimulate glucose transport, 
although the mechanism is unclear 494. Hypoxia and anoxia are potent stimulators of glucose 
transporter translocation 578. Ischaemia may also induce GLUT 4 translocation 517. In transgenic 
mice, increased expression of GLUT! increases glucose uptake and glycogen storage, implying that 
glucose transport is the rate-limiting step of glucose utilisation. 
While most factors regulating glucose uptake act via GLUT4 translocation to the membrane, GLUT4 
carriers in the membrane must also be correctly orientated to ensure uptake. Adenosine and 
isoprenaline do not appear to affect the subcellular distribution of GLUT4, but rather their function 
within the membrane 548. Other factors may also modulate glucose uptake by affecting orientation of 
transporters in the membrane, such that glucose uptake may be increased without any measurable 
change in sarcolemmal GLUT4 density. 
iv) Insulin 
Insulin increases the rate of synthesis of glycogen, fatty acids and proteins, promotes glucose entry 
and stimulates glycolysis, and inhibits glycogen and fat utilisation. Insulin binds to membrane 
receptors stimulating an intrinsic tyrosine kinase activity, with autophosphorylation of the receptor 
4 77. The activated receptors phosphorylate the insulin receptor substrate 1 (IRS-1) 4 77 which binds 
with Src homology 2 proteins (SH2-phosphotyrosine binding sites). SH2 proteins include 
phosphoinositide 3-kinase (PI 3-kinase ), Ras GTPase-activating protein, phospholipase C and others 
involved in the mitogenic role of insulin 379. PI 3-kinase phosphorylates phosphoinositides, and is 
involved in growth factor stimulation. In addition, PI 3-kinase may mediate GLUT4 translocation to 
the membrane 379 and increase glycogen synthesis. The insulin receptor in turn can be 
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phosphorylated by protein kinase Ca 317. How this affects the insulin receptor is not clear, but 
implies regulation of insulin activity by mechanisms involved in calcium regulation (IP3 pathway). 
c) Glucose utilisation 
i) Glycogen 
Glycogen is the storage form of glucose, and as such contributes significantly to glycolysis ( see 
Appendix I). Glycogen synthesis is stimulated by insulin, and an increased glucose or G6P, while 
glycogenolysis is strongly governed by cAMP, energy requirements and glucose. There are two 
distinct pathways for glycogen synthesis and breakdown, each regulated by hormones which stimulate 
one pathway, while inhibiting the other (see Appendix I for full pathways). Glycogen synthesis and 
utilisation is thought to follow the "last on, first off' principle, whereby the last carbon molecule to be 
attached is the first to be cleaved off, although this has recently been disputed 162. Production of 
glucose 1-phosphate (GlP) from glycogen occurs without the expenditure of an ATP molecule, and 
prevents diffusion out of the cell. The complete oxidation of GlP (or G6P) yields about 37 ATP, 
while storage consumes slightly more than one ATP. The equilibrium favours glycogen breakdown, 
thus the energy yield is very efficient, about 97%. 
The utilisation of glycogen can be separated from that of glucose, on the basis of cellular localisation 
of glycogen particles (see Ch II) which contain the enzymes for glycogen metabolism 10, 128, and 
form so-called "metabolons" 505. 
More recently, a new acid-precipitable "form" of glycogen, called proglycogen, was described 322. 
This 400 kDa molecule has a high protein content (10% vs. 0.35% in macromolecular form) 
accounting for its response to acid. It constitutes about 3% - 50% of total glycogen, depending on the 
tissue type (heart muscle - as much as 50% 10). Proglycogen acts as an efficient receptor of glucose 
residues from UDP-glucose and may be an intermediate in the synthesis and degradation of glycogen 
10, 322. Glycogenin, a self-glycosylating protein, is thought to be the primer, or backbone of glycogen 
synthesis, which then becomes part of the pro glycogen and eventually of the macroglycogen molecule 
10. These three forms are important in the regulation of glycogen synthesis and degradation. 
Gross measurement of glycogen, as used in this thesis (see Methods) usually detects both forms. 
Acid-extractable glycogen was found to reflect changes in ischaemia more closely, representing a 
subfraction of glycogen more responsive to degradation i.e. macromolecular glycogen. Glycogen in 
perchloric precipitate remained unchanged during ischaemia, i.e. proglycogen 40, 103. An estimated 
20% of initial glycogen stores may remain .in the tissue, consisting mainly of proglycogen and core 
macromolecular glycogen 40. 
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ii) The glycolytic pathway 
The glycolytic pathway is shown in Fig A. l. G6P is the entry point .of both glucose and glycogen to 
glycolysis. Glucose is phosphorylated by hexokinase (HK) with the hydrolysis of ATP, an essentially 
irreversible reaction. An additional ATP is consumed, but 4 ATP are produced if glycolysis goes 
through to pyruvate, together with 2 NADH+ff'. The net ATP production is 2 ATP. Pyruvate can then 
follow a number of options (see Appendix I), which determines the total amount of ATP derived from 
a glucose molecule. In hypoxia or ischaemia, lactate is formed from pyruvate, to regenerate NAD+ and 
allow continued glycolysis If glycogen is broken down, the net production is 3 ATP, as a molecule of 
Pi is utilised to produce G6P, rather than ATP. 
iii) Levels of regulation of glyco/ysis 
Several points along the glycolytic pathway are subject to regulation. These include glucose transport 
and glycogenolysis (discussed above), and reactions catalysed by HK, PFK, GAPDH, and PK. In 
addition, the activity of pyruvate dehydrogenase (PDH), which converts pyruvate to acetyl Co A, is 
tightly controlled by a number of factors (see Appendix I). 
Hexokinase is stimulated by an increased glucose, and inhibited by G6P, which builds up when PFK 
is blocked resulting in increased F 6P. If HK is inhibited, the glucose can pass out of the cell again, or 
if the extracellular concentration is high, glucose can accumulate intracellularly. If G6P accumulates, 
glycogen can be synthesised. The role of G6P in determining the activity of HK plays an important 
role in determining glucose utilisation in the muscle. Recent studies 241 , 335 have shown that in the 
presence of physiological concentrations of glucose and insulin i.e. adequate supply of substrate, the 
rate-limiting step in glucose utilisation is phosphorylation by hexokinase. Glucose transport is not 
limited under these conditions. As extracellular glucose increases, intracellular glucose 6-phosphate 
(G6P) reaches a plateau, which does not change with glucose concentrations greater than 2 mM. The 
estimated intracellular glucose at this point is about 300 µM. Hexokinase is then saturated with 
glucose, limiting glycolysis. The increased G6P stimulates glycogen synthesis. Regulation of 
glycolysis at steps below phosphoglucoisomerase is limited to less than 25% under these conditions. 
Phosphofructokinase is inhibited allosterically by a high ATP content, an effect enhanced by citrate 
(from the TCA cycle) and reversed by cAMP. The reaction catalysed by this enzyme is virtually 
irreversible, thus this becomes an important step in the regulation of glycolysis 541 (see Fig A.2). The 
rate of glucose breakdown is signalled by the need for ATP as determined by the ATP/AMP ratio. 
The reaction catalysed by adenylate kinase 
ATP+ AMP ~ ADP 
amplifies the signal. If ATP falls by 15%, ADP levels increase 2-fold, with a greater than 5-fold 
increase in AMP. A relatively small decrease in total tissue ATP markedly stimulates glycolysis (and 
glycogenolysis). PFK is also inhibited by an increased [Ir]i 541, which may prevent excessive lactate 
and Ir accumulation. The NADH/NAD+ ratio is also an important determinant of activity where an 
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Fig A. 1. The glycolytic pathway. HK phosphorylates glucose after entering the cell. G6P then undergoes a 
conformational change to fructose 6-phosphate (F6P), which is modulated by phosphoglucose isomerase. This 
reaction is fully reversible, with concentrations of G6P generally 10-fold higher than F6P. F6P is 
phosphorylated to fructose 1,6-bisphosphate (FDP) by phosphofructokinase (PFK), with an additional 
hydrolysis of ATP. The utilisation of glucose has thus consumed two ATP molecules by this stage, whereas 
glycogenolysis has consumed only one ATP per gluc:ose residue, and a Pi. Because this reaction uses the energy 
of ATP hydrolysis, the equilibrium favours the formation of FDP. 
The above compounds are all hexose sugars. However, with 2 phosphate groups attached, the 6-C chain can be 
symmetrically broken down to two phosphorylated 3-C chains. Two distinct molecules are formed -
glyceraldehyde 3-phosphate (GAP), and dihydroxyacetone phosphate (DHAP): These molecules are 
interconverted by triose phosphate isomerase. DHAP is either converted to GAP or to a-glycerophosphate 
(aGP). To continue glycolysis, GAP is simultaneously oxidised and phosphorylated to 1,3-bisphosphoglycerate 
by glyceraldehyde 3-phosphate dehydrogenase (GAP DH), with the conversion of NAD+ to NADH+F, and the 
consumption of an additional · Pi molecule per 3-carbon. One phosphate group on each 3-C mo'lecule is 
· subsequently cleaved off to form ATP, when 1,3-bisphosphoglycerate is converted to 3-phosphoglycerate (3PG) 
by phosphoglycerate kinase. 3PG undergoes a conformational change to 2-phosphoglyceratt. which is 
dehydrated with the formation of an enol group, to form phosphoenolpyruvate (PEP). The high phosphoryl-
transfer potential of PEP allows the transfer of the remaining high energy phosphate group to ADP+F, with 
the end products of pyruvate and ATP. This reaction, catalysed by pyruvate kinase (PK), is virtually irreversible. 
The net ATP production from the breakdown of glucose to pyruvate is 2 ATP; from glycogen, 3 ATP are 
produced. 
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increase in NADH inhibits the enzyme 362. Mechanisms which lower NADH are crucial for the 
regulation of glycolysis (see Appendix I). cAMP stimulates PFK, possibly by stimulating F2,6-P2 
formation . This compound may be the most important regulator of the enzyme 208, 301 _ 
F2,6-P2 is formed from F6P by hydrolysis of ATP, catalysed by an enzyme called PFK-2 (to 
distinguish from PFK-1) 208_ This reaction is stimulated by F6P. F2,6-P2 is a potent stimulator of PFK, 
with a feed forward effect 301 . The reconversion of F2,6-P2 to F6P releases a Pi molecule, allowing 
continued glycolysis with F6P (See Appendix I). 
Glyceraldehyde 3-phosphate dehydrogenase is the next major regulatory step, especially in ischaemia 
468; otherwise the control is largely attributed to PFK (although this has been disputed - see HK). 
GAPDH is regulated mainly by the NADH/NAD+ ratio (inhibited by an accumulation of NADH), and 
lactate 361, 362_ Again, mechanisms to restore NAD+ levels are important. The product of the reaction, 
1,3-bisphosphoglycerate, is also a potent inhibitor of the enzyme. Breakdown products of ATP (i.e. 
ADP, AMP and Pi) may stimulate the enzyme. 
Pyruvate kinase may also be regulated, with inhibition by ATP, and stimulation by FOP. However, the 
importance of regulation of this enzyme may be outweighed by the other glycolytic enzymes, as well as 
pyruvate dehydrogenase (see Appendix I). 
iv) Distributive control of glycolysis in the normal heart 
There is some controversy over whether the control of glycolysis exists at certain defined points, as 
discussed above, or whether control is distributed along the entire length of the pathway 505 . Under 
conditions of ischaemia, the level of control was thought to be shifted from PFK to GAPDH 468. 
However, more recent concepts and analysis, as well as the present work, suggest that under control 
conditions with sufficient substrate, the rate of glycolysis is largely determined by the rate of glucose 
uptake 241 (see Fig A.2). 
''Top-down" and "bottom-up" analysis of glucose utilisation in an isolated working rat heart established 
control points including glucose transport, hexokinase, enolase and pyruvate kinase 241 . The relative 
importance of each of the control steps was found to be dependent on the conditions, including the 
presence of lactate, pyruvate, and/or glucose. However, despite slight differences with different 
substrates, all enzymes below phosphoglucoisomerase, including PFK, together contributed less than 
25% to glycolytic regulation under any condition (although the branch points - fructose 6-phosphate, 
glyceraldehyde 3-phosphate, hexose monophosphate pathway - see Appendix I - were not considered in 
this analysis). In the normoxic working rat heart with sufficient external substrate and insulin, glucose 
transport is not the main rate-limiting step, but rather that transport combines with hexokinase to control 
glucose utilisation 241 . Glucose transport and phosphorylation exerted 58% of the control of glycolysis. 
Additionally, increased expression of GLUTI transporters in transgenic mice increased 
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Fig A.2. Rate limiting steps regulating the rate of g/ycolysis in ischaemia vs the concept of distributive control, where the supply of substrate is the major detenninant of the subsequent rate of product 
I (lactate) accumulation (see. text for further discussion of concepts) 
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glycogen deposition and glycolysis in skeletal muscle 458, suggesting that glucose transport is rate-
limiting under conditions when intracellular utilisation of glucose was optimal. 
Glycolysis (as well as several other metabolic pathways including glycogen metabolism) should not 
be viewed as a number of single entities or enzyme reactions acting together, but rather as a cohesive 
unit, or "metabolon", whereby all the glycolytic enzymes are grouped together, by protein-protein, 
protein-membrane, and physico-chemical interactions 505, 506 .The concept of "channelling", 
whereby enzymes are spatially associated to allow efficient transfer of product from one enzyme 
reaction to the next as substrate 576, also substantiates this argument. 
These concepts also suggest that glycolysis is controlled throughout its "length"; such that while the 
activity of each enzyme contributes to regulation of the pathway to a varying extent, the pathway as a 
whole is ultimately driven by the flux-generating step i.e. substrate (glucose or glycogen) provision. 
When a metabolic pathway is inhibited or stimulated, the activities of all the enzymes of the pathway 
are co-ordinately increased or decreased." Thus glycolysis may be viewed as analogous to a car's 
engine. When the car runs out of petrol, the engine will not work. This does not mean that the engine 
is broken - if petrol is resupplied, the car will run. However, the maximum speed attained will be the 
same whether the tank is full or only half-full. 
4) REAPPRAISAL OF GLUCOSE UPTAKE AND UTILISATION IN ISCHAEMIA 
Given that control of glucose utilisation may rest mainly with provision of substrate, the previous 
assumptions regarding glycolysis in ischaemia must be reassessed. The evidence presented in this 
thesis suggest that glycolytic flux is determined primarily by the availability of substrate, determined 
by substrate concentration and coronary flow. The subsequent modification of rates of glycolysis by 
enzyme regulation appears secondary to substrate supply. 
i) Enzyme inhibition and glucose transport 
The concept of enzyme inhibition at specific sites as the major modulator of the glycolytic flux rate in 
ischaemia is flawed in several respects. Firstly, glucose extraction is increased in ischaemia (see 
Results Ch 3 for elaboration of this point). Secondly, we could find no evidence of GAPDH inhibition 
by analysis of metabolite accumulation (see Results Ch 3 for data and further discussion). Thirdly, 
limiting control of glycolysis to only two steps, specifically PFK and GAPDH, has come to be 
recognised as a simplification, and possibly erroneous 51,241,505. Glycolysis is controlled along the 
pathway, with distributive control affected by the metabolic state (see above). That this concept can 
be extended to glycolysis in ischaemia needs to be confirmed, but is supported by the present 
findings. 
Conceptually, if the number of glucose transporters in the membrane remains constant, the external 
substrate concentration should become "rate-limiting", until saturating concentrations are reached 
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(around 11 mM). If the number of transporters can be increased by a stimulus, such as insulin or 
ischaemia 4 72, 517, then a higher rate of glycolysis can be reached, again levelling off at saturating 
glucose concentrations independent of the status of the heart (normoxic or ischaemic ). Once the 
intracellular glucose concentration exceeds 2 mM ( e.g. when insulin and sufficient glucose are 
present), the rate of glycolysis may be controlled by hexokinase, with some regulation by other 
enzymes including PFK and PK (see above). This substrate-dependent regulation of glycolysis 
appears independent of other factors when the demand for glycolysis is high e.g. hypoxia, ischaemia, 
no alternate substrates. When oxygen saturation is high, or other substrates are present, factors such as 
citrate levels, work rate, ATP content etc. may be more important in regulating the rate of glycolysis. 
In ischaemia, the coronary flow rate and glucose concentration are fixed. However, the heart appears 
able to increase the extraction of glucose from that available to it, possibly by an upregulation of 
glucose transporters in the sarcolemma. The protective effect of glucose provision can thus be 
enhanced by intrinsic mechanisms to increase glycolytic flux, despite any enzyme inhibition. 
ii) Lactate production in vivo 
Lactate was thought to inhibit GAPDH, both directly, and by increasing NADH and ff" levels, which 
inhibit the reduction of NAD+. These effects were thought to result in end-product inhibition of 
glycolysis. However, considerable lactate accumulates in ischaemic tissue, despite a supposed 
inhibition of glycolysis. In vivo, lactate accumulates inversely with a reduction in coronary flow 175, 
and increases in a linear fashion in the ischaemic zone over 120 minutes 403. Glycolytic substrate 
under these conditions can only be derived from residual glucose delivery by collateral vessels, and 
from tissue glycogen. Once the substrate has been utilised, glycolysis should cease. 
If glycolysis were inhibited, both glucose and glycogen utilisation should be reduced. However, if 
glucose is available in limited amounts or is absent, glycogen breakdown is increased (Results Ch 1 ), 
resulting in the large amount of lactate observed in the tissue after 16 minutes ischaemia 468. In 
addition, a-glycerophosphate, another product of glycolysis accumulates markedly in ischaemic tissue 
403, 468 (Results Ch 3). Continued metabolite accumulation indicates that there is continued activity 
of glycolytic enzymes throughout ischaemia. Otherwise early production of lactate etc. would lead to 
later inhibition, and a slowing in the rate of glucose utilisation with time. Apstein et al. demonstrated 
this concept at a low residual flow with a high glucose (28 mM) and insulin able to sustain glycolytic 
flux i.e. lactate production over 3 hrs ischaemia. Alternatively, with a concentration of 5.5 mM 
glucose, lactate washout rates declined substantially 14, presumably because of the inability of the 
low glucose concentration to sustain glucose uptake (see Results Ch 2 3). 
The glycolytic pathway thus continues to produce lactate for a period well past that which would be 
expected if glycolysis were limited by enzyme inhibition. We have also found that addition of 10 mM 
lactate to glucose-containing perfusate infused at a flow rate of 0.5 ml/g/min does not affect glucose 
Discussion. A. Reappraisal of glycolysis in ischaemia 263 
uptake or recovery. Only if the lactate concentration is increased to 40 mM, or the flow rate is 
reduced, is some effect seen on glucose uptake and recovery after 30 min ischaemia (see Results Ch 
6). These findings further confirm the concept that glycolysis is not inhibited in ischaemia. 
iii) Glycogen 
It has been suggested that glycolysis is inhibited, because glycogen breakdown occurs only in the first 
period of ischaemia, and some residual glycogen is left in the tissue 225. In addition, increased G6P 
levels in ischaemia may be said to show inhibition; however, increased glycogen breakdown may also 
result in an excess of G6P which would saturate phosphoglucoisomerase. While the rate of glycolysis 
is certainly limited by substrate availability, and glycogen may be the sole source of glycolytic 
substrate, the fact that some glycogen remains in the ischaemic tissue is not evidence for cessation of 
glycolysis, but rather may indicate the presence of residual core macromolecular glycogen, or 
proglycogen, which is more resistant to ischaemia 103. In addition, the breakdown of glycogen is 
complex, requiring the actions of glycogen phosphorylase, and its activators. This enzyme may be 
modulated in severe ischaemia, as phosphorylation is required for activation (see Appendix I). The 
activity of this enzyme is inhibited in preconditioned hearts 575. 
In zero flow ischaemia, lactate accumulation occurs as glycogen is broken down. The increased 
lactate would be expected to inhibit glycolysis. However, there is less tissue glycogen remaining after 
30 min total global ischaemia than after subtotal ischaemia (Results Ch 1, 3). Thus the increased 
lactate is not associated with decreased glycogenolysis. In low flow ischaemia, the presence of 
glucose inhibits glycogen breakdown, while lactate build-up is reduced by washout. 
5) OPTIMAL RATES OF GLYCOLYTIC FLUX IN THE ISCHAEMIC MYOCARDIUM 
While the kinetics of glucose uptake indicate that the ischaemic heart can increase extraction of 
glucose, the ultimate determinant of viability is the rate of glycolytic ATP production 424. We have 
found that functional recovery of the heart over a range of low flows is optimal with a glucose 
concentration of 11 mM (Results Ch 1,2), which results in sufficient ATP production to reduce 
ischaemic injury, but does not lead to excess glycolytic metabolite accumulation. Obviously, if the 
excess metabolites could be removed, this would increase the benefit associated with increased 
glycolysis. However, the only candidate mechanism apparent at this point is an increase in the 
residual flow rate. 
Reducing the glucose concentration results in suboptimal delivery of glucose, and thus suboptimal 
ATP production; equally, increasing glucose entry into the cell by increasing the glucose 
concentration and/or adding insulin can impair recovery relative to the 11 mM hearts, because of 
excess metabolite accumulation, specifically sugar phosphates (see Results Ch 1,2, 4, 5). We do not 
find that glucose uptake relative to delivery is decreased, and thus that glycolysis is inhibited in 
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ischaemia. Rather the rate of glycolysis is limited in ischaemia by substrate availability. Alternatively. 
an ischaemic heart (with viable tissue) appears able to upregulate glucose uptake relative to control 
hearts. If glucose uptake is increased above a certain threshold level, e.g. by the factors above, or by 
preconditioning (see Results Ch 5), the glycolytic metabolites may again accumulate in excess, with 
detrimental effects. There is a complex interaction between glucose uptake, glycolytic ATP 
production and glycolytic metabolite accumulation. 
6) CONCLUSIONS 
In conclusion, while a build-up of metabolites does occur in ischaemia, and may have some inhibitory 
effect on glycolysis, accumulation of metabolites may also indicate upregulation of glycolysis, rather 
than inhibition. While an overload of the glycolytic cascade may occur, with a subsequent bottleneck 
effect, the overall flux cannot be said to be limited. This applies especially to ischaemia with any 
degree of residual flow, with continued delivery of substrate, as well as removal of inhibitory 
metabolites, ensuring continued glycolysis. Only in the extreme situation of total global ischaemia, is 
glycolysis fully limited by a lack of substrate. In low flow ischaemia, glucose extraction is increased 
relative to glucose delivery. We have found that tissue glycolytic metabolite content actually 
decreases as ischaemia is prolonged, indicating utilisation. of all available glycolytic metabolites for 
production of ATP, rather than any cessation of glycolysis (Results Ch 3). These data call for more 
precise metabolic control analysis of glycolysis in ischaemia and reperfusion, as has been done in 
normoxic isolated working rat hearts 241. 
The consequences to the heart of increased glucose uptake are dependent on the subsequent degree of 
metabolite accumulation, ATP production, and _the modifying influence of these factors on cytosolic 
Ca2+ accumulation, membrane stability etc. Thus while increased glucose concentrations may result in 
increased glucose uptake, a high glucose concentration (with or without insulin) may prove 
deleterious, as shown in Results Chapters 1 and 2, as a consequence possibly of increased sugar 
phosphate accumulation 219,282, 482. Increased contracture, increased incidence of arrhythmias, and 
reduced functional recovery were consequences of excess glycolytic substrate, as shown in Results 
Chapters 1, 2, 4, and 5. Thus an optimal delivery of glucose is required to ensure maximal ATP 
production, but this can be outweighed by excess metabolite accumulation. However, it must be · 
stressed that this hypothesis is in slight contradiction with previous concepts, in that an accumulation 
of lactate, W and NADH is not necessarily involved in deleterious effects by inhibiting glycolysis, 
but that other metabolites of glycolysis accumulating intracellularly have an effect on other factors 
including Ca2+ homeostasis 282. 
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B. HYPOTHETICAL MODEL OF ISCHAEMIC CONTRACTURE 
Based on the concepts elaborated in the literature review, and on the work presented in this thesis, the 
following conclusions have been reached regarding the genesis of contracture, its modulation, and 
finally its role as a predictor of reperfusion recovery i.e. its effect on, and index of ischaemic injury. 
There is some speculation in this discussion, indicating possible avenues of further research. In 
addition, some points are still not clear, despite fairly extensive research. The precise role of 
glycolytic ATP in contracture is not yet fully understood, as is highlighted in the following 
discussion. 
a) Genesis of contracture 
i) Unifying hypothesis of onset of contracture 
The seminal event in shortening of single hypoxic cells is rigor, which is soon followed by a rise in 
[Ca2Ji 9, 42 (see Ch I). Rigor complexes co-operatively activate adjacent myosin ATPases, 
accelerating ATP utilisation. In addition, ATP depletion limits activity of the ion pumps, leading to 
increased cytosolic Ca2+. Cell contracture can only occur in the presence of low ATP; contracture is 
inhibited in the absence of ATP (no myosin ATPase activity to allow shortening) and high ATP 
(inhibits rigor bond formation) 42. 
If one extends the findings in isolated myocytes to the whole heart, contracture can be seen as a co-
operative response, both intra- and intercellularly, involving ATP depletion triggering initial rigor 
bond formation, and Ca2+ entry, which in turn exacerbates contracture and ischaemic injury (see Fig 
B.1). 




Myosin A TPase 
l j Tension 
Fig B.1. Diagrammatic illustration of positive feeback relationship betwen ATP depletion and rise in cytosolic 
eel+ levels leading to an eventual rise is resting tension. 
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Heterogeneous dispersion of rigor complexes from intracellular localised depletion of ATP, and 
localised foci of contraction of individual cells with depleted ATP, lead to shortening of the whole 
muscle, and ischaemic contracture. 
Intracellular - local area~ of ATP depletion ~ single rigor bond formation ~ co-operative bond 
formation~ increased adjacent myosin ATPase activity~ depleted ATP~ increased Ca2+ ~ 
increased TnC affinity ~ increased myofibril contraction ~ further ATP depletion 
Intercellular - increased stretch of individual cells ~ increases stretch in adjacent cells ~ induced 
rupture of cell membranes 
ii) Heterogeneous contracture 
The evidence for heterogeneity of contracture is manifold, firstly on the basis of microscopic 
examination of tissue changes with contracture (see Ch I). In addition, Steenbergen 508 found a 
heterogeneous distribution of anoxic zones in low flow ischaemia. In the whole heart, with different 
substrates ( oxidative versus glycolytic) in low flow ischaemia, residual oxidative phosphorylation in 
the absence of glycolysis would continue in the better-perfused zones, while the non-perfused zones 
would be more ischaemic and undergo contracture faster. With maintained glycolysis, there would be 
a more homogenous spread of ATP production with anaerobic glycolytic ATP in anoxic zones 
preventing contracture of these cells. The slower onset of contracture would be less damaging. This 
hypothesis could explain the data of Bricknell et al. 49, who showed that anaerobic glycolysis 
prevented contracture better than the equivalent rates of ATP produced by oxidative phosphorylation. 
From these findings, it was assumed that glycolytically-derived ATP is more effective than oxidative 
ATP in inhibiting contracture at a cellular level. Subsequently, V anderwee et al. 54 7 found that the 
variability in glycogen content was the likely contributor to variability in ATP content and thus, time 
to onset of contracture. This hypothesis is confirmed by the present results. 
iii) Role of compartmentation of ATP 
With oxygen deprivation, the mitochondria are shut down. These are the powerhouses of the cell, in 
particular providing ATP to the myofibrils, near to which they are spatially located. In addition, 
glycogen granules located near the sarcoplasmic reticulum and the myofibrils, provide ATP for 
contraction (see Ch II). When these local sources of ATP are depleted, adjacent actin and myosin 
molecules bond. These bonds cause a co-operative binding of actomyosin in neighbouring molecules, 
thereby spreading bond formation outwards from a focal point. This effect may be relatively slow if 
glycolytic ATP is still available, providing some degree of relief of tension. However, the ATP 
derived from glucose must travel from the sarcolemma or SR, where the majority of the glycolytic 
enzymes are located 434, 593. 
Glycolytic ATP also serves an important function by providing ATP to maintain Na+/K+ ATPase 
function in the sarcolemma 94, 167, and membrane integrity 49, 203 preventing membrane leakiness, 
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both major mechanisms of Ca:+ entry. Both glucose- and glycogen-derived ATP, produced near the 
SR 128, 593 , may prevent cytosolic Ca2+ overload by maintaining actiyity of the SR Ca2+ ATPase, the 
main sink for cytosolic ATP. Compartmentation of glycolytic ATP production (glucose vs. glycogen), 
as well as of oxidative phosphorylation (see Ch II) is an essential concept in explaining the 
development of contracture. ATP from glycogen may be linked to the myofibril activity, as is 
oxidatively-derived ATP, while glucose-derived ATP is produced near the sarcolemma and SR. Thus 
there is an important functional dissociation between forms of ATP, important in ischaemia, when 
cellular transport process for ATP may break down. ATP derived from glycogen may be involved in 
determining myofilament binding, and thus glycogen-derived ATP would be important in maintaining 
diastolic relaxation in ischaemia, whereas glucose-derived ATP would be more important in 
maintaining levels of [Na +Ji and [Ca2+]i, thereby inhibiting ion overload and reducing the deleterious 
effects associated with increased cytosolic Ca2+. In addition, the metabolites from glucose and 
glycogen utilisation would accumulate at different regions in the cell where they may exert different 
effects. H+ produced at the myofibrils may reduce Ca2+ binding to the myofilaments, whereas 
increased H+ accumulation at the membrane will increase the capacity for Na+ /H+ exchange thereby 
increasing intracellular ca2+, especially on reperfusion. 
Once glycogen is depleted, rigor bonds may form, with the onset of rigor 253. When glucose is 
depleted, the drop in ATP leads to increased intracellular Ca2+ accumulation. The increased [Ca2+]i 
binds to Tn C, removing inhibition of actin-myosin bonding. Thus there is an active shortening of the 
myofibrils induced by ca2+, following on from the initial trigger of rigor bond formation. In addition, 
the increased Ca2+ hastens ATP depletion, which in turn increases [Ca2+]i accumulation by reduced 
re-uptake by the SR Ca2+ ATPase. However, maintained ATP production from glucose may prevent 
2+ attenuated SR Ca uptake, and thus reduce peak contracture. 
Apstein proposed that glycolytic ATP has a "plasticising" effect i.e. it exert its effects by enhancing 
relaxation of contracted myofibrils 13. However, this is not likely given compartmentation of ATP, 
except under conditions when ATP content is relatively high e.g. under relatively high flow 
conditions, and when glucose is present in reasonably high concentrations (at least 11 rnM). Only 
then can the ATP diffuse in sufficient amounts from its sites of production near the sarcolemma and 
' SR to affect myofibril contraction. We (Results Ch 1,2) and others 14, 424 have found that with a 
higher flow rate (0.5 ml/g wet wt/min) and with 11 rnM glucose, there is very little or no pontracture, _ 
indicating that glucose-derived ATP is preventing rigor bond formation, by diffusion to the sites on 
the myofibrils, as well as preventing cytosolic Ca2+ accumulation. At lower flow rates, changes in 
glucose concentration do not alter the time to onset of contracture, but do attenuate the rise in peak 
contracture (see Results Ch 1). However, an excess glucose concentration at low flow rates does 
increase contracture more than with 11 rnM glucose (see Results, Ch 1, 2), suggesting that some other 
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factor, possibly sugar phosphates which have been implicated in a loss of Ca2+ homeostasis and a rise 
in diastolic pressure 281 , is involved. While there are still some points which are not clear regarding 
the precise role of glycolytic ATP in determining the onset of contracture, a direct effect of this ATP 
on contracting myofibrils in severe ischaemia is unlikely. 
- iv) Glycolytir: vs glycogenolytic ATP 
Apstein et al. 14 and more directly Owen et al. 424, provided evidence that a certain minimum rate of 
glycolytic ATP production is required to prevent the onset of contracture. A rate of 2 µmol /g wet 
wt/min in an isolated heart perfused at a low flow rate of 0.5 ml/g wet wt/min was required. This 
finding appears to be contradictory to the hypothesis presented that a reduction in glycogenolytic ATP 
production is the main determinant of the onset of contracture. However, the point is still valid for 
several reasons : firstly , a larger flow rate ensures that the heart function is better maintained. Thus the 
capacity of the cells to transport ATP within the cytosol is improved. By simple diffusion, a higher 
rate of ATP production to the sarcolemma will ensure that the ATP is translocated to the myofibrils. 
Secondly, the increased ATP ensures maintenance of Ca2+ homeostasis, both by maintaining the 
Na+/K+ ATPase and preventing cytosolic Na+ accumulation, preserving membrane integrity, and also 
to a lesser extent, by maintaining the sarcolemmal Ca2+ ATPase pump. 
The concept that inhibition of glycogenolytic ATP production is coincident with the onset of 
contracture is supported by the findings of Kingsley et al. 253 and Cross et al. 93, the former in total . 
global ischaemia where glycogen is the sole glycolytic substrate, and in the latter with low flow 
ischaemia (0.5 ml/g wet wt/min) where glucose was absent, and glycogen again thus the sole 
glycolytic substrate. In each case, the onset of contracture occurred with cessation of glycolysis, 
measured by a steady state in the fall of pHi during ischaemia 253, and a fall-off in lactate washout 
93 . However, it must be emphasised that glycolytic ATP from glucose was not present in either case. 
When glucose is present in low flow ischaemia, contracture is still present (see Results Ch 1, 2, 5), 
despite a rate of glycolytic ATP production above 2 µmol/g wet wt/min (the threshold value given by 
Owen et al. 424). Thus under severe low flow conditions with glucose, the initiation and potentiation 
of contracture are more complex, and affected by other factors such as metabolite accumulation, and 
Ca2+ and H+ levels. 
The hypothesis that glycogen depletion will reduce the time to onset of contracture is also challenged 
by the findings in preconditioned low flow hearts (Results Ch 5). In zero flow ischaemia, the reduced 
time to onset of contracture in preconditioned hearts is explained by a reduced pre-ischaemic 
glycogen, and reduced high energy phosphate levels 266. However, in low flow hearts, despite a 
reduced glycogen levels with preconditioning, which we would have expected to reduce the time to 
onset of contracture (see Results Ch 1) there was no difference in time to onset compared to control 
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low flow hearts. However, the preconditioned hearts did show a significantly increased glucose 
uptake, prior to onset of contracture, and the greatly increased glycolytic ATP produced at the 
sarcolemma may have been able to diffuse to the myofibrils, and exert a "plasticising" effect 13. 
However the benefits of increased glucose uptake on ischaemic contracture in the preconditioned 
hearts was counteracted by a higher metabolite accumulation, such that final recovery was no 
different from control hearts i.e. there was no protection associated with preconditioning in low flow 
hearts 
b) Modulation of peak contracture 
ADP is an important modifier of cross-bridge cycling, but may not play an important role in 
ischaemia, as it is broken down rapidly. While a lower pH should lessen peak contracture by 
decreasing Ca2+ binding, this beneficial effect may be counteracted by the deleterious consequences 
ofNa+/H+ and Na+/Ca2+ exchange stimulation by increased [H+]i accumulation. This mechanism may 
only be important on reperfusion 119, when reperfusion leads to increased contracture i.e. increased 
diastolic tension (see Results Ch 1), due to Ca2+ overload inducing contraction of the cells. In 
addition, in low flow ischaemia with maintained glycolytic ATP, the Na+/K+ ATPase pump continues 
to function, removing excess Na+. Inhibition of this pump abolishes the protective effect of glucose 
94, 167. Pi may also modify contracture, by reducing the extent of cross-bridge cycling 280. 
However, increased Pi is a direct reflection of reduced high energy phosphates, and also reduces the 
affinity of ATP and its free energy change on hydrolysis 235. Thus this mechanism also has 
contradictory effects. We found that tissue with high Pi levels i.e. acetate-perfused hearts, showed the 
highest contracture (see Results Ch 1, 4 and 5). 
Finally the most important modifiers of contracture are ATP and Ca2+. While contracture may be 
precipitated despite continued production of glycolysis (as we found in low flow ischaemia - Results 
Ch 1, 2, 5) which appears to be contrary to the findings of Kingsley et al. in total global ischaemia, 
where cessation of glycolysis was associated with the onset of contracture 253), the extent of 
contracture will be reduced if some residual glycolytic ATP is present. Owen et al. found a minimum 
rate of 2 µmol/g wet wt/min (from glucose) was required to prevent contracture 424. Equivalent 
amounts of glycogenolytic ATP were inadequate, a finding confirmed by our results with modulation 
of pre-ischaemic glycogen contents (Results Ch 1), and in preconditioned hearts (Results Ch 4 and 5). 
In the absence of glucose, despite sufficient ATP from glycogen, we found a large contracture -
especially if the metabolic rate was increased by an increased flow rate (Results Ch 1, 2, 5). The 
greater demand on ATP depleted the ATP levels at a faster rate. Thus the time to onset of contracture 
appears to be mainly dependent on glycogenolytic ATP (the ATP present in the globally ischaemic rat 
heart - i.e. Kingsley et al. 253), although of course glycolytic (glucose-derived) ATP will also play 
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some role in this - a cell deprived of glycolytic ATP will utilise its other sources of ATP faster. 
Oxidative ATP may also help to reduce ischaemic contracture, but the contribution of this source of 
ATP is fairly small, and only relevant when the residual coronary flow is increased significantly. 
The peak contracture is modified by the extent of Ca2+ entry, the accumulation of H+ and Pi, and 
residual rates of ATP utilisation. Increased glycogen can reduce peak contracture (see Results Ch 4 
and 5) but not as much as the presence vs. the absence of glucose (see Results Ch 1). A depletion of 
glycogen will precipitate contracture, but this can be modified by the presence of glucose (Results Ch 
1). Thus the source of ATP is crucial in determining the onset and the peak of contracture, again 
emphasising the important role of glycolytic ATP. 
c) Time course of contracture - consequences of altered rate of rise of tension 
The faster the onset of contracture, the higher the peak of contracture (see Results Ch 1, 2, 4 and 5), 
and the more deleterious the consequences in that the higher the peak, the greater the tension, and the 
greater the cell rupture. Thus a high contracture should be deleterious. A delay in time to onset of 
contracture generally ensures that the peak of contracture will also be reduced. Mechanisms during 
the lag period in which heart adjusts to ischaemia may allow the heart to tolerate the extended period 
better. If perturbations occur largely in these early periods, the tolerance to ischaemia appears to be 
lessened. This relationship can be seen if time to peak, time to onset of contracture, and peak 
contracture are correlated (see Results Ch 1, 2, 4 and 5). Relationship of time to onset of contracture 
with functional recovery not always as clear cut (see Results Ch 1, 2, 4 and 5). This may be attributed 
to other modifying influences e.g. preconditioned hearts in total global ischaemia tend to have 
increased contracture, but recovery is significantly improved (see Results Ch 4). 
d) Contracture as a determinant of recovery 
Recovery on reperfusion is more or less determined by the extent of ischaemic injury (see Ch I). 
Increased contracture should reflect increased injury, as increased stress on the cells by the 
mechanical stretch would be expected to lead to cell rupture. In addition, increased contracture 
presumably indicates a state of reduced ATP and increased Ca2+ overload, both precipitators of 
reperfusion injury. However, there appears to be about three "ranges" of peak contracture, within 
each range there is no direct correlation with recovery. The first range is that where there is very little 
contracture, or a complete absence - as a very rough guide 0-20% of pre-ischaemic developed 
pressure. The recoveries should be good - more than 60%, possibly up to 100%. This state is only 
really possible with either very brief ischaemia (less than 15 -20 min), with reperfusion prior to the 
onset of contracture, or else with less severe ischaemia, i.e. maintained residual flow of at least 0.5 
ml/g wet wt/min, and a glucose concentration of 11 mM (or 5 mM with insulin) (see Results Ch 1, 2). 
The second "range" of contracture is a peak of about 20-60%. Recoveries will generally be in the 
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range of about 40-60% (see R~sults Ch 1, 2). Thus a significant difference in contracture within this 
range will not greatly affect recovery of function, and there may in fact be a lack of correlation 
between groups i.e. increased contracture but increased recovery as in preconditioned hearts (Results 
Ch 4, 5). The third range, with peak contractures greater than 60%, will generally lead to recoveries 
less than 40% (Results Ch 1, 2, 4, 5). In this range the predictive value of contracture becomes more 
accurate. This is due to the increased contracture precipitating cell rupture, indicated by the rapid fall 
off in tension seen after the attainment of peak values e.g. in acetate hearts. This reduction in tension 
can be attributed to cell rupture, indicative of cell death and irreversible injury. The greater the fall off 
in tension, the greater the irreversible injury. However, contracture is a heterogeneous phenomenon 
i.e. individual cells contract, and cause contracture and rupture in adjacent cells. Foci of contracture 
develop 181 , leading to shortening of the whole myocardium. However despite quite severe 
shortening there may still be some degree of salvageable myocardium e.g. acetate preconditioned 
hearts subjected to low flow ischaemia show reasonable recoveries despite a large peak contracture 
(Results Ch 5). The amount of residual salvageable myocardium is dependent on other modifiers of 
ischaemic injury as well as the amount of tissue still perfused after a period of time. In the contracting 
myocardium, the endocardium is more severely ischaemic. This is the normal occurrence in any 
ischaemic · heart, but with an intra ventricular balloon, as the heart contracts, the endocardium is more 
compressed by the epicardium, against the fixed volume of the balloon. The perfusate is thus forced 
to the epicardium. The degree of residual flow is an important determinant of functional recovery ( see 
Results Ch 1), presumably limiting infarction, and ensuring some degree of functional recovery. 
On reperfusion, an increase in diastolic pressure is often seen if contracture occurs during ischaemia 
(see Results Ch 1). This effect can be partially attributed to the "garden hose" effect i.e. increased 
turgidity due to filling of the vascular bed 210, 560. However, this explanation does not fully explain 
the phenomenon. On reperfusion, there is a large influx of Ca2+ via the Na+/Ca2+ exchange 
mechanism, and through leaky membranes 353. This Ca2+ influx causes contraction of the myofibrils 
i.e. active shortening, which then go into a state of tetany because of the increased Ca2+ and the 
reduction of ATP which is required for relaxation 14 7-149. This increase in diastolic tension on 
reperfusion may be dependent on the degree of injury during ischaemia - an increased H+ and Na+ 
I 
load during ischaemia, increased ATP depletion, and increased fragility of the membranes, as well as 
the percentage of contracted cells, all contribute to the degree of diastolic tension on rep~rfusion. i.e. 
the greater the changes in ions and high energy phosphates the greater the chance of ·precipitating 
irreversible contracture and cell rupture (leading to cell death) on reperfusion. If these changes are 
reduced, the chances of recovery are greatly improved. Increased duration of reperfusion should then 
result in a gradual increase in recovery. If, however, the changes are irreversible i.e. cell death, 
extended reperfusion will make no difference, with impaired diastolic function maintained. This will 
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result in the presence of an infarct, as measured after extended reperfusion. Preconditioning appears 
to exert its main effect by delaying the initiation of necrosis, and thus reducing the extent of 
irreversibly injured tissue _on reperfusion and reducing the increased diastolic tension on reperfusion 
(see Discussion C for furtner discussion on this point). However, this effect is somewhat contradicted 
_ by the exacerbation of contracture noted in the majority of preconditioned hearts (see Ch III) . 
The dichotomy of the . exacerbation of contracture by preconditioning, but the subsequent 
improvement in recovery of function in these hearts, as observed by ourselves, and a number of other 
investigators 18, 266-268 suggests that ischaemic contracture may not always be a good index of 
ischaemic injury. However, preconditioning only increases contracture by a relatively small degree, in 
the order of 10-20 mni.Hg 18, 266-268, i.e . within the intermediate range described above. 
Preconditioning may confer an ability to tolerate the increased contracture, although excess 
contracture with preconditioning (as found with acetate-perfused hearts - Results Ch. 4) may not be as 
easily tolerated, and may attenuate the protective effects of preconditioning, as observed. 
Contracture (ATP and Ca
2+-dependent) during ischaemia can precipitate increased contracture on 
reperfusion (mainly Ca
2+ -dependant) . This contracture is essentially irreversible (see reperfusion after 
30 min severe ischaemia - maintained diastolic dysfunction reaching a steady state - Results Ch 1, 2, 
4 and 5) and may indicate the degree of infarction, as implied by Jenkins et al. (in preconditioned 
hearts, the de_gree of functional recovery was associated with infarct size 220) . However, it must be 
noted that use of ischaemic contracture as an absolute index of ischaemic injury, and a predictor of 
functional recovery can be misleading. To reiterate, a full understanding of the mechanism of 
ischaemic contracture, and its effects on the tissue, is required to interpret the ;esults. 
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C. PRECONDITIONING -A REAPPRAISAL OF PROTECTION 
In Basic Res Cardiol 91 :5-7, 1996. 
a) Preconditioning - not always beneficial? 
Preconditioning has been described as the most potent form of protection against myocardial necrosis 
yet described 300. The protection conferred by preconditioning has been found against most of the 
deleterious effects induced by ischaemia and reperfusion, and in most animal models as well as in 
humans. While preconditioning undoubtedly delays infarct development, and offers intriguing 
mechanisms of endogenous protection, a word of caution is required before assuming that 
preconditioning could be the basis of a new-found therapy for patients. We attempt to take a critical 
look at the literature and to emphasise that the reduction of infarct size, often praised as an important 
consequence of preconditioning, has two important limitations. First, it is a delay in the development 
of necrosis that is achieved; thus preconditioning buys time but does not cheat death. Secondly, 
almost all the models used in the studies of infarct size reduction use regional ischaemia followed by 
reperfusion, so that the benefits of preconditioning could have occurred in either the ischaemic or in 
the reperfusion period, which is an important distinction. We will emphasise that preconditioning can 
have different end-points, and that not all of its effects are favourable. Specifically, there may be 
adverse effects during the ischaemic period, which differ from those on reperfusion. 
b) The mechanism of preconditioning - no consensus after 10 years of research 
Many proposals as to the mechanism of preconditioning have been made, without consensus being 
reached (see Ch III). Many diverse routes to preconditioning have been proposed, including limitation 
of glycolysis, maintenance of high-energy phosphate compounds, enhanced activity of ATP-sensitive 
potassium channels, and increased activity of the inhibitory G protein 300, besides an extensive 
literature implicating adenosine and protein kinase C activity (see Ch III for further discussion). 
Although the role of adenosine has been well studied, and it was one of the first major hypotheses for 
preconditioning, it can be eliminated as the mechanism in the rat 64, and it therefore can not be the 
universal mediator. Another tenable hypothesis involves protein kinase C translocation. However, the 
particular isoenzyme involved has not been identified; each may have very different actions and 
different responses to preconditioning ischaemia. Thus in the absence of any agreed single 
mechanism it becomes important to examine carefully the experimental conditions chosen for the 
various studies and to understand their limitations. 
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i) Variability of protection 
A major problem with attaining a consensus on preconditioning is reproducibility. Some authors 
claim that preconditioning is highly reproducible and very protective; others find the results so 
variable and that to obtain a consistent model, a number of different protocols must be tested. Such an 
attempt has been described by Weselcouch et al. 577 who reported that 4 episodes of preconditioning 
each of 5 min ischaemia followed by 5 min reperfusion were required, before any noticeable 
protection could be achieved. This is in contrast to previous reports using rat hearts, which suggested 
that one episode of ischaemia was as efficacious as two episodes 18. 
ii) Indices of protection - infarct size vs stunning and functional recovery 
A major point of difficulty lies in the choice of end points. Preconditioning was originally shown to 
reduce infarct size by 75% compared to control hearts 375. This observation has been confirmed in 
many subsequent studies and is indeed the most consistent, and most potent effect of preconditioning. 
While a reduction in infarct size is very important, in the context of the shorter laboratory experiment, 
recovery of function has generally been used. Preconditioning can be said to delay the time to onset of 
necrosis such that at any given time during the sustained ischaemic period (between onset of injury 
and final development of total necrosis) if the heart is reperfused, recovery of function would be 
expected to be greater because of a smaller infarct ( see Fig C.1 a and b ). The results, however, have 
been very contradictory. 
Preconditioning does not protect against stunning, the reversible component of injury, but rather 
delays the development of necrosis 220. A possible point of confusion lies in the definition of 
functional recovery. Stunning is defined as a transient postischaemic condition in which the cells have 
full viability, but are poorly functioning (Ch I). This is usually associated with reperfusion after short 
term ischaemia. Once there is a component of irreversible injury, as after long term ischaemia, then 
preconditioning may be more protective. 
However, in larger animals (pigs and dogs), no improvement in recovery of function with 
preconditioning has been reported to our knowledge, despite a significant reduction in infarct size. 
Preconditioning prior to short periods of ischaemia (15 min coronary occlusion) showed no benefit on 
functional recovery 421. Shizukuda et al. used a 60 min period of coronary occlusion, and showed 
that segment shortening during reperfusion was not improved by ischaemic preconditioning, despite a 
reduced ultimate infarct size 498. Some studies in rabbits found no improvement in functional 
recovery 532 despite reduced infarct size after 30 min ischaemia (a time which would be expected to 
induce at least some necrosis). Other studies have recorded improved function in rabbits 82, but after 
5 to 20 min sustained coronary occlusion, which would be expected to produce more stunning and 
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less necrosis. We have found that preconditioning is not always protective against reperfusion 
mechanical dysfunction in a rat heart model (see Results Ch. 4, 5). Changes in pre-ischaemic 
glycogen can abolish the protective effects (Results Ch 4), while no additional protection with 
preconditioning is observed with a sustained residual coronary flow for the test ischaemia (Results 
Ch. 5). Thus, unlike the effects on infarct size, preconditioning does not consistently induce benefits 
on postischaemic mechanical function. 
iii) Ischaemic contracture 
The importance of the end-point selected for preconditioning is emphasised by the finding that 
preconditioning exacerbates ischaemic contracture 18 even when functional recovery is improved 
(see Results Ch 4). Infarct size is generally measured after a period of reperfusion, which implies that 
both the components of ischaemia and reperfusion injury are present. Preconditioning may actually 
exacerbate ischaemic injury by increased contracture, but be beneficial in reperfusion by stimulation 
of the Na+ /It exchanger 449. The mechanism for this difference may lie in the following speculative 
sequences: 
1) the preconditioning ischaemic period depletes the heart of glycogen (see Results Ch 1) 
2) ischaemic contracture is therefore more likely to occur 
3) the mechanism may involve inhibition of the Na+/K+ ATPase pump, which would explain the 
increased cell Na+ values found by Ramasamy et al 449. 
4) in the reperfusion period Na+ and H+ exchange is enhanced, so that Ca2+ -mediated necrosis would 
be diminished and the ultimate infarct size after reperfusion would be less. 
iv) Effects in absence of full reperfusion 
Reduction in infarct size can be found even in the apparent absence of reperfusion, when there is an 
initial period of total ischaemia followed by low flow ischaemia 493. Two comments are appropriate; 
firstly, the low flow ischaemia does represent reperfusion when compared with no flow; secondly, 
during the subsequent low flow ischaemia there was a substantially reduced work index which could 
have contributed to infarct size reduction. 
c) Concluding comments 
While the undoubted benefits of preconditioning on reduction of infarct size after reperfusion are 
important, it would be prudent to maintain a degree of circumspection because of the variability of 
the protocol and the differing results according to the end-points chosen. Preconditioning is not 
always beneficial (see Results Ch 4, 5), and may have some detrimental effects especially in the 
ischaemic as opposed to the reperfusion period. Thus there should be due care in extrapolating from 
experiments to any possible clinical application. 
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Fig C.Ja: Effect of preconditioning on degree of residual function in the tissue with duration of ischaemia, as a 
ratio of reversible to irreversible injury 
a - rightward shift in preconditioned hearts of protection against irreversible injury 
b - at point b residual function is much greater in preconditioned hearts 
c - at point c control hearts have no residual function, with total infarction 
d - at point d the duration of tolerated ischaemia has increased but preconditioned hearts end up with the same 
degree of infarction as control hearts 
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Fig C. 1 b. Presumed recovery of function if control and preconditioned hearts are reperfused at point b. There 
would still be a component of stunned myocardium, which may not be affected by preconditioning. If overall 
functional recovery is improved, this may be attributed to reduced infarction; alternatively, if infarct size is 
reduced, there should be better recovery of function. However, this does not always hold true, and raises 
concerns as to the validity of preconditioning as a therapy. 
278 Discussion D. Reservations to studies 
D. RESERVATIONS TO STUDIES 
The isolated rat heart perfused in the Langendorff mode was used in all studies presented in this 
thesis. While this model is frequently used in studies of metabolism and ischaemia, there are certain 
limitations, which, while not detracting from the present observations, must be taken into 
consideration before a direct clinical application can be made. Reservations regarding the 
measurement of glycolysis/glucose uptake are discussed in Results Ch 3. 
a) Choice of species 
The rat myocardium is different m many respects from the human myocardium. Fundamental 
differences include metabolic rate, contractile performance, enzyme functioning, and 
electrophysiological characteristics 46, 145. The rat has a high metabolic rate inversely correlated 
with a low body weight, and a consequently high heart rate. This is reflected in a higher coronary 
flow (5-6 ml/g wet wt/min 279 vs. 1-2 ml/g wet wt/min 507) and more rapid enzyme activities, in 
particular those of the oxidative phosphorylation pathway 34. The rat has a characteristic short action 
potential with an attenuated plateau, a high intracellular Na+ content, and an excitation-contraction 
coupling mechanism unusually dependent on Ca2+ 145. The myosin ATPase isoform of the rat is 
predominantly Vi, i.e. the faster enzyme 113. The rat also has different Ca2+-handling mechanisms. 
Susceptibility to ischaemia also varies between species 145. In addition, with respect to 
preconditioning, some pathways common to other species, e.g. KArP channel opening, adenosine 
receptor activation etc. have been found not to be active in the rat despite the finding that there is a 
protective effect exerted by preconditioning (see Ch III). 
b) Choice of rats 
In the majority of studies using the isolated rat heart, the hearts are from young, healthy animals, 
without any coronary heart disease or other factor which may affect the response to ischaemia. Hearts 
from older rats are well known to show reduced tolerance to ischaemia, and thus more variability. 
These rats show a predominance of the V 3 myosin A TPase isoform, which is slower than V 1 113. In the 
interests of tighter data, and thus more precise information, younger rats are more frequently used 
(i.e. between 250-350 g). However, we wish to further our studies on the role of glucose in ischaemia 
in pathological models, concentrating particularly on hearts from diabetic animals, which show 
reduced glucose utilisation, and increased dependence of fatty acids. Fatty acids induce a toxic effect 
on the ischaemic heart, which may be counteracted by increased glucose uptake 399. 
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c) The isolated organ perfusion system 
The utilisation of an isolated organ is associated with problems not found in vivo. When removing the 
heart, it may be damaged in some way, while the heart is arrested i.e. ischaemic, for a brief period. 
This may induce preconditioning, glycogen depletion, and regional irreversible patches of ischaemia. 
While the time from excision of the heart until cannulation and restoration of flow is reduced (less 
than one minute), and the hearts are arrested in cold buffer to reduce the metabolic changes, there 
may still be more variation than would be found in vivo, and the response to ischaemia may be 
affected. However, the isolated organ allows for more precise and easy measurement of cardiac 
function under different stresses, with far easier administration of drugs etc. and easily manipulated 
changes in the perfusate, inducing changes in substrate. In addition, factors such as catecholamines 
released into the blood, and circulating anaesthetics are eliminated in this model. Strict exclusion 
criteria are used to ensure maximal consistency between hearts. 
We used the Langendorff mode in all the perfusions for this thesis. While this mode allows many 
experiments to be done within a reasonably short space of time, with a good reproducibility, and low 
exclusion rate, there are disadvantages in terms of the physiological application of the model. The 
heart does not work in this mode i.e. the heart does not eject perfusate against an afterload. However, 
in our studies dealing with ultra low flows, the hearts do not beat and thus would perform no work 
even if the working mode is used. Thus in comparing the changes in glucose uptake, glycogen 
utilisation etc. at extreme low coronary flow rates, there should be no differences between 
Langendorff and working hearts. In addition, with a relatively long period of ischaemia, very small 
degrees of recovery can be distinguished. In the working heart, there is a threshold of recovery, 
determined by the pre- and after-loads, below which no recordings can be made. 
We were also interested in measuring ischaemic contracture, as an index of ischaemic injury, and 
relative ATP and Ca2+ levels. This can only be measured with an intraventricular balloon, or with a 
tension transducer attached to the apex of the heart. The former technique cannot be applied in the 
working heart for obvious reasons; the latter technique imposes a tension on the heart which would 
interfere with the pump function, and may tear the tissue. 
We used a model of global ischaemia, whereas ischaemia in vivo usually only involves a portion of 
the myocardium. However, we believe that a low flow model is more representative of in vivo 
ischaemia. In addition, we used a fixed low flow rate, which may prevent some of the deleterious 
effects of contracture which may compress the vessels, and result in no-reflow. A low perfusion 
pressure system would be more physiological, with a reduction in blood flow over time. However, 
this system is more variable, and more difficult to interpret. 
280 Discussion D. Reservations to studies 
d) Perfusion solution 
We used a crystalloid solution with glucose 11 mM as the sole substrate in the majority of cases. This 
perfusion solution has been used frequently, and can maintain heart function for several hours, longer 
than was needed in the present protocols. However, a crystalloid solution results in maximal dilation 
of the arteries, because of the reduced oxygen-carrying capacity, resulting in a greatly increased 
coronary flow compared to in vivo hearts. In addition, myocardial contractile performance is tightly 
coupled to the perfusion pressure and oxygen availability. Thus function in "control" hearts may vary 
widely depending on the apparatus and conditions used. However, we were interested mainly in the 
response of hearts subjected to a low residual flow, at which point we believe that the differences 
between in vivo and in vitro hearts are reduced. While there will always be room for criticism, we 
have tried to allow for these differences. We believe that the range of coronary flow used in these 
studies (0.015 - 0.5 ml/g wet wt/min) more closely represents true in vivo ischaemia (with residual 
flow rates of 0.07-0.15 ml/g wet wt/min 360, 375, 507) than previous studies (0.5 - 6 ml/g wet wt/min 
389, 390,424, 468,469_ 
An alternate substrate, acetate, was included when a period of glucose-free normoxic perfusion was 
used, when we wished to deplete tissue glycogen levels, but did not wish for adverse effects 
associated with substrate-free perfusion. Acetate is not a truly a physiological substrate (although 
derived from ethanol) although it can be used in isolated heart perfusions in the absence of glucose, 
with no reduction in function over at least 30 min 524. While there may be some eventual decline in 
function because of the lack of anaplerosis from acetate in the absence of glucose, this effect is more 
likely to impair reperfusion function. However, even with hearts perfused throughout with 5 mM 
acetate only, (which reduces pre-ischaemic glycogen levels and thus further impairs anaplerosis) 
recovery of function was 15-30% (depending on ischaemic conditions) suggesting that in the absence 
of glucose, this substrate can supply some residual ATP production, and maintain some heart 
function. 
The addition of free fatty acids and insulin would have made the model more physiological, but the 
use of free fatty acids add another dimension of complexity, in that excess free fatty acids contribute 
to ischaemic injury. If we wish to extrapolate our findings and apply the principles to a clinical 
situation, for instance as therapy for patients with myocardial infarction, further work is required on 
the effect of glucose in the presence of alternate substrates, insulin etc. in ischaemic hearts. In 
particular, a primary mechanism of protection by insulin is a reduction in circulating free fatty acids 
399_ This effect was not investigated. For more complete information, these experiments should be 
done in hearts perfused with blood, either in vitro (paracorporeal blood-perfusion model) or in situ. 
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However, in these cases, the substrate concentrations are difficult to maintain at exact levels. We wish 
to confirm our simple observations in one of these more physiological models. 
e) Preconditioning 
We used one five minute episode of preconditioning, which may be insufficient to ensure complete 
protection. However, with the Langendorff model, two or more episodes of preconditioning 
ischaemia tend to impair function prior to the sustained period. In preliminary work, we have found 
no difference in protection with two or more episodes, especially with a low residual flow rate during 
ischaemia. These observations remain to be confirmed. 
We also used an insulin-free perfusate for our control hearts. After 30 min perfusion with 11 mM 
glucose only, there is some glycogen depletion compared to control (in situ) hearts. Thus our hearts 
were already relatively glycogen-depleted, which may have conferred some protection according to 
the Neely hypothesis 387. A further depletion in glycogen by acetate perfusion may have depleted 
glycogen in these hearts to an extent below which the hearts could recover. However, the 
preconditioned hearts had glycogen levels comparable to the preconditioned glucose-only hearts, and 
yet these hearts showed improved functional recovery. While there may be some outstanding question 
regarding a difference in the absolute levels of glycogen reported by different authors, and the 
meaning of the different levels, I believe that the conclusion that preconditioning is unrelated to 
glycogen depletion holds true. This proposal has been confirmed by a number of other authors, using 
different experimental conditions. 
The choice of end point for preconditioning studies can also be questioned. 
f) Choice of end point 
The choice of end point and the time of measurement are critical in terms of clinical application, 
where patients are generally only seen some considerable time after the ischaemic insult, which thus 
may also vary significantly in duration. In the isolated perfused heart, functional recovery and infarct 
size etc. are recorded after a relatively brief period of reperfusion, of 20-60 min (sometimes longer). 
While immediate functional recovery may indeed be a necessary requirement for the patient, the 
effects of reduced infarct size may become more important in the long term, with reduced scarring of 
the myocardium. This issue is particularly relevant to the discussion regarding preconditioning. While 
we and others do not find improved functional recovery with maintained low flow with 
preconditioning (see Results C 5), the effects on ultimate infarct development may be more important 
from the clinician's point of view. This can only be decided when preconditioning is applied in 
patients, but this can only be done after more research to clarify the issues still under debate. 
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Unfortunately, it is difficult to record infarct size reliably in an isolated rat heart (Derek Yellon, 
personal communication). A larger animal model is required for these assessments. 
g) Biochemical measurements 
We used a relatively crude model, the whole heart, to obtain tissue for biochemical measurements. 
With low flow ischaemia, there may be some degree of heterogeneity between totally ischaemic, and 
better perfused areas. We are then taking the whole heart, and making an estimate of average levels of 
the metabolites. This method may blunt the changes in the more extreme tissue. However, any 
attempt to investigate glycolysis under low residual flow conditions (which we believe to be more 
physiological) will have this flaw. The involved analysis by Kashiwaya et al. 241 of glucose 
metabolism in the normal working heart needs to be applied to a low flow model (and total global 
ischaemia) in order to determine precisely the points of regulation of glucose utilisation under these 
conditions. In addition, the techniques of nuclear magnetic resonance and positron emission 
tomography may allow a clearer determination of glucose uptake and coronary flow, and the 
consequences to the tissue in terms of ion changes, changes in high energy phosphate etc. 
h) Summary 
Despite all the above reservations, we feel that the observations made clarify some important issues, 
and contribute to our knowledge on the kinetics of glucose utilisation in ischaemic myocardium, and 
thus to the potential clinical application of substrate supplementation, including glucose-insulin-
potassium therapy in patients with myocardial infarction. 
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E. POSSIBLE THERAPEUTIC STRATEGIES UTILISING GLUCOSE 
a) Glucose insulin potassium (GIK) therapy 
i) Historical background 
Despite all the experimental evidence regarding the benefits of glucose provision to the ischaemic 
myocardium, its utilisation as a therapy for myocardial infarction has not been widely exploited. 
Acute myocardial infarction leads to major metabolic changes in heart muscle and affects the whole 
body. Impaired oxygenation, reduced substrate supply and inhibited washout of end products impairs 
membrane ionic transport, increases free fatty acid concentrations and reduces ATP availability. 
Increased substrate provision should attenuate these changes. 
The development of glucose insulin potassium (GIK) therapy for use in patients with cardiac 
problems is attributed to Demetrio Sodi Pallares. In 1944, his mother developed a serious heart 
condition, for which he prescribed a low Na+, high K+ diet. This treatment greatly improved her 
health, and was applied in other patients 501 _ At that time there was very little support for his 
treatment. He believed in a harmful role of Na+, and a protective one for K+ in the development of 
cardiac necrosis. In 1960, the "polarising solution" of Henri Laborit, consisting of glucose, insulin 
and K+ was described for use with anaesthesia. K+ enters the myocardial fibres, increasing Na+ efflux, 
while insulin enhances glucose uptake into the cells. The effects of the diet developed by Sodi 
Pallares were linked to the benefits associated with the polarising solution. The GIK solution was then 
tested on a dog with a recent myocardial infarction. Intra- and extracellular Na+ and K+ levels were 
measured. The optimum effects were found with 20% glucose (in 1000 ml), 40 mEq KCl, and 40 U 
insulin administered intravenously at a rate of 40 drops per minute. A reduction in Na+ and an 
increase in K+ was found. 
The possible benefits of the polarising solution include repolarisation, increased anaerobic glycolysis, 
increased tissue glycogen, increased tissue a glycerophosphate for free fatty acid esterification, 
decreased circulating free fatty acids, membrane effects, hyperosmolar effects, increased oxidative 
metabolism of glucose, decreased lysosomal activity, accelerated wound healing 401, 501 _ The K+ 
concentration is the major determinant of transmembrane potential, which in turn regulates most of 
cell functioning. 
ii) Early experimental studies 
The effects of GIK have been tested on many of the changes brought about by ischaemia, including 
infarct size, electrolyte balance, arrhythmias, myocardial contraction, healing, cardiac shock, 
mortality rate, prevention of myocardial infarction, and treatment of severe angina pectoris 501. An 
early clinical study by Sodi Pallares showed favourable ECG changes following intravenous 
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administration of GIK in patients with acute MI and other coronary syndromes. Mittra et al. 357 
published the results of a trial in the Lancet, in which insulin was given subcutaneously, with oral 
doses of glucose. A 50% reduction in mortality when given to patients with myocardial infarction was 
found. However, the British Medical Research Council subsequently published results of a similar 
trial in the Lancet in 1968. No significant benefit was associated with a GIK regimen in terms of 
mortality and arrhythmias. This publication resulted in a loss of interest in GIK therapy. However, a 
number of faults were apparent in this study, namely very low doses of insulin, glucose and 
potassium, poor selection of patients, and late administration of the therapy 401. 
Despite the clinical setback, further experimental evidence was presented to show the benefits of 
GIK. GIK infusion 30 min after coronary occlusion exerted beneficial effects against myocardial 
ischaemia, and reduced the extent of necrosis in the region distal to the ligation 341. GIK infused 60 
min after coronary ligation increased glycogen, CP and ATP in the central infarct zone and decreased 
Pi 411. GIK thus prevented early tissue metabolic deterioration in the infarcting heart. Similar results 
were reported by Dalby et al. 95 in dogs. 
iii) Renewed interest in GIK 
Apstein published two important papers detailing the effects of high and low glucose concentrations 
under low flow conditions in rabbit hearts 14, 123. A high glucose concentration (28 mM) + insulin 
improved functional recovery and reduced ischaemic contracture at a higher flow rate (0.5 ml/min/g 
wet wt). Tissue high energy phosphates after 180 minutes of "moderate" ischaemia were higher with 
glucose supplement, while lactate production was greatly increased. Cellular ultrastructure was better 
preserved with substrate enhancement. With a lower flow rate (0.06 ml/min/g wet wt), high glucose + 
insulin reduced ischaemic contracture but did not affect recoveries. Lactate washout was maintained 
during ischaemia, indicating sustained glycolysis. High energy phosphate levels were no different. 
Eberli confirmed these findings in a model of the rat heart perfused with an erythrocyte suspension 
123. These findings, and others, led to a slow resurgence of interest in GIK. 
GIK has a glycogen-sparing effect, thought to prolong the availability of metabolic substrate for high 
energy phosphate metabolism 204, with increased glycogen available if given prior to ischaemia 398. 
Glucose and insulin (30% glucose+ 300 U insulin+ 5 g KCl in 500 ml at a rate of 1.66 ml/kg/hr) 
infused 1 hr prior to cardiopulmonary bypass 159 improved protection of hearts during operations and 
on reperfusion. 
Metabolic support for the postischaemic heart has recently been advocated by Taegtmeyer 198, 
specifically indicated for refractory left ventricular failure following cardiopulmonary bypass. A 
significant improvement in time to recovery of function is found with GIK. In addition, the use of 
other metabolic substrates e.g. anaplerotic substrates is proposed. Fibrinolytic therapy allows 
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controlled reperfusion of an ischaemic zone. Reperfusion reduces mortality, but may also potentiate 
injury. Glucose attenuates experimental reperfusion arrhythmias and other deleterious effects, 
specifically increased Ca2+ 229. 
A recent abstract 132 reports the results of a meta-analysis of studies using GIK. While most of these 
studies had very low sample numbers, the overall results showed reduced mortality with GIK after 
acute MI. It was also suggested that this regimen would be complimentary to thrombolysis by 
reducing the risk of reperfusion injury. A need for a large randomised trial on the effects of GIK with 
thrombolysis was indicated. 
iv) Other applications 
In an experimental model of anoxic cardiac arrest, GIK retrogradely infused into the coronary 
circulation, greatly improved mechanical function and cardiac rhythm 321 . GIK administered prior to 
60 min hypothermic arrest, significantly reduced SR ca2+ uptake and protected the excitation-
contraction coupling system, possibly by free radical scavenging effects 200. 
Lazar 302 suggested that substrate enhancement in "surgical" stunning may be advantageous, with 
application in surgical revascularisation of acute ischaemia. Reduced necrosis and stunning were 
found. GIK (high dose regimen) was infused during coronary occlusion (with cardioplegic arrest) and 
reperfusion. GIK hearts had significantly less tissue acidosis and higher wall motion scores, and less 
necrosis. 
v) Concentrations of glucose, insulin and potassium 
The major problem with GIK has been the establishment of a regimen which is practical, beneficial 
with limited side effects. A wide range of regimens of GIK have been used, including oral 
supplements and intravenous solutions with high concentrations of glucose. While sufficient glucose 
is required to provide ATP, the possible side effects of a high glucose concentration in a severely 
ischaemic zone must be taken into consideration. Reported adverse effects of GIK include 
hypoglycaemia 435, hyperglycaemia and hyperkalaemia 463, hypophosphalaemia 344, and effects on 
the conduction system 168. In severe ischaemia, with low coronary flow, glycolysis may be impaired 
to such an extent that the addition of exogenous glucose may not benefit the ischaemic zone. In this 
case the benefit would be limited to reduction of circulating free fatty acids. The findings presented in 
this thesis advocate the careful utilisation of glucose, at a range of concentrations consistent with 
those found to be optimal in the isolated heart. While systemic effects may indeed play an important 
role, a careful assessment of the relative detriment of a high glucose and insulin to the ischaemic 
tissue, versus the systemic effects, of reducing free fatty acid levels in the blood, is required. Results 
from this thesis suggest that maintaining a (fasting) blood concentration of 5-10 mM glucose (the 
higher end of the physiological range), with insulin, may be beneficial in patients with myocardial 
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infarction. In addition, the possible resistance to insulin in patients with chronic heart failure argue for . 
substrate supplementation 518. In general terms, less glucose would have little effect; more glucose 
would be detrimental to the disadvantaged heart. However, hyperglycaemia should be avoided. 
However, caution must be taken before extrapolating the results of the present thesis directly to the 
clinical situation, because ofreservations discussed above (see Discussion D). 
b) Cardioplegia 
i) Cold cardioplegia and glucose 
Many different formulations of cardioplegic solutions have been described. The most commonly used 
cardioplegic solutions include the St Thomas' Hospital solution (STH) 188, the University of 
Wisconsin (UW) solution and Bretschneider's HTK 47, none of which have glucose in their standard 
formulation. Addition of glucose to STH was detrimental when given in a bolus dose at the onset of 
70 min arrest at a temperature of 28°C 193. If STH were administered at the onset of 3 hrs arrest, at a 
temperature of 10°C, the addition of 11 mM glucose also had no benefit; when administered in a 
multidose regimen, especially if gassed with 95% 0 2 5% CO2, the recoveries were substantially 
improved with glucose 252, 563. The optimal glucose conce~tration was 11 mM, with excess glucose 
(20 and 50 mM) proving deleterious to the hearts 425. Higher glucose concentrations inhibited 
glycogenolysis, reducing total glycolysis and ATP production 425. These results are in agreement 
with concepts presented in this thesis. 
ii) Warm blood cardioplegia 
A more recent advance in cardiac preservation has been the introduction of warm blood cardioplegia 
314. The concept works on the premise that if the heart is arrested, cessation of electromechanical 
function accounts for 90% of myocardial oxygen consumption. An additional 10% saving in energy is 
outweighed by the benefits of the more physiological temperature, and thus a reduction in 
temperature is not required if mechanical arrest is maintained. Continued perfusion with warm blood 
supports continued aerobic metabolism and also allows for myocardial substrate replenishment. 
Warm blood cardioplegia preserves function and metabolism at near pre-arrest levels 55. Glucose was 
present at a concentration of 56.6 mM (after admixture with blood), delivered at a flow rate of 3.14 ± 
0.37 ml/kg/min i.e. 0.78 µmol/g/min. Hanafy et a1178 used warm cardioplegia with glucose (0.222 M 
- 250 -300 ml/min for 2 min - total 13 mmol) to induce arrest followed by use of cold cardioplegia. 
This regimen was especially beneficial in patients with severe underlying coronary disease. 
The findings presented in this thesis are applicable to warm blood cardioplegia administered 
continuously. The findings also suggest that glucose would be beneficial to the heart. but that the 
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concentrations should be carefully monitored. While the "stone heart" 86, 242 is a consequence of 
surgery to be avoided, largely by glucose provision, excess glucose at low flow rates may be equally 
deleterious. 
c) Other interventions 
Recently, interest in manipulating carbohydrate metabolism e.g. by inhibiting fatty acid oxidation and 
increasing glucose oxidation, or activating pyruvate dehydrogenase (PDH) and thus also increasing 
glucose oxidation have received attention. Fatty acid oxidation can be inhibited by carnitine palmitoyl 
transferase I (CPT-1) inhibitors such as etomoxir and oxfenicine, which inhibits fatty acyl Co A 
transport into the mitochondria 201, 323. Thus, glucose oxidation can be increased, and presumably 
increase ATP production if residual oxygen is present. Increased pyruvate or stimulation of PDH (by 
dichloroacetate 351, 581) may also increase ATP production by increased oxidation, but again this is 
dependent on the availability of oxygen 92. The benefits of the above mechanisms should thus only 
be present if oxygen is available, delivered by a residual coronary flow. Alternatively, a simple 
increase in residual flow may prove as beneficial. The benefits of the above interventions have been 
shown particularly on reperfusion, when oxygen is resupplied 324, 326, 351. 
Alternative strategies would be to modulate the effects of the metabolites associated with increased 
glucose metabolism. For instance, a decrease in NADH levels or H+ accumulation may enhance ATP 
production. Trimetazidine, an anti-ischaemic agent, may act as an intracellular buffer 41, thereby 
exerting protective effects. The deleterious effects of sugar phosphates on Ca2+ homeostasis also need 
to be investigated, as a focus of possible avenues of therapy. 
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Appendix I: Aspects of glucose metabolism 
1) PATHWAYS OF GLYCOGEN SYNTHESIS AND BREAKDOWN 
a) Glycogen synthesis 
Glycogen is synthesised from UDP-glucose (uridine diphosphate glucose), an activated form of 
glucose derived from G lP and uridine triphosphate (UTP), with formation of pyrophosphate (PPi) 
(see Fig AI. 2). Pyrophosphate is hydrolysed to 2 Pi, an essentially irreversible reaction which drives 
glycogen synthesis. The UDP is then cleaved from the glucose by glycogen synthase and the glucose 
moiety is attached to the non-reducing end of a glycogen branch (see Fig AI. 1 ). 
0 a-1,4 
ea-1,6 
O First molecules cleaved by phosphorylase 
e Molecules transferred to other branch by transferase 
for cleavage by phosphorylase 
Non-reducing end 
Fig AI.I: Classic macromolecular glycogen is a branched molecule, with 93% a-1,4 linkages, and 7% a-1,6 
linkages. Glycogen consists of about 10 000-30 000 molecules of glucose, with a molecular weight of 107 Da 
and constitutes about 1% of muscle mass. It forms large granules in the cytoplasm which can be clearly seen 
under the electron microscope. A portion of the glycogen molecule is illustrated showing points of cleavage. 
Phosphorylase (see Fig AI.2) stops cleaving when there are 4 terminal residues from the branch point. A 
transferase transfers the remaining a-1,4 residues to the linear branch. The remaining a-1,6 bond is hydrolysed 
by amylo-1, 6 glucosidase. Each circle represents a C6 molecule. 
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Fig Al.2. Glycogen synthesis - Glucose is activated by the addition of UDP. Glycogen synthase then cleaves UDP from UDP-glucose, and attaches the glucose moiety to the non-reducing end of a glycogen branch. Synthase phosphatase activates glycogen synthase by converting the enzyme from an inactive phosphorylated (b or DJ to an active dephosphorylated form (a or I) (D - dependent on; I - independent of G6P). PKA phosphorylates and thus inhibits glycogen synthase. G6P is a potent stimulator of glycogen synthase activity 
(from 10,522). 
Glycogen breakdown - Phosphorylase is the main enzyme of glycogen breakdown. Phosphorylase activity is upregulated by phosphorylation (from b - inactive to a - active) by a Ca-dependent phosphorylase b kinase, using a molecule of ATP. The Ca-dependence of phosphorylase b kinase ensures a close co-operation between · contraction and glycogen breakdown. This kinase is in turn activated by phosphorylation, which· is catalysed by 
cAMP-dependent protein kinase following /3-stimulation. PKA simultaneously inhibits glycogen synthesis. a-1,6 bonds, however, cannot be degraded by phosphorylase. Debranching is required for the exposure of single chain residues for phosphorylation (see Fig AI.1). 
Phosphorylase phosphatase inhibits phosphorylase by dephosphorylation 100, 297_ Inactive phosphorylase b can be directly stimulated by increases in AMP, and decreases in G6P and ATP, while phosphorylase a is inhibited by high concentrations of glucose. 
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About 9 protein kinases also FJhosphorylate/dephosphorylate the enzyme 297, the most important 
being the cAMP-dependent protein kinase A 100. PK.A phosphorylates glycogen synthase, inhibiting 
glycogen synthesis 289. Protein kinase C and phosphorylase kinase also inhibit the enzyme. 
Insulin stimulates glycogen synthesis by enhanced glycogen synthase dephosphorylation, via a 
number of protein kinases 297. Insulin promotes dephosphorylation, and thus inactivation, of 
phosphorylase, the primary enzyme in glycogen breakdown. Insulin also greatly increases glucose 
uptake, increasing substrate levels for glycogen synthesis. Fasting (short term) increases glycogen 
deposition by enhanced fatty acid oxidation, and inhibition of glycolysis 487. Transient ischaemia 
also activates glycogen synthase, possibly via G6P-mediated activation of phosphatase 350, thereby 
stimulating glycogen synthesis. This is contrary to the normal concept of ischaemia-induced glycogen 
breakdown. Two forms of glycogen synthase, one acting on proglycogen another on macromolecular 
glycogen, have been identified 10, possibly accounting for different rates of synthesis of the different 
forms. The rates of breakdown may also be different 103 . Glycogen appears to oscillate between 
proglycogen and macromolecular glycogen, with proglycogen as a stable intermediate 10. 
b) Glycogen breakdown 
Glycogen breakdown follows a simple pathway (Fig AI.2), with a molecule of Pi consumed per 
glycogen residue, catalysed by phosphorylase. G lP is produced, which is converted to G6P by 
phosphoglucomutase, an enzyme which favours the formation of G6P, unless this is in high 
concentrations. G6P then enters the glycolytic pathway, for conversion to pyruvate. Glycogenolysis is 
stimulated by hypoxia and ischaemia, glucagon, and epinephrine. 
2)ALTERNATE FATES OF METABOLITES OF GLYCOLYSIS 
a) Glucose 6-phosphate 
G6P is one of the main branch points of carbohydrate metabolism (see Fig AI.3). G6P is the precursor 
of glycogen synthesis, as well as the entry point of glycogen breakdown into glycolysis. G6P can also 
be used to restore levels ofNADPH and D-ribose 5-phosphate by the pentose phosphate pathway. 
b) Glyceraldehyde 3-phosphate and dihydroxyacetone phosphate. 
GAP and DHAP are interconverted by triose phosphate isomerase (see Fig AI.3). GAP can be 
converted to glycerol, and then glycerol 3-phosphate ( a-glycerophosphate - aGP) but the more usual 
reaction is the conversion ofDHAP to aGP, which can then be incorporated into triglycerides. 
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Fig Al.3. Altemative fates of metabolites of glycolysis. 
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G6P is a junction for the formation and breakdown of glycogen, as well as the pentose shunt. G6P is converted to D-6-P glucono-o-lactone by glucose 6-phosphate dehydrogenase, which uses NADP. This compound is hydrolysed to 6-phosphogluconate which is converted to D-ribose 5-phosphate, with an additional NADP utilised. 12 molecules of NADPH are thus regenerated. D-ribose 5-phosphate can then be converted to F6P or GAP, thereby re-entering the glycolytic pathway. The proportions which flow along the pathway are dependent on the requirement.of the cell for D-ribose 5-phosphate, NADPH. and continued glycolysis. aGP shuttle - conversion of DHAP to aGP is catalysed by a-glycerophosphate dehydrogenase, with reduction of NADH to NAD+. aGP, readily permeable to the mitochondrial memhrane, can subsequently be re-oxidised to DHAP by aGP oxidase, a transmembrane mitochondrial protein linked to FAD with the consumption of a molecule of Oz, and production of Hz() .. This system allows transport ofNADH into the mitochondria against a high concentration gradient, although the cost is an ATP molecule, given that only 2 ATP an produced per FADHz, rather than 3 per NADH. However, the level of aGP oxidase is low in muscle m_ aGP· increases during isch~mia as a product of glycolysis. In addition, aGP is required in the formation of trlglycerltks. Other glycolytic metabolites contrlbute to various pathways as shown. These an not considered important in isch~mia. For fates of pyrwate see Fig AI.4. 
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c) Pyruvate 
The major product of glycolysis is pyruvate. From this point there are a number of options, dependent 
on the status of the cell (see Fig AI.4). Under normal conditions, pyruvate is converted to acetyl Co A 
by pyruvate dehydrogenase (PDH). Acetyl CO A then enters the TCA cycle by combining with 
oxaloacetate to form citrate (Fig AI.5), or goes to the formation of fatty acids. Pyruvate can also be 
exported from the cell, together with a H+. 
In anaerobic conditions, or with exercise, the TCA cycle is inhibited by an accumulation of NADH. 
Pyruvate is then converted to lactate by lactate dehydrogenase, with the regeneration ofNAD. Lactate 
is a "dead end", its only possible fate reconversion to pyruvate under conditions of adequate 
oxygenation, or else export from the cell (also with a H\ However, the regeneration of NAD+ during 
the pyruvate-to-lactate conversion allows glycolysis to continue. 'vVhen sufficient oxygen is available, 
NADH will be regenerated, with the oxidation of lactate to pyruvate. NAPH can then be transported 
into the mitochondria, and utilised by oxidative phosphorylation. If glycolysis continues in the 
' 
absence of oxygen, H" accumulate from a reduced turnover of ATP 156. Thus lactate and H+ 
accumulate as a result of increased anaerobic glycolysis. Pyruvate is also important as an anaplerotic 
substrate (mechanisms which "top up" the TCA cycle intermediates), supplying a-ketoglutarate. and 
oxaloacetate to the TCA cycle (see Fig AI.5). Pyruvate is converted to oxaloacetate in the 
mitochondria by pyruvate carboxylase (see Fig AI.4). While activity of this enzyme is low in heart 
muscle, pyruvate carboxylation and subsequent contribution to anaplerotic pathways has been found 
431 _ Phosphoenolpyruvate can be converted to oxaloacetate in the cytosol by phosphopyruvate 
carboxylase. Alanine is an important product of glycolysis, and accumulates during ischaemia 432_ 
Alanine can also contribute to anaplerotic mechanisms, and to amino acid synthesis from glycolysis. 
3) SEQUENTIAL PATHWAYS AND ALTERNATE SUBSTRATES 
1) TRICARBOXYLIC ACID CYCLE 
The TCA cycle (see . Fig AI.5) is the meeting point of substrate metabolism, whereby reducing 
equivalents for subsequent generation of ATP by the respiratory chain are produced. Acetyl ~o A is 
the entry point of most substrates into the TCA cycle, and NADH and F ADH2 are the end products, 
which enter oxidative phosphorylation with the formation of high energy phosphates. The i:-cA cycle 
is the most important generator of ATP of each substrate, such that an additional 36 ATP can be 
produced from glucose, and for a fatty acid such as palmitate, 130 ATP can be formed (after oxidative 
phosphorylation). Completion of the TCA cycle is required for the complete oxidation of these 
substrates. Several glycolytic metabolites are important as anaplerotic substrates, to replenish the 
TCA substrates (see above). 
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Fig AJA. Fates of pyritJJate. Pyruvate is normally converted to acetyl Co A by pyruvate dehydrogenase (PDH) . 
PDH is a complex of three enzymes which require a number of cofactors. The enzyme complex is tightly 
regulated by the ratios of NADHINAD•, acetyl Co A/Co A, and ATP/AMP ratios (increases in which inhibit the 
enzyme - end product inhibition), as well as phosphorylation (inactivation - by PDH. kinase) and _ 
dephosphorylation (activation - by PDH phosphate phosphatase). 
Under anaerobic conditions, pyruvate is converted to lactate to allow regeneration of NAD•. and continuation 
of glycolysis. Pyruvate can also be converted to alanine, with the concomitant transamination of glutamate, and 
the formation of a-ketoglutarate. Pyruvate can also be converted to oxaloacetate by pyruvate carboxylase, and 
then to ma/ate, or directly to ma/ate by ma/ate dehydrogenase. 
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Fig Al.5. Acetyl Co A crosses the mitochondrial barrier, and then combines with oxaloacetate, with the release 
of Co A. The reaction is catalysed by citrate synthase. one of the ,;_egulatory enzymes of the TCA cycle. 
dependent largely on the level of oxaloacetate (OAA) and acetyl Co A. Citrate is transformed by aconitase to 
isocitrate, which is then oxidised to a~ketoglutarate ( aKG or 2-oxoglutarate), with the release of C01, and the 
formation of NADH. aKG is the second regulated compound of the TCA cycle, as it can be used for the 
transamination of many amino acids, with the concomitant production of glutamate. aKG is involved in the 
anaplerotic pathways. and regeneration of NAD • and is the entry point for some of the 5-C amino acids into the 
TCA cycle. 
The conversion of aKG to succinyl Co A is catalysed by aKG dehydrogenase. This step can be inhibited leading 
to unspanning of the TCA cycle. NADH and F ADH1 are released. with the release of C01. The Co A picked up in 
this reaction is lost in the next in the sequence. with the conversion of succinyl Co A to succinate, with the 
concomitant conversion of GDP + Pi to GTP. Succinate is then oxidised to J;umarate, with the production of 
FADH1- Fumarate is hydrolysed to malate, another important regulated metabolite. Ma/ate is oxidised to 
oxaloacetate by ma/ate dehydrogenase (MDH) using NAD•. This enzyme has a high activity, 'with the 
equilibrium largely towards ma/ate formation. MDH and citrate synthase compete for OAA as substrate. 
Cytosolic and mitochondrial MDH is important in the regulation of redox potential, and cell metabolism. 
Following a surge in metabolic activity, e.g. increased work load, change in substrate etc., the isolated heart 
demonstrates that the TCA cycle operates in two "spans" - one regulated by citrate synthase (from citrate to 
aKG) and one by aKG synthase ( aKG to OAA). If there is a large increase in acetyl Co A, flux through citrate 
synthase is increased while that through aKG synthase is reduced 587. aKG in the mitochondria increases and 
can be exported out of the mitochondria in exchange for malate (Fig Al.6). Malate is then converted to OAA to 
supply substrate for citrate synthase. The TCA cycle is thus "unspanned". aKG synthase is possibly inhibited by 
end product inhibition i.e., NADH+Jt and succinyl Co A. Balance is restored by glutamate-aspartate exchange, 
with increased formation of aKG from OAA overcoming inhibition of aKG synthase (Fig A/..6). 
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The "rate" of the TCA cycle is controlled by the rate of ATP production by oxidative phosphorylation 
of ADP. The determinants of mitochondrial respiration are the extra-mitochondrial [ATP]/[ADP]x[Pi] 
(cytosolic phosphorylation potential 553) and the intramitochondrial NADH/NAD+ as well as the 
oxygen availability. If ATP increases, NADH and F ADH2 will not be oxidised, and the lack of FAD 
and NAD+ will slow down the TCA cycle . 
2) REGULATION OF NAD+/NADH, GLYCOLYSIS AND THE TCA CYCLE 
a) Lactate and a-glycerophosphate 
Under conditions where acetyl Co A accumulates, when there is insufficient oxygen, or when NADH 
accumulates, NAD+ must be regenerated, both to ensure continued glycolysis at the levels of PFK and 
GAPDH, and maintain turnover of the TCA cycle. The former is cytosolic, the latter mitochondrial. 
Cytosolic NADH can be converted to NAD+ by the pyruvate-lactate reaction catalysed by lactate 
dehydrogenase (Fig AI.4). As mentioned above, this is a dead end - a temporary mechanism whereby 
NAD+ can be regenerated to allow continued glycolysis. Levels of cytosolic NADH can also be 
lowered by the reduction of DHAP to aGP by aGP dehydrogenase (Fig AI.3). However, the 
importance of this shuttle in the heart has been disputed 473 , given t~e low activity of aGP 
dehydrogenase in heart muscle 349. In addition, under normal conditions, the level of aGP is far 
below the Km for aGP oxidase. In ischaemia, aGP would be expected to increase 468 and may be 
important under these conditions 214, 4 73. 
b) Malate-aspartate shuttle 
The malate-aspartate shuttle is perhaps the most important mechanism whereby the cytosolic and 
mitochondrial levels ofNADH are regulated 473 (Fig AI.6). There is an overall shift of malate 
into the mitochondria, and aspartate out of the organelle. This exchange is also involved in regulation 
of the TCA cycle (see Fig AI.5). 
This flux is readily reversible. Its direction is determined by the cytosolic to mitochondrial 
NADH/NAD, such that a higher cytosolic ratio drives NADH transport into the mitochondria. This 
' transfer does not utilise energy, but allows production of 3 ATP per NADH. If oxygen is limiting, 
NADH will accumulate in the mitochondria, and will prevent transport of NADH from the cytosol. 
Cytosolic NADH will then accumulate, which may affect redox-dependent reactions including 
glycolysis. The malate-aspartate shuttle can be reversed if there is an increase in NADH in the 
mitochondria. with the formation of malate. Malate can be transported out of the mitochondria, and 
converted to pyruvate by NADP-dependent malic enzyme, or to oxaloacetate by MDH (Fig AI.6). 
The formation of alanine from pyruvate, with the concomitant transamination of glutamate to a-
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Fig AI. 6. The malate-aspartate shuttle. A cytosolic accumulation of NADH following increased glycolysis, shifts 
the activity of MDH in the direction of ma/ate formation from oxaloacetate. The ma/ate crosses the 
mitochondrial membrane in exchange for a-ketoglutarate, and is then reconverted to oxaloacetate by 
mitochondrial MDH. NADH is thus regenerated in the mitochondria and can enter the respiratory chain. In 
addition, oxa/oacetate replenishes the TCA cycle, combining with acetyl Co A to form citrate. Oxa/oacetate can 
also combine with glutamate to form a-ketoglutarate and aspartate. a-ketog/utarate then continues to drive the 
entry of ma/ate, as aspartate exits the cell in exchange for glutamate. In the cytosol, the a-ketogl~tarate and 
aspartate recombine to form oxa/oacetate and glutamate. There is thus an overall shift of malate into the 
mitochondria, and aspartate out of the organelle when cytosolic NADH increases. The whole shuttle can 
reverse, such that ma/ate is transported out of the mitochondria, converted to oxaloacetate, and then to 
pyruvate. Pyruvate can also contribute to oxa/oacetate formation via pyruvate carboxylase, or to malate by 
malic enzyme. These mechanisms, and the malate-aspartate shuttle, result in the anaplerotic contributions of 
pyruvate. 
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ketoglutarate, replenishes the latter as well, in an important anaplerotic mechanism. The levels of a-
ketoglutarate are important in maintaining the second "span" of the TCA cycle (see Fig AI.5). 
3) OTHER SUBSTRATES 
a) Fatty acid metabolism 
Free fatty acids are the major substrate in the normal heart, especially in the fasted state. Increased 
free fatty acids reduce glucose utilisation 388, 452, 496_ Fatty acids are taken up across the cell 
membrane in a concentration-dependent process. Triglycerides are formed from acyl Co A and 
aglycerophosphate, the latter a product of glycolysis. For each mol of triglyceride produced, 3 mol 
H+ are produced, which can increase acidosis in ischaemia 107. Endogenous lipids are not normally 
used as an energy source, given sufficient external substrate, but may provide energy substrate e.g. in 
a perfused heart with limited external substrate 409. When required as substrates, free fatty acids are 
activated by Co A and ATP, and converted to acyl Co A. Acyl Co A is transported into the 
mitochondria by carnitine, and converted to acetyl Co A by [3 oxidation. [3 oxidation is stimulated by 
falls in NADH+H+ and F ADH2, and inhibited by increased reducing equivalents which occurs when 
oxygen falls. 
Fatty acids have a higher requirement for oxygen than other substrates, but yield a higher ATP per 
molecule. Fatty acids are therefore useful when oxygenation is high, but are "oxygen-wasting" . In 
conditions of ischaemia, fatty acids exert a toxic effect, as well as consuming available oxygen 
rapidly. The breakdown products of fatty acids (acyl Co A, acyl carnitine, and 
lysophosphoglycerides) may be involved in many of the deleterious effects in ischaemia, particularly 
arrhythmogenesis 409. 
b) Acetate metabolism 
Acetate is a 2-carbon compound which can be utilised as a substrate under aerobic conditions. It is 
broken down to acetyl Co A by a two step process catalysed by acetyl Co A synthetase. 
ATP PPi Co A-SH AMP 
AcetaW acetyl adenylateVacetyl Co A 
Acetate is the metabolite of ethanol which can be utilised by the TCA cycle. Two high energy 
phosphate bonds from a molecule of ATP are required for acetate utilisation, which may be 
detrimental when ATP is depleted e.g. ischaemia. Acetate has a lower PIO ratio, implying reduced 
efficiency as a substrate, and a greater requirement for oxygen. Acetate perfusion increases the tissue 
content of acetyl Co-A, citrate, glutamate and malate, increasing the TCA cycle turnover by 50-60%, 
and inhibits glycolysis by increasing citrate levels 386. However, acetate can be used to deplete 
glycogen in an isolated perfused heart, in the absence of any additional substrate. The mechanism 
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may be the lower PIO ratio which reduces the efficiency of ATP production, stimulating glycogen 
utilisation to prevent a shortfall in energy. 
4) OXIDATIVE PHOSPHORYLATION 
The end products of substrate utilisation are NADH+H+ and F ADH2. These reducing equivalents 
provide the energy for the coupled phosphorylation of ATP from ADP+ Pi via the oxidation 
NADH + H+ + Y.0 2 ~ H20 + NAD 
This reaction is driven by the proton-motive force across the mitochondrial membrane i.e., a pH 
gradient. 
ADP+ Pi +NADH +H+ ~ATP+ H20 + NAO 
Three electrons are associated with NADH + H+, each of which allows phosphorylation of an ADP. 
FADH2 only generates 2 ATP because its electrons enter lower down the respiratory chain. Ca2+ can 
compete with H\ and enter the mitochondria in this way. 
ADP and ATP are not freely permeable to the membrane, and are moved by a ATP-ADP translocase, 
the activity of which may be inhibited by acyl Co A. The amount of ADP is a critical regulator of 
oxidative phosphorylation, and therefore of the TCA cycle. This is usually described as the energy 
charge, or phosphorylation potential [ATP]/[ADP]*[Pi] 158, 553 . 
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Appendix II: Adaptation of macrocuvette spectrophotometric methods for 
the Cobas Fara II Clinical Analyser 
a) Adaptation of biochemical methods for the Co bas Fara 
A standard reagent volume of 120 µl was chosen for the majority of adapted assays, as this gives 
allows for a greater substrate content. This allows for a total end-reaction volume (reagent+ sample+ 
diluent+ enzymes) of less than 250 µl, which gives absorbance data approximately equivalent to a 1 
cm fixed light path reading. The sample to volume ratio was maintained initially, but altered 
according to different concentrations in the samples. A standard sample volume of 10 µ1 was chosen 
initially. The diluent volume should initially be set at twice the sample volume, or a minimum of 20 
µ1. The principles of each reaction were considered, and the above calculations taken into account. 
The manual techniques were used, with selection of the appropriate reaction mode on the Cobas Fara 
II. The appropriate calibration mode was chosen (usually linear regression with a series of 
incremental standards). A reagent blank was included for all assays (usually distilled H20). The 
wavelength was usually set at 340 nm, either at room temperature or at 37°C. 
If pre-made kits were used ( cited in notes), the reagents were sometimes reconstituted at a factor less 
than that recommended by the manufacturers for the macro-cuvette methods. The factor was 
calculated from the diluent (at least 20 µ1 * no of samples in kit for macro method). The volumes used 
to reconstitute the reagents are given with the methods. The incubation periods were generally shorter 
because of much smaller volumes. A standard curve was generated for each assay to determine 
changes in substrates, reagents enzymes etc. While one standard curve can be used for several runs on 
the same day, it is recommended that new standards are run each day for the majority of the assays. 
Most standards are stored in the freezer ( except where stated) in 1 mM aliquots, made from a 10 mM 
stock solution. Most solutions used in the assays can be stored in the fridge or freezer (unless stated 
otherwise). 
Given that each rotor has 30 cuvettes, 1 air + 1 blank + 4 standards allows 24 samples to be 
determined in each run. For each assay, the amount of reagent for 35 samples is calculated to allow 
for dead space. If more or less samples are to be done, this can be calculated from the volume/cuvette 
for each reagent, taking into account dead space volumes (see below). 
b) Standard procedure 
Reagents - the reagent cocktail (for 35 samples) is placed into large reagent container in position Ron 
reagent rack (see Fig M.6). 
Start reagent 1 (enzyme) into cup in position P 1 
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Reagent 2 (enzyme) into cup in position P2. 
If three reagents are added (see ADP+ AMP assay), the first reagent can be placed in position R once 
initial reagent pipetting is completed, and then reagent 2 is placed in Pl and reagent 3 in P2. If 4 
reagents are used (see ATP+ CP assay), the first reagent is added to the reagent mixture (if this does 
not affect baseline reading), and the others in R, Pl and P2 respectively. 
Enzymes - place in diluent cups in larger reagent cups to reduce dead volume. At least 70 µl dead 
volume+ additional enzyme adequate for total number of samples assayed is needed (usually 200 µl 
added). A standard volume of 5 µl enzyme per sample was used in the assays. Only 1 µl enzyme was 
generally needed, thus enzymes were diluted 1 :5 on day of use. 
If the start reagent was placed in R position, the total volume must be increased because the larger 
pipette tip is used, which is less accurate. A minimum volume which can be taken up by the reagent 
pipette is 20 µl (see ATP + CP assay). A 1 :20 dilution is used in these cases. 
Fig M 6. Illustration of reagent positions on reagent rack. 
Samples - Approximately 200 µl of sample (from extractions or effluent) is pipetted into sample cups 
(dead volume of 90 µl, so add more sample volume if greater amount taken for each assay, if assay to 
be run several times, or several assays to be run on each sample). 
Standards - for assays of multiple substrates, include all standards in each standard cup, i.e. for two 
standards (see ATP+ CP assay) make sure that final concentration is as required for each standard, 
taking into account dilution by other standard. The standards as shown below can be altered according 
to predicted values of samples. 
Blanks - distilled water from source in machine 
Methods - the programmes as set up on the Cobas Fara II are included below. 
Calculations - while the Cobas Fara II prints out final concentrations calculated on the basis of the 
calibration mode chosen (usually linear regression) in the interests of saving reagent, samples etc. 
multiple reactions were carried out in some cases (e.g. ATP+ CP, ADP+ AMP). In these cases. the 
linear regression for each standard needs to be calculated, and the subsequent sample concentrations 
calculated from the absorbances measured at time points as specified below for each assay. 
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v) Programme on Cobas Fara for G6P + F6P 
General 
Measurement mode: Absorbance 
Reaction mode: PI SRl I SR2 A 
Calibration mode: Linear regression 
Reagent blank: Reagent/diluent 
Wavelength: 340nm 
Temperature: 25 °C 
Decimal position: 4 
Unit: mmol/1 
Analysis 
p Sample volume: 40 µl 
Diluent name: H20 
Volume: 20 µl 
Reagent volume: 120 µl 
I Incubation: 100 secs 
Ml: 100 secs 
SRl Start Reagent 1: 5 µl 
Diluent name: H20 
Volume: 5 µl 
I Incubation: 150 secs 
M2: 150 secs 
SR2 Start Reagent 2: 5 µl 
Diluent name: H20 
Volume: 5 µl 
A Readings: 
First: 100 secs 
Number: 5 
Interval: 40 secs 
Calculation: Manual 
Calibration 
Std 1: 0.03125 
Std 2: 0.0625 
Std 3: 0.125 
Std 4: 0.25 
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